WEST Search History

Hide Items Restore Clear Cancel

DATE: Friday, May 13, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB	B, USPT, USOC, EPAB, JPAB, DWPI; PLUR=YE	S; OP=ADJ
	L11	= 1994	81
	L10	= 1994	23
	L9	L8 AND monoclonal antibody	1477
	L8	(beta-amyloid OR a-beta OR Abeta)	3589
	Ĺ7	= 1994	21
	L6	= 1994	8
	L5	L4 AND amyloid	237
	L4	530/387.1,387.3,388.1,388.15.CCLS.	4979
	L3	Solomon.IN.	6005
	L2	Solomon-B.IN.	20
	L1	(Solomon-Beka.IN.)	19

END OF SEARCH HISTORY

Art Unit: 1647

WO199012871A

Hit List

Clear Generate Collection Print Fwd Refs Bkwd Refs Generate OACS

Search Results - Record(s) 1 through 19 of 19 returned.

☐ 1. Document ID: US 20050089510 A1

L1: Entry 1 of 19

File: PGPB

Apr 28, 2005

Mar 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050089510

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050089510 A1

TITLE: Agents and compositions and methods utilizing same useful in diagnosing

and/or treating or preventing plaque forming diseases

PUBLICATION-DATE: April 28, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Solomon, Beka Herzlia Pituach IL Hanan, Eilat Tel Aviv ILFrenkel, Dan Rehovot IL

US-CL-CURRENT: <u>424</u>/93.2

ABSTRACT:

A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization.

Full Title Citation Front Review Classifi	ication Date Reference Sequences A	ttachments Claims KMC Draw De
☐ 2. Document ID: US 2005005	53575 A1	
L1: Entry 2 of 19	File: PGPB	Mar 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050053575

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050053575 A1

TITLE: Antigenic product displaying multiple copies of an epitope of a deposit-

Record List Display Page 2 of 13

forming polypeptide involved in plaque-forming diseases and methods of using same

PUBLICATION-DATE: March 10, 2005

INVENTOR-INFORMATION:

NAME C

CITY STATE

COUNTRY

RULE-47

Solomon, Beka

Pituach

 $_{
m IL}$

US-CL-CURRENT: <u>424</u>/78.27; 424/185.1, 525/54.1

ABSTRACT:

The present invention relates to an antigenic product for inducing an immune response to a deposit-forming polypeptide, such as amyloid ss, which antigenic product is a multiple antigenic peptide (MAP) that contains multiple copies of an epitope of a deposit-forming polypeptide involved in a plaque-forming disease. This antigenic product can be formulated into an immunizing composition and used to elicit an immune response against a deposit-forming polypeptide involved in a plaque-forming disease or disorder.

Full Title Citation	Front Review	Classification	Date	Reference	Sequences	Attachments	Claims	юмс	Drawi De

☐ 3. Document ID: US 20040052766 A1

L1: Entry 3 of 19

File: PGPB

Mar 18, 2004

PGPUB-DOCUMENT-NUMBER: 20040052766

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040052766 A1

TITLE: Immunization against amyloid plaques using display technology

PUBLICATION-DATE: March 18, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Solomon, Beka Herzlia Pituach IL Frenkel, Dan Rehovot IL

US-CL-CURRENT: 424/93.2

ABSTRACT:

A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization.

Record List Display

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw, De

☐ 4. Document ID: US 20040013647 A1

L1: Entry 4 of 19

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040013647

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040013647 A1

TITLE: Methods and compositions for treating a plaque-forming disease

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME CITY

STATE COUNTRY

RULE-47

Solomon, Beka

Herzlia Pitauch

IL

Frenkel, Dan

Rehovot

ΙL

US-CL-CURRENT: <u>424/93.2</u>; <u>514/44</u>

ABSTRACT:

A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization. The methods of the present invention also generally relates to treating and/or diagnosing neurological diseases and disorders of the central nervous, regardless of whether the disease or disorder is plaque-forming or non-plaque forming.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Drawt De

5. Document ID: US 20030077252 A1

L1: Entry 5 of 19

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077252

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030077252 A1

TITLE: Agents and compositions and methods utilizing same useful in diagnosing

and/or treating or preventing plaque forming

PUBLICATION-DATE: April 24, 2003

Record List Display Page 4 of 13

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Solomon, Beka Herzlia Pituach IL
Hanan, Eilat Tel Aviv IL
Frenkel, Dan Rehovot IL

US-CL-CURRENT: <u>424/93.2</u>; <u>435/235.1</u>, <u>435/456</u>, 514/44

ABSTRACT:

A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization.

- 1	Full	Title	Citation f	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMAC	Draw, De
		***************************************		····									
		6.	Document	t ID:	US 20	030022244	A 1						

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022244

PGPUB-FILING-TYPE: new

L1: Entry 6 of 19

DOCUMENT-IDENTIFIER: US 20030022244 A1

TITLE: Single chain antibody against mutant P53

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Solomon, Beka Herzlia Pituach IL
Cohen, Gerald Raanana IL
Govorko, Dimitri Herzlia IL

US-CL-CURRENT: <u>435/7.1</u>; <u>435/320.1</u>, <u>435/326</u>, <u>435/69.1</u>, <u>530/388.1</u>, 536/23.53

ABSTRACT:

More than 90% of mutations found in the p53 protein produce a conformational change in p53 which results in the exposure of an epitope, which is otherwise hidden in the hydrophobic core of the molecule. A single chain antibody (scFv) which specifically recognizes this common mutant epitope in mutant p53 but not in wild type p53 is disclosed. Also described are a DNA molecule encoding the scFv, pharmaceutical compositions comprising the antibody and methods of treatment using the pharmaceutical compositions.

Record List Display Page 5 of 13

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 7. Document ID: US 20020052311 A1

L1: Entry 7 of 19

File: PGPB

May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020052311

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020052311 A1

TITLE: Methods and compostions for the treatment and/or diagnosis of neurological

diseases and disorders

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Solomon, Beka Herzlia Pituach IL Frenkel, Dan Rehovot IL

US-CL-CURRENT: 514/2; 424/93.21

ABSTRACT:

A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization. The methods of the present invention also generally relates to treating and/or diagnosing neurological diseases and disorders of the central nervous, regardless of whether the disease or disorder is plaque-forming or non-plaque forming.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw, De

□ 8. Document ID: US 6703015 B1

L1: Entry 8 of 19 File: USPT Mar 9, 2004

US-PAT-NO: 6703015

DOCUMENT-IDENTIFIER: US 6703015 B1

TITLE: Filamentous bacteriophage displaying an .beta.-amyloid epitope

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Record List Display

Page 6 of 13

Solomon; Beka

Herzlia Pituach

 $_{
m IL}$

Frenkel; Dan

Rehovot

IL

US-CL-CURRENT: <u>424/93.2</u>; <u>435/320.1</u>

ABSTRACT:

A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g. Alzheimer's disease) which rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g. Alzheimer's disease) which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization.

11 Claims, 27 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 21

_										•			
1	Full	Title	Citation	Front	Review	Classification	Data	Reference	A Contract of	Alter Interits	Claims	MAGAC:	Draw Do
1			- Citation	1.011	11501500	CIBBBRICATION	Date	Mererence	90000000000000000000000000000000000000	Section Control	Clamin	None	D1200 D6
•													
******			·///			······································							

9. Document ID: US 6630584 B1

L1: Entry 9 of 19

File: USPT

Oct 7, 2003

US-PAT-NO: 6630584

DOCUMENT-IDENTIFIER: US 6630584 B1

TITLE: Single chain antibody against mutant p53

DATE-ISSUED: October 7, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Solomon; Beka Herzlia Pituach IL

Cohen; Gerald Raanana IL

Govorko; Dimitri Herzlia IL

US-CL-CURRENT: <u>536/24.5</u>; <u>424/130.1</u>, <u>424/133.1</u>, <u>424/135.1</u>, <u>424/138.1</u>, <u>424/139.1</u>, <u>424/141.1</u>, <u>424/152.1</u>, <u>424/155.1</u>, <u>424/156.1</u>, <u>424/172.1</u>, <u>424/174.1</u>, <u>530/387.1</u>, <u>530/387.3</u>, <u>530/387.7</u>, <u>530/387.9</u>, <u>530/388.8</u>, <u>530/388.85</u>

ABSTRACT:

More than 90% of mutations found in the p53 protein produce a conformational change in p53 which results in the exposure of an epitope, which is otherwise hidden in the hydrophobic core of the molecule. A single chain antibody (scFv) which specifically recognizes this common mutant epitope in mutant p53 but not in wild type p53 is disclosed. Also described are a DNA molecule encoding the scFv, pharmaceutical compositions comprising the antibody and methods of treatment using the pharmaceutical compositions.

Record List Display Page 7 of 13

6 Claims, 7 Drawing figures Exemplary Claim Number: 1,4 Number of Drawing Sheets: 7

Full Title Citation Front Review Classification Date Reference Security 213 June 145 Claims KWIC Draw De

□ 10. Document ID: US 5688651 A

L1: Entry 10 of 19 File: USPT Nov 18, 1997

US-PAT-NO: 5688651

DOCUMENT-IDENTIFIER: US 5688651 A

TITLE: Prevention of protein aggregation

DATE-ISSUED: November 18, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Solomon; Beka Herzlya II

US-CL-CURRENT: <u>435/7.1</u>; <u>424/130.1</u>, <u>436/63</u>, 530/388.1

ABSTRACT:

A method of selecting anti-aggregation molecules with chaperone-like activity that have characteristics including binding to a native target molecule epitope with a high binding constant and are non-inhibitory to the biological activity of the target molecule. The method molecules denaturating a target molecule in the presence of presumptative antiaggregation molecules to prevent the target molecules from self-or induced-aggregation. The nonaggregated target molecule coupled to the anti-aggregation molecule is then tested for bioactivity.

4 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Altachments	Claims	KWIC	Draw, De
	······································	***************************************		······································	······································	·····					 .

☐ 11. Document ID: US 4948836 A

L1: Entry 11 of 19 File: USPT Aug 14, 1990

US-PAT-NO: 4948836

DOCUMENT-IDENTIFIER: US 4948836 A

TITLE: Immobilized antibodies

DATE-ISSUED: August 14, 1990

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Solomon; BekaHerzellya PituachILHadas; EranRishon LezionILFleminger; GideonRehovotIL

US-CL-CURRENT: 525/54.1; 436/531, 436/532, 530/815, 530/816

ABSTRACT:

Antibodies which are immobilized and covalently bound to a matrix polymer by means of a modification in a carbohydrate region of the antibodies; wherein the binding of the antibodies is effected by condensing at least one aldehyde group in an oxidized carbohydrate region and at least one epoxide function of an epoxy-group-containing matrix polymer, said condensation being conducted in the presence of a bifunctional reagent which has, on one end position of a spacer unit having at least three members, an amino group capable of condensing with the aldehyde group, and which has on the other end position a group which reacts covalently with the epoxide function.

16 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Clas	sification Date Reference Sequences 3	cidinento Claims KVMC Draw De
		(
☐ 12. Document ID: US 3873	426 A	
L1: Entry 12 of 19	File: USPT	Mar 25, 1975

US-PAT-NO: 3873426

DOCUMENT-IDENTIFIER: US 3873426 A

TITLE: INSOLUBLE ENZYMES

DATE-ISSUED: March 25, 1975

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY
Katchalski; Ephraim Rehovot IL
Levin; Yehuda Tel-Aviv IL
Solomon; Beka Rehovot IL

US-CL-CURRENT: <u>435/176</u>

ABSTRACT:

Water-insoluble enzymes wherein the enzyme is stably retained on an alumina carrier are prepared by adsorbing the enzyme and a dye on an activated alumina carrier at a pH below about 7.

7 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 13. Document ID: JP 01165600 A

L1: Entry 13 of 19

File: JPAB

Jun 29, 1989

PUB-NO: JP401165600A

DOCUMENT-IDENTIFIER: JP 01165600 A

TITLE: IMMOBILIZED ANTIBODY AND ITS PRODUCTION

PUBN-DATE: June 29, 1989

INVENTOR-INFORMATION:

NAME

COUNTRY

SOLOMON, BEKA HADAS, ERAN

FLEMINGER, GIDEON

US-CL-CURRENT: <u>530/391.1</u>; <u>530/815</u>

INT-CL (IPC): CO7K 17/08; CO7K 17/06; GO1N 33/547; A61K 39/44; C12P 21/00

ABSTRACT:

PURPOSE: To obtain the antibody which maintains original effects as an antibody and high bond-ability to a carrier and are stable by binding the antibody in which the carbohydrate region is oxidized, with a matrix polymer containing epoxy functional groups in a specific manner.

CONSTITUTION: First, the hemiacetal group of carbonhydrates in the antibody is converted to a aldehyde group by oxidation with periodate. The aldehyde group of the oxidized carbohydrate region of the antibody and the epoxy group of the matrix polymer containing an epoxide group are bound in the presence of a bifunctional reagent which has, on one end of a spacer unit having at least three members, an amino group capable of condensing with the aldehyde group and, on the other end, a group of formula I which reacts covalently with the epoxy group, (wherein, A is a spacer unit; n is 0 or 1; X is formula II, III or the like; O is X-NH

COPYRIGHT: (C) 1989, JPO

Full	Title	Citation	Front	Review	Classification	Date	Reference	Control of Section	Attachments	Claims	KOMAC	Drain De
-	,							Silver of the State of the Stat	THE ASSESSMENT OF THE PARTY OF	- 18 min j		, 5 16 W 5 C
 ······································				·····	······································	·····						
	14.	Docum	ent ID	: WO	3104441 A2	2						
L1: E	ntry	14 of	19				File: E	PAB		Dec	18,	2003

PUB-NO: WO003104441A2

DOCUMENT-IDENTIFIER: WO 3104441 A2

TITLE: NOVEL BACTERIAL STRAIN, COMPOSITIONS DERIVED THEREFROM AND METHODS OF USING

SAME FOR TREATING BETA-AP-ASSOCIATED DESEASES

Record List Display Page 10 of 13

PUBN-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME COUNTRY

SOLOMON, BEKA IL ROSENBERG, EUGENE IL

INT-CL (IPC): C12 N 1/00

EUR-CL (EPC): A61K035/74; C07K014/195

ABSTRACT:

CHG DATE=20040413 STATUS=O>An isolated bacterial strain is provided. The isolated bacterial strain has a genome comprising a 16S nucleic acid sequence region being at least 97 % identical to SEQ ID NO: 1. Also provided are compositions derived from the isolated bacterial strains and methods of using same for treating betaAP-associated diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences 4ttac	in entr a (Haims	KWMC	Draw, De

☐ 15. Document ID: WO 3086310 A2

L1: Entry 15 of 19

File: EPAB

Oct 23, 2003

PUB-NO: WOO03086310A2

DOCUMENT-IDENTIFIER: WO 3086310 A2

TITLE: PREVENTION OF BRAIN INFLAMMATION AS A RESULT OF INDUCED AUTOIMMUNE RESPONSE

PUBN-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME COUNTRY

SOLOMON, BEKA II.

INT-CL (IPC): A61 K 0/

ABSTRACT:

CHG DATE=20040306 STATUS=O>A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors of the patient are blocked, preferably by administration of an effective amount of IVIg, prior to the procedure of causing the antibodies to come into contact with the amyloid.

Full	Title	Citation	Front	Review	Classification	Date Reference	Can appea	A STATE OF THE PARTY OF THE PAR	01 :	14000	
		ORBHOT	1 10116	11 E VIEVO	Classification	Date Reference			Claims	KUMU	Draw, De
										_	

Record List Display Page 11 of 13

☐ 16. Document ID: WO 3076455 A2

L1: Entry 16 of 19 File: EPAB

Sep 18, 2003

PUB-NO: WO003076455A2

DOCUMENT-IDENTIFIER: WO 3076455 A2

TITLE: IMMUNIZING COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST

THE SS-SECRETASE CLEAVAGE SITE OF AMYLOID PRECURSOR PROTEIN

PUBN-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME

COUNTRY

IL

SOLOMON, BEKA

INT-CL (IPC): <u>CO7</u> <u>K</u> <u>0</u>/

EUR-CL (EPC): A61K039/385; C07K016/18

ABSTRACT:

Full Title Citation Front Review Classification Date Reference Security 568 Attachments. Claims KMC Draw. De

☐ 17. Document ID: WO 3000719 A2

L1: Entry 17 of 19

File: EPAB

Jan 3, 2003

PUB-NO: WO003000719A2

DOCUMENT-IDENTIFIER: WO 3000719 A2

TITLE: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPITOPE OF A DEPOSIT-FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METHODS OF USING SAME

PUBN-DATE: January 3, 2003

INVENTOR-INFORMATION:

1774

NAME COUNTRY

SOLOMON, BEKA IL

INT-CL (IPC): C07 K 14/00

EUR-CL (EPC): C07K014/36; C07K014/465, C07K014/47 , C07K014/47 , C12N015/62

ABSTRACT:

CHG DATE=20040306 STATUS=0>The present invention relates to an antigenic product for inducing an immune response to a deposit-forming polypeptide, such as amyloid ss, which antigenic product is a multiple antigenic peptide (MAP) that contains multiple copies of an epitope of a deposit-forming polypeptide involved in a plaque-forming disease. This antigenic product can be formulated into an immunizing composition and used to elicit an immune response against a deposit-forming polypeptide involved in a plaque-forming disease or disorder.

Record List Display Page 12 of 13

Full Title Citation Front Review Classification Date Reference Sequences Alsonitaris: Claims KWC Draw De

☐ 18. Document ID: WO 2074243 A2

L1: Entry 18 of 19

File: EPAB

Sep 26, 2002

PUB-NO: WO002074243A2

DOCUMENT-IDENTIFIER: WO 2074243 A2

TITLE: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF NEUROLOGICAL

DISEASES AND DISORDERS

PUBN-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME

COUNTRY

SOLOMON, BEKA

IL

FRENKEL, DAN

IL

INT-CL (IPC): A61 K 0/

EUR-CL (EPC): A61K049/00; C07K016/18

ABSTRACT:

CHG DATE=20031112 STATUS=O>A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization. The methods of the present invention also generally relates to treating and/or diagnosing neurological diseases and disorders of the central nervous, regardless of whether the disease or disorder is plaque-forming or non-plaque forming.

Full	Title	Citation	Front	Review	Classification	Date	Reference	of perfects	Altackments	Claims	KOMC	Draw, De

☐ 19. Document ID: WO 9618900 A1

L1: Entry 19 of 19

File: EPAB

Jun 20, 1996

PUB-NO: WO009618900A1

DOCUMENT-IDENTIFIER: WO 9618900 A1

TITLE: PREVENTION OF PROTEIN AGGREGATION

PUBN-DATE: June 20, 1996

INVENTOR-INFORMATION:

NAME

COUNTRY

SOLOMON, BEKA

IL

Record List Display Page 13 of 13

INT-CL (IPC): $\underline{G01}$ \underline{N} $\underline{33}/\underline{53}$; $\underline{A61}$ \underline{K} $\underline{38}/\underline{00}$; $\underline{A61}$ \underline{K} $\underline{31}/\underline{66}$; $\underline{C12}$ \underline{N} $\underline{15}/\underline{00}$; $\underline{C12}$ \underline{P} $\underline{21}/\underline{06}$

ABSTRACT:

A method of selecting anti-aggregation molecules with chaperone-like activity that have characteristics including binding to a native target molecule epitope with a high binding constant and which are non-inhibitory to the biological activity of the target molecule when bound. The method includes the steps of mixing a denatured target molecule with a presumptive anti-aggregation molecule and then determining if the target molecules are prevented from self- or induced-aggregation. The nonaggregated target molecule coupled to the anti-aggregation molecule is then tested for bioactivity.

Full	Title Citation	Front Review	Classification	Date	Reference	Sequendes	Alta Firma	ils Claims	KWC	Drawi De
	-4							en e		
Clear	Gener	ate Collection	Print	F	wd Refs	Bkwo	l Refs	Gener	ate OA	.cs 🌼
	Terms					Docume	ents	· · · · · · · · · · · · · · · · · · ·		
	(Solomon-I	Beka.IN.)							19	

Display Format: - Change Format

<u>Previous Page</u> <u>Next Page</u> <u>Go to Doc#</u>

Hit List



Search Results - Record(s) 1 through 20 of 20 returned.

☐ 1. Document ID: WO 7901121 A1

L2: Entry 1 of 20

File: EPAB

Dec 27, 1979

PUB-NO: WO007901121A1

DOCUMENT-IDENTIFIER: WO 7901121 A1

TITLE: PROCESS FOR SEPARATING BLOOD CELL-CONTAINING LIQUID SUSPENSIONS BY

FILTRATION

PUBN-DATE: December 27, 1979

INVENTOR-INFORMATION:

NAME COUNTRY
FRIEDMAN, L US
LYSAGHT, M US
CASTINO, F US
SOLOMON, B US

US-CL-CURRENT: 210/195.2; 604/FOR.102 INT-CL (IPC): B01D 13/00; A61M 5/00

EUR-CL (EPC): A61M001/34

ABSTRACT:

CHG DATE=19990617 STATUS=0>A blood cell-containing liquid suspension is separated into a cell-containing fraction and a cell-free fraction by filtration. The suspension, under pressure, is conducted in laminar flow across the surface of a microporous membrane (18, 118) along a flow path (12, 112) which is substantially parallel to the upstream side of the membrane (18, 118), the cell-containing fraction being recovered from the outlet end (16, 116) of the flow path (12, 112) and the cell-free fraction being recovered as filtrate (24, 124). The process is carried out under conditions providing a high filtration rate per are a of membrane (18, 118) without causing damage to the blood cells. This is done by controlling the membrane wall shear rate of the suspension along the flow path (12, 112) so that such shear rate is sufficiently high to induce axial cell migration and inhibit interactions of the cells with the membrane surface (18, 118) at the requisite pressure conditions. Such shear rate is also maintained sufficiently low so as not to itself induce damage of the cells. Useful applications of the process include the separation of plasma from whole blood in a continuous flow plasmapheresis procedure, and the removal of cryoprotective agents from previously frozen, thawed preparations of red blood cells, white blood cells, or platelets.

Document ID: US 20040214564 A1

L2: Entry 2 of 20

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2004-820263

DERWENT-WEEK: 200481

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Wide area network access point evaluating method for use by e.g. development engineer, involves transmitting performance evaluation data from virtual station to access point under test and recovering performance data from point

INVENTOR: ROSEN, D; SOLOMON, B

PRIORITY-DATA: 2003US-0424161 (April 25, 2003)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES MAIN-IPC

US 20040214564 A1

October 28, 2004

006

H04Q007/20

INT-CL (IPC): $\underline{H04}$ Q $7/\underline{20}$

ABSTRACTED-PUB-NO: US20040214564A

BASIC-ABSTRACT:

NOVELTY - The method involves creating a virtual station for a wide area network access point under test (28). Performance evaluation data is transmitted from the virtual station to the access point. The performance data is recovered from the access point and stored in a log and statistics file (30). A virtual station creating mechanism is employed to create a differential virtual station for association with the access point.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a test environment for evaluating a local area network.

USE - Used for evaluating a wireless local area network access point by a development engineer, network administrator and network testing organization.

ADVANTAGE - The method efficiently provides variable and realistic network load conditions, and allows the network builders to quickly determine the efficiency and capacity of the access point under test. The method makes the network configuration adjustments to optimize overall performance of the network.

DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram illustrating internal functional units of a load emulator and connections of the load emulator to a command and report computer and to an access point under test.

Command report computer 22

Load emulator 24

Access point under test 28

Input/output controller 32

Log and statistics file 36

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claim	s KWMC	Draw, De

☐ 3. Document ID: AU 2003288508 A1, US 20040120570 A1, WO 2004059567 A2

L2: Entry 3 of 20

File: DWPI

Jul 22, 2004

DERWENT-ACC-NO: 2004-524681

DERWENT-WEEK: 200476

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Automatic optical inspection system for article e.g. printed circuit board, has integrated automatic apparatus and controller that transfers article to be inspected between inspection, verification and correction locations

INVENTOR: ASPIR, D; BERNARD, S ; FRIDMAN, E ; LEVI, M ; SOLOMON, B

PRIORITY-DATA: 2002US-0327115 (December 24, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003288508 A1	July 22, 2004		000	G06K009/00
US 20040120570 A1	June 24, 2004		012	G06K009/00
WO 2004059567 A2	July 15, 2004	E	000	G06K009/00

INT-CL (IPC): $\underline{G01}$ \underline{N} $\underline{21}/\underline{00}$; $\underline{G06}$ \underline{K} $\underline{9}/\underline{00}$

ABSTRACTED-PUB-NO: US20040120570A

BASIC-ABSTRACT:

NOVELTY - The system has an integrated automatic apparatus with an automatic optical inspection (AOI) device (20), verification device (22) and defect corrector (24) for inspecting, evaluating and correcting possible defects in an article (10) e.g. printed circuit board (PCB), respectively. A controller (280) on operation transfers the article to be inspected between an AOI location and a verification and correction location.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method for manufacture of printed circuit board.

USE - Used for inspecting article e.g. printed circuit board (PCB), flat panel display (FPD), chip interconnect packaging (ICP).

ADVANTAGE - The integrated apparatus provides the possibility of inspection, verification and correction of the article e.g. printed circuit board (PCB) in a single integrated station, thereby improving the throughput of AOI systems and hence increases the flexibility in the manufacturing process by diminishing or eliminating bottlenecks in the manufacturing flow.

DESCRIPTION OF DRAWING(S) - The drawing shows a simplified pictorial illustration of a system for automatic optical inspection, verification and correction of articles.

Article 10

Record List Display Page 4 of 25

Chassis 14

Automatic optical inspection (AOI) device 20

Verification device 22

Defect corrector 24

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

4. Document ID: US 20040013647 A1

L2: Entry 4 of 20

File: DWPI

Jan 22, 2004

DERWENT-ACC-NO: 2004-108188

DERWENT-WEEK: 200411

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Treating neurological disease CNS e.g., Alzheimer's disease, by displaying therapeutic molecule capable of treating the disease on viral display vehicle which is then administered to subject through olfactory system

INVENTOR: FRENKEL, D; SOLOMON, B

PRIORITY-DATA: 2003US-0384788 (March 11, 2003), 1999US-152417P (September 3, 1999), 1999US-0473653 (December 29, 1999), 2000US-0629971 (July 31, 2000), 2000WO-IL00518 (August 31, 2000), 2001US-0808037 (March 15, 2001), 2001US-0830954 (August 7, 2001), 2002US-371735P (April 12, 2002), 2002US-0162889 (June 6, 2002)

PATENT-FAMILY:

 PUB-NO
 PUB-DATE
 LANGUAGE
 PAGES
 MAIN-IPC

 US 20040013647 A1
 January 22, 2004
 068
 A61K048/00

INT-CL (IPC): <u>A61 K 48/00</u>

ABSTRACTED-PUB-NO: US20040013647A

BASIC-ABSTRACT:

NOVELTY - Treating (M1) a neurological disease or disorder of the central nervous system (CNS), involves displaying a therapeutic molecule capable of treating the neurological disease or disorder of the CNS on a viral display vehicle (I); and introducing (I) into a subject by applying (I) displaying the therapeutic molecule to an olfactory system of the subject.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a pharmaceutical composition (II) for treating a neurological disease or disorder of CNS comprising a carrier and (I) displaying a therapeutic molecule and being capable of treating a neurological disease or disorder of the CNS;
- (2) diagnosing (M2) the presence or extent of a neurological disease or disorder of CNS by in vivo imaging, involves displaying on (I) a diagnostic agent capable of being detected by in vivo imaging, introducing (I) into a subject by applying (I) displaying the diagnostic agent to an olfactory system of the subject, and detecting the displayed diagnostic agent in the subject by in vivo imaging to disease the presence or extent of the neurological disease or disorder;

(3) a pharmaceutical composition for diagnosing the presence or extent of a neurological disease or disorder of CNS comprising a carrier and (I) which displays a diagnostic agent capable of being detected by in vivo imaging;

- (4) delivering (M3) a molecule to CNS, involves displaying the molecule on (I), and introducing (I) into a subject by applying (I) displaying the molecule to an olfactory system of the subject;
- (5) preparing a papillomavirus-like particle display vehicle for treating a plaque-forming disease, involves inserting into the nucleic acid encoding papillomavirus major capsid protein L1 a polynucleotide sequence encoding a polypeptide representing at least one epitope of an aggregating protein associated with plaque forming in the plaque-forming disease, where the at least one peptide is displayed by the papillomavirus-like particle display vehicle and is capable of eliciting antibodies capable of disaggregating the aggregating protein and/or inhibiting aggregation of the aggregating protein; and
- (6) an immunizing composition, comprising a carrier, diluent, excipient or auxiliary agent and papillomavirus-like particle display vehicle displaying a polypeptide representing at least one epitope of an aggregating protein associated with plaque formation in a plaque-forming disease, where at least one epitope is capable of eliciting antibodies capable of disaggregating the aggregating protein and/or inhibiting aggregation of the aggregating protein.

ACTIVITY - Nootropic; Neuroprotective; Antimicrobial; Cytostatic; Anticonvulsant; Virucide.

MECHANISM OF ACTION - Vaccine; Inhibitor of aggregation of aggregating protein.

The anti-aggregating epitope within beta -amyloid peptide (AP) (Glu-Phe-Arg-His) map to positions 3-6 of the amino acid sequence of beta AP. In order to generate specific immune response against beta AP, mice were immunized with genetically engineered fd phage carrying the peptide Tyr-Tyr-Glu-Phe-Arg-His fused to its minor coat gpIII. Doses of 1010 phage particles per injection were used to immunize, at 14-day intervals, through intraperitoneal injection. Following 7 days of each injection, mice were bled and their sera tested by enzyme linked immunosorbent assay (ELISA) for IgG antibody reactivity against wild-type phage (not bearing the peptide Tyr-Tyr-Glu-Phe-Arg-His (on its surface) and against beta AP. This route of administration had a very high response against beta AP (1:750) following the third injection. Furthermore, it was found that injection through phage carrying epitope is long lasting, it is non-toxic and may be given without adjuvant. The phage vector was found to be an immunogenic tool to raise a high affinity immune response within 14 days from the first injection.

USE - (M1) is useful for treating a neurological disease or disorder of CNS such as a plaque-forming disease such as Alzheimer's disease, late onset Alzheimer's disease, presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic syndrome, senility, multiple myeloma, scrapie, bovine spongiform encephalopathy (BSE), kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Streussler-Sheinker disease (GSS) or fatal familial insomnia (FFI). (M1) is also useful for treating a non-plaque-forming disease or disorder chosen from Huntington's chorea, viral infections of the brain, brain tumors, lysosomal storage diseases which cause neurodegeneration and are manifested by enzyme deficiencies, and multiple sclerosis. The non-plaque-forming disease or disorder is associated with the formation of Lewy bodies. (M2) is useful for diagnosing the presence or extent of a neurological disease or disorder of CNS e.g., plaque-forming disease or disorder such as Alzheimer's disease, by in vivo imaging such as magnetic resonance imaging (MRI). The plaque-forming disease or disorder is associated with the presence of a scrapie isoform (PrPSc) of prion protein in plaques and the targeting agent is a

Record List Display Page 6 of 25

polypeptide comprising an immunological portion of an antibody that binds at least one epitope of prion protein (all claimed).

DESCRIPTION OF DRAWING(S) - The figure shows the serum IgG titer of different bleeds from mice immunized with f3 filamentous phage displaying Glu-Phe-Arg-His epitope of beta -amyloid peptide as a fusion of phage glycoprotein III.

Full Title Citation Front Review Classification Date Reference Sequences Affachments Claims KWIC Draw De

5. Document ID: AU 2003233175 A1, WO 2003104441 A2

L2: Entry 5 of 20

File: DWPI

Dec 22, 2003

DERWENT-ACC-NO: 2004-062356

DERWENT-WEEK: 200445

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New bacterial strain having a genome comprising a 16S nucleic acid sequence region and having all identifying characteristics of the AZ4 strain, useful for preparing a composition for treating a beta-amyloid associated disease

INVENTOR: ROSENBERG, E; SOLOMON, B

PRIORITY-DATA: 2002US-386712P (June 10, 2002)

PATENT-FAMILY:

 PUB-NO
 PUB-DATE
 LANGUAGE
 PAGES
 MAIN-IPC

 AU 2003233175 A1
 December 22, 2003
 000
 C12N001/00

 WO 2003104441 A2
 December 18, 2003
 E
 055
 C12N001/00

INT-CL (IPC): <u>C12</u> <u>N</u> <u>1/00</u>

ABSTRACTED-PUB-NO: WO2003104441A

BASIC-ABSTRACT:

NOVELTY - An isolated bacterial strain comprising a genome comprising a 16S nucleic acid sequence region being at least 97 % identical to a 1473-base pair (bp) sequence, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) a bacterial strain having a genome including a 16S nucleic acid sequence region being at least 97 % identical to 1473-bp sequence;
- (2) an isolated nucleic acid being at least 97 % identical to the 1473-bp sequence;
- (3) an oligonucleotide that is specifically hybridizable with the isolated nucleic acid;
- (4) a composition of matter comprising an intracellular or secreted fraction of a bacterial strain having a genome including a 16S nucleic acid sequence region being at least 97 % identical to the 1473-bp sequence;
- (5) obtaining a composition capable of preventing beta-amyloid peptide self-

Record List Display Page 7 of 25

assembly and/or of disassembling pre-assembled beta-amyloid peptide aggregates;

- (6) purifying agents capable of preventing beta-amyloid self-assembly and/or of disassembling pre-assembled beta-amyloid aggregates;
- (7) treating a beta-amyloid associated disease in a subject; and
- (8) a pharmaceutical composition for preventing beta-amyloid peptide self-assembly and/or disassembling pre-assembled beta-amyloid peptide comprising the intracellular or secreted fraction of a bacterial strain having a genome including the 16S nucleic acid sequence region or the anthranilic acid and/or cyclic tyrosylproline and a carrier or diluent.

ACTIVITY - Nootropic; Neuroprotective. No biological data given.

MECHANISM OF ACTION - Gene Therapy. No biological data given.

USE - The bacterial strain having a genome comprising a 16S nucleic acid sequence region is useful for preparing a composition for treating a beta -amyloid associated disease (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De

6. Document ID: AU 2003226356 A1, WO 2003086310 A2

L2: Entry 6 of 20

File: DWPI

Oct 27, 2003

DERWENT-ACC-NO: 2003-865302

DERWENT-WEEK: 200436

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Preventing and treating a disease e.g. Alzheimer's disease associated with amyloid aggregation comprises contacting the antibodies against a peptide component with aggregated or soluble amyloid

INVENTOR: SOLOMON, B

PRIORITY-DATA: 2002US-371719P (April 12, 2002)

PATENT-FAMILY:

 PUB-NO
 PUB-DATE
 LANGUAGE
 PAGES
 MAIN-IPC

 AU 2003226356 A1
 October 27, 2003
 000
 A61K000/00

 WO 2003086310 A2
 October 23, 2003
 E
 007
 A61K000/00

INT-CL (IPC): A61 K 0/00

ABSTRACTED-PUB-NO: WO2003086310A

BASIC-ABSTRACT:

NOVELTY - Preventing and treating a disease associated with amyloid aggregation comprising contacting antibodies against a peptide component of an amyloid deposit with aggregated or soluble amyloid, where the antibody diminishes the improvement of inflammation by blocking Fc receptor prior to the contacting with amyloid, is new.

ACTIVITY - Nootropic; Neuroprotective; CNS-Gen.; Antiparkinsonian; Anti-HIV. No biological data given.

MECHANISM OF ACTION - Fc receptor blocker. No biological data given.

USE - The method is used for the prevention and treatment of central nervous system disorders and Alzheimer's disease characterized by amyloid aggregation in a patient (claimed). The method is also useful for treating neurodegenerative disease, e.g. Parkinson's disease, multiple sclerosis, AIDS dementia complex and amyotropic lateral sclerosis.

ADVANTAGE - The antibody diminishes the improvement of inflammation by blocking Fc receptor prior to the contacting with amyloid.

Full	Title	Citation	Front	Review	Classification	Date	Reference	SAMPLE NEW	Stietelaufelee	Claims	KWIC	Draw, De
······································												

7. Document ID: EP 1480666 A2, WO 2003076455 A2, AU 2003225636 A1

L2: Entry 7 of 20

File: DWPI

Dec 1, 2004

DERWENT-ACC-NO: 2003-865017

DERWENT-WEEK: 200478

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Immunizing composition, useful for treating Alzheimer's disease by inhibiting processing of amyloid precursor protein, also antibodies for passive immunization

INVENTOR: SOLOMON, B

PRIORITY-DATA: 2002US-361344P (March 5, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1480666 A2	December 1, 2004	E	000	A61K038/00
WO 2003076455 A2	September 18, 2003	E	076	C07K000/00
AU 2003225636 A1	September 22, 2003		000	C07K000/00

INT-CL (IPC): $\underline{A61}$ \underline{K} $\underline{38/00}$; $\underline{A61}$ \underline{K} $\underline{38/04}$; $\underline{A61}$ \underline{K} $\underline{39/395}$; $\underline{A61}$ \underline{K} $\underline{39/40}$; $\underline{A61}$ \underline{K} $\underline{39/42}$; $\underline{C07}$ \underline{K} $\underline{0/00}$; $\underline{C07}$ \underline{K} $\underline{16/00}$

ABSTRACTED-PUB-NO: WO2003076455A

BASIC-ABSTRACT:

NOVELTY - Immunizing composition (A) comprising:

- (i) an antigenic product (I) which induces an immune response against the beta secretase cleavage site of amyloid precursor protein (APP); and
- (ii) a carrier, diluent, excipient, adjuvant or auxiliary, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) molecule (II) comprising the antigen-binding part of an antibody (Ab) directed against the beta -secretase cleavage site of APP;

Record List Display Page 9 of 25

(2) filamentous bacteriophage (FB) that displays (II), where this is a single-chain Ab, on its surface; and

(3) composition containing FB.

ACTIVITY - Nootropic; Neuroprotective.

Amyloid precursor protein (APP)-transgenic mice were immunized with an 8-branched dendritic polymer linked to the APP epitope (iii), in presence of Freund's adjuvant (dose not specified), once every 2 weeks. After 5 months of this treatment, brain slices were analyzed by the ThS plaque staining protocol. Plaque numbers were about 50 for immunized mice and over 150 for non-immunized controls.

Ile-Ser-Glu-Val-Lys-Leu-Asp-Ala (iii).

MECHANISM OF ACTION - Vaccine or passive immunization; inhibiting cleavage of amyloid precursor protein, thus preventing formation of beta -amyloid.

USE - (A) is used to induce an immune response against the beta -secretase cleavage site of amyloid precursor protein, specifically for treatment and prevention of Alzheimer's disease (AD). A molecule (II) that contains the antigen-binding part of an antibody (Ab) directed against the cleavage site, or a filamentous phage that displays such an Ab (as a single-chain molecule) can be used similarly, for passive immunization. Also, detecting an immune response to the specified cleavage site can be used to monitor treatment of AD.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments	Claims	KWIC	Draw, De

□ 8. Document ID: US 20030061469 A1

L2: Entry 8 of 20

File: DWPI

Mar 27, 2003

DERWENT-ACC-NO: 2003-503727

DERWENT-WEEK: 200347

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Front-end unit for processor, has instruction cache system whose output is coupled to segment builder that is selectively disabled by access filter coupled to input of cache system

INVENTOR: RONEN, R; SOLOMON, B

PRIORITY-DATA: 2001US-0961202 (September 24, 2001)

PATENT-FAMILY:

PUB-NO PUB-DATE LANGUAGE PAGES MAIN-IPC

<u>US 20030061469 A1</u> March 27, 2003 010 G06F009/30

INT-CL (IPC): $\underline{G06} + \underline{9/30}$

ABSTRACTED-PUB-NO: US20030061469A

BASIC-ABSTRACT:

NOVELTY - An instruction cache system has an input for new addresses and an output for decoded instructions. A segment builder having an input coupled to the cache

Record List Display Page 10 of 25

system's output, is disabled selectively by an access filter coupled to the cache system's input. A segment cache is coupled to the segment builder.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) cache hit control method;
- (2) cache; and
- (3) access filter.

USE - Front-end unit for processor.

ADVANTAGE - The access filter selectively enables or disables segment builders within the front-end, to ensure that only instruction segments that are likely to be reused by program flow is stored in the segment cache, thereby achieving power conservation.

DESCRIPTION OF DRAWING(S) - The figure shows the processor conservation method.

Full Title Citation Front Review Classification Date Reference Sequences Attechments Claims KWIC Draw, De

9. Document ID: US 20030009620 A1

L2: Entry 9 of 20

File: DWPI

Jan 9, 2003

DERWENT-ACC-NO: 2003-267135

DERWENT-WEEK: 200326

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Front end processing system for mobile computing application, has instruction processing system whose enable control input is coupled to hit/miss output of UOP cache connected to instruction cache

INVENTOR: ORENSTIEN, D; RONEN, R; SOLOMON, B

PRIORITY-DATA: 2001US-0892566 (June 28, 2001)

PATENT-FAMILY:

PUB-NO PUB-DATE LANGUAGE PAGES MAIN-IPC

<u>US 20030009620 A1</u> January 9, 2003 011 G06F012/00

INT-CL (IPC): $\underline{G06} + \underline{12/00}$

ABSTRACTED-PUB-NO: US20030009620A

BASIC-ABSTRACT:

NOVELTY - The system has a UOP cache (240) and an instruction cache (210) inputs which are coupled to a common addressing input. An instruction processing system comprising instruction synchronizer (220) and an instruction decoder(230), is in communication with the instruction cache, and has an enabling control input coupled to the hit/miss output of the UOP cache

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for cache.

USE - For execution of program in processors used in mobile computing applications.

Record List Display Page 11 of 25

ADVANTAGE - The instruction processing system enables and disables internal circuits of processor based on output received from UOP cache, thereby the power consumed by front end unit of processor is reduced.

DESCRIPTION OF DRAWING(S) - The figure shows the block diagram of front end unit of processor.

Instruction cache 210

instruction synchronizer 220

instruction decoder 230

UOP cache 240

Full	Title	Citation	Front I	Review	Classification	Date	Reference	Sequences	Altachments	Claims	KWC	Draw, De
			*									
	10.	Docum	nent ID:	US 2	2005005357	75 A1	, WO 200	03000719 A	A2, EP 1397	7380 A2	2, AU	
20	023104	74 A1										

L2: Entry 10 of 20

File: DWPI

Mar 10, 2005

DERWENT-ACC-NO: 2003-239139

DERWENT-WEEK: 200519

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Antigenic product has dendritic polymer built on core molecule having terminal functional groups to which antigenic peptide that has epitope of deposit-forming polypeptide involved in plaque-forming disease is joined

INVENTOR: MCINNIS, P; SOLOMON, B

PRIORITY-DATA: 2002US-371717P (April 12, 2002), 2001US-299201P (June 20, 2001), 2004US-0481642 (August 13, 2004)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20050053575 A1	March 10, 2005		000	A61K039/00
WO 2003000719 A2	January 3, 2003	E	070	C07K014/00
EP 1397380 A2	March 17, 2004	E	000	C07K014/00
AU 2002310474 A1	January 8, 2003		000	C07K014/00

INT-CL (IPC): A61 K 39/00; C07 K 14/00; C08 G 63/48; C08 G 63/91

ABSTRACTED-PUB-NO: WO2003000719A

BASIC-ABSTRACT:

NOVELTY - An antigenic product (A) comprising a dendritic polymer built on a core molecule which is at least difunctional to provide branching and containing up to 16 terminal functional groups to which an antigenic peptide that comprises an epitope of a deposit-forming polypeptide involved in plaque-forming disease or disorder is joined by covalent bonds, is new.

Record List Display Page 12 of 25

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an immunizing composition comprising (I) and a carrier, excipient, adjuvant, or auxiliary agent.

ACTIVITY - Nootropic; Neuroprotective; Antiinflammatory.

MECHANISM OF ACTION - Vaccine; Modulator of A beta metabolism.

Multiple antigenic peptide (MAP)-Tyr-Tyr-Glu-Phe-Arg-His-Asp-Ser was biotinylated, and the biotinylated antigen was added to streptavidin in four portions in tubes during each 30 minutes. The tubes were incubated at room temperature with gentle shaking. The streptavidin, MAP-Tyr-Tyr-Glu-Phe-Arg-His-Asp-Ser molar ratio was 1:4. After incubation, the mix was dialyzed against phosphate buffer saline (PBS) or H2O. Two female mice 8 weeks old (named G and H) were immunized at approximately two week intervals with the streptavidin and biotinylated MAP-Tyr-Tyr-Glu-Phe-Arg-His-Asp-Ser complex (100 micro g of MAP-Tyr-Tyr-Glu-Phe-Arg-His-Asp-Ser per mouse) by intraperitoneal injection without adjuvant. The complex was injected on day 0, 15, 34, 48 and 62. Enzyme linked immunosorbent assay (ELISA) was carried out against the EFRH-epitope at various dilutions. Immunization with the complex of streptavidin and biotinylated MAP-Tyr-Tyr-Glu-Phe-Arg-His-Asp-Ser, produced a good immune response.

USE - (A) Is useful for eliciting an immune response against a deposit-forming polypeptide involved in a plaque-forming disease or disorder, by administering (A) to a subject in need of it. The occurrence, symptoms or progression of the plaqueforming disease is treated or inhibited by (A). The plaque-forming disease is Alzheimer's disease, early onset Alzheimer's disease, late onset Alzheimer's disease, presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-Jakob disease, Kuru, Gerstmann-Straussler-Scheinker disease, fatal familial insomnia, scrapie or bovine spongiform encephalitis (claimed.) (A) Is useful for the prevention, inhibition of formation, and/or reabsorption of deposits of a plaque-forming disease such as against A beta in Alzheimer's disease. (A) Is useful in various diagnostic tests, including radioimmunoassay, precipitation, complement fixation, direct and indirect immunofluoresence, agglutination or enzyme linked immunoassay. (A) Is useful for treating patient susceptible to, or at risk of plaque-forming disease such as Alzheimer's disease, to eliminate or reduce the risk, lessen the severity, or delay the onset of the disease, including biochemical, histologic and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presented during development of the disease. (A) Is also useful for reducing or eliminating myocognitive impairment in patients who have not yet developed characteristic Alzheimer's pathology.

ADVANTAGE - (A) Has superior immunological response compared with that obtained by immunization with either the full length amyloid beta peptide (A beta P) or the EFRG epitope displayed on the surface of a filamentous bacteriophage in the range of hundreds to thousands of copies per phage. Dendritic polymer serve as a carrier for two or more different antigens.

DESCRIPTION OF DRAWING(S) - The drawing shows a schematic representation of multiple antigenic peptide (MAP) on octa-branched homo Wang resin.

Full Title Citation Front Review Classification	Date Reference Sergistricas A	hadanerik:	Claims	KWAC	Drawd De
☐ 11. Document ID: US 6854033 B	2, US 20030005230 A1	***************************************			***************************************
L2: Entry 11 of 20	File: DWPI	-	Feb	8,	2005

DERWENT-ACC-NO: 2003-352963

Record List Display Page 13 of 25

DERWENT-WEEK: 200511

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Data caching method in computer system, involves storing pair of pointers pointing different data lines, in tag cache and block data array respectively

INVENTOR: MENDELSON, A; SOLOMON, B

PRIORITY-DATA: 2001US-0895693 (June 29, 2001)

PATENT-FAMILY:

 PUB-NO
 PUB-DATE
 LANGUAGE
 PAGES
 MAIN-IPC

 US 6854033 B2
 February 8, 2005
 000
 G06F012/08

 US 20030005230 A1
 January 2, 2003
 014
 G06F012/00

INT-CL (IPC): G06 F 12/00; G06 F 12/08

ABSTRACTED-PUB-NO: US20030005230A

BASIC-ABSTRACT:

NOVELTY - A tag which identifies block of data, is stored in a cache (230). A pointer pointing a data line in a block data array, is stored in the tag cache and another pointer pointing different data line is stored in block data array.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) data caching system; and
- (2) computer readable medium storing data caching program.

USE - For caching data in computer system.

ADVANTAGE - Provides an enhanced method which organizes tags and data blocks of variable length in cache resulting in more efficient use of hardware space and higher cache hit ratio.

DESCRIPTION OF DRAWING(S) - The figure shows a block diagram of the computer system.

cache 230

	Full	Title	Citation	Front	Review	Classification	Date	Reference	State of Company	s distribution is	Claims	KOMO	Draint De
-										W. W	0.051	100010	01500 00

12. Document ID: AU 2002252373 A1, WO 200274243 A2, EP 1379282 A2

L2: Entry 12 of 20

File: DWPI

Oct 3, 2002

DERWENT-ACC-NO: 2003-040542

DERWENT-WEEK: 200432

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Treating or diagnosing neurological diseases of the central nervous system, e.g. Alzheimer's disease, comprises displaying a polypeptide or diagnostic agent on viral display vehicle and introducing or detecting the display vehicle

Record List Display Page 14 of 25

INVENTOR: FRENKEL, D; SOLOMON, B

PRIORITY-DATA: 2001US-0808037 (March 15, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2002252373 A1	October 3, 2002		000	A61K000/00
WO 200274243 A2	September 26, 2002	E	214	A61K000/00
EP 1379282 A2	January 14, 2004	E	000	A61K049/00

INT-CL (IPC): A61 K 0/00; A61 K 49/00

ABSTRACTED-PUB-NO: WO 200274243A

BASIC-ABSTRACT:

NOVELTY - Treating (M1) a neurological disease or disorder of the central nervous system (CNS), comprises:

- (i) displaying a therapeutic molecule capable of treating the neurological disease or disorder on a viral display vehicle; and
- (ii) introducing the viral display vehicle into a subject by applying an amount of the viral display vehicle to the olfactory system to treat the neurological disease or disorder.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) diagnosing (M2) the presence or extent of the neurological disease or disorder of the CNS by in vivo imaging, comprising:
- (a) displaying on the viral display vehicle a diagnostic agent capable of being detected by in vivo imaging;
- (b) introducing the viral display vehicle into the subject by applying the viral display vehicle having the diagnostic agent to the olfactory system of the subject; and
- (c) detecting the displayed diagnostic agent in the subject by in vivo imaging to diagnose the presence or extent of the neurological disease or disorder; and
- (2) pharmaceutical compositions for treating or diagnosing the presence or extent of a neurological disease or disorder of the CNS, comprising a carrier and an amount of the viral display vehicle.

ACTIVITY - Cerebroprotective; Virucide; Cytostatic; Neuroprotective; Nootropic; Anticonvulsant; Antiparkinsonian; Immunostimulant.

No biological data given.

MECHANISM OF ACTION - Vaccine; Gene therapy.

No biological data provided.

USE - The method is useful in preventing, treating and diagnosing neurological diseases or disorders of the central nervous system, such as Alzheimer's disease, multiple myeloma, scrapie, kuru, Creutzfeld-Jakob Disease, Huntington's chorea, viral infections of the brain, brain tumors, lysosomal storage diseases, Parkinson's disease or multiple sclerosis (claimed). The method may also be used

for rapid and cost-effective screening of products, such as pharmaceuticals, foods, cosmetics or any materials that might contain prions.

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 13. Document ID: US 6630584 B1, WO 200168801 A2, AU 200139517 A, EP 1272609 A2, US 20030022244 A1

L2: Entry 13 of 20

File: DWPI

Oct 7, 2003

DERWENT-ACC-NO: 2001-590047

DERWENT-WEEK: 200374

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Novel single chain antibody molecule specifically recognizing common mutant epitope in mutant p53 but not in wild-type p53, and polynucleotides encoding antibodies, useful for preparing medicament for treating cancer

INVENTOR: COHEN, G; GOVORKO, D; SOLOMON, B

PRIORITY-DATA: 2000US-0526738 (March 16, 2000), 2002US-0247488 (September 20, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6630584 B1</u>	October 7, 2003		000	C12P021/08
WO 200168801 A2	September 20, 2001	E	046	C12N000/00
AU 200139517 A	September 24, 2001		000	C12N000/00
EP 1272609 A2	January 8, 2003	E	000	C12N001/00
US 20030022244 A1	January 30, 2003		000	G01N033/53

INT-CL (IPC): $\underline{A61}$ \underline{K} $\underline{39/395}$; $\underline{A61}$ \underline{K} $\underline{39/40}$; $\underline{C07}$ \underline{H} $\underline{21/04}$; $\underline{C07}$ \underline{K} $\underline{16/18}$; $\underline{C07}$ \underline{K} $\underline{16/40}$; $\underline{C12}$ \underline{N} $\underline{0/00}$; $\underline{C12}$ \underline{N} $\underline{1/00}$; $\underline{C12}$ \underline{N} $\underline{5/06}$; $\underline{C12}$ \underline{P} $\underline{21/02}$; $\underline{C12}$ \underline{P} $\underline{21/08}$; $\underline{G01}$ \underline{N} $\underline{33/53}$

ABSTRACTED-PUB-NO: WO 200168801A

BASIC-ABSTRACT:

NOVELTY - A single chain antibody (scFv) molecule (I) which specifically recognizes the common mutant epitope in mutant p53 but not in wild-type p53, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a DNA molecule (II) encoding (I);
- (2) a DNA molecule (III) where one or more nucleotides of (II) encoding ME1 scFv (i.e. (I)), have been added to, deleted from or substituted, the antibody encoded by (III) specifically recognizes the common mutant epitope in mutant p53 but not in wild-type p53;
- (3) a vector (IV) comprising (I);
- (4) a host cell (V) containing (IV);
- (5) a pharmaceutical composition comprising (I), (II) or (IV) and an excipient; and

Record List Display Page 16 of 25

(6) an immunodiagnostic kit for detecting presence of mutant p53 comprising (I).

ACTIVITY - Cytostatic.

No biological data is given.

MECHANISM OF ACTION - Gene therapy.

USE - (I), (II), (IV) are useful in the preparation of the pharmaceutical composition for treating a patient suffering from a disease whose etiology is related to a mutation in the p53 gene, e.g. cancer (claimed). (I) can serve as a valuable research and diagnostic tool, allowing specific tagging of mutant p53 molecules inside the cell.

ADVANTAGE - (I) serves as a powerful auxiliary agent capable of specifically enhancing the specificity and effectiveness of the two major existent anti-cancer gene therapies. Expression of the scFv ME1 molecules as an intrabody fused to the F-box domain responsible for the targeting of the cell proteins to the degradation cascade may be capable of significantly reducing the level of mutant p53 in the cell, thereby broadening the range of possible tumor targets for the original therapy. The substitution of the original antibody by the scFv ME1 specific to the mutant form of p53 may restrict the therapeutic effect to cancer cells only, allowing a systemic application of this therapy. (I) has high specificity, towards the peptide epitope which appears only in mutant variants of p53, lacks the Fc portion which binds specifically to the antigen, and has high permeability in the cells, and thus is suitable probe for immunodiagnostic clinical detection of mutant p53 in tissues using conventional immunohistochemistry techniques.

Full	Title	Citation	Front	Review	Classification	Date	Reference	200100	-trechments	Claims	KMC	Drawi De

14. Document ID: US 20040052766 A1, WO 200118169 A2, AU 200067232 A, EP 1180938 A2, US 20020052311 A1, JP 2003509020 W, US 20030077252 A1, US 6703015 B1

L2: Entry 14 of 20

File: DWPI

Mar 18, 2004

DERWENT-ACC-NO: 2001-244564

DERWENT-WEEK: 200421

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Treating amyloidgenic disease such as Alzheimer's disease, BSE or CJD comprises presentation of plaque derived antigens or epitopes on a display vehicle, and introducing the vehicle into the recipient

INVENTOR: FRENKEL, D; HANAN, E; SOLOMON, B

PRIORITY-DATA: 2000US-0629971 (July 31, 2000), 1999US-152417P (September 3, 1999), 1999US-0473653 (December 29, 1999), 2001US-0808037 (March 15, 2001), 2002US-0162889 (June 6, 2002), 2003US-0618856 (July 15, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040052766 A1	March 18, 2004		000	A61K048/00
WO 200118169 A2	March 15, 2001	E	120	C12N000/00
AU 200067232 A	April 10, 2001		000	C12N015/00

EP 1180938 A2	February 27, 2002	E	000	A01N063/00
US 20020052311 A1	May 2, 2002		000	A61K048/00
JP 2003509020 W	March 11, 2003		143	C12N015/02
US 20030077252 A1	April 24, 2003		000	A61K048/00
US 6703015 B1	March 9, 2004		000	A01K063/00

INT-CL (IPC): $\underline{A01}$ \underline{K} $\underline{63/00}$; $\underline{A01}$ \underline{N} $\underline{63/00}$; $\underline{A01}$ \underline{N} $\underline{65/00}$; $\underline{A61}$ \underline{K} $\underline{35/74}$; $\underline{A61}$ \underline{K} $\underline{35/76}$; $\underline{A61}$ \underline{K} $\underline{38/00}$; $\underline{A61}$ \underline{K} $\underline{39/395}$; $\underline{A61}$ \underline{K} $\underline{48/00}$; $\underline{A61}$ \underline{P} $\underline{19/08}$; $\underline{A61}$ \underline{P} $\underline{25/28}$; $\underline{A61}$ \underline{P} $\underline{35/00}$; $\underline{A61}$ \underline{P} $\underline{43/00}$; $\underline{C07}$ \underline{K} $\underline{16/00}$; $\underline{C07}$ \underline{K} $\underline{16/18}$; $\underline{C12}$ \underline{N} $\underline{0/00}$; $\underline{C12}$ \underline{N} $\underline{7/00}$; $\underline{C12}$ \underline{N} $\underline{7/01}$; $\underline{C12}$ \underline{N} $\underline{15/02}$; $\underline{C12}$ \underline{N} $\underline{15/85}$; $\underline{C12}$ \underline{N} $\underline{15/86}$; $\underline{C12}$ \underline{N} $\underline{15/87}$; $\underline{G01}$ \underline{N} $\underline{33/53}$

Full Title Citation Front Review Classification Date Reference Sequences Affectments Claims KMC Draw De

☐ 15. Document ID: WO 9618900 A1, US 5688651 A, AU 9645975 A

L2: Entry 15 of 20

File: DWPI

Jun 20, 1996

DERWENT-ACC-NO: 1996-300785

DERWENT-WEEK: 199801

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Selecting anti-aggregation mols. with chaperone-like activity - that can bind to native target mol. epitope with high binding constant and are non-inhibitory to biological activity of target mol., useful to prevent protein aggregation

INVENTOR: SOLOMON, B

PRIORITY-DATA: 1994US-0358786 (December 16, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9618900 A1	June 20, 1996	E	061	G01N033/53
<u>US 5688651 A</u>	November 18, 1997		014	G01N033/53
<u>AU 9645975 A</u>	July 3, 1996		000	G01N033/53

INT-CL (IPC): A61 K 31/66; A61 K 38/00; A61 K 39/395; C07 K 16/00; C12 N 15/00; C12 P 21/06; G01 N 33/48; G01 N 33/53

ABSTRACTED-PUB-NO: US 5688651A

BASIC-ABSTRACT:

Selecting anti-aggregation mols. with chaperone-like activity and with characteristics including binding to a native target mol. epitope with a high binding constant, and that are non-inhibitor to the biological activity of the target mol. comprises: (a) denaturing the target mol. which aggregates; (b) mixing the target mol. with a presumptive anti-aggregation mol.; (c) incubating the mixt. to allow aggregation; (d) selecting non-aggregated mixts.; and (e) testing the non-aggregated target mol. coupled to the anti-aggregation mol. for bioactivity, so selecting an anti-aggregation mol. with chaperone-like activity. Alternatively, the method can be used to select an anti-aggregation mol. as above which reverses aggregation effects by: (i) preparing an aggregated target mol.; (ii) (b) as above; (iii) selecting mixts. with non-aggregated target mols.; and (iv) testing the

Record List Display Page 18 of 25

target mol. coupled to the anti-aggregation mol. for bioactivity, so identifying an anti-aggregation mol. with chaperone-like activity. Also claimed are: (A) treating a protein aggregation disease by: (i) preparing 1 anti-aggregation mol. that binds an aggregating protein causing a disease and prevents aggregation while allowing bioactivity; (ii) creating an expression vector with a sequence encoding the antiaggregation mol. in expressible formation; and (iii) administering the expression vector; (B) a compsn. contg. the expression vector and a carrier; (C) the expression vector as above; (D) treating a protein aggregation disease by preparing 1 monoclonal antibody (MAb) which binds an aggregating protein causing a disease and allows bioavailability when bound, and administering the MAb; and (E) improving solubility and yields in the prodn. of recombinant proteins by preparing a recombinant vector contg. a sequence for an anti-aggregation mol. that suppresses the kinetics of aggregate formation while encouraging the formation of native protein structure, and favours the desired folding reaction of a recombinant protein, and co-transforming a host cell with the vector and an expression vector for a recombinant protein, so increasing intracellular prodn. of fusion proteins, preventing formation of inclusion bodies and facilitating protein secretion.

USE - The anti-aggregation mols. prevent or reverse aggregation. They bind to a native target mol. epitope with a high binding constant, and are non-inhibitory to its biological activity. The vector and methods are useful in the treatment of protein aggregation disease.

ADVANTAGE - The vectors allow lateral infection and targetting specificity. ABSTRACTED-PUB-NO:

WO 9618900A EQUIVALENT-ABSTRACTS:

Selecting anti-aggregation mols. with chaperone-like activity and with characteristics including binding to a native target mol. epitope with a high binding constant, and that are non-inhibitor to the biological activity of the target mol. comprises: (a) denaturing the target mol. which aggregates; (b) mixing the target mol. with a presumptive anti-aggregation mol.; (c) incubating the mixt. to allow aggregation; (d) selecting non-aggregated mixts.; and (e) testing the nonaggregated target mol. coupled to the anti-aggregation mol. for bioactivity, so selecting an anti-aggregation mol. with chaperone-like activity. Alternatively, the method can be used to select an anti-aggregation mol. as above which reverses aggregation effects by: (i) preparing an aggregated target mol.; (ii) (b) as above; (iii) selecting mixts. with non-aggregated target mols.; and (iv) testing the target mol. coupled to the anti-aggregation mol. for bioactivity, so identifying an anti-aggregation mol. with chaperone-like activity. Also claimed are: (A) treating a protein aggregation disease by: (i) preparing at least 1 anti-aggregation mol. that binds an aggregating protein causing a disease and prevents aggregation while allowing bioactivity; (ii) creating an expression vector with a sequence encoding the anti-aggregation mol. in expressible formation; and (iii) administering the expression vector; (B) a compsn. contg. the expression vector and a carrier; (C) the expression vector as above; (D) treating a protein aggregation disease by preparing at least 1 monoclonal antibody (MAb) which binds an aggregating protein causing a disease and allows bioavailability when bound, and administering the MAb; and (E) improving solubility and yields in the prodn. of recombinant proteins by preparing a recombinant vector contg. a sequence for an anti-aggregation mol. that suppresses the kinetics of aggregate formation while encouraging the formation of native protein structure, and favours the desired folding reaction of a recombinant protein, and co-transforming a host cell with the vector and an expression vector for a recombinant protein, so increasing intracellular prodn. of fusion proteins, preventing formation of inclusion bodies and facilitating protein secretion.

USE - The anti-aggregation mols. prevent or reverse aggregation. They bind to a native target mol. epitope with a high binding constant, and are non-inhibitory to its biological activity. The vector and methods are useful in the treatment of

Record List Display Page 19 of 25

protein aggregation disease.

ADVANTAGE - The vectors allow lateral infection and targetting specificity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	2 3 (Hall 2)	पालकामाना <i>ण</i>	Claims	KWC	Draw, De
				····								
	16.	Docum	nent II): CA 2	2048349 C,	AU 9	181573	A, CA 204	8349 A, JP	042267	52 A.	NZ
					491009 A,			•			,	

L2: Entry 16 of 20

File: DWPI

Apr 15, 2003

DERWENT-ACC-NO: 1992-123713

DERWENT-WEEK: 200330

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Multilayer, vacuum packaging film - with an oxygen-barrier core, layers of amorphous nylon and heat-sealable and heat-resistant layers

INVENTOR: BEKELE, S; SOLOMON, B

PRIORITY-DATA: 1990US-0562514 (August 3, 1990)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CA 2048349 C	April 15, 2003	E	000	C08L077/00
AU 9181573 A	February 6, 1992		018	
CA 2048349 A	February 4, 1992		000	
JP 04226752 A	August 17, 1992		007	B32B027/00
NZ 239248 A	July 27, 1993		000	B32B027/08
AU 645334 B	January 13, 1994		000	B32B027/08
US 5491009 A	February 13, 1996		000	B29D022/00
JP 3092987 B2	September 25, 2000		006	B32B027/32

INT-CL (IPC): B29D 22/00; B32B 7/02; B32B 27/00; B32B 27/08; B32B 27/28; B32B 27/30; B32B 27/32; B32B 27/34; B65D 65/40; B65D 81/20; C08L 77/00; C08L 77/02; C08L 77/06; C08L 101/00

ABSTRACTED-PUB-NO: AU 9181573A

BASIC-ABSTRACT:

High oxygen barrier, implosion resistant film (I) comprises: (a) a heat-sealable polymer layer; (b) an olefin (co)polymer layer; (c) a polymeric adhesive layer; (d) amorphous nylon layer; (e) an oxygen barrier material layer; (f) amorphous nylon layer; (g) a polymeric adhesive layer; (h) an olefin (co)polymer layer; and (i) a heat resistant polymer layer; and (2) a compsn. comprising a blend of amorphous nylon and a low modulus polymer and a film made of the blend.

USE - For vacuum packaging fresh and cooked (red) meat prods. (0/0) ABSTRACTED-PUB-NO:

US 5491009A EQUIVALENT-ABSTRACTS:

A high oxygen barrier implosion resistant film comprising: a) a first layer comprising a heat sealable polymeric material; b) a second layer comprising an

Record List Display Page 20 of 25

olefin polymer or copolymer; c) a third layer comprising a polymeric adhesive; d) a fourth layer comprising amorphous nylon; e) a fifth layer comprising an oxygen barrier material; f) a sixth layer comprising amorphous nylon; g) a seventh layer comprising a polymeric adhesive; h) an eighth layer comprising an olefin polymer or copolymer; and i) a ninth layer comprising a heat resistant polymeric material.

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 17. Document ID: EP 322199 A, DK 171511 B, AU 8827376 A, DK 8807101 A, FI 8805896 A, US 4886690 A, CA 1307086 C, NZ 227233 A, EP 322199 B1, DE 3854116 G, ES 2074443 T3, FI 97344 B

L2: Entry 17 of 20

File: DWPI

Jun 28, 1989

DERWENT-ACC-NO: 1989-186554

DERWENT-WEEK: 199705

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Peelable composite heat-seal barrier film for vacuum skin packaging - has gas-impermeable layer weakly bonded to permeable layer and is manually strippable

INVENTOR: BEKELE, S; DAVIS, K A ; STOCKLEY, H W ; KENT, A D ; SOLOMON, B ; WALKER, S

PRIORITY-DATA: 1987US-0136680 (December 21, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 322199 A	June 28, 1989	E	009	,
DK 171511 B	December 16, 1996		000	B32B027/08
AU 8827376 A	June 22, 1989		000	•
DK 8807101 A	June 22, 1989		000	
FI 8805896 A	June 22, 1989		000	
<u>US 4886690 A</u>	December 12, 1989		007	
CA 1307086 C	September 8, 1992		000	B32B027/08
NZ 227233 A	March 26, 1993		000	B32B027/08
EP 322199 B1	July 5, 1995	E	012	B32B027/08
DE 3854116 G	August 10, 1995		000	B32B027/08
ES 2074443 T3	September 16, 1995		000	B32B027/08
FI 97344 B	August 30, 1996		000	B32B027/08

INT-CL (IPC): B32B 1/08; B32B 27/08; B65B 11/52; B65B 25/06; B65D 65/40; B65D 75/26; B65D 81/20

ABSTRACTED-PUB-NO: EP 322199A

BASIC-ABSTRACT:

A forming web for vacuum skin packaging which is separable into permeable and impermeable films comprises a co-extruded, multilayer composite film web consisting of (A) a gas-permeable film bonded to (B) a gas-impermeable film which can be manually delaminated from (A), the former including a heat-sealable layer capable of sealing to a polymer surface with bond strength greater than that required to

Record List Display Page 21 of 25

rupture and delaminate (B) from (A). (A) has a plurality of layers including (1) the heat-sealable polymer layer; and (2) a layer of linear ethylene/alpha-olefin copolymer having density less than 0.915 g/cc (ULDPE or VLDPE). (B) has a plurality of layers including (1) a barrier layer of hydrolysed EVA copolymer (EVOH) or vinylidene chloride co- or ter-polymer, next to (A2) (so that when delamination occurs it becomes a surface layer); and (2) an outer or second layer of polymer.

USES/ADVANTAGES - The webs are useful in the vacuum skin packaging of materials requiring to be kept in absence of O2 and/ or moisture, or in modified atmospheres within the package. Upon stripping away the barrier layer in (A), access of gases to the package contents through the remaining (B) becomes possible. The packages are esp. useful for red meat; prior to display for sale the outer layer is removed to allow access of O2 and development of a healthy bright red "bloom" on the meat. ABSTRACTED-PUB-NO:

EP 322199B EQUIVALENT-ABSTRACTS:

A forming web for vacuum skin packaging which web is separable into permeable and impermeable films comprising: a coextruded, multi-layer composite film comprising a gas permeable film and a gas impermeable film which can be manually delaminated from each other; (1) the gas permeable film having a plurality of layers including; (a) a heat sealable, polymeric layer; and (b) a layer comprising a linear ethylene/alpha-olefin copolymer having a density of less than 0.915 x 10 power 3 kg/m3 (0.915 gms/cm3) and, (2) the gas impermeable film comprising a plurality of layers including: (a) a barrier layer comprising a hydrolysed ethylene vinyl acetate copolymer (EVOH) or vinylidene chloride copolymer or terpolymer (PVDC), the barrier layer being immediately adjacent to and in contact with the linear ethylene/alpha-olefin copolymer (1) (b) so that when delamination occurs the barrier layer will become a first surface layer; and, (b) an outer or second surface layer of polymeric material; the heat sealable layer being capable of sealing to a polymeric surface with a bond strength greater than the force required to delaminate the permeable film from the impermeable film.

US 4886690A

A forming vacuum skin packaging, separatable web is a coextruded film of A) a multiply gas permeable film including a) a heat sealable ethane (co)polymer (blend layer and b) a layer of linear ethane/1-olefin copolymer of density below 0.915 g/cm3 and B) a multiply gas impermeable layer including c) a barrier layer of hydrolysed ethane/vinyl acetate copolymer or vinylidene chloride co- or terpolymer adjacent to and in contact with Ab) and d) an outer surface layer of a polymeric material. Layer Aa) can be heat sealed to a polymeric surface with a greater bond strength than the force required to separate A) from B). Layer Ab) becomes the outer layer after separation.

B) is pref. 0.076-0.089 mm thick and A) is 0.038-0.076 mm thick. B) includes 2 barrier films of which the 2nd one is coated on both sides with an adhesive and is covered with an outer surface layer of high density polyethene.

ADVANTAGE - Readily openable packages can be produced. (7pp)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Altachments	Claims	KWIC	Draw, De
										·		
												•

☐ 18. Document ID: DE 3738721 A, CH 677363 A, DE 3738721 C2, DK 8806353 A, FR 2623193 A, GB 2212500 A, GB 2212500 B, IL 87550 A, JP 01165600 A, NL 8802236 A, SE 8804100 A, US 4948836 A

L2: Entry 18 of 20

File: DWPI

May 24, 1989

Record List Display Page 22 of 25

DERWENT-ACC-NO: 1989-158513

DERWENT-WEEK: 198922

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Immobilised antibodies covalently bonded to matrix polymer - by a condensn. reaction between aldehyde gp. of antibody and epoxy function of polymer

INVENTOR: FLEMINGER, G; HADAS, E; SOLOMON, B

PRIORITY-DATA: 1987DE-3738721 (November 14, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 3738721 A	May 24, 1989		800	
CH 677363 A	May 15, 1991		000	
DE 3738721 C2	October 5, 1995		800	C07K017/08
DK 8806353 A	May 15, 1989		000	
FR 2623193 A	May 19, 1989		000	
GB 2212500 A	July 26, 1989		000	
GB 2212500 B	January 22, 1992		000	
<u>IL 87550 A</u>	November 15, 1993		000	C07K017/06
JP 01165600 A	June 29, 1989		000	
NL 8802236 A	June 1, 1989		000	
SE 8804100 A	May 15, 1989		000	
<u>US 4948836 A</u>	August 14, 1990		000	

INT-CL (IPC): A61K 35/14; A61K 39/44; C07K 17/06; C07K 17/08; C08F 8/00; C08H 1/00; C08L 89/00; G01N 33/54

ABSTRACTED-PUB-NO: DE 3738721A

BASIC-ABSTRACT:

Immobilised antibodies which are covalently bonded, via their modified carbohydrate region onto a matrix polymer are produced by bonding the antibody onto a matrix polymer contg. epoxy gps., by a condensation reaction between at least one aldehyde gp. of the oxidised carbohydrated region of the antibody and at least one epoxy function of the matrix polymer, using a bifunctional reagent which has at one end amino gp. capable of condensation with the aldehyde gp. and an at least 3-membered spacer and at the other end a gp. which is capable of reacting covalently with the epoxy function.

USE/ADVANTAGE - The polymer fixed antibodies can be used as a versatile biochemical-analytical agent for the detection of the presence of specific substances, such as hormones, blood components, normal and abnormal cell types, causes of diseases and molecules which are indicative of the presence of benign tumours. The chemial bonds are stable and inert. Non-specific bonding of the antibody is minimised. Blocking after fixing the antibodies remains. ABSTRACTED-PUB-NO:

DE 3738721C EQUIVALENT-ABSTRACTS:

Immobilised antibodies covalently bound through their modified carbohydrate region to a matrix polymer (MP) are new. The binding is between an aldehyde gp. of the oxidised carbohydrate region and an epoxy gp. of the MP, by condensation using a bifunctional reagent (BR). BR has at one end, a unit contg. at least a 3-membered

Record List Display Page 23 of 25

spacer and an amino gp. that can react with aldehyde and, at the other end, a unit that can react with epoxy.

Pref. the CHO is formed by periodate oxidn. at pH 5-5.5, followed by treatment with ethylene glycol. BR has the formula H2N-(X)n-A-Q or (CH2)m(CONHNH2), X = CONH, CSNH, NHCONH2 or NHCSNH, n = 0 or 1, A = a spacer unit with 30 more numbers. Q =XNH2 or NH2, m = 3-6.

USE/ADVANTAGE - The antibodies are used analytically, for hormones, tumours etc. The antibody activity is not affected and the immobilised material is stable.

GB 2212500B

Antibodies immobilized on a matrix polymer wherein at least one aldehyde group of the carbohydrate region that has been oxidized of the antibody and at least one epoxy group of a reactive matrix polymer carrying epoxy groups are bound via a bifunctional reagent, said bifunctional reagent comprising (a) a first terminal group capable of covalently reacting with said epoxy group and a second terminal group which is an amino group capable of condensing with said aldehyde group, and (b) a spacer consisting of a C3-12 alkyl or cycloalkyl group between said first and second terminal groups.

US 4948836A

Immobilised antibody compsn. comprises a polymer matrix linked through the carbohydrate moiety of the antibody by means of a bifunctional reagent of formula H2N-(X)n-AQ (I). In (I), A is opt. oxa-substd. 3-12C alkylene or cycloalkylene; X is CONH, CSNH, NHCONH or NHCSNH; n is 0 or 1; and Q is XNH2 or NH2. The antibody carbohydrate moiety is first oxidised with periodate to form CHO gps.; and then polycondensed with a polymer contg. epoxide gps., in the presence of the coupling agent (I).

USE - The prods. are stable and serve as reagents for rapid immunoanalysis. (6pp)a

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KNNC Draw De ☐ 19. Document ID: US 4680103 A

L2: Entry 19 of 20

File: DWPI

Jul 14, 1987

DERWENT-ACC-NO: 1987-213468

DERWENT-WEEK: 198730

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Positive particles for use in electrophoretic display devices - release rapidly from viewing electrode do not agglomerate and allow flexibility in choice of anode materials

INVENTOR: SOLOMON, B; TRUONG, L K

PRIORITY-DATA: 1986US-0822297 (January 24, 1986)

PATENT-FAMILY:

PUB-NO PUB-DATE LANGUAGE PAGES MAIN-IPC

US 4680103 A July 14, 1987 010 Record List Display Page 24 of 25

INT-CL (IPC): B01K 5/02; C23B 13/00; C25D 1/12; G03G 13/00

ABSTRACTED-PUB-NO: US 4680103A

BASIC-ABSTRACT:

A compsn. for use in electrophoretic displays comprises pigment particles with an attached organosilane which includes a positively charged covalently bonded ionic functional moiety.

Also claimed is an electrophoretic display device with an enclosed space contg. (a) a dielectric fluid, (b) a first electrode, and (c) an opposed grid structure which has a second electrode and a third control electrode with a dielectric spacer in between. The dielectric fluid comprises pigment particles with an attached quat. ammonium moiety. The particles are movable between positions adjacent the electrodes in response to applied electric fields.

Also claimed is method of synthesising the positively charged pigment particles by providing pigment particles with an OH gp. on their surface and reacting this gp. with a silyl quat. ammonium salt at, an elevated temp. in non-aq. solvent, to attach a silyl quat. ammonium moiety to the particle surface.

The organosilane (by which the quat. ammonium gp. is pref. attached) is pref. derived from a precursor of formula (I). R1=(cyclo)alkyl, (alkyl)aryl, or alkenyl; R1, R''=alkyl, n=3-ca.18; and R2-4=alkoxy or acetoxy.

ADVANTAGE - The particles are fast moving and release rapidly from the viewing electrode, giving faster overall response times. The particles have fixed and controllable charges, are resistant to agglomeration, and allow greater flexibility in the choice of anode materials.

Full	Title	Citation	Front	Review	Classification	Date	Reference	early entract	al dimens	Claims	KWIC	Drawi De

☐ 20. Document ID: CA 1123568 A

L2: Entry 20 of 20

File: DWPI

May 18, 1982

DERWENT-ACC-NO: 1982-G6532E

DERWENT-WEEK: 198223

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Preformed and nestable panel for roof - has corrugated panel with shaped

side edges to allow interlock with adjacent panel

INVENTOR: SOLOMON, B

PRIORITY-DATA: 1979CA-0342208 (December 19, 1979)

PATENT-FAMILY:

PUB-NO PUB-DATE LANGUAGE PAGES MAIN-IPC

<u>CA 1123568 A</u> May 18, 1982 014

INT-CL (IPC): E04D 3/30

ABSTRACTED-PUB-NO: CA 1123568A

BASIC-ABSTRACT:

Record List Display Page 25 of 25

The rectangular panel for adjacent connection together to form walls, or ceilings is preformed and comprises alternately situated depressed and raised troughs. One (14) side edge formed on one longitudinal side of the panel engages the second side edge of the adjacent panel.

A portion of the first side edge overlies and shields the second side edge (15) of the adjacent panel and the junction between the adjacent panels. The first edge and second edge include vertically (17) situated portions in partial interfacial relationship when the panels are adjacently connected together. Fastenings extend through the vertically situated portions in the partial interfacial relationship, for adjacently connecting the panels together.

Full Title Citation Front Review Cla	ssification Date Reference	Sequences Attachmen	ts Claims k	NMC Draw, De
				•
Clear Generate Collection	Print Fwd Refs	Bkwd Refs	Generate	OACS
Terms	Dog	cuments		1
Solomon-B.IN.		ourients .	20	

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List



Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 5310879 A

L6: Entry 1 of 8

File: USPT

May 10, 1994

US-PAT-NO: 5310879

DOCUMENT-IDENTIFIER: US 5310879 A

TITLE: Antibodies which immunoreact with lapine lipopolysaccharide binding protein

(LBP)

DATE-ISSUED: May 10, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Ulevitch; Richard J.

Del Mar

CA

Tobias; Peter S.

Encinitas

CA

US-CL-CURRENT: <u>530/388.1</u>; <u>530/388.25</u>, <u>530/389.1</u>, <u>530/389.3</u>

ABSTRACT:

A lipopolysaccharide binding protein, LBP, which is present in acute phase serum of an animal host, but is substantially absent from the normal serum of the host, method of detection, and antibodies that bind to LBP are described.

4 Claims, 32 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences.	Altachments.	Claims	KWIC	Draw, De
			***							in and the second		

☐ 2. Document ID: US 5231170 A

L6: Entry 2 of 8

File: USPT

Jul 27, 1993

US-PAT-NO: 5231170

DOCUMENT-IDENTIFIER: US 5231170 A

TITLE: Antibodies to dense microspheres

DATE-ISSUED: July 27, 1993

Record List Display Page 2 of 7

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Averback; Paul Montreal, Quebec CA

US-CL-CURRENT: 530/388.1; 435/70.21, 436/548, 530/388.85, 530/389.1, 530/839

ABSTRACT:

Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at intissue concentrations of 10.sup.-5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis. Antibodies to DMS (dense microspheres) are also disclosed.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classific	ation Date Reference Scalabones A	liadimens Claims KWC Dra m De
☐ 3. Document ID: US 5231000	A	•
I.C. Patron 2 - 5 0		
L6: Entry 3 of 8	File: USPT	Jul 27, 1993

US-PAT-NO: 5231000

DOCUMENT-IDENTIFIER: US 5231000 A

TITLE: Antibodies to A4 amyloid peptide

DATE-ISSUED: July 27, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Majocha; Ron Wayland MA Marotta; Charles A. Cambridge MA Zain; Sayeeda Pittsford NY

US-CL-CURRENT: 435/7.1; 435/331, 435/7.2, 435/7.21, 436/501, 436/506, 530/388.1

ABSTRACT:

Monoclonal antibodies to a 28-mer peptide present within A4-amyloid are described. These antibodies exhibit unexpected specificity for <u>amyloid</u> plaque structures previously unrecognized in Alzheimer's disease brains. These monoclonal antibodies are useful as reagents for use in assays and imaging of A4-amyloid in Alzheimer's disease patients.

9 Claims, 1 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KVMC	Draw, De
		,,,,,,,	····		·							

☐ 4. Document ID: US 5223409 A

L6: Entry 4 of 8

File: USPT

Jun 29, 1993

US-PAT-NO: 5223409

DOCUMENT-IDENTIFIER: US 5223409 A

TITLE: Directed evolution of novel binding proteins

DATE-ISSUED: June 29, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ladner; Robert C.	Ijamsville	MD		
Guterman; Sonia K.	Belmont	MA		
Roberts; Bruce L.	Milford	MA	•	
Markland; William	Milford	MA		
Ley; Arthur C.	Newton	MA	•	
Kent; Rachel B.	Boxborough	MA		

US-CL-CURRENT: <u>435/69.7</u>; <u>435/252.3</u>, <u>435/320.1</u>, <u>435/472</u>, <u>435/5</u>, <u>435/69.1</u>, <u>530/387.3</u>, 530/387.5

ABSTRACT:

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

66 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16

F٤	ıll	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	килс	Draw De
											,		

☐ 5. Document ID: US 5218100 A

L6: Entry 5 of 8

File: USPT

Jun 8, 1993

US-PAT-NO: 5218100

DOCUMENT-IDENTIFIER: US 5218100 A

TITLE: DNA encoding for the precursor protein of APC polypeptide associated with

Alzheimer's disease

DATE-ISSUED: June 8, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Muller-Hill; Benno Cologne DE Kang; Jie Bonn DE Lemaire; Hans-Georg Cologne DΕ

Unterbeck; Axel West Haven CT

US-CL-CURRENT: <u>536/23.5</u>; <u>530/350</u>, 530/388.1

ABSTRACT:

The present invention relates to the precursor protein of amyloid plaque core (APC) polypeptide, to fragments of the precursor protein and to the diagnostic use of the precursor protein and of the fragments. Furthermore, the invention relates to the DNA coding for the precursor protein, to fragments of this DNA and to the diagnostic use of the DNA and of the fragments.

3 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Fall	Title	Citation	Front	Review	Classification	Date	Rafaranca	1.5	tar men	Claime	KOMC	Drawt De
		Oildion		11201200	Olassineation	Care	Mererence	CAS ALL A	* 124 M	Claims	NOME	D1300 D 6

☐ 6. Document ID: US 5182107 A

L6: Entry 6 of 8

File: USPT

Jan 26, 1993

US-PAT-NO: 5182107

DOCUMENT-IDENTIFIER: US 5182107 A

TITLE: Transferrin receptor specific antibody-neuropharmaceutical or diagnostic

agent conjugates

DATE-ISSUED: January 26, 1993

INVENTOR-INFORMATION:

NAME CITY ZIP CODE STATE COUNTRY

Friden; Phillip M. Bedford MA

US-CL-CURRENT: 424/179.1; 424/143.1, 424/178.1, 424/94.1, 514/21, 530/387.3, <u>530</u>/<u>388.22</u>, <u>530</u>/<u>391.1</u>, <u>530</u>/<u>391.7</u>, <u>530</u>/<u>391.9</u> , <u>530</u>/<u>399</u>

Record List Display Page 5 of 7

ABSTRACT:

The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.

27 Claims, 10 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full Title Citation Front Review Classification Date Reference Equalities 246-266-25 Claims KWIC Draw. De

☐ 7. Document ID: JP 02138995 A

L6: Entry 7 of 8

File: JPAB

May 28, 1990

PUB-NO: JP402138995A

DOCUMENT-IDENTIFIER: JP 02138995 A

TITLE: MONOCLONAL ANTIBODY AGAINST NOVEL PROTEIN

PUBN-DATE: May 28, 1990

INVENTOR-INFORMATION:

NAME

COUNTRY

KITAGUCHI, NOBUYA ITO, HIRATAKA TAKAHASHI, YASUYUKI TOKUSHIMA, YASUO

US-CL-CURRENT: 530/388.1

INT-CL (IPC): C12P 21/08; C12N 5/20; G01N 33/53; G01N 33/577; C07K 7/06; C07K 7/08;

C07K 13/00; C07K 15/12; C12N 15/06

ABSTRACT:

PURPOSE: To obtain a monoclonal antibody against protein by cultivating mouse fused cell strain ADI 1-7-5-2, mouse fused cell strain ADI 1-4-6-1, mouse fused cell strain ADI 1-05-44-2, etc.

CONSTITUTION: A monoclonal antibody producing strain such as mouse fused cell strain ADI 1-7-5-2, mouse fused cell strain ADI 1-05-44-2 or mouse fused cell strain ADI-5-3-7 is prepared by cell fusion method and the antibody-forming strain is cultured to give a monoclonal antibody. The prepared monoclonal antibody is a monoclonal antibody specific to amino acid sequence having continuous five or more residues among amino acid sequence of <u>amyloid</u> precursor protein of human cerebral senile spot having inhibitory activity against protease and is useful for diagnosing cerebral nerve dysbolism including senile dementia.

COPYRIGHT: (C)1990, JPO&Japio

Full Title Citation Front Review Classification D	ate Reference Sequences Attac	Imments Claims KWIC Draw De
□ 8. Document ID: WO 9012871 A1		
L6: Entry 8 of 8	File: FPAR	Nov 1 1990

PUB-NO: WO009012871A1

DOCUMENT-IDENTIFIER: WO 9012871 A1

TITLE: CEREBROVASCULAR AMYLOID PROTEIN-SPECIFIC MONOCLONAL ANTIBODY SV17-6E10

PUBN-DATE: November 1, 1990

INVENTOR-INFORMATION:

NAME	COUNTRY
KIM, KWANG S	US
WISNIEWSKI, HENRYK M	US
WEN, GUANG Y	US
CHEN, CHENG-MO JAMES	US
SAPIENZA, VICTOR J	US

US-CL-CURRENT: 435/332; 435/FOR.111, 530/388.1

INT-CL (IPC): C07K 15/28; C12N 5/20; G01N 33/533; G01N 33/534; G01N 33/535

EUR-CL (EPC): C07K016/18; C07K014/47


ABSTRACT:

Disclosed is monoclonal antibody SV17-6E10 and a specific-binding fragment thereof which is specifically reactive with a peptide whose concentration level is elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted and which does not react with other peptides of human origin. Also disclosed is a hybridoma cell line capable of producing the monoclonal antibody, a reagent composition which incorporates the monoclonal antibody or specific-binding fragments thereof and an immunoassay method for their use.

Full Title Citation Front Review Classification Date Reference Sequences Attachments: Claim	ns KWMC Drawl De
Clear Generate Collection Print Fwd Refs Bkwd Refs Gen	erate OACS
Terms Documents	
L5) AND @PY <= 1994	<u></u>

Display Format: - Change Format ::

Hit List



Search Results - Record(s) 1 through 21 of 21 returned.

☐ 1. Document ID: US 6329508 B1

L7: Entry 1 of 21

File: USPT

Dec 11, 2001

US-PAT-NO: 6329508

DOCUMENT-IDENTIFIER: US 6329508 B1

TITLE: Transferrin receptor reactive chimeric antibodies

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Friden; Phillip M.

Bedford

MΔ

US-CL-CURRENT: <u>530/387.3</u>; 530/388.15

ABSTRACT:

The present invention pertains to chimeric antibodies that are reactive with transferrin receptors on brain capillary endothelial cells. These antibodies are composed of a variable region, immunologically reactive with the transferrin receptors, that is obtained from one animal source, and a constant region that is derived from an animal source other than the one that provided the variable region. These chimeric antibodies can exist either as isolated entities or as conjugates with a neuropharmaceutical agent for transferal across the blood brain barrier.

4 Claims, 79 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 77

Full	Title	Citation Fro	nt Review	Classification	Date	Reference	Someness	Alica Informação	Claims	KWIC	Draw, De
					auaa <i>aa</i> aaaa						
	2	Dogumant I	D. HC (2	04471 D1							

L. 2. Document ID: US 6284471 B1

L7: Entry 2 of 21

File: USPT

Sep 4, 2001

US-PAT-NO: 6284471

DOCUMENT-IDENTIFIER: US 6284471 B1

TITLE: Anti-TNFa antibodies and assays employing anti-TNFa antibodies

DATE-ISSUED: September 4, 2001

Record List Display Page 2 of 16

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Le; Junming	Jackson Heights	NY		
Vilcek; Jan	New York	NY		
Dadonna; Peter	Palo Alto	CA		
Ghrayeb; John	Thorndale	PA		
Knight; David	Berwyn	PA		
Siegel; Scott A.	Westborough	MA		

US-CL-CURRENT: $\underline{435}/\underline{7.1}$; $\underline{424}/\underline{133.1}$, $\underline{424}/\underline{139.1}$, $\underline{424}/\underline{141.1}$, $\underline{435}/\underline{69.6}$, $\underline{435}/\underline{70.21}$, $\underline{530}/\underline{387.3}$, $\underline{530}/\underline{388.23}$, $\underline{530}/\underline{391.3}$

ABSTRACT:

Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.

9 Claims, 48 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 36

Full Title Citation Front Review Classification	Date Reference Sequences Stra	Shineria: Claims KWC Draw. De
☐ 3. Document ID: US 5976816 A		
L7: Entry 3 of 21	File: USPT	Nov 2, 1999

US-PAT-NO: 5976816

DOCUMENT-IDENTIFIER: US 5976816 A

TITLE: Cell tests for alzheimer's disease

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	•	CITY	STATE	ZIP CODE	COUNTRY
Alkon; Daniel L.		Bethesda	MD		
Etcheberrigaray;	Rene	Rockville	MD		
Kim; Christopher	S.	Silver Spring	MD		
Han; Yi-Fan		Shanghai			CN
Nelson; Tom J.		Silver Spring	MD		

US-CL-CURRENT: $\underline{435}/\underline{7.21}$; $\underline{435}/\underline{7.1}$, $\underline{435}/\underline{7.92}$, $\underline{436}/\underline{548}$, $\underline{530}/\underline{300}$, $\underline{530}/\underline{387.1}$

ABSTRACT:

Record List Display Page 3 of 16

The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.

9 Claims, 49 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Altachments	Claims	KWC	Draw De
									•			
	4.	Docume	nt ID:	US 59	19452 A							

File: USPT

US-PAT-NO: 5919452

L7: Entry 4 of 21

DOCUMENT-IDENTIFIER: US 5919452 A

TITLE: Methods of treating TNF.alpha.-mediated disease using chimeric anti-TNF

antibodies

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Le; Junming	Jackson Heights	NY		
Vilcek; Jan	New York	NY		
Dadonna; Peter	Palo Alto	CA		
Ghrayeb; John	Thorndale	PA		
Knight; David	Berwyn	PA		
Seigal; Scott	Westborough	MA		

US-CL-CURRENT: 424/133.1; 424/145.1, 424/158.1, 530/387.3, 530/388.23, 530/389.2

ABSTRACT:

Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which compounds are specific for tumor necrosis factor-.alpha. (TNF.alpha.) or tumor necrosis factor-.beta. (TNF.beta.) and which are useful for in vivo therapy or diagnosis of TNF.alpha.-mediated pathologies and conditions, wherein the anti-TNF compound is selected from the group consisting of at least one of an immunoglobulin variable region, a fragment of a TNF receptor and an anti-TNF peptide, such as a structural analog of a anti-TNF antibody fragment or a TNF receptor fragment.

13 Claims, 48 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 36

Jul 6, 1999

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 5. Document ID: US 5811310 A

L7: Entry 5 of 21

File: USPT

Sep 22, 1998

US-PAT-NO: 5811310

DOCUMENT-IDENTIFIER: US 5811310 A

TITLE: The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Ghanbari; Hossein A. Lake Forest IL
Davies; Peter Rye NY
Wolozin; Benjamin Columbia MD

US-CL-CURRENT: <u>436/518</u>; <u>435/326</u>, <u>435/7.1</u>, <u>435/7.21</u>, <u>435/7.92</u>, <u>435/70.21</u>, <u>436/528</u>, <u>436/531</u>, <u>436/811</u>, <u>530/388.1</u>

ABSTRACT:

The invention relates to an antigen associated with Alzheimer's disease and to antibodies specific for said antigen. This invention further relates to methods for diagnosing Alzheimer's disease utilizing assays containing Alzheimer's associated antigen, antibodies specific for said antigen and samples from an individual suspected of having Alzheimer's disease.

5 Claims, 24 Drawing figures Exemplary Claim Number: 3 Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments CI	aims	KWMC	Drawi De

☐ 6. Document ID: US 5750349 A

L7: Entry 6 of 21

File: USPT

May 12, 1998

US-PAT-NO: 5750349

DOCUMENT-IDENTIFIER: US 5750349 A

TITLE: Antibodies to .beta. -amyloids or their derivatives and use thereof

DATE-ISSUED: May 12, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Suzuki; Nobuhiro Ibaraki JP Odaka; Asano Ibaraki JP Kitada; Chieko Osaka JP

US-CL-CURRENT: <u>435/7.1</u>; <u>435/326</u>, <u>435/331</u>, <u>435/7.92</u>, <u>435/7.94</u>, <u>435/7.95</u>, <u>435/70.21</u>, <u>530/387.9</u>, <u>530/388.1</u>, 530/389.1

ABSTRACT:

According to this invention, antibodies which are useful and novel in that they have binding specificity to .beta._amyloids or derivatives thereof, namely recognize the N-terminal, the C-terminal or central portions of the .beta._amyloids, respectively, were obtained. By combining these antibodies, determination methods by which the .beta._amyloids could be determined sensitively and specifically are provided. These determination methods are useful for diagnosis of diseases to which the .beta._amyloids or their derivatives are related (for example, Alzheimer's disease), and the antibodies of this invention are useful for the development of preventive-therapeutic compositions for Alzheimer's disease.

9 Claims, 32 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16

Full Title C	itation Front R	eview Classification	Date Reference	Sequences A	ttachments Claim	is KONC Drawn De
		e en constantina en				

☐ 7. Document ID: US 5733734 A

L7: Entry 7 of 21

File: USPT

Mar 31, 1998

US-PAT-NO: 5733734

DOCUMENT-IDENTIFIER: US 5733734 A

TITLE: Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Trojanowski; John Q. Philadelphia PA Lee; Virginia M-Y. Philadelphia PA

US-CL-CURRENT: $\frac{435}{7.1}$; $\frac{435}{40.52}$, $\frac{435}{7.21}$, $\frac{435}{7.92}$, $\frac{435}{960}$, $\frac{436}{547}$, $\frac{436}{548}$, $\frac{436}{811}$, $\frac{530}{387.9}$, $\frac{530}{388.1}$, $\frac{530}{389.1}$

ABSTRACT:

Substantially purified antibodies, including substantially purified monoclonal antibodies, which are specifically reactive with .tau. that has an abnormally phosphorylated serine in the sequence LysSerProVal SEQ ID NO:3 are disclosed. Methods of screening persons for diseases associated with pair helical filaments, including Alzheimer's disease, by detection of .tau. that has an abnormally phosphorylated serine in the sequence LysSerProVal SEQ ID NO:3 in test samples

Record List Display Page 6 of 16

taken from such persons and test kits useful to perform such methods are disclosed.

14 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

ull	Title	Citation	Front	Review	Classification	Date	Reference 🚷	and the	Talisonnanes	Claims	KWIC	Drawi, De

□ 8. Document ID: US 5698195 A

L7: Entry 8 of 21

File: USPT

Dec 16, 1997

US-PAT-NO: 5698195

DOCUMENT-IDENTIFIER: US 5698195 A

TITLE: Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies

DATE-ISSUED: December 16, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Le; Junming	Jackson Heights	NY		
Vilcek; Jan	New York	NY		
Daddona; Peter	Menlo Park	CA		
Ghrayeb; John	Thorndale	PA		
Knight; David	Berwyn	PA		
Siegel; Scott	Westborough	MA		

US-CL-CURRENT: <u>424/133.1</u>; <u>424/141.1</u>, <u>424/142.1</u>, <u>424/145.1</u>, <u>514/825</u>, <u>530/351</u>, <u>530/387.3</u>, <u>530/388.1</u>, <u>530/388.23</u>

ABSTRACT:

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-.alpha. (TNF.alpha.) and are useful in vivo for diagnosis and therapy of a number of TNF.alpha.-mediated pathologies and conditions, including rheumatoid arthritis as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

16 Claims, 33 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 36

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Altankrianis	Claims	KWIC	Draw, De

☐ 9. Document ID: US 5688651 A

L7: Entry 9 of 21

File: USPT

Nov 18, 1997

Record List Display Page 7 of 16

US-PAT-NO: 5688651

DOCUMENT-IDENTIFIER: US 5688651 A

TITLE: Prevention of protein aggregation

DATE-ISSUED: November 18, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Solomon; Beka Herzlya IL

US-CL-CURRENT: 435/7.1; 424/130.1, 436/63, 530/388.1

ABSTRACT:

A method of selecting anti-aggregation molecules with chaperone-like activity that have characteristics including binding to a native target molecule epitope with a high binding constant and are non-inhibitory to the biological activity of the target molecule. The method molecules denaturating a target molecule in the presence of presumptative antiaggregation molecules to prevent the target molecules from self-or induced-aggregation. The nonaggregated target molecule coupled to the anti-aggregation molecule is then tested for bioactivity.

4 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full	Title	Citation	Front	Renderor	Classification	Date	Reference		diachments.	Claims	MODE	Draw, De
					010001110011011	0.01.0	13 at at all live	State of the second	Sec. 12.	Cialina	MODIC	D1260 D18

☐ 10. Document ID: US 5656272 A

L7: Entry 10 of 21

File: USPT

Aug 12, 1997

US-PAT-NO: 5656272

DOCUMENT-IDENTIFIER: US 5656272 A

TITLE: Methods of treating TNF-.alpha.-mediated Crohn's disease using chimeric

anti-TNF antibodies

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Le; Junming Jackson Heights NY Vilcek; Jan New York NY Dadonna; Peter Palo Alto CA Ghrayeb; John Thorndale PA Knight; David Berwyn PΑ Siegel; Scott A. Westborough MA

US-CL-CURRENT: 424/133.1; 424/139.1, 424/145.1, 435/69.1, 435/69.6, 435/69.7,

Record List Display Page 8 of 16

<u>530/387.3</u>, <u>5</u>30/388.23

ABSTRACT:

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-.alpha. (TNF.alpha.) and are useful in vivo for diagnosis and therapy of a number of TNF.alpha.-mediated pathologies and conditions, including Crohn's disease, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

7 Claims, 48 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 36

Full	Title	Citation	Front	Review	Classification	Date	Reference	Seguençes	Attachments	Claims	KWIC	Draw, De
								-		_		

☐ 11. Document ID: US 5538845 A

L7: Entry 11 of 21

File: USPT

Jul 23, 1996

US-PAT-NO: 5538845

DOCUMENT-IDENTIFIER: US 5538845 A

TITLE: Beta-amyloid peptide production inhibitors and methods for their

identification

DATE-ISSUED: July 23, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Knops; Jeroen San Francisco CA Sinha; Sukanto San Francisco CA

US-CL-CURRENT: $\underline{435/6}$; $\underline{435/183}$, $\underline{435/69.2}$, $\underline{435/7.21}$, $\underline{436/530}$, $\underline{436/531}$, $\underline{530/387.1}$

ABSTRACT:

A method for identifying compounds capable of inhibiting the production of .beta.—amyloid peptide in cells comprises exposing cultured cells in one or more test compounds. The cells are cultured under conditions which produce amyloid precursor protein and which result in intracellular accumulation of an approximately 22 kD polypeptide which includes the entire sequence of the .beta.—amyloid peptide. Test compounds which cause a change in the accumulation of the 22 kD polypeptide are considered likely candidates for use as drugs for treating .beta.—amyloid diseases, such as Alzheimer's disease.

38 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 12. Document ID: US 5427931 A

L7: Entry 12 of 21

File: USPT

Jun 27, 1995

US-PAT-NO: 5427931

DOCUMENT-IDENTIFIER: US 5427931 A

TITLE: Monoclonal antibody produced against native .beta.amyloid precursor protein

DATE-ISSUED: June 27, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Van Nostrand; William E. Irvine CA Cunningham; Dennis D. Laguna Beach CA Wagner; Steven L. Balboa Island CA

US-CL-CURRENT: <u>435/70.2</u>; <u>435/326</u>, <u>435/332</u>, <u>435/334</u>, <u>435/343</u>, <u>435/70.21</u>, <u>436/547</u>, <u>436/548</u>, <u>530/386</u>, <u>530/388.1</u>, <u>530/388.15</u> , <u>530/389.1</u>

ABSTRACT:

Monoclonal antibody and the hybridoma producing the antibody are disclosed. The antibody is produced against an epitope on native secreted forms of .beta.APP. A characteristic of the antibody is that the antibody specifically binds to at least one protein in culture medium in which neuroblastoma cells have been grown. This protein co-migrates in non-reducing polyacrylamide gel electrophoresis with PN-2 isolated from human fibroblast cultures. Other characteristics of the antibody are that the antibody specifically binds to PN-2 and to the secreted form of .beta.APP lacking the Kunitz-type inhibitor domain, the antibody selectively binds to neuritic plaques, and the antibody is sufficiently sensitive to detect secreted forms of .beta.APP in CSF, down to a total concentration of the secreted forms of .beta.APP of 3.75 .mu.g/ml or lower.

2 Claims, 8 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

=												
	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sentence: Attachments	Claims	KWIC	Draw, De
								-				

☐ 13. Document ID: US 5424221 A

L7: Entry 13 of 21

File: USPT

Jun 13, 1995

US-PAT-NO: 5424221

DOCUMENT-IDENTIFIER: US 5424221 A

** See image for Certificate of Correction **

TITLE: Kit for detection of islet amyloid polypeptide (IAPP)

Record List Display Page 10 of 16

DATE-ISSUED: June 13, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Westermark; Per Balinge SE

Johnson; Kenneth H. Minneapolis MN

US-CL-CURRENT: <u>436/518</u>; <u>435/7.92</u>, <u>435/7.94</u>, <u>435/7.95</u>, <u>435/975</u>, <u>436/501</u>, <u>436/533</u>, <u>436/548</u>, <u>530/387.1</u>, <u>530/387.9</u>, 530/388.24

ABSTRACT:

This invention is directed to kits for the detection of human islet amyloid
polypeptide (IAPP) comprising (a) purified preparations of antibodies which react
specifically with insulin or calcitonin gene-related peptides and (b) a preselected
amount of human islet amyloid polypeptide which is essentially free of islet
amyloid, which polypeptide is one subunit of islet amyloid and which is prepared by
depolymerizing human islet amyloid; or a preselected amount of human islet amyloid
polypeptide which is essentially free of islet amyloid and has the amino acid
sequence: amyloid
sequence: amyloid
sequence: amyloid
sequence: <a href="mailto:lys-cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr.

13 Claims, 1 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full	Title	Citation Front	Review	Classification	Date	Reference	Septembro	eticellinens)	Claims	KWAC	Drawi De
										•	
	14	Document ID	. IIC 5	210970 A			······································				

File: USPT

May 10, 1994

US-PAT-NO: 5310879

L7: Entry 14 of 21

DOCUMENT-IDENTIFIER: US 53108.79 A

TITLE: Antibodies which immunoreact with lapine lipopolysaccharide binding protein

(LBP)

DATE-ISSUED: May 10, 1994

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Ulevitch; Richard J. Del Mar CA

Tobias; Peter S. Encinitas CA

US-CL-CURRENT: <u>530/388.1</u>; <u>530/388.25</u>, <u>530/389.1</u>, <u>530/389.3</u>

ABSTRACT:

A lipopolysaccharide binding protein, LBP, which is present in acute phase serum of an animal host, but is substantially absent from the normal serum of the host, method of detection, and antibodies that bind to LBP are described.

Record List Display Page 11 of 16

4 Claims, 32 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 18

Full Title Citation Front Review Classification Date Reference Sequences Statischments Claims KWIC Drava De

☐ 15. Document ID: US 5231170 A

L7: Entry 15 of 21

File: USPT

Jul 27, 1993

US-PAT-NO: 5231170

DOCUMENT-IDENTIFIER: US 5231170 A

TITLE: Antibodies to dense microspheres

DATE-ISSUED: July 27, 1993

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE

COUNTRY

Averback; Paul

Montreal, Quebec

 $C\Delta$

US-CL-CURRENT: 530/388.1; 435/70.21, 436/548, 530/388.85, 530/389.1, 530/839

ABSTRACT:

Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at intissue concentrations of 10.sup.-5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis. Antibodies to DMS (dense microspheres) are also disclosed.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title	Citation Front F	Review Classifi	cation Date	Reference	Sequences	I straid messes	Claims	KWIC	Draw De
T 16.	Document ID:	US 523100	0 A	***************************************				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	***************************************
L7: Entry	16 of 21			File: 0	JSPT		Jul	27,	1993

US-PAT-NO: 5231000

DOCUMENT-IDENTIFIER: US 5231000 A

TITLE: Antibodies to A4 amyloid peptide

DATE-ISSUED: July 27, 1993

Record List Display Page 12 of 16

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Majocha; Ron Wayland MA Marotta; Charles A. Cambridge MA Zain; Sayeeda Pittsford NY

US-CL-CURRENT: 435/7.1; 435/331, 435/7.2, 435/7.21, 436/501, 436/506, 530/388.1

ABSTRACT:

Monoclonal antibodies to a 28-mer peptide present within A4-amyloid are described. These antibodies exhibit unexpected specificity for amyloid plaque structures previously unrecognized in Alzheimer's disease brains. These monoclonal antibodies are useful as reagents for use in assays and imaging of A4-amyloid in Alzheimer's disease patients.

9 Claims, 1 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Seguerose.	Alisabilitatika	Claims	KWIC	Drawi De
•												
·····	***************************************					···	***************************************	***************************************				

☐ 17. Document ID: US 5223409 A

L7: Entry 17 of 21

File: USPT

Jun 29, 1993

US-PAT-NO: 5223409

DOCUMENT-IDENTIFIER: US 5223409 A

TITLE: Directed evolution of novel binding proteins

DATE-ISSUED: June 29, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Ladner; Robert C. Ijamsville MD Guterman; Sonia K. Belmont MA Roberts; Bruce L. Milford MA Markland; William Milford MA Ley; Arthur C. Newton MA Kent; Rachel B. Boxborough MA

US-CL-CURRENT: 435/69.7; 435/252.3, 435/320.1, 435/472, 435/5, 435/69.1, 530/387.3, 530/387.5

ABSTRACT:

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are

Record List Display Page 13 of 16

introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

66 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De
								•				

☐ 18. Document ID: US 5218100 A

L7: Entry 18 of 21

File: USPT

Jun 8, 1993

US-PAT-NO: 5218100

DOCUMENT-IDENTIFIER: US 5218100 A

TITLE: DNA encoding for the precursor protein of APC polypeptide associated with

Alzheimer's disease

DATE-ISSUED: June 8, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Muller-Hill; Benno Cologne DE Kang; Jie Bonn DE Lemaire; Hans-Georg Cologne DE Unterbeck; Axel West Haven CT

US-CL-CURRENT: <u>536/23.5</u>; <u>530/350</u>, <u>530/388.1</u>

ABSTRACT:

The present invention relates to the precursor protein of amyloid plaque core (APC) polypeptide, to fragments of the precursor protein and to the diagnostic use of the precursor protein and of the fragments. Furthermore, the invention relates to the DNA coding for the precursor protein, to fragments of this DNA and to the diagnostic use of the DNA and of the fragments.

3 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3 ☐ 19. Document ID: US 5182107 A

L7: Entry 19 of 21

File: USPT

Jan 26, 1993

US-PAT-NO: 5182107

DOCUMENT-IDENTIFIER: US 5182107 A

TITLE: Transferrin receptor specific antibody-neuropharmaceutical or diagnostic

agent conjugates

DATE-ISSUED: January 26, 1993

INVENTOR-INFORMATION:

NAME

CITY .

STATE ZIP CODE

COUNTRY

Friden; Phillip M.

Bedford

MA

US-CL-CURRENT: <u>424/179.1</u>; <u>424/143.1</u>, <u>424/178.1</u>, <u>424/94.1</u>, <u>514/21</u>, <u>530/387.3</u>, <u>530/388.22</u>, <u>530/391.1</u>, <u>530/391.7</u>, <u>530/391.9</u> , 530/399

ABSTRACT:

The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.

27 Claims, 10 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

												
Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	. Hackments	Claims	MODE	Dirator De
				كمسمسمي			, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	and the second second	200	21011112	140010	D1800 D1

☐ 20. Document ID: JP 02138995 A

L7: Entry 20 of 21

File: JPAB

May 28, 1990

PUB-NO: JP402138995A

DOCUMENT-IDENTIFIER: JP 02138995 A

TITLE: MONOCLONAL ANTIBODY AGAINST NOVEL PROTEIN

PUBN-DATE: May 28, 1990

INVENTOR-INFORMATION:

NAME

COUNTRY

KITAGUCHI, NOBUYA

ITO, HIRATAKA

TAKAHASHI, YASUYUKI

Record List Display Page 15 of 16

TOKUSHIMA, YASUO

US-CL-CURRENT: 530/388.1

INT-CL (IPC): C12P 21/08; C12N 5/20; G01N 33/53; G01N 33/577; C07K 7/06; C07K 7/08;

CO7K 13/00; CO7K 15/12; C12N 15/06

ABSTRACT:

PURPOSE: To obtain a monoclonal antibody against protein by cultivating mouse fused cell strain ADI 1-7-5-2, mouse fused cell strain ADI 1-4-6-1, mouse fused cell strain ADI 1-05-44-2, etc.

CONSTITUTION: A monoclonal antibody producing strain such as mouse fused cell strain ADI 1-7-5-2, mouse fused cell strain ADI 1-05-44-2 or mouse fused cell strain ADI-5-3-7 is prepared by cell fusion method and the antibody-forming strain is cultured to give a monoclonal antibody. The prepared monoclonal antibody is a monoclonal antibody specific to amino acid sequence having continuous five or more residues among amino acid sequence of amyloid precursor protein of human cerebral senile spot having inhibitory activity against protease and is useful for diagnosing cerebral nerve dysbolism including senile dementia.

COPYRIGHT: (C) 1990, JPO& Japio

·											
Full	Title	Citation	Front	Review	Classification	Date	Reference	Attachments	Claims	KWAC	Draw. De

☐ 21. Document ID: WO 9012871 A1

L7: Entry 21 of 21

File: EPAB

Nov 1, 1990

PUB-NO: WO009012871A1

DOCUMENT-IDENTIFIER: WO 9012871 A1

TITLE: CEREBROVASCULAR AMYLOID PROTEIN-SPECIFIC MONOCLONAL ANTIBODY SV17-6E10

PUBN-DATE: November 1, 1990

INVENTOR-INFORMATION:

NAME	COUNTRY
KIM, KWANG S	US
WISNIEWSKI, HENRYK M	US
WEN, GUANG Y	US
CHEN, CHENG-MO JAMES	US
SAPIENZA, VICTOR J	US

US-CL-CURRENT: <u>435/332</u>; <u>435/FOR.111</u>, <u>530/388.1</u>

INT-CL (IPC): C07K 15/28; C12N 5/20; G01N 33/533; G01N 33/534; G01N 33/535

EUR-CL (EPC): C07K016/18; C07K014/47

ABSTRACT:

Disclosed is monoclonal antibody SV17-6E10 and a specific-binding fragment thereof which is specifically reactive with a peptide whose concentration level is elevated in individuals having Down's syndrome or Alzheimer's disease as compared to individuals of substantially the same age who are not so-afflicted and which does

Record List Display Page 16 of 16


not react with other peptides of human origin. Also disclosed is a hybridoma cell line capable of producing the monoclonal antibody, a reagent composition which incorporates the monoclonal antibody or specific-binding fragments thereof and an immunoassay method for their use.

Full	Title Citat	ion Fro	nt Review	Classification	Date	Reference	SEQUETRO	is estate		Claims	KWIC	Drawu De
Clear	Ge	nerate	Collection	Print		wd Refs	. Bk	wd Refs		Gener	ate OA	CS .
	Terms						D	ocument	s			
	(L5) AN	D @A	Y <= 199	94						,	21	

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List



Search Results - Record(s) 1 through 23 of 23 returned.

☐ 1. Document ID: US 5348963 A

L10: Entry 1 of 23

File: USPT

Sep 20, 1994

US-PAT-NO: 5348963

DOCUMENT-IDENTIFIER: US 5348963 A

TITLE: Method of screening for modulators of amyloid formation

DATE-ISSUED: September 20, 1994

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Gandy; Samuel E. New York NY
Caporaso; Gregg L. New York NY
Greengard; Paul New York NY

US-CL-CURRENT: $\underline{514}/\underline{313}$; $\underline{206}/\underline{569}$, $\underline{435}/\underline{7.21}$, $\underline{436}/\underline{507}$, $\underline{514}/\underline{453}$, $\underline{514}/\underline{468}$, $\underline{514}/\underline{510}$, $\underline{514}/\underline{691}$, $\underline{514}/\underline{729}$, $\underline{514}/\underline{739}$, $\underline{514}/\underline{766}$

ABSTRACT:

Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and its related derivatives such as primaquine.

1 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	STANDARD STANDARD	Sign ments	Claims	KWIC	Draw, De
 											w.i	

☐ 2. Document ID: US 5292652 A

L10: Entry 2 of 23

File: USPT

Mar 8, 1994

US-PAT-NO: 5292652

DOCUMENT-IDENTIFIER: US 5292652 A

TITLE: Amyloidin protease and uses thereof

Record List Display Page 2 of 20

DATE-ISSUED: March 8, 1994

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Dovey; Harry F. Pacifica CA
Seubert; Peter A. San Mateo CA
Sinha; Sukanto San Francisco CA

US-CL-CURRENT: <u>435</u>/<u>226</u>; <u>435</u>/219

ABSTRACT:

A proteolytic enzyme isolated from human tissue which exhibits a proteolytic activity to hydrolyze Met-Asp peptide bond in an amyloid-like substrate is disclosed. This enzyme has been designated "amyloidin" because it proteolytically cleaves a Met-Asp bond similar to the one present in the amyloid precursor protein to release a fragment having the mature Asp terminus of the beta.-amyloid peptide. Antibodies to the amyloidin protease are also provided. Methods to isolate and purify the amyloidin protease are provided, as well as assays to screen for inhibitors of the amyloidin protease. Also disclosed is the gene encoding the protease and methods for expression of the protease by recombinant DNA means.

15 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full	Title	Citation	Erant	Passions	Classification	D	Datassas	Construction Section	Attachments		14640	D D
ı VII	11111	Citation	LIDIN	Wentenn	Classification	vale	Reference		Particular	Ulaims	KOOL	Drawii De
												

☐ 3. Document ID: US 5281521 A

L10: Entry 3 of 23 File: USPT Jan 25, 1994

US-PAT-NO: 5281521

DOCUMENT-IDENTIFIER: US 5281521 A

TITLE: Modified avidin-biotin technique

DATE-ISSUED: January 25, 1994

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Trojanowski; John Q. Philadelphia PA Lee; Virginia M-Y. Philadelphia PA

US-CL-CURRENT: $\underline{435/7.5}$; $\underline{435/7.2}$, $\underline{435/7.92}$, $\underline{435/960}$, $\underline{435/962}$, $\underline{436/501}$, $\underline{436/548}$

ABSTRACT:

A method for preparing an antigen specific probe is provided by incubating a primary antigen specific <u>monoclonal antibody</u> with a biotinylated secondary antibody to produce a complex of the primary and secondary antibodies. The staining pattern produced by these probes reflects the specificity of the <u>monoclonal antibody</u> in the

Record List Display Page 3 of 20

complex and the labeling of irrelevant, endogenous immunoglobulins is reduced substantially. This novel, indirect immunohistochemical method can be used to study normal and diseased tissues using a variety of monoclonal antibodies.

8 Claims, 23 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KØIC	Drawi De
						-					- :	

☐ 4. Document ID: US 5270165 A

L10: Entry 4 of 23

File: USPT

Dec 14, 1993

US-PAT-NO: 5270165

DOCUMENT-IDENTIFIER: US 5270165 A

** See image for Certificate of Correction **

TITLE: Method of diagnosis of amyloidoses

DATE-ISSUED: December 14, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Van Nostrand; William E. Irvine CA
Cunningham; Dennis D. Laguna Beach CA
Wagner; Steven L. La Jolla CA

US-CL-CURRENT: 435/7.1; 435/7.92, 435/7.93, 435/7.94, 435/7.95, 530/380, 530/387.9,

<u>530/388.2</u>

ABSTRACT:

A method of diagnosing a disease with cerebrovascular deposition of amyloid, including Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis-Dutch type and other amyloidoses, in a mammal is disclosed in which a sample of cerebrospinal fluid is obtained, the level of immunoreactivity toward a monoclonal antibody raised against native PN-2/.beta.APP or other amyloid precursor protein in the sample is measured, and this measured level is compared to the level of immunoreactivity toward this antibody in a sample from

NOTICE OF GOVERNMENT SUPPORT

This invention was made with Government support under Grant No. GM-31609 awarded by the National Institutes of Health. The Government has certain rights in this invention. American Cancer Society Grants CD 390 and BC 602/BE 22A provided further support for the development of this invention.

35 Claims, 32 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16 Record List Display Page 4 of 20

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 5. Document ID: US 5262332 A

L10: Entry 5 of 23

File: USPT

Nov 16, 1993

US-PAT-NO: 5262332

DOCUMENT-IDENTIFIER: US 5262332 A

TITLE: Diagnostic method for Alzheimer's disease: examination of non-neural tissue

DATE-ISSUED: November 16, 1993

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE

COUNTRY

Selkoe; Dennis J.

Jamaica Plain

MA

US-CL-CURRENT: $\frac{436}{518}$; $\frac{435}{167}$, $\frac{435}{7.1}$, $\frac{435}{7.9}$, $\frac{435}{960}$, $\frac{436}{174}$, $\frac{436}{501}$, $\frac{436}{547}$, $\frac{436}{548}$, $\frac{436}{63}$, $\frac{436}{811}$

ABSTRACT:

This invention provides a method as well as a kit for diagnosing Alzheimer's disease. The method comprises the steps of obtaining a non-neural tissue biopsy sample, contacting at least a portion of the sample with a quantity of antibodies capable of identifying .beta.AP, a .beta.-amyloid precursor protein fragment comprising .beta.AP, or a .beta.AP peptide fragment of about 8 or more amino acids sufficient to allow detection of said protein, protein fragment or peptide fragment, and monitoring the extent of the reaction between the sample and the antibodies. The kit comprises antibodies specific for .beta.-amyloid protein, or a .beta.-amyloid precursor protein fragment comprising .beta.-amyloid protein, or a peptide fragment of .beta.-amyloid protein of at least about eight amino acids, and a means for detecting the extent of the reaction of the antibodies with a non-neural tissue sample.

20 Claims, 0 Drawing figures Exemplary Claim Number: 1

			_									
Full	Title	: Citation	Front	Review	Classification	Date	Reference	Concension	Alcondus.	Claims	KWIC	Draw, De
······································		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		***************************************								
	6.	Documer	nt ID:	US 52	42932 A							
		rv 6 of			,		File	IIC DT		Son	7	1993

US-PAT-NO: 5242932

DOCUMENT-IDENTIFIER: US 5242932 A

TITLE: Treatment of amyloidosis associated with Alzheimer disease

DATE-ISSUED: September 7, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Gandy; Samuel E. New York NY
Caporaso; Gregg L. New York NY
Greengard; Paul New York NY

US-CL-CURRENT: 514/313; 514/453, 514/468, 514/510, 514/691, 514/729, 514/739,

<u>514/766</u>

ABSTRACT:

Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and its related derivatives such as primaquine.

8 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full Titl	e Citation	Front	Review	Classification	Date	Reference	Sequences	Altachments	Claims	KAMC	Draw, De

☐ 7. Document ID: US 5234814 A

L10: Entry 7 of 23

File: USPT

Aug 10, 1993

US-PAT-NO: 5234814

DOCUMENT-IDENTIFIER: US 5234814 A

TITLE: Diagnostic assay for alzheimer's disease

DATE-ISSUED: August 10, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Card; John P. Wilmington DE
Davis; Leonard G. Newark DE
Siman; Robert G. Wilmington DE

US-CL-CURRENT: 435/7.21; 435/7.92, 436/516, 530/350, 530/395

ABSTRACT:

A method to assist in the diagnosis of Alzheimer's disease comprising detecting, in bodily fluids, two APP-related proteins, in soluble form, said proteins have an apparent molecular size of about 130 kDa and about 35 kDa, and each of said proteins shares at least one epitope with the C-terminus of APP corresponding substantially to amino acids 676-695 of APP as shown in FIG. 1.

4 Claims, 5 Drawing figures Exemplary Claim Number: 1

Record List Display Page 6 of 20

Number of Drawing Sheets: 5

Full Title Citation Front Review Classification Date Reference Security Allactivities Claims KWIC Draw. De

□ 8. Document ID: US 5231170 A

L10: Entry 8 of 23

File: USPT

Jul 27, 1993

US-PAT-NO: 5231170

DOCUMENT-IDENTIFIER: US 5231170 A

TITLE: Antibodies to dense microspheres

DATE-ISSUED: July 27, 1993

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE

COUNTRY

Averback; Paul

Montreal, Quebec

CA

US-CL-CURRENT: 530/388.1; 435/70.21, 436/548, 530/388.85, 530/389.1, 530/839

ABSTRACT:

Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at intissue concentrations of 10.sup.-5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis. Antibodies to DMS (dense microspheres) are also disclosed.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences:	Alto Uniterits	Claims	KWAC	Draw De
								- <u>-</u>				

☐ 9. Document ID: US 5231000 A

L10: Entry 9 of 23

File: USPT

Jul 27, 1993

US-PAT-NO: 5231000

DOCUMENT-IDENTIFIER: US 5231000 A

TITLE: Antibodies to A4 amyloid peptide

DATE-ISSUED: July 27, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Majocha; Ron Marotta; Charles A. Wayland MA Cambridge MA NY

Zain; Sayeeda

Pittsford

US-CL-CURRENT: $\underline{435}/\underline{7.1}$; $\underline{435}/\underline{331}$, $\underline{435}/\underline{7.2}$, $\underline{435}/\underline{7.21}$, $\underline{436}/\underline{501}$, $\underline{436}/\underline{506}$, $\underline{530}/\underline{388.1}$

ABSTRACT:

Monoclonal antibodies to a 28-mer peptide present within A4-amyloid are described. These antibodies exhibit unexpected specificity for amyloid plaque structures previously unrecognized in Alzheimer's disease brains. These monoclonal antibodies are useful as reagents for use in assays and imaging of A4-amyloid in Alzheimer's disease patients.

9 Claims, 1 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full 1	Title	Citation	Front	Review	Classification	Date	Reference	Sequences:	ettaglimens	Claims	KWIC	Drawi De
									•			

☐ 10. Document ID: US 5223482 A

L10: Entry 10 of 23

File: USPT

Jun 29, 1993

US-PAT-NO: 5223482

DOCUMENT-IDENTIFIER: US 5223482 A

TITLE: Recombinant Alzheimer's protease inhibitory amyloid protein and method of

use

DATE-ISSUED: June 29, 1993

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE COUNTRY

Schilling, Jr.; James W.

Palo Alto

CA

Ponte; Phyllis A.

Mountain View

CA

Cordell; Barbara

Palo Alto

CA

US-CL-CURRENT: 514/12; 435/69.2, 435/910, 530/324, 530/350, 530/839

ABSTRACT:

DNA sequences encoding .beta.-amyloid-related proteins associated with Alzheimer's disease are disclosed. Also provided herein is a DNA sequence encoding a novel protease inhibitor. These sequences are used in producing or constructing recombinant .beta.-amyloid core protein, .beta.-amyloid-related proteins and recombinant or synthetic immunogenic peptides. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.

10 Claims, 28 Drawing figures Exemplary Claim Number: 1

Record List Display Page 8 of 20

Number of Drawing Sheets: 25

Full Title Citation Front Review Classification Date Reference Sequences Stackments Claims KWIC Draw De

☐ 11. Document ID: US 5223409 A

L10: Entry 11 of 23

File: USPT

Jun 29, 1993

US-PAT-NO: 5223409

DOCUMENT-IDENTIFIER: US 5223409 A

TITLE: Directed evolution of novel binding proteins

DATE-ISSUED: June 29, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Ladner; Robert C. Ijamsville MD Guterman; Sonia K. Belmont MA Roberts: Bruce L. Milford MA Markland; William Milford MA Ley; Arthur C. Newton MA Kent; Rachel B. Boxborough MA

US-CL-CURRENT: <u>435/69.7</u>; <u>435/252.3</u>, <u>435/320.1</u>, <u>435/472</u>, <u>435/5</u>, <u>435/69.1</u>, <u>530/387.3</u>, 530/387.5

ABSTRACT:

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

66 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Altschmenis	Claims	KWIC	Drawi De

Record List Display Page 9 of 20

☐ 12. Document ID: US 5221607 A

L10: Entry 12 of 23 File: USPT Jun 22, 1993

US-PAT-NO: 5221607

DOCUMENT-IDENTIFIER: US 5221607 A

TITLE: Assays and reagents for amyloid deposition

DATE-ISSUED: June 22, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Cordell; Barbara Palo Alto CA Wolf; David Palo Alto CA

US-CL-CURRENT: $\underline{435/6}$; $\underline{435/320.1}$, $\underline{435/7.21}$, $\underline{435/70.1}$, $\underline{435/70.3}$, $\underline{436/811}$, $\underline{530/300}$, $\underline{530/806}$, $\underline{530/839}$, $\underline{536/23.5}$

ABSTRACT:

The present invention provides an in vitro tissue culture-based assay for amyloid deposition specific for Alzheimer's disease which is suitable for routine drug screening analysis. Immunological diagnostic reagents for Alzheimer's disease are also provided.

7 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Affachments	Claims	KWIC	Draw, De

☐ 13. Document ID: US 5220013 A

L10: Entry 13 of 23 File: USPT Jun 15, 1993

US-PAT-NO: 5220013

DOCUMENT-IDENTIFIER: US 5220013 A

TITLE: DNA sequence useful for the detection of Alzheimer's disease

DATE-ISSUED: June 15, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Ponte; Phyllis A. Mountain View CA Cordell; Barbara Palo Alto CA

US-CL-CURRENT: $\underline{536}/\underline{23.5}$; $\underline{435}/\underline{6}$, $\underline{436}/\underline{84}$, $\underline{530}/\underline{324}$, $\underline{536}/\underline{24.31}$

ABSTRACT:

Record List Display Page 10 of 20

DNA sequences encoding the <u>beta-amyloid</u> core protein, and beta-amyloid-related proteins associated with Alzheimer's disease are disclosed. These sequences are used in producing or constructing recombinant <u>beta-amyloid</u> core protein, beta-amyloid-related proteins and recombinant or synthetic immunogenic peptides. These sequences are also used to identify genomic mutations and/or restriction site alterations which are associated with a predisposition to Alzheimer's disease, for purposes of genetic screening. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.

5 Claims, 14 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
								-				

☐ 14. Document ID: US 5218100 A

L10: Entry 14 of 23

File: USPT

Jun 8, 1993

US-PAT-NO: 5218100

DOCUMENT-IDENTIFIER: US 5218100 A

TITLE: DNA encoding for the precursor protein of APC polypeptide associated with

Alzheimer's disease

DATE-ISSUED: June 8, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Muller-Hill; Benno Cologne DE Kang; Jie Bonn DE Lemaire; Hans-Georg Cologne DE Unterbeck; Axel West Haven СТ

US-CL-CURRENT: <u>536/23.5</u>; <u>530/350</u>, <u>530/388.1</u>

ABSTRACT:

The present invention relates to the precursor protein of amyloid plaque core (APC) polypeptide, to fragments of the precursor protein and to the diagnostic use of the precursor protein and of the fragments. Furthermore, the invention relates to the DNA coding for the precursor protein, to fragments of this DNA and to the diagnostic use of the DNA and of the fragments.

3 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw De

Record List Display Page 11 of 20

☐ 15. Document ID: US 5213962 A

L10: Entry 15 of 23 File: USPT May 25, 1993

US-PAT-NO: 5213962

DOCUMENT-IDENTIFIER: US 5213962 A

TITLE: Purification, detection and methods of use of protease Nexin-2

DATE-ISSUED: May 25, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Van Nostrand; William E. Irvine CA
Cunningham; Dennis D. Laguna Beach CA
Wagner; Steven L. Balboa Island CA

US-CL-CURRENT: $\underline{435}/\underline{7.1}$; $\underline{435}/\underline{7.2}$, $\underline{435}/\underline{7.21}$, $\underline{435}/\underline{7.9}$, $\underline{435}/\underline{7.92}$, $\underline{436}/\underline{548}$

ABSTRACT:

Immunopurification of Protease Nexin-2 and .beta. amyloid precursor protein is disclosed. Methods of detecting Protease Nexin-2 and the use of these methods in the diagnosis of Alzheimer's disease and other conditions are also disclosed. Additionally, pharmaceutical preparations including Protease Nexin-2 or modified forms thereof are disclosed. Medical uses for the pharmaceutical preparations are also disclosed. These uses include the treatment and prevention of amyloid plaques in Alzheimer's disease and Down's Syndrome

30 Claims, 20 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	-tiacoments	Claims	KWIC	Drawi De
								**************************************			T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-	

☐ 16. Document ID: US 5187153 A

L10: Entry 16 of 23 File: USPT Feb 16, 1993

US-PAT-NO: 5187153

DOCUMENT-IDENTIFIER: US 5187153 A

TITLE: Methods of treatment using Alzheimer's amyloid polypeptide derivatives

DATE-ISSUED: February 16, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Cordell; Barbara Palo Alto CA Schilling; James W. Palo Alto CA

Katunuma; Nobuhiko Tokushima JP

Record List Display Page 12 of 20

US-CL-CURRENT: 514/12; 424/94.64, 514/2, 530/324, 930/250

ABSTRACT:

Pharmaceutical compositions containing a 57 amino acid protease inhibitor and uses for those compositions are taught. The protease inhibitor is referred to as A4i which is associated with Alzheimer's disease. In addition to the A4i protease, other analogs are taught as are pharmaceutical compositions containing such analogs and their uses in treating a variety of abnormalities associated with Kunitz-type basic protease inhibitors. For example, it has been found that pharmaceutical compositions containing A4i protease and analogs thereof inhibit plasmin and tryptase, and also inhibit pancreatic trypsin, alpha-chymotrypsin, tissue kallikrein and serum kallikrein. In that certain diseases are associated with a general release of proteases such as trypsin, chymotrypsin and elastase into the circulatory system pharmaceutical compositions containing A4i and analogs thereof can be used in the management of such diseases.

3 Claims, 25 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference	Secretary.	Altachments	Claims	KWiC	Draw, De
								•				
П	17.	Docum	ent ID	· US 5	134121 A					•		

17. Document ID: US 5134121 A

L10: Entry 17 of 23

File: USPT

Jul 28, 1992

US-PAT-NO: 5134121

DOCUMENT-IDENTIFIER: US 5134121 A

TITLE: Nerve growth factor peptides

DATE-ISSUED: July 28, 1992

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Mobley; William C. Moraga CA
Longo; Frank M. San Francisco CA

Kauer; James C. Kennett Square PA

US-CL-CURRENT: <u>514/14</u>; <u>514/15</u>, <u>514/16</u>, <u>514/17</u>, <u>514/18</u>, <u>530/326</u>, <u>530/327</u>, <u>530/328</u>, <u>530/329</u>, <u>530/330</u>, <u>530/839</u>, <u>930/120</u>, <u>930/DIG.800</u>

ABSTRACT:

The present invention provides both agonist and antagonist nerve growth factor peptides. The NGF blocking peptides can be used to inhibit the expression of mRNA and their encoded proteins whose expression is stimulated by NGF, such as .beta.-protein precursor and prion proteins, which proteins or their products are associated with neurodegenerative disorders, whereas the NGF agonist peptides can be used to treat neoplastic disorders such as neuroblastomas.

9 Claims, 8 Drawing figures

Record List Display Page 13 of 20

Exemplary Claim Number: 1 Number of Drawing Sheets: 7

Full Title Citation Front Review Classification Date Reference Sequences Stachments Claims KMC Draw De

☐ 18. Document ID: US 4919915 A

L10: Entry 18 of 23

File: USPT

Apr 24, 1990

US-PAT-NO: 4919915

DOCUMENT-IDENTIFIER: US 4919915 A

TITLE: Method for detecting the ability to prevent red-to-green congophilic

birefringence

Averback; Paul

DATE-ISSUED: April 24, 1990

INVENTOR-INFORMATION:

CITY STATE St. Liquori, Quebec

ZIP CODE COUNTRY

CA

US-CL-CURRENT: 435/40.52; 435/4, 436/164, 436/174, 436/177, 436/183, 436/2, 436/811

ABSTRACT:

A method for detecting the ability of a compound to prevent development of red-togreen congophilic birefringence. The method is carried out by contacting the compound with dense microspheres which are derived from mammalian brain tissue and which, when disrupted, display red-to-green congophilic birefringence upon staining with Congo Red dye under conditions such that said dense microspheres are disrupted. Thereafter the disrupted dense microspheres are stained with Congo Red dye and any development of red-to-green congophilic birefringence in the stained disrupted dense microspheres is detected.

13 Claims, 2 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawi De

19. Document ID: DE 69432629 E, WO 9417197 A1, JP 06516868 X, EP 683234 A1, US 5750349 A, US 5955317 A, EP 1308461 A2, EP 683234 B1

L10: Entry 19 of 23

File: DWPI

Jun 12, 2003

DERWENT-ACC-NO: 1994-264110

DERWENT-WEEK: 200346

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Antibodies recognising specific parts of beta-amyloid - can be used for diagnosis of diseases implicating beta-amyloid, such as Alzheimer's disease

INVENTOR: KITADA, C; ODAKA, A; SUZUKI, N

PRIORITY-DATA: 1993JP-0334773 (December 28, 1993), 1993JP-0010132 (January 25, 1993), 1993JP-0019035 (February 5, 1993), 1993JP-0286985 (November 16, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69432629 E	June 12, 2003		000	C12P021/08
WO 9417197 A1	August 4, 1994		000	C12P021/08
JP 06516868 X	March 2, 1995		000	C07K016/18
EP 683234 A1	November 22, 1995	E	066	C12P021/08
US 5750349 A	May 12, 1998		000	G01N033/53
US 5955317 A	September 21, 1999		000	C12P021/04
EP 1308461 A2	May 7, 2003	E	000	C07K016/18
EP 683234 B1	May 7, 2003	E	000	C12P021/08

INT-CL (IPC): $\underline{\text{C07}}$ K $\underline{15/06}$; $\underline{\text{C07}}$ K $\underline{15/28}$; $\underline{\text{C07}}$ K $\underline{16/00}$; $\underline{\text{C07}}$ K $\underline{16/06}$; $\underline{\text{C07}}$ K $\underline{16/18}$; $\underline{\text{C07}}$ K $\underline{16/28}$; $\underline{\text{C12}}$ N $\underline{5/00}$; $\underline{\text{C12}}$ N $\underline{5/20}$; $\underline{\text{C12}}$ N $\underline{15/00}$; $\underline{\text{C12}}$ P $\underline{5/20}$; $\underline{\text{C12}}$ P $\underline{15/06}$; $\underline{\text{C12}}$ P $\underline{21/04}$; $\underline{\text{C12}}$ P $\underline{21/08}$; $\underline{\text{C12}}$ P $\underline{\text{C$

ABSTRACTED-PUB-NO: US 5750349A BASIC-ABSTRACT:

Antibodies which recognise specific portions (N-terminal, central or C-terminal) of the <u>beta-amyloid</u> molecule and its derivatives are new. The antibodies are pref. monoclonal.

(a) C-terminal: antibodies recognising a peptide corresponding to positions (25-35) of the beta-amyloid molecule but not (35-43); recognising (35-43) but not (25-35); or not recognising either of these. (b) N-terminal: antibodies recognising (1-16) and/or (1-28). (c) Central: antibodies recognising (18-28). (d) Monoclonal antibodies specifically claimed: BAN-052a and BAN-50a, recognising N-terminal sequences (1-16) and (1-28).

Hybridomas are produced by the fusion of spleen cells of mice immunised against a beta-amyloid peptide, with a myeloma cell line such as P3U1, NS-1, AP-1 or SP2/0. The hybridomas are then screened for the production of appropriate antibody.

USE/ADVANTAGE - Assay of <u>beta-amyloid</u> and its derivatives in biological samples, using these antibodies or combinations of them, for the diagnosis of diseases in which <u>beta-amyloid</u> or its derivatives are implicated, such as Alzheimer's disease. The antibodies can also be used in the production of agents for the treatment and prevention of Alzheimer's disease.

ABSTRACTED-PUB-NO:

US 5955317A EQUIVALENT-ABSTRACTS:

Antibodies which recognise specific portions (N-terminal, central or C-terminal) of the <u>beta-amyloid</u> molecule and its derivatives are new. The antibodies are pref. monoclonal.

(a) C-terminal: antibodies recognising a peptide corresponding to positions (25-35) of the beta-amyloid molecule but not (35-43); recognising (35-43) but not (25-35); or not recognising either of these. (b) N-terminal: antibodies recognising (1-16) and/or (1-28). (c) Central: antibodies recognising (18-28). (d) Monoclonal antibodies specifically claimed: BAN-052a and BAN-50a, recognising N-terminal

Record List Display Page 15 of 20

sequences (1-16) and (1-28).

Hybridomas are produced by the fusion of spleen cells of mice immunised against a beta-amyloid peptide, with a myeloma cell line such as P3U1, NS-1, AP-1 or SP2/0. The hybridomas are then screened for the production of appropriate antibody.

USE/ADVANTAGE - Assay of beta-amyloid and its derivatives in biological samples, using these antibodies or combinations of them, for the diagnosis of diseases in which beta-amyloid or its derivatives are implicated, such as Alzheimer's disease. The antibodies can also be used in the production of agents for the treatment and prevention of Alzheimer's disease.

Antibodies which recognise specific portions (N-terminal, central or C-terminal) of the beta-amyloid molecule and its derivatives are new. The antibodies are pref. monoclonal.

(a) C-terminal: antibodies recognising a peptide corresponding to positions (25-35) of the beta-amyloid molecule but not (35-43); recognising (35-43) but not (25-35); or not recognising either of these. (b) N-terminal: antibodies recognising (1-16) and/or (1-28). (c) Central: antibodies recognising (18-28). (d) Monoclonal antibodies specifically claimed: BAN-052a and BAN-50a, recognising N-terminal sequences (1-16) and (1-28).

Hybridomas are produced by the fusion of spleen cells of mice immunised against a beta-amyloid peptide, with a myeloma cell line such as P3U1, NS-1, AP-1 or SP2/0. The hybridomas are then screened for the production of appropriate antibody.

USE/ADVANTAGE - Assay of beta-amyloid and its derivatives in biological samples, using these antibodies or combinations of them, for the diagnosis of diseases in which beta-amyloid or its derivatives are implicated, such as Alzheimer's disease. The antibodies can also be used in the production of agents for the treatment and prevention of Alzheimer's disease.

WO 9417197A

Full Title Citation Front Review Classification	Date Reference Secu	aicas Atlactiments (Claims KWMC	Draw. De
☐ 20. Document ID: US 5270165 A				***************************************
L10: Entry 20 of 23	File: DWPI		Dec 14,	1993

DERWENT-ACC-NO: 1993-404921

DERWENT-WEEK: 199350

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Diagnosis of Alzheimer's disease and other amyloidoses - by detecting lowered levels of amyloid precursor protein in cerebrospinal fluid of a patient

INVENTOR: CUNNINGHAM, D D; VAN NOSTRAND, W E ; WAGNER, S L

PRIORITY-DATA: 1991US-0779070 (October 15, 1991), 1990US-0513786 (April 24, 1990)

PATENT-FAMILY:

PUB-NO PUB-DATE LANGUAGE **PAGES** MAIN-IPC US 5270165 A December 14, 1993 038 G01N033/53 Record List Display Page 16 of 20

INT-CL (IPC): G01N 33/53

ABSTRACTED-PUB-NO: US 5270165A

BASIC-ABSTRACT:

Diagnosing Alzheimer's Disease (AD) in a mammal comprises; (a) obtg. a sample of cerebrospinal fluid (CSF) from the mammal, (b) measuring the level of immunoreactivity toward a monoclonal antibody (MAb) raised against native protease nexin-2 (PN-2)/beta-amyloid precursor protein (bAPP) in the sample, and (c) determining the level of immunoreactivity toward the antibody in a sample from a similar mammal known to be free of AD, whereby a lower level neasured in step (b) than in step (c) indicates a likelihood of AD.

Also claimed is the method of diagnosing AD in a mammal by (a) obtd. a sample with a vol. less than 100 micro-l or CSF from the mammal, (b) measuring the level of PN-2/bAPP in the sample and (c) determining the level of PN-2/bAPP in a sample of the same vol. of CSF from a similar mammal known to be free of AD, whereby a lower level measured in step (b) indicates a likelihood of AD.

Used for the diagnosis of AD and other diseases such as Hereditary Cerebral Haemorrhage with Amyloidosis, Dutch or Icelandic type (claimed). Can be used to diagnose the diseases prior to any clinical manifestations of the diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Séquences	Attachments c	laims KOMC	Draw, De

☐ 21. Document ID: WO 9116628 A, EP 527823 A1, US 5213962 A, JP 05506990 W, EP 527823 A4, US 5427931 A

L10: Entry 21 of 23

File: DWPI

Oct 31, 1991

DERWENT-ACC-NO: 1991-339971

DERWENT-WEEK: 200152

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Detecting circulating levels of amyloid precursor protein - for use in diagnosing neuro:degenerative conditions e.g. Alzheimer's disease and Down's syndrome

INVENTOR: CUNNINGHAM, D D; VAN NOSTRAND, W'E; WAGNER, S L; VANNOSTRAN, W E

PRIORITY-DATA: 1990US-0513786 (April 24, 1990), 1992US-0924417 (July 30, 1992), 1993US-0056423 (April 27, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9116628 A	October 31, 1991		000	
EP 527823 A1	February 24, 1993	E	054	G01N033/53
US 5213962 A	May 25, 1993		023	C12Q001/70
JP 05506990 W	October 14, 1993		017	C12P021/08
EP 527823 A4	April 6, 1994		000	
<u>US</u> 5427931 A	June 27, 1995		022	C12P021/08

INT-CL (IPC): A61K 39/395; C12P 21/08; C12Q 1/70; G01N 33/53

Record List Display Page 17 of 20

ABSTRACTED-PUB-NO: US 5213962A BASIC-ABSTRACT:

The method comprises obtaining platelets from a patient and determining the presence or level of amyloid precursor protein (APP) in the platelets. The platelets may be lysed before determination or may be activated with a platelet agonist e.g. thrombin and collagen.

Also claimed are a MAb specific to protease nexin-2 (PN-2) or beta-APP and a recombinant cell line that expresses PN-2 which lacks a portion of the A4 region.

USE/ADVANTAGE - The method is used to diagnose neurodegenerative conditions e.g. Alzheimer's disease and Down's syndrome, by determining levels of PN-2 or beta-APP in platelets. PN-2 is used to inhibit deposition of amyloid plaques by inhibiting cleavage of APP to release A4 in preventing further neurodegeneration. This has application in the treatment of stroke, myocardial infarction and phlebitis. Antibodies to PN-s are used to diagnose Alzheimer's disease at autopsy. ABSTRACTED-PUB-NO:

US 5427931A EQUIVALENT-ABSTRACTS:

Method of diagnosing a neurodegenerative condition associated with cerebral deposition of amyloid, comprises (a) obtaining a platelet sample; (b) determining the secreted forms of beta-AIP in the sample; and (c) comparing the level with normal levels, where a decreased level is indicative of the condition.

USE/ADVANTAGE - For diagnosing Alzheimer's disease and Down syndrome. Diagnosis is early

Hybridoma strain ATCC HB-10424 produces a $\underline{\text{monoclonal antibody}}$ that binds specifically with an epitope on natural secreted forms of $\underline{\text{beta-amyloid}}$ precursor protein and one o more proteins produced in neuroblastoma cell cultures.

USE/ADVANTAGE - The prods. provide a means of determining amyloid precursor protein and related fragments in blood platelet samples for the diagnosis of neurodegenerative conditions, e.g. Alzheimer's disease.

ADVANTAGE - The prods. facilitate the early diagnosis of these conditions and possible therapy.

WO 9116628A

Full Title Citation Front Review Classification Date Reference Sequences Attachneris Claims KMC Draw De

☐ 22. Document ID: WO 9104339 A, AU 9064311 A, EP 493470 A1, JP 05502368 W, US 5221607 A, AU 641434 B, EP 493470 A4, CA 2065404 C

L10: Entry 22 of 23

File: DWPI

Apr 4, 1991

DERWENT-ACC-NO: 1991-117526

DERWENT-WEEK: 200306

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: In vitro tissue culture-based assay for amyloid deposition - specific for Alzheimer's disease, useful for drug screening analysis

INVENTOR: CORDELL, B; WOLF, D

Record List Display Page 18 of 20

PRIORITY-DATA: 1989US-0408767 (September 18, 1989), 1991US-0785142 (October 29, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9104339 A	April 4, 1991		000	
AU 9064311 A	April 18, 1991		000	
EP 493470 A1	July 8, 1992	E	035	C12Q001/68
JP 05502368 W	April 28, 1993		012	C12Q001/68
<u>US 5221607 A</u>	June 22, 1993		013	C12Q001/68
AU 641434 B	September 23, 1993		000	G01N033/564
EP 493470 A4	November 25, 1992		000	
CA 2065404 C	December 24, 2002	E	000	C12Q001/04

INT-CL (IPC): A61K 35/14; C07K 13/00; C07K 15/12; C12N 15/00; C12N 15/12; C12P 21/02; C12Q 1/02; C12Q 1/04; C12Q 1/68; G01N 33/53; G01N 33/531; G01N 33/564; G01N 33/68

ABSTRACTED-PUB-NO: US 5221607A BASIC-ABSTRACT:

Method of screening agents (I) capable of intervention in Alzheimer's disease amyloidosis comprises: (a) culturing a cell line capable of expressing a gene encoding beta-amyloid protein under conditions suitable to produce the beta-amyloid protein as an insol. preamyloid aggregate; (b) combining a known quantity of (I) with the cell culture; and (c) monitoring the combination to determine whether preamyloid aggregate formation is reduced.

The <u>beta-amyloid</u> gene pref. encodes a protein comprising the amyloid plaque core domain and the carboxy-terminal domains. Also claimed is an immunological reagent capable of detecting preamyloid aggregate formation. The reagent is pref. a <u>monoclonal antibody</u>. A kit is also provided.

USE- The efficiency of (I) is monitored through observation of reduced antibody binding to the amyloid deposit. Redn. in such binding is indicative of reduced preamyloid deposition. (I) may be tested to see whether it can inhibit peamyloid formation, in which case the cpd. is introduced to the culture medium before monitoring for preamyloid aggregation. Alternatively (I) is introduced to the culture medium after preamyloid formation has been established and this reaction mixt. is monitored to see whether the cpd. induces amyloid resorption. ABSTRACTED-PUB-NO:

WO 9104339A EQUIVALENT-ABSTRACTS:

Screening agents affecting amt. of preamyloit deposits comprises:- (a) culturing a cell line transfected with a DNA sequence encoding and intracellularly expressing a given polypeptide (beta-amyloid protein as an insol., preamyloid aggregate undetectable by Congo red stain); (b) combining a known amt. of the agent with the culture; and (c) monitoring the combination to determine the effect of the aggregate.

USE/ADVANTAGE - Screening agents useful as diagnostics for Alzheimer's disease

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De

☐ 23. Document ID: WO 9012871 A, AU 9054397 A

L10: Entry 23 of 23

File: DWPI

Nov 1, 1990

DERWENT-ACC-NO: 1990-348474

DERWENT-WEEK: 199046

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Cerebrovascular amyloid protein-specific <u>monoclonal antibody</u> SV17-6E10 - for immunoassay of peptide whose levels are raised in Down's syndrome or Alzheimer's disease patients

INVENTOR: CHEN, C M J; KIM, K S ; SAPIENZA, V J ; WEN, G Y ; WISNIEWSKI, H M

PRIORITY-DATA: 1989US-0338983 (April 14, 1989)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES MA

MAIN-IPC

WO 9012871 A AU 9054397 A November 1, 1990 November 16, 1990 000

INT-CL (IPC): C07K 15/28; C12N 5/20; G01N 33/53

ABSTRACTED-PUB-NO: WO 9012871A


BASIC-ABSTRACT:

MAb SV17-6E10 and its Ag-binding fragments are new. The MAb is specifically reactive with a cerebrovascular amyloid protein whose elevated levels are characteristic of Alzheimer's disease or Down's syndrome. Preferably the MAb is of subclass IgG1. The MAb or fragment is preferably one which specifically binds with a peptide of sequence Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-Gln- Lys-Leu . The MAb is produced by fusion of murine myeloma cells especially from an NSO myeloma line and Ab-producing cells from a mouse previously immunised with the amyloid protein. The hybridoma cell line is also claimed. Compositions for the quantitative determination of the peptide comprise the MAb and a detectable moiety. Specifically the MAb is conjugated to an enzyme and the moiety is a chromogenic redox substance for the enzyme or the moiety is attached to an Ab specifically bindable with an Ig or the MAb is conjugated to 1 partner of a specific binding pair the other partner being conjugated to the detectable moiety. Preferably one partner is biotin or its binding analogues.

USE/ADVANTAGE - The MAb is highly specific for the amyloid peptide. It can be used in immunoassays for characterising the peptide or its precursors in connection with biogenesis of beta-amyloid peptide plaques found in Alzheimer's disease and Down's afflicted brains.

Full Titl	e Citation Front Review Classification Da	te Reference Sequences Attachments	Claims KWIC Draw D
Clear	Generate Collection Print	Fwd Refs Bkwd Refs	Generate OACS
T	erms	Documents	
To	L9) AND @PY <= 1994		

Hit List



Search Results - Record(s) 1 through 81 of 81 returned.

☐ 1. Document ID: US 6365414 B1

Ll1: Entry 1 of 81

File: USPT

Apr 2, 2002

US-PAT-NO: 6365414

DOCUMENT-IDENTIFIER: US 6365414 B1

TITLE: Vitro system for determining formation of A.beta. amyloid

DATE-ISSUED: April 2, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tanzi; Rudolph E. Canton MA Bush; Ashley I. Boston MA

US-CL-CURRENT: <u>436/86</u>; <u>436/164</u>, <u>436/177</u>, <u>436/811</u>

ABSTRACT:

The invention relates to rapid methods for determining formation of A.beta. amyloid and screening compounds which inhibit formation of A.beta. amyloid in vitro, as well as kits for carrying out the present methods. Such an agent used in vivo may prevent, ameliorate or reverse the symptoms of Alzheimer's disease and A.beta. amyloidotic disorders related to Alzheimer's disease, Down's syndrome, and Guamanian amyotrophic lateral sclerosis/Parkinson's dementia complex. The process described in this invention involves the rapid induction of A.beta. amyloid by a heavy metal cation capable of binding to a polypeptide comprising at least amino acids 6 to 28 of A.beta., such as zinc to form amyloid and determination of formation of tinctorial A.beta. amyloid. Moreover, a method of determining effectiveness of a candidate anti-amyloidotic agent for prevention or treatment of A.beta. amyloidosis is described which uses cell cultures which express at least a human A.beta. peptide.

4 Claims, 25 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 25

Fuli	Title	Citation	Front	Review	Classification	Date	Reference	santanes.	Attachments	Claims	KWMC	Drawd De
 	_									***************************************		

☐ 2. Document ID: US 6200768 B1

L11: Entry 2 of 81

File: USPT

Mar 13, 2001

Record List Display Page 2 of 47

US-PAT-NO: 6200768

DOCUMENT-IDENTIFIER: US 6200768 B1

TITLE: Method of screening for compounds that dissolve paired helical filaments

DATE-ISSUED: March 13, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Mandelkow; Eva-Maria Hamburg DE Mandelkow; Eckhard Hamburg DE Lichtenberg-Kraag; Birgit Barenklau DE Biernat; Jacek Hamburg DΕ Drewes; Gerard Hamburg DE Steiner; Barbara Cold Spring Harbor NY

US-CL-CURRENT: 435/15; 435/7.1, 435/961, 436/811

ABSTRACT:

The invention relates to epitopes of the protein which are specifically occurring in a phosphorylated state in tau protein from Alzheimer paired helical filaments, to protein kinases which are responsible for the phosphorylation of the amino acids of the tau protein giving rise to said epitopes, and to antibodies specific for said epitopes. The invention further relates to pharmaceutical compositions for the treatment or prevention of Alzheimer's disease, to diagnostic compositions and methods for the detection of Alzheimer's disease and to the use of said epitopes for the generation of antibodies specifically detecting Alzheimer tau protein. Additionally, the invention relates to methods for testing drugs effective in dissolving Alzheimer paired helical filaments or preventing the formation thereof.

1 Claims, 138 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 55

Full Title Citation Front R	leview Classification Date	Reference Sequences Altachments	Claims KOMC Draw De
			C131113 1000C D1300 D1

☐ 3. Document ID: US 6114133 A

L11: Entry 3 of 81

File: USPT

Sep 5, 2000

US-PAT-NO: 6114133

DOCUMENT-IDENTIFIER: US 6114133 A

** See image for Certificate of Correction **

TITLE: Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreg.41)

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE COUNTRY

Seubert; Peter A. South San Francisco CA
Vigo-Pelfrey; Carmen Mountain View CA
Schenk; Dale B. Pacifica CA
Barbour; Robin Newark CA

US-CL-CURRENT: $\underline{435}/\underline{7.94}$; $\underline{435}/\underline{7.1}$, $\underline{435}/\underline{7.92}$, $\underline{436}/\underline{518}$, $\underline{436}/\underline{811}$

ABSTRACT:

This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-.beta. peptide (x-.gtoreq.41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis.

20 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 2

Full "	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments	Claims	KWIC	Drawi De
							•	-			·

☐ 4. Document ID: US 6090775 A

L11: Entry 4 of 81

File: USPT

Jul 18, 2000

US-PAT-NO: 6090775

DOCUMENT-IDENTIFIER: US 6090775 A

** See image for <u>Certificate of Correction</u> **

TITLE: Treatment of neurological conditions by an interleukin-1 inhibiting compound

DATE-ISSUED: July 18, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Rothwell; Nancy Jane Poulton-le-Fylde GB
Roberts; Gareth London GB

US-CL-CURRENT: 514/2; 424/85.2, 514/12, 530/350, 530/351

ABSTRACT:

The use of a compound which prevents, inhibits or modifies the action of interleukin-1 as an active agent for the treatment of conditions of neurological degeneration. The active agent may be IL-1 receptor antagonist, particularly recombinant IL-1 ra.

22 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 2

Record List Display Page 4 of 47

Full Title Citation Front Review Classification Date Reference Sequences Altachments Claims KMC Draw De

☐ 5. Document ID: US 6057287 A

L11: Entry 5 of 81

File: USPT

May 2, 2000

US-PAT-NO: 6057287

DOCUMENT-IDENTIFIER: US 6057287 A

TITLE: Kallikrein-binding "Kunitz domain" proteins and analogues thereof

DATE-ISSUED: May 2, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Markland; William Milford MA Ladner; Robert Charles Ijamsville MD

US-CL-CURRENT: 514/2; 435/4, 435/69.1, 435/7.4, 435/7.72, 514/12, 530/300, 530/317,

530/324

ABSTRACT:

This invention relates to Kunitz domain proteins that bind to, and preferably inhibit, one or more kallikreins, and to therapeutic, diagnostic, and purification use of these proteins.

8 Claims, 14 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 15

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWC Draw. De											
	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments Claims	KOMC	Drawi De

☐ 6. Document ID: US 5981208 A

Ll1: Entry 6 of 81

File: USPT

Nov 9, 1999

US-PAT-NO: 5981208

DOCUMENT-IDENTIFIER: US 5981208 A

TITLE: Diagnostic assay for Alzheimer's disease based on the proteolysis of the

amyloid precursor protein

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tamburini; Paul P. Kensington CT Dreyer; Robert N. Wallingford CT

Record List Display Page 5 of 47

Bausch; Kathryn M.

West Haven

CT

US-CL-CURRENT: <u>435/23</u>; <u>435/7.1</u>, <u>436/518</u>, <u>436/811</u>

ABSTRACT:

A method useful in the diagnosis of Alzheimer's Disease in a patient in which an amyloid protein precursor (APP) substrate is combined with a sample of cerebrospinal fluid or blood obtained from the patient to be tested, and poteolytic cleavage of the APP substrate is detected. The absence of detectable proteolytic cleavage, or the detection of a substantially lesser degree of proteolytic cleavage, in the presence of the patient's sample compared to that detected when an APP substrate is combined with test samples from control individuals, indicates affliction with Alzheimer's Disease. Convenient test reagents and kits for aiding the diagnosis of Alzheimer's Disease are provided, such as comprising an APP substrate and immunoreagents for detecting a fragment formed by proteolytic cleavage as well as chromogenic APP substrates.

5 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full	Т	itle	Citation	Front	Review	Classification	Date	Reference	Salanga	Altrament	Claims	KWIC	Draw, De
					* T ~ ~ ^	01186		iiininuunaaa					

☐ 7. Document ID: US 5981175 A

L11: Entry 7 of 81

File: USPT

Nov 9, 1999

US-PAT-NO: 5981175

DOCUMENT-IDENTIFIER: US 5981175 A

TITLE: Methods for producing recombinant mammalian cells harboring a yeast

artificial chromosome

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Loring; Jeanne F. Foster City CA
Choi; Theodore Burlingame CA
Kay; Robert M. San Francisco CA

US-CL-CURRENT: <u>435/6</u>; <u>435/458</u>

ABSTRACT:

The present invention provides methods and compositions for transferring large transgene polynucleotides and unlinked selectable marker polynucleotides into eukaryotic cells by a novel method designated co-lipofection. The methods and compositions of the invention are used to produce novel transgenic non-human animals harboring large transgenes, such as a transgene comprising a human APP gene or human immunoglobulin gene.

Record List Display Page 6 of 47

11 Claims, 10 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Altachments	Claims	киис	Draw, De

□ 8. Document ID: US 5976816 A

L11: Entry 8 of 81

File: USPT

Nov 2, 1999

CN

US-PAT-NO: 5976816

DOCUMENT-IDENTIFIER: US 5976816 A

TITLE: Cell tests for alzheimer's disease

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Alkon; Daniel L. Bethesda MD Etcheberrigaray; Rene Rockville MD Kim; Christopher S. Silver Spring MD

Han; Yi-Fan Shanghai

Nelson; Tom J. Silver Spring MD

US-CL-CURRENT: 435/7.21; 435/7.1, 435/7.92, 436/548, 530/300, 530/387.1

ABSTRACT:

The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.

9 Claims, 49 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 30

Full	Title	Citation	Front	Raviem	Classification	Dista	Rafaranca		Cinima	KWAC	Drawa De
0.0	Title	Citation	1 10 116	1100000	Classification	vale	Mererence		Claims	KOOL	DIAME DE

☐ 9. Document ID: US 5955343 A

L11: Entry 9 of 81

File: USPT

Sep 21, 1999

US-PAT-NO: 5955343

DOCUMENT-IDENTIFIER: US 5955343 A

Record List Display Page 7 of 47

TITLE: Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor

DATE-ISSUED: September 21, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Holmes; Todd Somerville MA
Zhang; Shuguang Cambridge MA
Rich; Alexander Cambridge MA
DiPersio; C. Michael Norton MA
Lockshin; Curtis Lexington MA

US-CL-CURRENT: 435/325; 435/378, 435/395, 435/401

ABSTRACT:

Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK).sub.2 (ARARADAD).sub.2, were shown to selfassemble into macroscopic membranes. Conditions under which the peptides selfassemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic. The membranes are potentially useful in biomaterial applications such as slow-diffusion drug delivery systems, artificial skin, and separation matrices, and as experimental models for Alzheimer's disease and scrapie infection. The sequence of the peptide, EAK16, was derived from a putative Z-DNA binding protein from yeast, called zuotin. The cloning and characterization of the ZUO1 gene are also described.

4 Claims, 25 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 14

Full	Title	Citation	Front	Review	Classification	Date	Reference	ed and a	Alleghments	Claims	KWIC	Draw, De

☐ 10. Document ID: US 5948634 A

L11: Entry 10 of 81 File: USPT Sep 7, 1999

US-PAT-NO: 5948634

DOCUMENT-IDENTIFIER: US 5948634 A

TITLE: Neural thread protein gene expression and detection of alzheimer's disease

DATE-ISSUED: September 7, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Cambridge de la Monte; Suzanne MA Wands; Jack R. Waban MΑ

US-CL-CURRENT: <u>435/69.1</u>; <u>435/252.3</u>, <u>435/252.8</u>, <u>435/320.1</u>, <u>536/23.1</u>, <u>536/23.5</u>

ABSTRACT:

The present invention is directed to recombinant hosts expressing novel proteins associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. This invention is specifically directed to the recombinant hosts and vectors which contain the genes coding for the neuronal thread proteins. This invention is also directed to substantially pure neural thread protein, immunodiagnostic and molecular diagnostic methods to detect the presence of neural thread proteins, and the use of nucleic acid sequences which code for neural thread proteins in gene therapy.

28 Claims, 104 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 52

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawi De

☐ 11. Document ID: US 5877015 A

L11: Entry 11 of 81 File: USPT Mar 2, 1999

US-PAT-NO: 5877015

DOCUMENT-IDENTIFIER: US 5877015 A

** See image for Certificate of Correction **

TITLE: APP770 mutant in alzheimer's disease

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Hardy; John Anthony Tampa FL

Chartier-Harlin; Marie-Christine Villeneuve d'Ascq FR

Goate; Alison Mary Michael MO

Owen; Michael John South Glamorgan GB6

Mullan; Michael John Tampa FL

US-CL-CURRENT: 435/325; 435/252.3, 536/23.5

ABSTRACT:

Model systems of Alzheimer's disease comprise a DNA sequence encoding an amyloid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding to amino acid residue position 717 of APP770. Methods of determining genetic predisposition to Alzheimer's disease are also disclosed.

Record List Display Page 9 of 47

12 Claims, 29 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 29

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw De

☐ 12. Document ID: US 5854392 A

L11: Entry 12 of 81

File: USPT

Dec 29, 1998

US-PAT-NO: 5854392

DOCUMENT-IDENTIFIER: US 5854392 A

** See image for Certificate of Correction **

TITLE: .beta. APP-C100 receptor

DATE-ISSUED: December 29, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Manly; Susan P. Wallingford CT
Kozlowski; Michael R. Noank CT
Neve; Rachael L. Belmont MA

US-CL-CURRENT: <u>530/350</u>; <u>435/69.1</u>, <u>530/327</u>, <u>530/395</u>, <u>536/23.5</u>

· ABSTRACT:

The present invention relates to the cloning of .beta.APP-C100 receptor (C100-R), and genetically engineered host cells which express the C100-R. Such engineered cells may be used to evaluate and screen drugs and analogs of .beta.-APP involved in Alzheimer's Disease.

7 Claims, 23 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 19

Ī	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments Clair	ns KWWC	Draw, De
										·	·

☐ 13. Document ID: US 5851787 A

L11: Entry 13 of 81

File: USPT

Dec 22, 1998

US-PAT-NO: 5851787

DOCUMENT-IDENTIFIER: US 5851787 A

** See image for Certificate of Correction **

TITLE: Nucleic acid encoding amyloid precursor-like protein and uses thereof

DATE-ISSUED: December 22, 1998

Record List Display Page 10 of 47

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Wasco; Wilma Boston MA

Bupp; Keith Orsay FR

Magendantz; Margaret Summerville MA
Tanzi; Rudolph Canton MA
Solomon; Frank Cambridge MA

US-CL-CURRENT: <u>435/69.1</u>; <u>435/320.1</u>, <u>435/325</u>, <u>536/23.1</u>, <u>536/23.5</u>

ABSTRACT:

The present invention is directed to isolated amyloid precursor-like proteins (APLPs), nucleotide sequences coding for and regulating expression of these protein, antibodies directed against these proteins, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of these protein sequences. The invention is also directed to isolated genomic DNA, cDNA anti-sense RNA, and RNA containing the protein sequence. Antibodies can be used to detect an APLP in biological specimens, including, for example, fluid, serum or tissue samples. APLP1 and APLP2 are candidate genes for late onset familial Alzheimer's disease.

9 Claims, 29 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 21

Full Titl	e Citation	Front	Review	Classification	Date	Reference	Stations	Attachments	Claims	KWIC	Draw, De

☐ 14. Document ID: US 5849988 A

L11: Entry 14 of 81 File: USPT Dec 15, 1998

US-PAT-NO: 5849988

DOCUMENT-IDENTIFIER: US 5849988 A

** See image for Certificate of Correction **

TITLE: Rat comprising straight filaments in its brain

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Trojanowski; John Q. Philadelphia PA Lee; Virginia M.-Y. Philadelphia PA

Shin; Ryong-Woon Fukuoka JP

US-CL-CURRENT: 800/12; 424/682, 424/685, 424/9.2, 514/2, 530/324, 530/352, 530/839

ABSTRACT:

Methods of generating a rat having A.beta. deposits in the brain of the rat by injecting an amount of human A68 protein sufficient to result in formation of the

Record List Display Page 11 of 47

deposits and subsequently examining the rat for the formation of the deposits are disclosed. Rats characterized by the presence of A.beta. deposits similar to those found in individuals with Alzheimer's disease are also disclosed. Methods of screening test compositions for prophylactic or therapeutic activity by generating a rat having A.beta. deposits in its brain, treating the animal with the test composition and examining the animal for therapeutic or prophylactic effectiveness are also disclosed.

28 Claims, 17 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sentences	e-Gardintenier	Claims	KWC	Draw, De
			······································					***************************************				***************************************

☐ 15. Document ID: US 5849600 A

L11: Entry 15 of 81

File: USPT

Dec 15, 1998

US-PAT-NO: 5849600

DOCUMENT-IDENTIFIER: US 5849600 A

TITLE: Diagnostic assays for Alzheimer's disease

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE COUNTRY

Nixon; Ralph

Arlington

MΑ

JP

Honda; Toshiyuki

Yokohama

US-CL-CURRENT: <u>436/518</u>; <u>436</u>/<u>161</u>, <u>436/528</u>, <u>436</u>/529, 436/530, 436/811

ABSTRACT:

The invention provides a method of diagnosing Alzheimer's disease in a human patient by measuring the amount of p33 present in a biological sample from a patient who may have Alzheimer's disease relative to the amount of p33 in a control sample from an unaffected human. Also included in the invention are diagnostic kits for Alzheimer's disease and methods of screening for effective therapeutics for Alzheimer's disease.

5 Claims, 19 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 13

Ful	Title	Citation	Front	Review	Classification	Date	Reference	servicio es	elladimenta	Claims	KOMC	Drawi De
	 		·									

☐ 16. Document ID: US 5795954 A

L11: Entry 16 of 81

File: USPT

Aug 18, 1998

Record List Display Page 12 of 47

US-PAT-NO: 5795954

DOCUMENT-IDENTIFIER: US 5795954 A

TITLE: Factor VIIa inhibitors from Kunitz domain proteins

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

CA

Lazarus; Robert A. Milbrae

Dennis; Mark S. San Carlos CA

US-CL-CURRENT: 530/324; 530/300

ABSTRACT:

A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, and plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.

16 Claims, 8 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Drawd De

☐ 17. Document ID: US 5766846 A

L11: Entry 17 of 81

File: USPT

Jun 16, 1998

US-PAT-NO: 5766846

DOCUMENT-IDENTIFIER: US 5766846 A

TITLE: Methods of screening for compounds which inhibit soluble .beta.-amyloid

peptide production

DATE-ISSUED: June 16, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Schlossmacher; Michael G. Vienna AT

Selkoe; Dennis J. Jamaica Plain MA

US-CL-CURRENT: $\underline{435/6}$; $\underline{435/41}$, $\underline{435/69.1}$, $\underline{435/7.1}$, $\underline{435/7.2}$, $\underline{435/7.21}$, $\underline{435/7.92}$,

435/7.94

ABSTRACT:

Soluble <u>.beta.-amyloid</u> peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from

cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.

21 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De

☐ 18. Document ID: US 5750349 A

Ll1: Entry 18 of 81

File: USPT

May 12, 1998

US-PAT-NO: 5750349

DOCUMENT-IDENTIFIER: US 5750349 A

TITLE: Antibodies to .beta.-amyloids or their derivatives and use thereof

DATE-ISSUED: May 12, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY
Suzuki; Nobuhiro Ibaraki JP
Odaka; Asano Ibaraki JP
Kitada; Chieko Osaka JP

US-CL-CURRENT: $\underline{435/7.1}$; $\underline{435/326}$, $\underline{435/331}$, $\underline{435/7.92}$, $\underline{435/7.94}$, $\underline{435/7.95}$, $\underline{435/7.95}$, $\underline{435/7.95}$, $\underline{530/387.9}$, $\underline{530/388.1}$, $\underline{530/389.1}$

ABSTRACT:

According to this invention, antibodies which are useful and novel in that they have binding specificity to <u>.beta.-amyloids</u> or derivatives thereof, namely recognize the N-terminal, the C-terminal or central portions of the <u>.beta.-amyloids</u>, respectively, were obtained. By combining these antibodies, determination methods by which the <u>.beta.-amyloids</u> could be determined sensitively and specifically are provided. These determination methods are useful for diagnosis of diseases to which the <u>.beta.-amyloids</u> or their derivatives are related (for example, Alzheimer's disease), and the antibodies of this invention are useful for the development of preventive-therapeutic compositions for Alzheimer's disease.

9 Claims, 32 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16 ☐ 19. Document ID: US 5733734 A

L11: Entry 19 of 81

File: USPT

Mar 31, 1998

US-PAT-NO: 5733734

DOCUMENT-IDENTIFIER: US 5733734 A

TITLE: Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Trojanowski; John Q. Philadelphia PA Lee; Virginia M-Y. Philadelphia PA

US-CL-CURRENT: <u>435/7.1</u>; <u>435/40.52</u>, <u>435/7.21</u>, <u>435/7.92</u>, <u>435/960</u>, <u>436/547</u>, <u>436/548</u>, <u>436/811</u>, <u>530/387.9</u>, <u>530/388.1</u>, <u>530/389.1</u>

ABSTRACT:

Substantially purified antibodies, including substantially purified monoclonal antibodies, which are specifically reactive with .tau. that has an abnormally phosphorylated serine in the sequence LysSerProVal SEQ ID NO:3 are disclosed. Methods of screening persons for diseases associated with pair helical filaments, including Alzheimer's disease, by detection of .tau. that has an abnormally phosphorylated serine in the sequence LysSerProVal SEQ ID NO:3 in test samples taken from such persons and test kits useful to perform such methods are disclosed.

14 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

	Claims Ki	t shineri	Reference	Date	Classification	Review	Front	Citation	Title	Full
			-							

☐ 20. Document ID: US 5720936 A

L11: Entry 20 of 81 File: USPT Feb 24, 1998

US-PAT-NO: 5720936

DOCUMENT-IDENTIFIER: US 5720936 A

TITLE: Transgenic mouse assay for compounds affecting amyloid protein processing

DATE-ISSUED: February 24, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Wadsworth; Samuel Shrewsbury MA

Record List Display Page 15 of 47

Snyder; Benjamin
Wei; Cha-Mer
Leibowitz: Paul J.

Worcester MA
Framingham MA
Brookline MA

US-CL-CURRENT: 424/9.1; 800/3

ABSTRACT:

The construction of transgenic animal models for testing potential treatments for Alzheimer's disease are described. The models are characterized by a greater similarity to the conditions existing in naturally occurring Alzheimer's disease, based on expression of all three forms of the .beta.-amyloid precursor protein (APP), APP.sub.695, APP.sub.751, and APP.sub.770), as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, and predicted mutations in the APP gene. The APP gene constructs are prepared using the naturally occurring promoter, as well as inducible promoters such as the mouse metallothionine promoter, which can be regulated by addition of heavy metals such as zinc to the animal's water or diet, and promoters such as the rat neuron specific enolase promoter, human .beta. actin gene promoter, human platelet derived growth factor B (PDGF-B) chain gene promoter, rat sodium channel gene promoter, mouse myelin basic protein gene promoter, human copper-zinc superoxide dismutase gene promoter, and mammalian POU-domain regulatory gene promoter. The constructs are introduced into animal embryos using standard techniques such as microinjection. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's Disease as measured by their effect on the amount and histopathology of APP and .beta.-amyloid peptide in the animals, as well as by behavioral alterations.

6 Claims, 14 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

	.,							
Full	Title	Citation	Front	Review	Classification	Date	Reference Sequences Attackments Claims KWIC Draw.	Dε

☐ 21. Document ID: US 5705401 A

L11: Entry 21 of 81

File: USPT

Jan 6, 1998

US-PAT-NO: 5705401

DOCUMENT-IDENTIFIER: US 5705401 A

** See image for <u>Certificate of Correction</u> **

TITLE: Method of assaying for alzheimer's disease

DATE-ISSUED: January 6, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Masters; Colin Louis Clifton Hill AU

Bush; Ashley Ian Boston MA

Record List Display Page 16 of 47

Beyreuther; Konrad Traugott

Heidelberg

DE

US-CL-CURRENT: <u>436/518</u>; <u>436/530</u>, <u>436/531</u>, <u>436/811</u>

ABSTRACT:

The present invention relates to a method of assaying for Alzheimer's disease in a human by determining the relative abundance of one or more forms of amyloid precursor protein (APP) or the enzyme responsible for said forms in circulatory fluid and to a method for treating the disease by modulating divalent cation, trivalent cation and/or heparin interaction with APP.

3 Claims, 12 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 10

Full Titl	e Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De

☐ 22. Document ID: US 5688651 A

L11: Entry 22 of 81

File: USPT

Nov 18, 1997

US-PAT-NO: 5688651

DOCUMENT-IDENTIFIER: US 5688651 A

TITLE: Prevention of protein aggregation

DATE-ISSUED: November 18, 1997

INVENTOR-INFORMATION:

NAME CITY

OIII

STATE

ZIP CODE

COUNTRY

TT.

Solomon; Beka Herzlya

US-CL-CURRENT: 435/7.1; 424/130.1, 436/63, 530/388.1

ABSTRACT:

A method of selecting anti-aggregation molecules with chaperone-like activity that have characteristics including binding to a native target molecule epitope with a high binding constant and are non-inhibitory to the biological activity of the target molecule. The method molecules denaturating a target molecule in the presence of presumptative antiaggregation molecules to prevent the target molecules from self-or induced-aggregation. The nonaggregated target molecule coupled to the anti-aggregation molecule is then tested for bioactivity.

4 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Altachments	Claims	KOOAC	Drawi De
						0.010	, merenende i		120000000000000000000000000000000000000	Claims	NOUS	DISON DE

☐ 23. Document ID: US 5686269 A

L11: Entry 23 of 81

File: USPT

Nov 11, 1997

US-PAT-NO: 5686269

DOCUMENT-IDENTIFIER: US 5686269 A

TITLE: Method of diagnosing Alzheimer's disease by detecting the level of cathepsin

D in cerebrospinal fluid

DATE-ISSUED: November 11, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Nixon; Ralph A.

Arlington

MA

US-CL-CURRENT: 435/7.1; 435/18, 435/7.4, 435/7.92, 436/811

ABSTRACT:

Disclosed is a method of diagnosing Alzheimer's disease in a patient by measuring the level of cathepsin D in the patient's cerebrospinal fluid.

8 Claims, 6 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments	Claims	KWIC	Draw, De
									· · · · ·		

☐ 24. Document ID: US 5672805 A

L11: Entry 24 of 81

File: USPT

Sep 30, 1997

US-PAT-NO: 5672805

DOCUMENT-IDENTIFIER: US 5672805 A

TITLE: Transgenic mice expressing the neurotoxic C-terminus of .beta.-amyloid

precursor protein

DATE-ISSUED: September 30, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE

CA

ZIP CODE

COUNTRY

Neve; Rachael L.

Irvine

US-CL-CURRENT: 800/3; 424/9.2, 800/12

ABSTRACT:

The present invention provides non-human, transgenic animals for use as a model for the study of Alzheimer's Disease. The animals exhibit pathology associated with

Record List Display Page 18 of 47

Alzheimer's Disease. The phenotype is conferred in the animals by the introduction of an amyloid-containing polypeptide fragment of amyloid precursor protein, through the introduction of the DNA into the germ and somatic cells of the animal by transgenic methods.

8 Claims, 26 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Altachments	Claims	KWIC	Draw, De
**************************************				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				·····				

☐ 25. Document ID: US 5670483 A

L11: Entry 25 of 81

File: USPT

Sep 23, 1997

US-PAT-NO: 5670483

DOCUMENT-IDENTIFIER: US 5670483 A

** See image for Certificate of Correction **

TITLE: Stable macroscopic membranes formed by self-assembly of amphiphilic peptides

and uses therefor

DATE-ISSUED: September 23, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Zhang; Shuguang Cambridge MA Lockshin; Curtis Lexington MA Rich; Alexander Cambridge MA Holmes; Todd Cambridge MA

US-CL-CURRENT: 514/14; 514/12, 514/13, 530/300, 530/324, 530/325, 530/326, 530/327,

530/350

ABSTRACT:

Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK).sub.2 (ARARADAD).sub.2, were shown to selfassemble into macroscopic membranes. Conditions under which the peptides selfassemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic. The membranes are potentially useful in biomaterial applications such as slow-diffusion drug delivery systems, artificial skin, and separation matrices, and as experimental models for Alzheimer's disease and scrapie infection. The sequence of the peptide, EAK16, was derived from a putative Z-DNA binding protein from yeast, called zuotin. The cloning and characterization of the ZUO1 gene are also described.

Record List Display Page 19 of 47

48 Claims, 25 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 14

Full Title Citation Front Review Classification Date Reference Sequences Attechnients Claims KWIC Draw De

☐ 26. Document ID: US 5656477 A

L11: Entry 26 of 81

File: USPT

Aug 12, 1997

US-PAT-NO: 5656477

DOCUMENT-IDENTIFIER: US 5656477 A

TITLE: Amyloid precursor proteins and method of using same to assess agents which

down-regulate formation of .beta.-amyloid peptide

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Vitek; Michael Peter

East Norwich

NY

Jacobsen; Jack Steven

Ramsey

NJ

US-CL-CURRENT: <u>435/325</u>; <u>435/252.3</u>, <u>435/254.11</u>, <u>435/348</u>, <u>435/358</u>, <u>435/365</u>,

<u>435/365.1</u>, <u>435/366</u>, <u>530/839</u>, <u>536/23.5</u>

ABSTRACT:

This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of beta.-amyloid protein.

14 Claims, 54 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 54

=		***************************************											
388	Full	T:41 -				A 100 10			The state of the s	THE RESERVE THE PARTY OF THE PA			
-	F 11111	1 :III e	I CRARON I	2 0101	Rement	Liassitication	Date	- Matatanca :	THE PARTY OF THE P	I Strombrome	Claimel	KWIC	Drawi De
					11071011	-102211100110111	2 2 3 4 2	11010101190	Control Control	Attachments	O I d III I S	(COOL)	C 1000 100
								· · · · · · · · · · · · · · · · · · ·					1

☐ 27. Document ID: US 5643726 A

L11: Entry 27 of 81

File: USPT

Jul 1, 1997

US-PAT-NO: 5643726

DOCUMENT-IDENTIFIER: US 5643726 A

TITLE: Methods for modulating transcription from the amyloid .beta.-protein

precursor (APP) promoter

Record List Display Page 20 of 47

DATE-ISSUED: July 1, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tanzi; Rudolph E. Canton MA Kovacs; Dora M. Cambridge MA

US-CL-CURRENT: 435/6; 435/463

ABSTRACT:

The application concerns methods for modulating transcription from the amyloid .beta.-protein precursor (APP) promoter. The upstream stimulatory factor (USF) is described as being capable of activating transcription from the APP promoter. Also described are USF binding compounds which are capable of down-regulating expression from the APP promoter. Preferred USF binding compounds are the amyloid precursor-like proteins APLP1 and APLP2. The application further concerns a screening assay for determining which candidate USF binding compounds are capable of causing down-regulation of transcription from the APP promoter.

18 Claims, 41 Drawing figures Exemplary Claim Number: 15 Number of Drawing Sheets: 34

Full Title	Citation Front Review Classification Date Reference Serviences Attachments Claims KIMC Draw. De
□ 28.	Document ID: US 5624807 A

File: USPT

Apr 29, 1997

US-PAT-NO: 5624807

L11: Entry 28 of 81

DOCUMENT-IDENTIFIER: US 5624807 A

TITLE: Methods for detecting Alzheimer's disease by measuring ratios of calcium-

activated neutral protease isoforms

DATE-ISSUED: April 29, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Nixon; Ralph A. Arlington MA

Saito; Ken-Ichi Yokohama Jp

US-CL-CURRENT: 435/7.4; 435/7.9, 435/7.92, 436/518, 436/547, 436/548, 436/63,

436/811

ABSTRACT:

Methods for screening individuals for Alzheimer's disease are disclosed. Also disclosed are antibodies that immunochemically react with the isoforms of calcium-activated neutral proteinases which are characteristic of Alzheimer's disease. Also disclosed are methods for screening drugs which are useful in treating or

Record List Display Page 21 of 47

preventing Alzheimer's disease.

34 Claims, 10 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw De

☐ 29. Document ID: US 5616311 A

L11: Entry 29 of 81

File: USPT

Apr 1, 1997

US-PAT-NO: 5616311

DOCUMENT-IDENTIFIER: US 5616311 A

TITLE: Non-crosslinked protein particles for therapeutic and diagnostic use

DATE-ISSUED: April 1, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Yen; Richard C. K.

Glendora

CA

US-CL-CURRENT: 424/1.33; 424/1.29, 424/1.37, 424/484, 424/499, 427/2.14, 427/2.21, 427/213.3, 427/213.33, 428/402.2, 428/402.24, 435/177, 977/DIG.1

ABSTRACT:

Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a crosslinking agent and without denaturation, by the incorporation of hemoglobin in the particle composition. Particles which are primarily hemoglobin in the nanometer and micrometer size range in an aqueous suspension are rendered stable against aggregation by the incorporation of either albumin, surface active agents or gelatin.

26 Claims, O Drawing figures
Exemplary Claim Number: 1,26

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw. De

☐ 30. Document ID: US 5612486 A

Lll: Entry 30 of 81

File: USPT

Mar 18, 1997

US-PAT-NO: 5612486

DOCUMENT-IDENTIFIER: US 5612486 A

TITLE: Transgenic animals harboring APP allele having swedish mutation

Record List Display Page 22 of 47

DATE-ISSUED: March 18, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

McConlogue; Lisa C. San Francisco CA Zhao; Jun San Diego CA

US-CL-CURRENT: 800/12; 536/23.1, 536/23.5, 800/18

ABSTRACT:

The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.

4 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	S trockment	Claims	KWIC	Draw, De
					· · · · · ·		•			,		

☐ 31. Document ID: US 5604131 A

L11: Entry 31 of 81 File: USPT Feb 18, 1997

US-PAT-NO: 5604131

DOCUMENT-IDENTIFIER: US 5604131 A

TITLE: cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA

insert of the KI and OX-2 regions

DATE-ISSUED: February 18, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Wadsworth; Samuel Shrewsbury MA
Snyder; Benjamin Worcester MA
Reddy; Vermuri B. Westborough MA
Wei; Chamer Westborough MA

US-CL-CURRENT: <u>435/320.1</u>; <u>536/23.5</u>, <u>536/24.1</u>

ABSTRACT:

A nucleic acid construct is described which when expressed in cells, results in the production of APP695, APP751 and APP770. The construct is the cDNA for APP770 with the genomic sequences encoding the KI and OX-2 regions substituting for those regions present in the cDNA.

3 Claims, 38 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 26 Record List Display Page 23 of 47

Full Title Citation Front Review Classification Date Reference **Sequences Attackments** Claims KWIC Draw. Ds

☐ 32. Document ID: US 5604102 A

L11: Entry 32 of 81

File: USPT

Feb 18, 1997

US-PAT-NO: 5604102

DOCUMENT-IDENTIFIER: US 5604102 A

TITLE: Methods of screening for .beta.-amyloid peptide production inhibitors

DATE-ISSUED: February 18, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY McConloque; Lisa C. San Francisco CA Schenk; Dale B. Pacifica CA Seubert; Peter A. South San Francisco CA Sinha; Sukanto San Francisco CA Zhao; Jun La Jolla CA

US-CL-CURRENT: 435/7.1; 424/9.2, 435/7.21, 530/350

ABSTRACT:

19 Claims, 13 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	\$ power and	Alian Interior	Claims	KWC	Drawi De

☐ 33. Document ID: US 5593848 A

L11: Entry 33 of 81

File: USPT

Jan 14, 1997

US-PAT-NO: 5593848

DOCUMENT-IDENTIFIER: US 5593848 A

TITLE: Target component assay utilizing specific gravity-altering liposomes

Record List Display Page 24 of 47

DATE-ISSUED: January 14, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Levine; Robert A. Guilford CT
Wardlaw; Stephen C. Old Saybrook CT
Rodriguez; Rodolfo Owings Mills MD
Britz; Judith Laurel MD
Mercolino; Thomas J. Pleasanton CA

US-CL-CURRENT: $\underline{435/7.24}$; $\underline{435/7.22}$, $\underline{435/7.23}$, $\underline{435/7.25}$, $\underline{435/7.92}$, $\underline{436/528}$, $\underline{436/538}$,

<u>436/829</u>

ABSTRACT:

An improved assay of target components in a sample utilizes specific gravity-altering particles which are attached to the target components by specific antibodies. The attached specific gravity-altering particles are preferably liposomes which will buoy or sink the targets to a common level in the specimen sample when the latter has been centrifuged in a transparent tube. The liposomes can provide an accentuated and more pronounced indication of the presence of the targets in the sample due to their ability to contain many multiples of fluorescent or non-fluorescent dye molecules with minimal steric interference with the attached antibodies' binding ability.

5 Claims, 1 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	September	Altaninente	Claims	KMC	Drawt De
•		,		-			1					ريبسسسس

☐ 34. Document ID: US 5589154 A

L11: Entry 34 of 81 File: USPT Dec 31, 1996

US-PAT-NO: 5589154

DOCUMENT-IDENTIFIER: US 5589154 A

TITLE: Methods for the prevention or treatment of vascular hemorrhaging and

Alzheimer's disease

DATE-ISSUED: December 31, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Anderson; Stephen Princeton NJ

US-CL-CURRENT: 424/1.41; 424/1.49, 424/1.69, 424/130.1, 424/145.1, 424/9.34,

<u>424/9.6, 435/7.1, 436/543, 436/547, 530/380</u>

ABSTRACT:

Record List Display Page 25 of 47

Methods for preventing or treating vascular hemorrhaging such as that incident to thrombolytic therapy, or characteristic of Alzheimer's and related diseases are provided. Such methods provide improved thrombolytic therapy to individuals who receive such therapy, and permit the diagnosis and treatment of diseases, such as Alzheimer's disease, that are characterized by the deposition of amyloid deposits.

5 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full	Title	Citation Front	Review	Classification	Date	Reference	Standardess (SignA)	ienis Clai	ms / KWC	Draw, De
		-							· •	
								*		······································
	35.	Document ID:	US 53	578493 A						

File: USPT

Nov 26, 1996

US-PAT-NO: 5578493

DOCUMENT-IDENTIFIER: US 5578493 A

TITLE: Wilson's disease gene

L11: Entry 35 of 81

DATE-ISSUED: November 26, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Gilliam; T. Conrad New York NY Tanzi; Rudolph E. Canton MA

US-CL-CURRENT: 435/320.1; 435/183, 435/196, 536/23.5, 536/24.31

ABSTRACT:

This invention provides an isolated, vertebrate nucleic acid molecule encoding the normal protein that prevents development of Wilson's disease. This invention also provides a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the above-described nucleic acid molecule. Finally, this invention provides various uses of the isolated Wilson's disease gene.

12 Claims, 26 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 20

Full Title Citation Front Revi	ew Classification Date Reference Sequences	Alfashments Claims KWMC Draw De
☐ 36. Document ID: U	S 5576209 A	
L11: Entry 36 of 81	File: USPT	Nov 19, 1996

US-PAT-NO: 5576209

DOCUMENT-IDENTIFIER: US 5576209 A

Record List Display Page 26 of 47

TITLE: Method for increasing the resistance of neural cells to .beta.-amyloid peptide toxicity

DATE-ISSUED: November 19, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Bredesen; Dale E. Palos Verdes Estates CA

US-CL-CURRENT: 435/325; 435/368, 514/12, 514/2

ABSTRACT:

Neural cells which express P75 nerve growth factor receptor (p75.sup.NTR) and which have a low resistance to <u>.beta.-amyloid</u> peptide toxicity are treated with a binding agent that binds with p75.sup.NTR. The resulting neural cells display an increased resistance to <u>.beta.-amyloid</u> peptide toxicity. Mutant and transfected neural cells are also disclosed in which the ability to express p75.sup.NTR has been removed with a resultant increase in resistance to <u>.beta.-amyloid</u> peptide toxicity.

4 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full Title Citation Front Review Classification Da	te Reference Seguences Attach	menta Claims KWMC Drawu De
☐ 37. Document ID: US 5571698 A		1874 ^{чен} 2000 онд о осолост, кого учес своя чен чисть в <mark>до н</mark> еколостично от осолостичного осолостичного осолост
L11: Entry 37 of 81	File: USPT	Nov 5, 1996

US-PAT-NO: 5571698

DOCUMENT-IDENTIFIER: US 5571698 A

** See image for Certificate of Correction **

TITLE: Directed evolution of novel binding proteins

DATE-ISSUED: November 5, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Ladner; Robert C. Ijamsville MD Guterman; Sonia K. Belmont Roberts; Bruce L. Milford MA Markland; William Milford MA Ley; Arthur C. Newton MA Kent; Rachel B. Boxborough MA

US-CL-CURRENT: $\underline{435}/\underline{69.7}$; $\underline{435}/\underline{252.3}$, $\underline{435}/\underline{320.1}$, $\underline{435}/\underline{477}$, $\underline{435}/\underline{6}$, $\underline{435}/\underline{69.1}$

ABSTRACT:

Record List Display Page 27 of 47

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

83 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16

Full Title Citation	Front Review	Classification	Date Referer	e Seguences	Attachments	Claims	KWIC	Dravo De
							-	

☐ 38. Document ID: US 5567720 A

L11: Entry 38 of 81

File: USPT

Oct 22, 1996

US-PAT-NO: 5567720

DOCUMENT-IDENTIFIER: US 5567720 A

TITLE: Pharmaceutically active agents that impede amyloid formation in vivo

DATE-ISSUED: October 22, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Averback; Paul Montreal CA

US-CL-CURRENT: $\underline{514}/\underline{345}$; $\underline{514}/\underline{262.1}$, $\underline{514}/\underline{274}$, $\underline{514}/\underline{378}$, $\underline{514}/\underline{379}$, $\underline{514}/\underline{407}$, $\underline{514}/\underline{460}$, $\underline{514}/\underline{724}$, $\underline{514}/\underline{883}$, $\underline{514}/\underline{903}$

ABSTRACT:

Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at intissue concentrations of 10.sup.-5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis.

7 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw De

☐ 39. Document ID: US 5550262 A

L11: Entry 39 of 81

File: USPT

Aug 27, 1996

US-PAT-NO: 5550262

DOCUMENT-IDENTIFIER: US 5550262 A

** See image for <u>Certificate of Correction</u> **

TITLE: Multicatalytic protease inhibitors

DATE-ISSUED: August 27, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY
Iqbal; Mohamed Malvern PA

Diebold; James L. Norristown PA Siman; Robert Wilmington DE Chatterjee; Sankar Wynnewood PA

Kauer; James C. Kennett Square PA

US-CL-CURRENT: $\underline{554}/\underline{57}$; $\underline{554}/\underline{36}$, $\underline{554}/\underline{42}$, $\underline{554}/\underline{51}$, $\underline{554}/\underline{54}$, $\underline{558}/\underline{432}$, $\underline{564}/\underline{123}$

ABSTRACT:

Disclosed herein are inbibitors of the multicatalytic protease enzyme which are represented by the general formula: ##STR1## Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.

10 Claims, 7 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sections	Altachments	Claims	KOMO	Draint De
	<u>. </u>								**************************************			

☐ 40. Document ID: US 5547841 A

L11: Entry 40 of 81

File: USPT

Aug 20, 1996

US-PAT-NO: 5547841

DOCUMENT-IDENTIFIER: US 5547841 A

TITLE: In vitro method for screening for drugs that inhibit production or

degradation of human A4-amyloid

DATE-ISSUED: August 20, 1996

INVENTOR-INFORMATION:

Record List Display Page 29 of 47

NAME CITY STATE ZIP CODE COUNTRY

Marotta; Charles A. Cambridge MA Zain; Sayeeda Pittsford NY

US-CL-CURRENT: 435/6; 435/7.1, 435/7.92, 436/518, 436/811

ABSTRACT:

The invention relates to an in vitro method of screening for drugs, potentially useful for treatment of Alzheimer's Disease. The method involves contacting a drug with a host transformed with a DNA construct which contains at least the DNA coding for human A4-amyloid peptide and overexpresses the peptide and then detecting the prevention of production or increased degradation of the A4-peptide due to the drug.

3 Claims, 12 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC	Draw, De

☐ 41. Document ID: US 5538983 A

L11: Entry 41 of 81 File: USPT Jul 23, 1996

US-PAT-NO: 5538983

DOCUMENT-IDENTIFIER: US 5538983 A

TITLE: Method of treating amyloidosis by modulation of calcium

DATE-ISSUED: July 23, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Buxbaum; Joseph D. Flushing NY Greengard; Paul New York NY

US-CL-CURRENT: 514/313; 514/453, 514/468, 514/510, 514/691, 514/729, 514/739,

<u>514</u>/<u>766</u>

ABSTRACT:

Various first messengers linked to phospholipase C, including acetylcholine and interleukin-1, regulate the production both of the secreted form of the amyloid protein precursor and of amyloid .beta.-protein. Intracellular signals which are responsible for mediating these effects have now been identified, and that activation of phospholipase C may affect APP processing by either of two pathways, one involving an increase in protein kinase C and the other an increase in cytoplasmic calcium levels. The effects of calcium on APP processing appear to be independent of protein kinase C activation. The observed effects of calcium on APP processing are of therapeutic utility in the treatment of Alzheimer-type amyloidosis.

Record List Display Page 30 of 47

13 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw. De

☐ 42. Document ID: US 5538845 A

Ll1: Entry 42 of 81 File: USPT Jul 23, 1996

US-PAT-NO: 5538845

DOCUMENT-IDENTIFIER: US 5538845 A

TITLE: Beta-amyloid peptide production inhibitors and methods for their

identification

DATE-ISSUED: July 23, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Knops; Jeroen San Francisco CA Sinha; Sukanto San Francisco CA

US-CL-CURRENT: <u>435/6</u>; <u>435/183</u>, <u>435/69.2</u>, <u>435/7.21</u>, <u>436/530</u>, <u>436/531</u>, <u>530/387.1</u>

ABSTRACT:

A method for identifying compounds capable of inhibiting the production of beta.-amyloid peptide in cells comprises exposing cultured cells in one or more test compounds. The cells are cultured under conditions which produce amyloid precursor protein and which result in intracellular accumulation of an approximately 22 kD polypeptide which includes the entire sequence of the beta.-amyloid peptide. Test compounds which cause a change in the accumulation of the 22 kD polypeptide are considered likely candidates for use as drugs for treating beta.-amyloid diseases, such as Alzheimer's disease.

38 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

		<u> </u>							
Full	Title	Citation	Front	Review	Classification	Date	Reference Sequences Attachments Claims	KWIC	Drawi, De

☐ 43. Document ID: US 5536639 A

L11: Entry 43 of 81 File: USPT Jul 16, 1996

US-PAT-NO: 5536639

DOCUMENT-IDENTIFIER: US 5536639 A

TITLE: Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products

Record List Display Page 31 of 47

DATE-ISSUED: July 16, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Siman; Robert Wilmington DE Bozyczko-Coyne; Donna Norristown PA

US-CL-CURRENT: 435/7.1; 435/7.9, 435/7.92

ABSTRACT:

The invention provides methods for detecting calpain activation by measuring levels of calpain-generated spectrin BDPs using antibodies that specifically bind to these spectrin BDPs, but not intact spectrin, or spectrin BDPs generated by other proteases. Also included in the invention are kits for diagnosing diseases associated with increased levels of calpain activation, and methods for screening for effective therapeutics for these diseases.

10 Claims, 23 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 11

Full Title Citation Front Review Classification D	Date Reference Sequences Attact	homents Claims KWWC Drawd De
☐ 44. Document ID: US 5525714 A		and the state of t
L11: Entry 44 of 81	File: USPT	Jun 11, 1996

US-PAT-NO: 5525714

DOCUMENT-IDENTIFIER: US 5525714 A

TITLE: Mutated form of the .beta.-amyloid precursor protein gene

DATE-ISSUED: June 11, 1996

INVENTOR-INFORMATION:

NAME STATE ZIP CODE CITY COUNTRY Van Broeckhoven; Christine Antwerpen BE Martin; Jean-Jacques Antwerpen BF. Hendriks; Lydia Antwerpen ΒE Cras; Patrick Antwerpen BE

US-CL-CURRENT: 536/23.5; 536/24.31

ABSTRACT:

The invention relates to a polypeptide containing a sequence of contiguous amino acids of the polypeptide sequence coded by exon 17 of the cDNA of the APP 770 gene, with said sequence of contiguous amino acids being such that:

it has from 5 to the total number of amino acids coded by said exon 17,

Record List Display Page 32 of 47

and it contains the amino acid corresponding to codon 692 in the cDNA of the APP 770 gene and which is alanine substituted for glycine. (no figure).

20 Claims, 12 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawt De

☐ 45. Document ID: US 5512457 A

L11: Entry 45 of 81

File: USPT

Apr 30, 1996

US-PAT-NO: 5512457

DOCUMENT-IDENTIFIER: US 5512457 A

TITLE: Cytokine designated elk ligand

DATE-ISSUED: April 30, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Lyman; Stewart Seattle WA
Beckmann; M. Patricia Poulsbo WA
Baum; Peter R. Seattle WA
Carpenter; Melissa K. Issaquah WA

US-CL-CURRENT: $\underline{435/69.5}$; $\underline{424/85.1}$, $\underline{435/320.1}$, $\underline{530/351}$, $\underline{536/23.5}$, $\underline{536/24.31}$, $\underline{930/140}$

ABSTRACT:

elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.

13 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front F	Review Classification	Date Reference Seguences	Attachments Claims KWC Draw De
Tan Title Station Tront	Mediena Ciassification	Date Reference Segue Dec	CONTROL DISTRICT DISTRICT DISTRICT

☐ 46. Document ID: US 5508167 A

L11: Entry 46 of 81

File: USPT

Apr 16, 1996

US-PAT-NO: 5508167

DOCUMENT-IDENTIFIER: US 5508167 A

** See image for Certificate of Correction **

TITLE: Methods of screening for Alzheimer's disease

Record List Display Page 33 of 47

DATE-ISSUED: April 16, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Roses; Allen D. Durham NC
Strittmatter; Warren J. Durham NC
Salvesen; Guy S. Chapel Hill NC
Enghild; Jan Durham NC
Schmechel; Donald E. Durham NC

US-CL-CURRENT: 435/6; 435/4, 435/91.2, 435/91.52

ABSTRACT:

Methods of diagnosing or prognosing Alzheimer's disease in a subject are disclosed. The methods involve directly or indirectly detecting the presence or absence of an apolipoprotein E type 4 (ApoE4) isoform or DNA, encoding ApoE4 in the subject. The presence of ApoE4 indicates the subject is afflicted with Alzheimer's disease or at risk of developing Alzheimer's disease. A novel immunochemical assay for detecting the presence or absence of the Apoliprotein E (ApoE) E4 allele in a subject is also disclosed.

27 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Strachinants	Claims	KWIC	Draws De
	47.	Docume	nt ID	: US 5	492812 A							

File: USPT

Feb 20, 1996

US-PAT-NO: 5492812

DOCUMENT-IDENTIFIER: US 5492812 A

TITLE: Diagnostic method for Alzheimer's disease by screening for tau-peptides in

the blood of a patient

L11: Entry 47 of 81

DATE-ISSUED: February 20, 1996

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Vooheis; H. Paul Dublin IE

US-CL-CURRENT: <u>435/7.1</u>; <u>435/7.92</u>, <u>435/7.93</u>, <u>435/7.94</u>, <u>435/7.95</u>, <u>436/518</u>, <u>436/804</u>, 436/811

ABSTRACT:

The present invention is directed to methods and kits for diagnosing, Alzheimer's disease. The invention is based, in part, on the discovery that proteolytic fragments of the amino and carboxy terminal amino acid residues of tau-proteins are

Record List Display Page 34 of 47

released from the neurofibrillary tangles associated with the disease and can be detected in body fluids outside the brain. The tau-proteins will be purified or chemically synthesized and peptide fragments of the amino terminal and carboxy terminal regions will be obtained proteolytically or synthesized chemically and will be used in generating tau specific antibodies for use in diagnostic kits for the detection of Alzheimer's disease. These diagnostic kits will be used in screening the body fluids of individuals for the presence of tau-peptide fragments. Alternatively, the tau-peptides themselves may be used in diagnostic kits for screening the body fluids of individuals for the presence of circulating autoantibodies.

2 Claims, 2 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments	Claims	KWIC	Drawi De
										• •	

☐ 48. Document ID: US 5478857 A

L11: Entry 48 of 81

File: USPT

Dec 26, 1995

US-PAT-NO: 5478857

DOCUMENT-IDENTIFIER: US 5478857 A

TITLE: Use of PLA.sub.2 inhibitors as treatment for alzheimer's disease

DATE-ISSUED: December 26, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Clemens; James A. Indianapolis IN Sofia; Michael J. Lawrenceville NJ Stephenson; Diane T. Indianapolis IN

US-CL-CURRENT: $\underline{514}/\underline{381}$; $\underline{514}/\underline{454}$, $\underline{514}/\underline{455}$, $\underline{514}/\underline{456}$, $\underline{514}/\underline{457}$, $\underline{514}/\underline{458}$, $\underline{514}/\underline{568}$, $\underline{514}/\underline{570}$, $\underline{514}/\underline{571}$, $\underline{514}/\underline{622}$

ABSTRACT:

This invention provides methods for the treatment or prevention of Alzheimer's disease in a mammal which comprises administering to a mammal in need thereof an effective amount of an inhibitor of phospholipase A.sub.2. This invention also provides a series of compounds which are useful as inhibitors of phospholipases A.sub.2, especially cytosolic phospholipase A.sub.2.

12 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Altachments	Claims	KWIC	Draw De
					•		-			·		

☐ 49. Document ID: US 5466675 A

L11: Entry 49 of 81 File: USPT Nov 14, 1995

US-PAT-NO: 5466675

DOCUMENT-IDENTIFIER: US 5466675 A

** See image for Certificate of Correction **

TITLE: Immunological activity of rhamnolipids

DATE-ISSUED: November 14, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Piljac; Goran Davis CA 95616 Piljac; Visnja Davis CA 95616

US-CL-CURRENT: 514/25; 514/814, 514/861, 514/863, 514/864, 514/878, 514/883, 514/885, 514/886, 514/887, 514/889, 514/903, 514/908

ABSTRACT:

Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STRl## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;

R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;

R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl and

R.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl;

are provided.

13 Claims, 0 Drawing figures Exemplary Claim Number: 1

<mark>chments</mark> Claims KWC D	Attachments	:e []	Referenc	Date	Classification	Review	Front	Citation	Title	Full

☐ 50. Document ID: US 5455338 A

L11: Entry 50 of 81 File: USPT Oct 3, 1995

US-PAT-NO: 5455338

DOCUMENT-IDENTIFIER: US 5455338 A

TITLE: DNA encoding novel human kunitz-type inhibitors and methods relating thereto

DATE-ISSUED: October 3, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Sprecher; Cindy A.

Seattle WA

Kisiel; Walt

Albuquerque

Foster; Donald C.

Seattle

US-CL-CURRENT: 536/23.5; 435/252.33, 435/6, 435/69.1, 435/69.6, 435/91.1, 530/350,

NM

WA

<u>530/381, 530/384</u>

ABSTRACT:

The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.

17 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Auschments	Claims	KMC	Draw, De

☐ 51. Document ID: US 5455169 A

. L11: Entry 51 of 81

File: USPT

Oct 3, 1995

US-PAT-NO: 5455169

DOCUMENT-IDENTIFIER: US 5455169 A

TITLE: Nucleic acids for diagnosing and modeling Alzheimer's disease

DATE-ISSUED: October 3, 1995

INVENTOR-INFORMATION:

NAME.

CITY

STATE ZIP CODE

COUNTRY

Mullan; Michael J.

Tampa

ipa FL

US-CL-CURRENT: $\underline{435}/\underline{325}$; $\underline{435}/\underline{320.1}$, $\underline{536}/\underline{23.1}$, $\underline{536}/\underline{23.5}$, $\underline{536}/\underline{24.31}$, $\underline{536}/\underline{24.33}$

ABSTRACT:

The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.

12 Claims, 1 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De
						<u>. </u>		•			

☐ 52. Document ID: US 5441931 A

L11: Entry 52 of 81

File: USPT

Aug 15, 1995

US-PAT-NO: 5441931

DOCUMENT-IDENTIFIER: US 5441931 A

TITLE: Human amyloid protein precursor homologue and Kunitz-type inhibitors

DATE-ISSUED: August 15, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Sprecher; Cindy A. Seattle WA 98115 Foster; Donald C. Seattle WA 98115

Norris; Kjeld E. 2900 Hellerup DK

US-CL-CURRENT: <u>514/2</u>; <u>435/212</u>, <u>435/213</u>, <u>435/252.3</u>, <u>435/320.1</u>, <u>435/69.1</u>, <u>435/69.2</u>, <u>530/350</u>, <u>536/22.1</u>, <u>536/23.1</u>, <u>536/23.2</u> , <u>536/23.5</u>

ABSTRACT:

The present invention provides isolated DNA molecules comprising a DNA segment encoding a novel human amyloid protein precursor homologue and novel Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human amyloid protein precursor homologue or a novel Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.

3 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments	Claims F	QWC Draw De
				•				. *	•	
		·		·						

☐ 53. Document ID: US 5441870 A

L11: Entry 53 of 81

File: USPT

Aug 15, 1995

US-PAT-NO: 5441870

DOCUMENT-IDENTIFIER: US 5441870 A

** See image for Certificate of Correction **

TITLE: Methods for monitoring cellular processing of .beta.-amyloid precursor protein

Record List Display Page 38 of 47

DATE-ISSUED: August 15, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Seubert; Peter A. South San Francisco CA Schenk; Dale B. Pacifica CA

Fritz; Lawrence C. San Francisco CA

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.92, 436/518, 436/811

ABSTRACT:

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.

26 Claims, 8 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full Title	Citation Front	Review	Classification	Date	Reference	Sequences	Aledbarts.	Claims	KWMC	Draw, De

☐ 54. Document ID: US 5436153 A

Lll: Entry 54 of 81 File: USPT Jul 25, 1995

US-PAT-NO: 5436153

DOCUMENT-IDENTIFIER: US 5436153 A

TITLE: Human amyloid protein precursor homolog and Kunitz-type inhibitor

DATE-ISSUED: July 25, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Sprecher; Cindy A. Seattle WA 98115 Foster; Donald C. Seattle WA 98155

Norris; Kjeld E. 2900 Hellerup DK

US-CL-CURRENT: <u>435/252.33</u>; <u>435/212</u>, <u>435/213</u>, <u>435/252.3</u>, <u>435/320.1</u>, <u>435/6</u>, <u>435/69.1</u>, <u>536/22.1</u>, <u>536/23.1</u>, <u>536/23.2</u>, 536/23.5

ABSTRACT:

The present invention provides isolated DNA molecules comprising a DNA segment encoding a novel human amyloid protein precursor homolog and Kunitz-type inhibitor.

Record List Display Page 39 of 47

Also provided are DNA constructs comprising a first DNA segment encoding a novel human amyloid protein precursor homolog or a Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.

13 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classification	Date Reference Sequences Alech	th ers Claims KWC Draw De
☐ 55. Document ID: US 5424205 A		
L11: Entry 55 of 81	File: USPT	Jun 13, 1995

US-PAT-NO: 5424205

DOCUMENT-IDENTIFIER: US 5424205 A

TITLE: Amyloidin protease and uses thereof

DATE-ISSUED: June 13, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Dovey; Harry F. Pacifica CA

Seubert; Peter A. San Mateo CA

Sinha; Sukanto San Francisco CA

US-CL-CURRENT: <u>435/226</u>; <u>435/219</u>

ABSTRACT:

A proteolytic enzyme isolated from human tissue which exhibits a proteolytic activity to hydrolyze Met-Asp peptide bond in an amyloid-like substrate is disclosed. This enzyme has been designated "amyloidin" because it proteolytically cleaves a Met-Asp bond similar to the one present in the amyloid precursor protein to release a fragment having the mature Asp terminus of the beta.-amyloid peptide. Antibodies to the amyloidin protease are also provided. Methods to isolate and purify the amyloidin protease are provided, as well as assays to screen for inhibitors of the amyloidin protease. Also disclosed is the gene encoding the protease and methods for expression of the protease by recombinant DNA means.

11 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full Title Citation Front Review Classification Da	ate Reference <u>Sequences </u> Altachments	Claims KWNC Draw De
☐ 56. Document ID: US 5407581 A		
L11: Entry 56 of 81	File: USPT	Apr 18, 1995

Record List Display Page 40 of 47

US-PAT-NO: 5407581

DOCUMENT-IDENTIFIER: US 5407581 A

TITLE: Filter medium having a limited surface negative charge for treating a blood

material

DATE-ISSUED: April 18, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Onodera; Hirokazu Oita JP Yoshida; Makoto Oita JP

US-CL-CURRENT: 210/654; 210/321.69, 210/508, 210/767, 210/929, 502/403

ABSTRACT:

Disclosed is a filter medium for treating a blood material selected from the group consisting of a leukocyte-containing suspension and plasma, comprising a polymeric, porous element having, in a surface portion thereof, a negative charge and having a surface electric charge of not smaller than -30 .mu.eq/g of the polymeric, porous element. The filter medium and an apparatus having the filter medium packed in a casing having an inlet and an outlet, can be advantageously used for treating a blood material, for example, for separating leukocytes from a leukocyte-containing suspension including whole blood, for blood dialysis or for removing undesired proteinous substances and the like from whole blood or plasma by adsorption-filtration, while effectively controlling a concentration of bradykinin (which is causative of anaphylactic reactions) in a treated blood to a level not exceeding 4,000 pg/ml.

34 Claims, 0 Drawing figures Exemplary Claim Number: 1

		·						 			
Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KWAC	Draw De
-	•	' · · · · · · · · · · · · · · · · · · ·									

□ 57. Document ID: US 5403484 A

L11: Entry 57 of 81 File: USPT Apr 4, 1995

US-PAT-NO: 5403484

DOCUMENT-IDENTIFIER: US 5403484 A

TITLE: Viruses expressing chimeric binding proteins

DATE-ISSUED: April 4, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Ladner; Robert C. Ijamsville MD
Guterman; Sonia K. Belmont MA
Roberts; Bruce L. Milford MA
Markland; William Milford MA

Record List Display Page 41 of 47

Ley; Arthur C.

Newton

MΑ

Kent; Rachel B.

Boxborough

MA

US-CL-CURRENT: 435/235.1; 435/252.3, 435/320.1, 435/69.7, 530/350, 536/23.4

ABSTRACT:

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

49 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference Sequences Attachments Claims KWC Draw De
	•						

☐ 58. Document ID: US 5387742 A

L11: Entry 58 of 81

File: USPT

Feb 7, 1995

US-PAT-NO: 5387742

DOCUMENT-IDENTIFIER: US 5387742 A

TITLE: Transgenic mice displaying the amyloid-forming pathology of alzheimer's

disease

DATE-ISSUED: February 7, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Cordell; Barbara Palo Alto CA

US-CL-CURRENT: 800/12; 536/23.5, 800/18

ABSTRACT:

Cloned recombinant or synthetic DNA sequences related to the pathology of Alzheimer's disease are injected into fertilized mouse eggs. The injected eggs are implanted in pseudo pregnant females and are grown to term to provide transgenic mice whose cells express proteins related to the pathology of Alzheimer's disease. The injected sequences are constructed having promoter sequences connected so as to

Record List Display Page 42 of 47

express the desired protein in brain tissues of the transgenic mouse. The proteins which are preferably ubiquitously expressed include (1) <u>.beta.-amyloid</u> core precursor proteins; and (2) <u>.beta.-amyloid</u> related precursor proteins; and (3) serine protease inhibitor. The transgenic mice provide useful models for studying compounds being tested for their usefulness in treating Alzheimer's disease, and for studying the in vivo interrelationships of these proteins to each other.

4 Claims, 44 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 38

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De
		·										

☐ 59. Document ID: US 5348963 A

L11: Entry 59 of 81

File: USPT

Sep 20, 1994

US-PAT-NO: 5348963

DOCUMENT-IDENTIFIER: US 5348963 A

TITLE: Method of screening for modulators of amyloid formation

DATE-ISSUED: September 20, 1994

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Gandy; Samuel E. New York NY
Caporaso; Gregg L. New York NY
Greengard; Paul New York NY

US-CL-CURRENT: $\underline{514}/\underline{313}$; $\underline{206}/\underline{569}$, $\underline{435}/\underline{7.21}$, $\underline{436}/\underline{507}$, $\underline{514}/\underline{453}$, $\underline{514}/\underline{468}$, $\underline{514}/\underline{510}$, $\underline{514}/\underline{691}$, $\underline{514}/\underline{729}$, $\underline{514}/\underline{739}$, $\underline{514}/\underline{766}$

ABSTRACT:

Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and its related derivatives such as primaguine.

1 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences Attachments	Claims	KWIC	Drawi De
						·····			**************************************		

☐ 60. Document ID: US 5292652 A

L11: Entry 60 of 81

File: USPT

Mar 8, 1994

Record List Display Page 43 of 47

US-PAT-NO: 5292652

DOCUMENT-IDENTIFIER: US 5292652 A

TITLE: Amyloidin protease and uses thereof

DATE-ISSUED: March 8, 1994

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Dovey; Harry F. Pacifica CA
Seubert; Peter A. San Mateo CA
Sinha; Sukanto San Francisco CA

US-CL-CURRENT: <u>435/226</u>; <u>435/219</u>

ABSTRACT:

A proteolytic enzyme isolated from human tissue which exhibits a proteolytic activity to hydrolyze Met-Asp peptide bond in an amyloid-like substrate is disclosed. This enzyme has been designated "amyloidin" because it proteolytically cleaves a Met-Asp bond similar to the one present in the amyloid precursor protein to release a fragment having the mature Asp terminus of the beta.-amyloid peptide. Antibodies to the amyloidin protease are also provided. Methods to isolate and purify the amyloidin protease are provided, as well as assays to screen for inhibitors of the amyloidin protease. Also disclosed is the gene encoding the protease and methods for expression of the protease by recombinant DNA means.

15 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

											•		
Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Affachments	Claims	KWIC	Отаки Ое	
	,	•					<u>.</u>						

☐ 61. Document ID: US 5281521 A

L11: Entry 61 of 81 File: USPT Jan 25, 1994

US-PAT-NO: 5281521

DOCUMENT-IDENTIFIER: US 5281521 A

TITLE: Modified avidin-biotin technique

DATE-ISSUED: January 25, 1994

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Trojanowski; John Q. Philadelphia PA Lee; Virginia M-Y. Philadelphia PA

US-CL-CURRENT: $\frac{435}{7.5}$; $\frac{435}{7.2}$, $\frac{435}{7.92}$, $\frac{435}{960}$, $\frac{435}{960}$, $\frac{436}{501}$, $\frac{436}{548}$

ABSTRACT:

Record List Display Page 44 of 47

A method for preparing an antigen specific probe is provided by incubating a primary antigen specific <u>monoclonal antibody</u> with a biotinylated secondary antibody to produce a complex of the primary and secondary antibodies. The staining pattern produced by these probes reflects the specificity of the <u>monoclonal antibody</u> in the complex and the labeling of irrelevant, endogenous immunoglobulins is reduced substantially. This novel, indirect immunohistochemical method can be used to study normal and diseased tissues using a variety of <u>monoclonal antibodies</u>.

8 Claims, 23 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De
								-				
					······································	· · · · · · · · · · · · · · · · · · ·						

☐ 62. Document ID: US 5270165 A

L11: Entry 62 of 81

File: USPT

Dec 14, 1993

US-PAT-NO: 5270165

DOCUMENT-IDENTIFIER: US 5270165 A

** See image for Certificate of Correction **

TITLE: Method of diagnosis of amyloidoses

DATE-ISSUED: December 14, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Van Nostrand; William E. Irvine CA
Cunningham; Dennis D. Laguna Beach CA
Wagner; Steven L. La Jolla CA

US-CL-CURRENT: 435/7.1; 435/7.92, 435/7.93, 435/7.94, 435/7.95, 530/380, 530/387.9,

530/388.2

ABSTRACT:

A method of diagnosing a disease with cerebrovascular deposition of amyloid, including Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis—Dutch type and other amyloidoses, in a mammal is disclosed in which a sample of cerebrospinal fluid is obtained, the level of immunoreactivity toward a monoclonal antibody raised against native PN-2/.beta.APP or other amyloid precursor protein in the sample is measured, and this measured level is compared to the level of immunoreactivity toward this antibody in a sample from

NOTICE OF GOVERNMENT SUPPORT

This invention was made with Government support under Grant No. GM-31609 awarded by the National Institutes of Health. The Government has certain rights in this invention. American Cancer Society Grants CD 390 and BC $602/BE\ 22A$ provided further support for the development of this invention.

35 Claims, 32 Drawing figures

Record List Display Page 45 of 47

Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 63. Document ID: US 5262332 A

L11: Entry 63 of 81

File: USPT

Nov 16, 1993

US-PAT-NO: 5262332

DOCUMENT-IDENTIFIER: US 5262332 A

TITLE: Diagnostic method for Alzheimer's disease: examination of non-neural tissue

DATE-ISSUED: November 16, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Selkoe; Dennis J. Jamaica Plain MA

US-CL-CURRENT: 436/518; 435/167, 435/7.1, 435/7.9, 435/960, 436/174, 436/501,

<u>436/547</u>, <u>436/548</u>, <u>436/63</u>, <u>436/811</u>

ABSTRACT:

This invention provides a method as well as a kit for diagnosing Alzheimer's disease. The method comprises the steps of obtaining a non-neural tissue biopsy sample, contacting at least a portion of the sample with a quantity of antibodies capable of identifying .beta.AP, a .beta.-amyloid precursor protein fragment comprising .beta.AP, or a .beta.AP peptide fragment of about 8 or more amino acids sufficient to allow detection of said protein, protein fragment or peptide fragment, and monitoring the extent of the reaction between the sample and the antibodies. The kit comprises antibodies specific for .beta.-amyloid protein, or a .beta.-amyloid precursor protein fragment comprising .beta.-amyloid protein, or a peptide fragment of .beta.-amyloid protein of at least about eight amino acids, and a means for detecting the extent of the reaction of the antibodies with a non-neural tissue sample.

20 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawi De
					-					- '-		

☐ 64. Document ID: US 5242932 A

L11: Entry 64 of 81 File: USPT Sep 7, 1993

US-PAT-NO: 5242932

DOCUMENT-IDENTIFIER: US 5242932 A

TITLE: Treatment of amyloidosis associated with Alzheimer disease

Record List Display Page 46 of 47

DATE-ISSUED: September 7, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Gandy; Samuel E. New York NY
Caporaso; Gregg L. New York NY
Greengard; Paul New York NY

US-CL-CURRENT: 514/313; 514/453, 514/468, 514/510, 514/691, 514/729, 514/739,

<u>514/766</u>

ABSTRACT:

Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and its related derivatives such as primaquine.

8 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full	Title	Citation Front	Review	Classification	Date	Reference	Sanuances	Attachments	Claims	KWC	Draw De
	65.	Document ID:	US 52	234814 A	***************************************				······································		

File: USPT

Aug 10, 1993

US-PAT-NO: 5234814

L11: Entry 65 of 81

DOCUMENT-IDENTIFIER: US 5234814 A

TITLE: Diagnostic assay for alzheimer's disease

DATE-ISSUED: August 10, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Card; John P. Wilmington DE
Davis; Leonard G. Newark DE
Siman; Robert G. Wilmington DE

US-CL-CURRENT: $\frac{435}{7.21}$; $\frac{435}{7.92}$, $\frac{436}{516}$, $\frac{530}{350}$, $\frac{530}{395}$

ABSTRACT:

A method to assist in the diagnosis of Alzheimer's disease comprising detecting, in bodily fluids, two APP-related proteins, in soluble form, said proteins have an apparent molecular size of about 130 kDa and about 35 kDa, and each of said proteins shares at least one epitope with the C-terminus of APP corresponding substantially to amino acids 676-695 of APP as shown in FIG. 1.

4 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Allachmente	Claims	KWIC	Drawi De
												_

☐ 66. Document ID: US 5231170 A










All Databases	PubMed	Nucleotide	Protein	Genome	Structure	ОМІМ	PMC Jou	urnals Boo
Search PubMed	· · · · · · · · · · · · · · · · · · ·	for mon	oclonal a	ntibody AN	ID beta-amylo	oid	Go Clea	Save Sea
	Limit		ndex	History	Clipboard	Details	`	
About Entrez	Displa (1 All: 2	Summary	6 3	Show	500 Sort b	oy 🔽 Ser	nd to	
Text Version		206 Review: 1 1 - 206 of 206						One noce
Entrez PubMed		Paganetti P, Ca	lanca V, (Galli C, Stefa	ani M, Molinar	<u>i M.</u>	Related A	One page. Articles, Links
Overview Help FAQ Tutorial New/Noteworthy E-Utilities		beta-site spec Alzheimer's A J Cell Biol. 200 PMID: 1576746	Abeta po 5 Mar 14	eptide. ;168(6):863-	8.		eneration (of
PubMed Services Journals Database	□ 2:	Geylis V, Kour Steinitz M.	ilov V, M	einer Z, Nen	nesmo I, Bogd	anovic N,	Related A	Articles, Links
MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries		Human mono Neurobiol Agin PMID: 1570843	g. 2005 N	1ay;26(5):59	7-606.		om healthy	y adults.
Special Queries LinkOut My NCBI (Cubby)	□3:	Qi-Takahara Y, Hirotani N, Hor R, Ihara Y.	Morishir ikoshi Y,	na-Kawashii Kametani F	na M, Tanimu , Maeda M, Sa	ra Y, Dolios (ido TC, Wan	्रि Related A g	Articles, Links
Related Resources Order Documents NLM Catalog NLM Gateway TOXNET		Longer form intramembra J Neurosci. 200 PMID: 156474	ne cleav 5 Jan 12;	age by gai 25(2):436-45	nma-secreta		r the mech	anism of
Consumer Health Clinical Alerts	□ 4:	Wang YJ, Cher	GH, Hu	XY, Lu YP,	Zhou JN, Liu	RY.	Related A	Articles, Links
ClinicalTrials.gov PubMed Central		The expression the hippocam AD-related prain Res. 2005 PMID: 156210	npus of pathology Jan 7;10	oatients wi y. 31(1):101-8	th Alzheime	r's disease		
	□ 5:	Chauhan NB, S	iegel GJ.				Related A	Articles, Links
		Intracerebrov of Alzheimer Expert Rev Vac PMID: 156063:	's diseas ccines. 20	se. 04 Dec;3(6):	717-25.	on in transg	genic mous	se models
	□6:	Albrecht H, Zb	inden P, F oimbo BP	<u>Cizzi A, Ville</u> <u>-</u>	etti G, Riccardi	B, Puccini P	Related A	Articles, Links
		High through homogenous Comb Chem Hi PMID: 1557892	time-re	solved fluc ghput Screen	orescence. n. 2004 Dec;7(8):745-56.	nhibitors u	ısing
	□7:	Olsson A, Vano	lerstichele	H, Andreas	en N. De Meye	er G, Wallin	A. Related A	Articles, Links

	Simultaneous measurement of beta-amyloid(1-42), total phosphorylated tau (Thr181) in cerebrospinal fluid by the technology. Clin Chem. 2005 Feb;51(2):336-45. Epub 2004 Nov 24. PMID: 15563479 [PubMed - indexed for MEDLINE]	
□8:	Horikoshi Y, Mori T, Maeda M, Kinoshita N, Sato K, Yamaguchi H.	Related Articles, Links
	Abeta N-terminal-end specific antibody reduced beta-an Alzheimer-model mice. Biochem Biophys Res Commun. 2004 Dec 10;325(2):384-7. PMID: 15530403 [PubMed - indexed for MEDLINE]	nyloid in
□9:	Manea M, Mezo G, Hudecz F, Przybylski M.	Related Articles, Links
	Polypeptide conjugates comprising a beta-amyloid plaquas new vaccine structures against Alzheimer's disease. Biopolymers. 2004;76(6):503-11. PMID: 15499564 [PubMed - indexed for MEDLINE]	ue-specific epitope
□ 10	Zirah S, Stefanescu R, Manea M, Tian X, Cecal R, Kozin SA, Debey P, Rebuffat S, Przybylski M.	Related Articles, Links
	Zinc binding agonist effect on the recognition of the beepitope by anti-beta-amyloid antibodies. Biochem Biophys Res Commun. 2004 Aug 20;321(2):324-8. PMID: 15358179 [PubMed - indexed for MEDLINE]	eta-amyloid (4-10)
□11	Schenk D, Hagen M, Seubert P.	Related Articles, Links
	Current progress in beta-amyloid immunotherapy. Curr Opin Immunol. 2004 Oct;16(5):599-606. Review. PMID: 15342006 [PubMed - indexed for MEDLINE]	
□ 12	Zhang GR, Gao DL, Cao LG, Yin M.	Related Articles, Links
	[5-HT2C receptor subtype modulate production of secreptorin precursor in incubated rat hippocampal slices] Yao Xue Xue Bao. 2004 May;39(5):321-4. Chinese. PMID: 15338870 [PubMed - indexed for MEDLINE]	retory beta-amyloid
□ 13	Yasuoka K, Hirata K, Kuraoka A, He JW, Kawabuchi M.	Related Articles, Links
	Expression of amyloid precursor protein-like molecule of the subventricular zone and rostral migratory stream forebrain. J Anat. 2004 Aug;205(2):135-46. PMID: 15291796 [PubMed - indexed for MEDLINE]	
□ 14	Kowa H, Sakakura T, Matsuura Y, Wakabayashi T, Mann DM, Duff K, Tsuji S, Hashimoto T, Iwatsubo T.	Related Articles, Links
	Mostly separate distributions of CLAC- versus Abeta4 reactivities in senile plaques reveal two distinct subpop amyloid deposits. Am J Pathol. 2004 Jul;165(1):273-81. PMID: 15215182 [PubMed - indexed for MEDLINE]	
□ 15:	Mathis CA, Wang Y, Klunk WE.	Related Articles, Links
	Imaging beta-amyloid plaques and neurofibrillary tangles human brain.	les in the aging

Curr Pharm Des. 2004;10(13):1469-92. Review. PMID: 15134570 [PubMed - indexed for MEDLINE] ☐ **16**: Karkos J. Related Articles, Links [Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives Fortschr Neurol Psychiatr. 2004 Apr;72(4):204-19. Review. German. PMID: 15095177 [PubMed - indexed for MEDLINE] 17: Aleksandrova IY, Kuvichkin VV, Kashparov IA, Medvinskaya Related Articles, Links NI, Nesterova IV, Lunin SM, Samokhin AN, Bobkova NV. Increased level of beta-amyloid in the brain of bulbectomized mice. Biochemistry (Mosc). 2004 Feb;69(2):176-80. PMID: 15000684 [PubMed - indexed for MEDLINE] 18: Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Related Articles, Links Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry. 2003 Dec 9;42(48):14328-34. PMID: 14640701 [PubMed - indexed for MEDLINE] 19: Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Related Articles, Links Wegiel J. Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry. 2003 Oct 14;42(40):11682-92. PMID: 14529278 [PubMed - indexed for MEDLINE] 20: Wang DS, Iwata N, Hama E, Saido TC, Dickson DW. Related Articles, Links Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem Biophys Res Commun. 2003 Oct 10;310(1):236-41. PMID: 14511676 [PubMed - indexed for MEDLINE] 21: Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Related Articles, Links Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet. 2003 Nov 15;12(22):2949-56. Epub 2003 Sep 23. PMID: 14506131 [PubMed - indexed for MEDLINE] Related Articles, Links 22: Solomon B. Immunological approach for the treatment of Alzheimer's disease. J Mol Neurosci. 2003;20(3):283-6. PMID: 14501009 [PubMed - indexed for MEDLINE] 23: Chauhan NB, Siegel GJ. Related Articles, Links Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res. 2003 Oct 1;74(1):142-7. PMID: 13130516 [PubMed - indexed for MEDLINE] 24: Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung Related Articles, Links HH, Hegi T, Nitsch RM, Hock C. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol. 2003 Sep;60(9):1202-6. PMID: 12975284 [PubMed - indexed for MEDLINE]

□ 25:	LeVine H 3rd.	Related Articles, Links
	Y10W beta(1-40) fluorescence reflects epitope exposur Alzheimer's beta-peptide. Arch Biochem Biophys. 2003 Sep 1;417(1):112-22. PMID: 12921787 [PubMed - indexed for MEDLINE]	re in conformers of
□ 26:	Solomon B, Frenkel D.	Related Articles, Links
	Vaccination for the prevention and treatment of Alzheir Drugs Today (Barc). 2000 Sep;36(9):655-63. PMID: 12847570 [PubMed]	mer's disease.
□ 27:	Farr SA, Banks WA, Uezu K, Sano A, Gaskin FS, Morley JE.	Related Articles, Links
	Antibody to beta-amyloid protein increases acetylcholin hippocampus of 12 month SAMP8 male mice. Life Sci. 2003 Jun 20;73(5):555-62. PMID: 12770611 [PubMed - indexed for MEDLINE]	ne in the
□ 28:	Taylor BM, Sarver RW, Fici G, Poorman RA, Lutzke BS, Molinari A, Kawabe T, Kappenman K, Buhl AE, Epps DE.	Related Articles, Links
	Spontaneous aggregation and cytotoxicity of the beta-a a kinetic model. J Protein Chem. 2003 Jan;22(1):31-40. PMID: 12739896 [PubMed - indexed for MEDLINE]	myloid Abeta1-40:
□ 29:	Solomon B.	Related Articles, Links
	Protective Molecules in Alzheimer's Disease: Therapeu Drug News Perspect. 2002 Sep;15(7):410-416. PMID: 12677176 [PubMed - as supplied by publisher]	tic Antibodies.
□30:	Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R, Memo M.	Related Articles, Links
	Neutralization of TRAIL death pathway protects human from beta-amyloid toxicity. Cell Death Differ. 2003 Jan;10(1):134-41. PMID: 12655302 [PubMed - indexed for MEDLINE]	n neuronal cell line
□31:	Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T.	Related Articles, Links
	Epitope and isotype specificities of antibodies to beta - for protection against Alzheimer's disease-like neuropa Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2009 Proc Natl Acad Sci U S A. 2004 Aug 3;101(3):11526. PMID: 12566568 [PubMed - indexed for MEDLINE]	thology.
□32:	Solomon B, Frenkel D.	Related Articles, Links
	Generation and brain delivery of anti-aggregating antib amyloid plaques using phage display technology. J Neural Transm Suppl. 2002;(62):321-5. PMID: 12456075 [PubMed - indexed for MEDLINE]	odies against beta-
□33:	Krygowska-Wajs A, Adamek D, Szczudlik A, Kaluza J.	Related Articles, Links
	An attempt at evaluating borderline conditions of Parki its preclinical stage on the basis of clinical and morpho	

Folia Neuropathol. 2002;40(2):57-66. PMID: 12230257 [PubMed - indexed for MEDLINE] 34: Pan W, Solomon B, Maness LM, Kastin AJ. Related Articles, Links Antibodies to beta-amyloid decrease the blood-to-brain transfer of betaamyloid peptide. Exp Biol Med (Maywood). 2002 Sep;227(8):609-15. PMID: 12192102 [PubMed - indexed for MEDLINE] 35: Kovacs GG, Zerbi P, Voigtlander T, Strohschneider M, Related Articles, Links Trabattoni G, Hainfellner JA, Budka H. The prion protein in human neurodegenerative disorders. 国 Neurosci Lett. 2002 Sep 6;329(3):269-72. PMID: 12183028 [PubMed - indexed for MEDLINE] ☐ 36: Beher D, Wrigley JD, Owens AP, Shearman MS. Related Articles, Links Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J Neurochem. 2002 Aug;82(3):563-75. PMID: 12153480 [PubMed - indexed for MEDLINE] 37: Clamagirand C, Joulie C, Panchal M, Sekhri R, Hanquez C, Related Articles, Links Cohen P, Rholam M. Specific cleavage of beta-amyloid peptides by a metallopeptidase from Xenopus laevis skin secretions. Comp Biochem Physiol B Biochem Mol Biol. 2002 Aug;132(4):751-9. PMID: 12128061 [PubMed - indexed for MEDLINE] ☐ 38: Morley JE, Farr SA, Flood JF. Related Articles, Links Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem. 2002 Jul;78(1):125-38. PMID: 12071671 [PubMed - indexed for MEDLINE] 39: Frenkel D, Solomon B. Related Articles, Links Towards Alzheimer's beta-amyloid vaccination. Biologicals. 2001 Sep-Dec;29(3-4):243-7. PMID: 11851323 [PubMed - indexed for MEDLINE] 40: Cummings BJ, Mason AJ, Kim RC, Sheu PC, Anderson AJ. Related Articles, Links Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol Aging. 2002 Mar-Apr;23(2):161-70. PMID: 11804699 [PubMed - indexed for MEDLINE] ☐ **41**: Solomon B. Related Articles, Links Immunotherapeutic strategies for prevention and treatment of Alzheimer's DNA Cell Biol. 2001 Nov;20(11):697-703. PMID: 11788047 [PubMed - indexed for MEDLINE] 42: Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Related Articles, Links Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen



□ 50:	Frenkel D, Kariv N, Solomon B.	Related Articles, Links
	Generation of auto-antibodies towards Alzheimer's dise Vaccine. 2001 Mar 21;19(17-19):2615-9. PMID: 11257400 [PubMed - indexed for MEDLINE]	ease vaccination.
□ 51:	Lin B, Ginsberg MD, Busto R.	Related Articles, Links
	Hyperglycemic but not normoglycemic global ischemic early intraneuronal expression of beta-amyloid precurs Brain Res. 2001 Jan 5;888(1):107-116. PMID: 11146057 [PubMed - indexed for MEDLINE]	
□ 52:	Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E.	Related Articles, Links
	Standardization of measurement of beta-amyloid(1-42) fluid and plasma. Amyloid. 2000 Dec;7(4):245-58. PMID: 11132093 [PubMed - indexed for MEDLINE]	in cerebrospinal
□ 53:	Seiffert D, Mitchell T, Stern AM, Roach A, Zhan Y, Grzanna R.	Related Articles, Links
	Positive-negative epitope-tagging of beta amyloid precidentify inhibitors of A beta processing. Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):115-26. PMID: 11113538 [PubMed - indexed for MEDLINE]	ursor protein to
□ 54:	Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, Fujino Y, Nakajima M, Yamamoto T, Akatsu H, Mitsui S, Yamaguchi N.	Related Articles, Links
	Localization of a novel type trypsin-like serine protease brain tissues of Alzheimer's disease and Parkinson's dis Psychiatry Clin Neurosci. 2000 Aug;54(4):419-26. PMID: 10997858 [PubMed - indexed for MEDLINE]	
□ 55:	Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad B, Bogdanovi.	Related Articles, Links
	nNOS expression in reactive astrocytes correlates with death related DNA damage in the hippocampus and ent Alzheimer's disease. Exp Neurol. 2000 Sep;165(1):12-26. PMID: 10964481 [PubMed - indexed for MEDLINE]	
□ 56:	Sasaki A, Nakazato Y, Ogawa A, Sugihara S.	Related Articles, Links
	The immunophenotype of perivascular cells in the hum Pathol Int. 1996 Jan;46(1):15-23. PMID: 10846545 [PubMed - indexed for MEDLINE]	an brain.
□ 57:	Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA.	Related Articles, Links
	beta-amyloid (Abeta)42(43), abeta42, abeta40 and apol of plaques in fatal head injury. Neuropathol Appl Neurobiol. 2000 Apr;26(2):124-32. PMID: 10840275 [PubMed - indexed for MEDLINE]	E immunostaining
□ 58:	Rohn TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH.	Related Articles, Links

A monoclonal antibody to amyloid precursor protein induces neuronal

	apoptosis. J Neurochem. 2000 Jun;74(6):2331-42. PMID: 10820193 [PubMed - indexed for MEDLINE]	
□ 59:	Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C.	Related Articles, Links
	Presenilin-1 differentially facilitates endoproteolysis of precursor protein and Notch. Nat Cell Biol. 2000 Apr;2(4):205-11. PMID: 10783238 [PubMed - indexed for MEDLINE]	f the beta-amyloid
□ 60:	Yoshiyama Y, Asahina M, Hattori T.	Related Articles, Links
	Selective distribution of matrix metalloproteinase-3 (Malzheimer's disease brain. Acta Neuropathol (Berl). 2000 Feb;99(2):91-5. PMID: 10672313 [PubMed - indexed for MEDLINE]	IMP-3) in
□61 :	Jung SS, Gauthier S, Cashman NR.	Related Articles, Links
	Beta-amyloid precursor protein is detectable on monoc increased in Alzheimer's disease. Neurobiol Aging. 1999 May-Jun;20(3):249-57. PMID: 10588572 [PubMed - indexed for MEDLINE]	ytes and is
□ 62:	Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H.	Related Articles, Links
	Deposition of beta-amyloid subtypes 40 and 42 different with Lewy bodies from Alzheimer disease. Arch Neurol. 1999 Sep;56(9):1111-8. PMID: 10488812 [PubMed - indexed for MEDLINE]	ntiates dementia
□ 63:	Kaur B, Rutty GN, Timperley WR.	Related Articles, Links
	The possible role of hypoxia in the formation of axonal J Clin Pathol. 1999 Mar;52(3):203-9. PMID: 10450180 [PubMed - indexed for MEDLINE]	l bulbs.
□ 64:	Kurt MA, Davies DC, Kidd M.	Related Articles, Links
	beta-Amyloid immunoreactivity in astrocytes in Alzhei biopsies: an electron microscope study. Exp Neurol. 1999 Jul;158(1):221-8. PMID: 10448435 [PubMed - indexed for MEDLINE]	imer's disease brain
□ 65:	Yuan H, Zhai P, Anderson LM, Pan J, Thimmapaya B, Koo EH, Marquez-Sterling NR.	Related Articles, Links
	Recombinant adenovirus is an appropriate vector for er trafficking studies in cultured neurons. J Neurosci Methods. 1999 Apr 1;88(1):45-54. PMID: 10379578 [PubMed - indexed for MEDLINE]	ndocytotic protein
□ 66:	Ohsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S.	Related Articles, Links
	Amino-terminal region of secreted form of amyloid prestimulates proliferation of neural stem cells. Eur J Neurosci. 1999 Jun;11(6):1907-13. PMID: 10336659 [PubMed - indexed for MEDLINE]	ecursor protein
□ 67:	Johnson G, Moore SW.	Related Articles, Links

	The adhesion function on acetylcholinesterase is locate anionic site. Biochem Biophys Res Commun. 1999 May 19;258(3):758-62. PMID: 10329459 [PubMed - indexed for MEDLINE]	d at the peripheral
□ 68:	Abraham CR, Marshall DC, Tibbles HE, Otto K, Long HJ, Billingslea AM, Hastey R, Johnson R, Fine RE, Smith SJ, Simons ER, Davies TA.	Related Articles, Links
	Platelets and DAMI megakaryocytes possess beta-secred Lab Clin Med. 1999 May;133(5):507-15. PMID: 10235134 [PubMed - indexed for MEDLINE]	etase-like activity.
□ 69:	Frenkel D, Balass M, Katchalski-Katzir E, Solomon B.	Related Articles, Links
	High affinity binding of monoclonal antibodies to the sEFRH of beta-amyloid peptide is essential for modulat aggregation. J Neuroimmunol. 1999 Mar 1;95(1-2):136-42. PMID: 10229123 [PubMed - indexed for MEDLINE]	
□ 70:	Lin B, Schmidt-Kastner R, Busto R, Ginsberg MD.	Related Articles, Links
	Progressive parenchymal deposition of beta-amyloid prat brain following global cerebral ischemia. Acta Neuropathol (Berl). 1999 Apr;97(4):359-68. PMID: 10208275 [PubMed - indexed for MEDLINE]	recursor protein in
□71:	Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA.	Related Articles, Links
	Reverse relationship between beta-amyloid precursor pamyloid peptide plaques in Down's syndrome versus spalzheimer's disease. Acta Neuropathol (Berl). 1999 Feb;97(2):113-8. PMID: 9928821 [PubMed - indexed for MEDLINE]	
□ 72:	Leanza G.	Related Articles, Links
	Chronic elevation of amyloid precursor protein express neocortex and hippocampus of rats with selective choli Neurosci Lett. 1998 Nov 20;257(1):53-6. PMID: 9857964 [PubMed - indexed for MEDLINE]	
□ 73:	Mizuno T, Haass C, Michikawa M, Yanagisawa K.	Related Articles, Links
	Cholesterol-dependent generation of a unique amyloid apically missorted amyloid precursor protein in MDCk Biochim Biophys Acta. 1998 Aug 14;1373(1):119-30. PMID: 9733943 [PubMed - indexed for MEDLINE]	•
□ 74:	Hock C, Golombowski S, Muller-Spahn F, Peschel O, Riederer A, Probst A, Mandelkow E, Unger J.	Related Articles, Links
	Histological markers in nasal mucosa of patients with A disease. Eur Neurol. 1998 Jul;40(1):31-6. PMID: 9693230 [PubMed - indexed for MEDLINE]	Alzheimer's
□ 75:	Frenkel D, Balass M, Solomon B.	Related Articles, Links
	N-terminal EFRH sequence of Alzheimer's beta-amylo represents the epitope of its anti-aggregating antibodies	

J Neuroimmunol. 1998 Aug 1;88(1-2):85-90. PMID: 9688328 [PubMed - indexed for MEDLINE] ☐ **76:** <u>Tamaoka A.</u> Related Articles, Links [Characterization of amyloid beta protein species in the plasma, cerebrospinal fluid and brains of patients with Alzheimer's diseasel Nippon Ronen Igakkai Zasshi. 1998 Apr;35(4):273-7. Japanese. PMID: 9643008 [PubMed - indexed for MEDLINE] 77: Nakamura Y, Yamamoto M, Kumamaru E. Related Articles, Links A variant very low density lipoprotein receptor lacking 84 base pairs of O-linked sugar domain in the human brain myelin. Brain Res. 1998 May 18;793(1-2):47-53. PMID: 9630508 [PubMed - indexed for MEDLINE] 78: Honda S, Itoh F, Yoshimoto M, Hinoda Y, Imai K. Related Articles, Links Changes in morphology of neuroblastoma cells treated with all-trans retinoic acid combined with transfer of the C-terminal region of the amyloid precursor protein. J Clin Lab Anal. 1998;12(3):172-8. PMID: 9591705 [PubMed - indexed for MEDLINE] **79:** Rossner S. Related Articles, Links Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease. Int J Dev Neurosci. 1997 Nov;15(7):835-50. Review. PMID: 9568532 [PubMed - indexed for MEDLINE] 80: Dwork AJ, Liu D, Kaufman MA, Prohovnik I. Related Articles, Links Archival, formalin-fixed tissue: its use in the study of Alzheimer's type changes. Clin Neuropathol. 1998 Jan-Feb; 17(1):45-9. PMID: 9496540 [PubMed - indexed for MEDLINE] 81: Friedman LM, Matsuda Y, Lazarovici P. Related Articles, Links The microbial alkaloid toxin staurosporine blocks the phorbol esterinduced increase in beta-amyloid precursor protein in PC12 cells. Nat Toxins. 1997;5(5):173-9. PMID: 9496375 [PubMed - indexed for MEDLINE] 82: Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Related Articles, Links Papadimitriou JM. Age-related congophilic inclusions in the brains of apolipoprotein Edeficient mice. Neuroscience. 1998 Jan;82(1):171-80. PMID: 9483513 [PubMed - indexed for MEDLINE] 83: Kobayashi K, Muramori F, Aoki T, Hayashi M, Miyazu K, Related Articles, Links Fukutani Y, Mukai M, Koshino F. KP-1 is a marker for extraneuronal neurofibrillary tangles and senile plaques in Alzheimer diseased brains. Dement Geriatr Cogn Disord. 1998 Jan-Feb;9(1):13-9. PMID: 9469259 [PubMed - indexed for MEDLINE] Related Articles, Links Shalit F, Sredni B, Rosenblatt-Bin H, Kazimirsky G, Brodie C,

	Huberman M.	
	Beta-amyloid peptide induces tumor necrosis factor-alproduction in murine macrophage cultures. Neuroreport. 1997 Nov 10;8(16):3577-80. PMID: 9427329 [PubMed - indexed for MEDLINE]	pha and nitric oxide
□ 85:	Walker LC.	Related Articles, Links
	Animal models of cerebral beta-amyloid angiopathy. Brain Res Brain Res Rev. 1997 Sep 30;25(1):70-84. Review. PMID: 9370051 [PubMed - indexed for MEDLINE]	
□ 86:	Goodwin JL, Kehrli ME Jr, Uemura E.	Related Articles, Links
	Integrin Mac-1 and beta-amyloid in microglial release Brain Res. 1997 Sep 12;768(1-2):279-86. PMID: 9369326 [PubMed - indexed for MEDLINE]	of nitric oxide.
□ 87:	Lahiri DK, Farlow MR, Sambamurti K, Nall C.	Related Articles, Links
	The effect of tacrine and leupeptin on the secretion of the precursor protein in HeLa cells. Life Sci. 1997;61(20):1985-92. PMID: 9366505 [PubMed - indexed for MEDLINE]	the beta-amyloid
□ 88:	Lahiri DK, Farlow MR, Nurnberger JI Jr, Greig NH.	Related Articles, Links
	Effects of cholinesterase inhibitors on the secretion of precursor protein in cell cultures. Ann N Y Acad Sci. 1997 Sep 26;826:416-21. PMID: 9329715 [PubMed - indexed for MEDLINE]	beta-amyloid
□ 89:	Shea TB, Prabhakar S, Ekinci FJ.	Related Articles, Links
□ 89 :	Shea TB, Prabhakar S, Ekinci FJ. Beta-amyloid and ionophore A23187 evoke tau hyperp distinct intracellular pathways: differential involvement calpain/protein kinase C system. J Neurosci Res. 1997 Sep 15;49(6):759-68. PMID: 9335263 [PubMed - indexed for MEDLINE]	phosphorylation by
	Beta-amyloid and ionophore A23187 evoke tau hyperp distinct intracellular pathways: differential involvement calpain/protein kinase C system. J Neurosci Res. 1997 Sep 15;49(6):759-68.	phosphorylation by at of the
	Beta-amyloid and ionophore A23187 evoke tau hyperp distinct intracellular pathways: differential involvement calpain/protein kinase C system. J Neurosci Res. 1997 Sep 15;49(6):759-68. PMID: 9335263 [PubMed - indexed for MEDLINE] Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C,	phosphorylation by at of the Related Articles, Links
☐ 90: ☐	Beta-amyloid and ionophore A23187 evoke tau hyperp distinct intracellular pathways: differential involvement calpain/protein kinase C system. J Neurosci Res. 1997 Sep 15;49(6):759-68. PMID: 9335263 [PubMed - indexed for MEDLINE] Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C, Haran M, Stewart B. The recognition of haemoglobin by antibodies raised for immunoassay of beta-amyloid. FEBS Lett. 1997 Jul 28;412(2):341-5.	phosphorylation by at of the Related Articles, Links
☐ 90: ☐	Beta-amyloid and ionophore A23187 evoke tau hyperp distinct intracellular pathways: differential involvement calpain/protein kinase C system. J Neurosci Res. 1997 Sep 15;49(6):759-68. PMID: 9335263 [PubMed - indexed for MEDLINE] Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C, Haran M, Stewart B. The recognition of haemoglobin by antibodies raised for immunoassay of beta-amyloid. FEBS Lett. 1997 Jul 28;412(2):341-5. PMID: 9256248 [PubMed - indexed for MEDLINE] Yamada T, Wakabayashi K, Kakihara T, Gejyo F, Takahashi H,	phosphorylation by at of the Related Articles, Links or the Related Articles, Links
□ 90: □ 91: □	Beta-amyloid and ionophore A23187 evoke tau hyperp distinct intracellular pathways: differential involvement calpain/protein kinase C system. J Neurosci Res. 1997 Sep 15;49(6):759-68. PMID: 9335263 [PubMed - indexed for MEDLINE] Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C, Haran M, Stewart B. The recognition of haemoglobin by antibodies raised for immunoassay of beta-amyloid. FEBS Lett. 1997 Jul 28;412(2):341-5. PMID: 9256248 [PubMed - indexed for MEDLINE] Yamada T, Wakabayashi K, Kakihara T, Gejyo F, Takahashi H, Itoh Y. Further characterization of a monoclonal antibody recognolipoprotein E peptides in amyloid deposits. Ann Clin Lab Sci. 1997 Jul-Aug;27(4):276-81.	phosphorylation by at of the Related Articles, Links or the Related Articles, Links

Ann Neurol. 1997 Jun;41(6):809-13. PMID: 9189043 [PubMed - indexed for MEDLINE] ☐ 93: Sasaki A, lijima M, Yokoo H, Shoji M, Nakazato Y. Related Articles, Links Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural Brain Res. 1997 May 2;755(2):193-201. PMID: 9175887 [PubMed - indexed for MEDLINE] 94: Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Related Articles, Links Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4109-12. PMID: 9108113 [PubMed - indexed for MEDLINE] 55: Lim GP, Russell MJ, Cullen MJ, Tokes ZA. Related Articles, Links Matrix metalloproteinases in dog brains exhibiting Alzheimer-like characteristics. J Neurochem. 1997 Apr;68(4):1606-11. PMID: 9084432 [PubMed - indexed for MEDLINE] ☐ **96:** Xu S, Gaskin F. Related Articles, Links Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev. 1997 Mar;94(1-3):213-22. PMID: 9147373 [PubMed - indexed for MEDLINE] 97: McDermott JR, Gibson AM. Related Articles, Links Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res. 1997 Jan;22(1):49-56. PMID: 9021762 [PubMed - indexed for MEDLINE] 98: Drache B, Diehl GE, Bevreuther K, Perlmutter LS, Konig G. Related Articles, Links Bcl-xl-specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states. J Neurosci Res. 1997 Jan 1;47(1):98-108. PMID: 8981243 [PubMed - indexed for MEDLINE] ☐ 99: Nielson KA, Cummings BJ, Cotman CW. Related Articles, Links Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Brain Res. 1996 Nov 25;741(1-2):284-93. PMID: 9001734 [PubMed - indexed for MEDLINE] 100: Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe Related Articles, Links Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5. PMID: 8917563 [PubMed - indexed for MEDLINE]

Jung SS, Nalbantoglu J, Cashman NR.

□ 101	· · · · · · · · · · · · · · · · · · ·	Related Articles, Links
	Alzheimer's beta-amyloid precursor protein is express of immediately ex vivo brain cells: a flow cytometric J Neurosci Res. 1996 Nov 1;46(3):336-48. PMID: 8933373 [PubMed - indexed for MEDLINE]	
□ 102	Stephens DJ, Austen BM.	Related Articles, Links
	Metabolites of the beta-amyloid precursor protein ge secretase localise to the trans-Golgi network and late cells. J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE]	•
□ 103	Kuo H, Ingram DK, Walker LC, Tian M, Hengemihle JM, Jucker M.	Related Articles, Links
	Similarities in the age-related hippocampal deposition schiff-positive granules in the senescence-accelerated C57BL/6 mouse strains. Neuroscience. 1996 Oct;74(3):733-40. PMID: 8884769 [PubMed - indexed for MEDLINE]	_
□ 104	Yodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB.	Related Articles, Links
	Inducible nitric oxide synthase in tangle-bearing neur with Alzheimer's disease. J Exp Med. 1996 Oct 1;184(4):1425-33. PMID: 8879214 [PubMed - indexed for MEDLINE]	rons of patients
□ 105	De La Monte SM, Carlson RI, Brown NV, Wands JR.	Related Articles, Links
	Profiles of neuronal thread protein expression in Alzi J Neuropathol Exp Neurol. 1996 Oct;55(10):1038-50. PMID: 8858001 [PubMed - indexed for MEDLINE]	heimer's disease.
□ 106	Fraser SP, Suh YH, Chong YH, Djamgoz MB.	Related Articles, Links
	Membrane currents induced in Xenopus oocytes by t fragment of the beta-amyloid precursor protein. J Neurochem. 1996 May;66(5):2034-40. PMID: 8780033 [PubMed - indexed for MEDLINE]	he C-terminal
□ 107	Koo EH, Squazzo SL, Selkoe DJ, Koo CH.	Related Articles, Links
	Trafficking of cell-surface amyloid beta-protein precendocytosis and recycling as detected by labeled mor J Cell Sci. 1996 May;109 (Pt 5):991-8. PMID: 8743946 [PubMed - indexed for MEDLINE]	
□ 108	Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, Teplow DB, Selkoe DJ, Mori H.	Related Articles, Links
	Antibodies to amyloid beta protein (A beta) crossread glyceraldehyde-3-phosphate dehydrogenase (GAPDI Neurobiol Aging. 1996 May-Jun;17(3):405-14. PMID: 8725902 [PubMed - indexed for MEDLINE]	
□ 109	Nelson PT, Saper CB.	Related Articles, Links

	Injections of okadaic acid, but not beta-amyloid pepti immunoreactive dystrophic neurites in the cerebral con Neurosci Lett. 1996 Apr 19;208(2):77-80. PMID: 8859894 [PubMed - indexed for MEDLINE]	
□ 110	Zhang M, Olsson Y.	Related Articles, Links
	Beta-amyloid precursor protein accumulates in axons hematogenous metastases of the human brain: immur observations. Clin Neuropathol. 1996 Mar-Apr;15(2):74-8. PMID: 8925600 [PubMed - indexed for MEDLINE]	
□111	Liberski PP, Yanagihara R, Brown P, Kordek R, Kloszewska I, Bratosiewicz J, Gajdusek DC.	Related Articles, Links
	Microwave treatment enhances the immunostaining of in both the transmissible and non-transmissible brain Neurodegeneration. 1996 Mar;5(1):95-9. PMID: 8731388 [PubMed - indexed for MEDLINE]	
□ 112	Konig G, Graham P, Bushnell A, Webster S, Wunderlich D, Perlmutter LS.	Related Articles, Links
	Development and characterization of a monoclonal arspecific for the carboxyl-terminus of the beta A4 pept Ann N Y Acad Sci. 1996 Jan 17;777:344-55. PMID: 8624111 [PubMed - indexed for MEDLINE]	
□ 113	Solomon B, Koppel R, Hanan E, Katzav T.	Related Articles, Links
	Monoclonal antibodies inhibit in vitro fibrillar aggreg Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5. PMID: 8552659 [PubMed - indexed for MEDLINE]	gation of the
□114	Lahiri DK, Farlow MR.	Related Articles, Links
	Differential effect of tacrine and physostigmine on the beta-amyloid precursor protein in cell lines. J Mol Neurosci. 1996 Spring;7(1):41-9. PMID: 8835781 [PubMed - indexed for MEDLINE]	e secretion of the
□ 115	Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM.	Related Articles, Links
	Staging the pathological assembly of truncated tau pr helical filaments in Alzheimer's disease. Acta Neuropathol (Berl). 1996;91(6):633-41. PMID: 8781663 [PubMed - indexed for MEDLINE]	otein into paired
□ 116	Veerhuis R, Janssen I, Hack CE, Eikelenboom P.	Related Articles, Links
	Early complement components in Alzheimer's disease Acta Neuropathol (Berl). 1996;91(1):53-60. PMID: 8773146 [PubMed - indexed for MEDLINE]	e brains.
□ 117	Saito Y, Buciak J, Yang J, Pardridge WM.	Related Articles, Links
	Vector-mediated delivery of 125I-labeled beta-amylo 1-40 through the blood-brain barrier and binding to A amyloid of the A beta 1-40/vector complex. Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10227-31.	

PMID: 7479757 [PubMed - indexed for MEDLINE]

□ 118:	Link CD.	Related Articles, Links
	Expression of human beta-amyloid peptide in transger elegans. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9368-72. PMID: 7568134 [PubMed - indexed for MEDLINE]	nic Caenorhabditis
□ 119:	Davis DR, Brion JP, Couck AM, Gallo JM, Hanger DP, Ladhani K, Lewis C, Miller CC, Rupniak T, Smith C, et al.	Related Articles, Links
	The phosphorylation state of the microtubule-associat affected by glutamate, colchicine and beta-amyloid in cortical neuronal cultures. Biochem J. 1995 Aug 1;309 (Pt 3):941-9. PMID: 7639714 [PubMed - indexed for MEDLINE]	•
□ 120:	Crino PB, Martin JA, Hill WD, Greenberg B, Lee VM, Trojanowski JQ.	Related Articles, Links
	Beta-Amyloid peptide and amyloid precursor proteins mucosa of patients with Alzheimer's disease, Parkinso Down syndrome. Ann Otol Rhinol Laryngol. 1995 Aug;104(8):655-61. PMID: 7639477 [PubMed - indexed for MEDLINE]	-
□121:	Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK.	Related Articles, Links
	LDL receptor-related protein, a multifunctional ApoE secreted beta-amyloid precursor protein and mediates Cell. 1995 Jul 28;82(2):331-40. PMID: 7543026 [PubMed - indexed for MEDLINE]	
□ 122:	Griffith LS, Mathes M, Schmitz B.	Related Articles, Links
	Beta-amyloid precursor protein is modified with O-lir acetylglucosamine. J Neurosci Res. 1995 Jun 1;41(2):270-8. PMID: 7650762 [PubMed - indexed for MEDLINE]	nked N-
□ 123:	Yamada T, Kobayashi T.	Related Articles, Links
	The mutation in amyloid precursor protein inhibits bo secretion. Neurosci Lett. 1995 May 19;191(1-2):103-6. PMID: 7659274 [PubMed - indexed for MEDLINE]	th alpha- and beta-
□ 124:	Fang Q, Kannapell CC, Fu SM, Xu S, Gaskin F.	Related Articles, Links
	VH and VL gene usage by anti-beta-amyloid autoanti Alzheimer's disease: detection of highly mutated V re heavy and light chains. Clin Immunol Immunopathol. 1995 May;75(2):159-67. PMID: 7704974 [PubMed - indexed for MEDLINE]	
□ 125:	Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T, Horiuchi S.	Related Articles, Links
	Are advanced glycation end-products associated with Alzheimer's disease?	amyloidosis in

	PMID: 7612872 [PubMed - indexed for MEDLINE]	
□ 126	Oohira A, Kushima Y, Matsui F, Watanabe E.	Related Articles, Links
	Detection of Alzheimer's beta-amyloid precursor relabearing chondroitin sulfate both in the juvenile rat braconditioned medium of primary cultured astrocytes. Neurosci Lett. 1995 Apr 7;189(1):25-8. PMID: 7603617 [PubMed - indexed for MEDLINE]	
□ 127	: Pike CJ, Cummings BJ, Cotman CW.	Related Articles, Links
	Early association of reactive astrocytes with senile pl Alzheimer's disease. Exp Neurol. 1995 Apr;132(2):172-9. PMID: 7789457 [PubMed - indexed for MEDLINE]	aques in
□ 128	Yamazaki T, Selkoe DJ, Koo EH.	Related Articles, Links
	Trafficking of cell surface beta-amyloid precursor pro and transcytotic transport in cultured neurons. J Cell Biol. 1995 Apr;129(2):431-42. PMID: 7721945 [PubMed - indexed for MEDLINE]	otein: retrograde
□ 129	Kim CS, Han YF, Etcheberrigaray R, Nelson TJ, Olds JL, Yoshioka T, Alkon DL.	Related Articles, Links
	Alzheimer and beta-amyloid-treated fibroblasts demoin a memory-associated GTP-binding protein, Cp20. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3060-4. PMID: 7708775 [PubMed - indexed for MEDLINE]	enstrate a decrease
□ 130	Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I.	Related Articles, Links
	Ligand-dependent G protein coupling function of amtransmembrane precursor. J Biol Chem. 1995 Mar 3;270(9):4205-8. PMID: 7876177 [PubMed - indexed for MEDLINE]	yloid
□ 131	Cabal A, Alonso-Cortina V, Gonzalez-Vazquez LO, Naves FJ, Del Valle ME, Vega JA.	Related Articles, Links
	beta-Amyloid precursor protein (beta APP) in human reference to the enteric nervous system. Brain Res Bull. 1995;38(5):417-23. PMID: 8665264 [PubMed - indexed for MEDLINE]	gut with special
□ 132	Mangone CA, Castano EM, Levy E, Abiusi G, Wisniewski T, Marques MR, Faccio E, Gorelick PB, Frangione B, Sica RE.	Related Articles, Links
	Early onset Alzheimer's disease in a South American Argentina. Acta Neurol Scand. 1995 Jan;91(1):6-13. PMID: 7732777 [PubMed - indexed for MEDLINE]	pedigree from
□ 133	Mena R, Edwards P, Perez-Olvera O, Wischik CM.	Related Articles, Links
	Monitoring pathological assembly of tau and beta-am Alzheimer's disease. Acta Neuropathol (Berl). 1995;89(1):50-6. PMID: 7709731 [PubMed - indexed for MEDLINE]	yloid proteins in
□ 134	Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE.	Related Articles, Links

	Purification and characterization of brain clusterin. Biochem Biophys Res Commun. 1994 Nov 15;204(3):1131-6. PMID: 7980587 [PubMed - indexed for MEDLINE]	
□ 135:	Katsetos CD, Krishna L, Friedberg E, Reidy J, Karkavelas G, Savory J.	Related Articles, Links
	Lobar pilocytic astrocytomas of the cerebral hemisphere Pathobiologymorphogenesis of the eosinophilic granu Clin Neuropathol. 1994 Nov-Dec;13(6):306-14. PMID: 7851045 [PubMed - indexed for MEDLINE]	
□ 136:	McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG.	telated Articles, Links
	Pathological proteins in senile plaques. Tohoku J Exp Med. 1994 Nov;174(3):269-77. PMID: 7761992 [PubMed - indexed for MEDLINE]	
□ 137:	Yang F, Mak K, Vinters HV, Frautschy SA, Cole GM.	elated Articles, Links
	Monoclonal antibody to the C-terminus of beta-amyloic Neuroreport. 1994 Oct 27;5(16):2117-20. PMID: 7865758 [PubMed - indexed for MEDLINE]	i .
□ 138:	Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Cataldo AM, Nixon RA.	telated Articles, Links
	Degenerative changes in epinephrine tonic vasomotor n Alzheimer's disease. Brain Res. 1994 Oct 24;661(1-2):35-42. PMID: 7834382 [PubMed - indexed for MEDLINE]	eurons in
□ 139:	Dreyer RN, Bausch KM, Fracasso P, Hammond LJ, Wunderlich RD, Wirak DO, Davis G, Brini CM, Buckholz TM, Konig G, et al.	telated Articles, Links
	Processing of the pre-beta-amyloid protein by cathepsing by a familial Alzheimer's disease mutation. Eur J Biochem. 1994 Sep 1;224(2):265-71. PMID: 7523115 [PubMed - indexed for MEDLINE]	D is enhanced
□ 140:	van de Nes JA, Sluiter AA, Pool CW, Kamphorst W, Ravid R, Swaab DF.	telated Articles, Links
	The monoclonal antibody Alz-50, used to reveal cytosk Alzheimer's disease, also reacts with a large subpopulat somatostatin neurons in the normal human hypothalamu areas. Brain Res. 1994 Aug 29;655(1-2):97-109. PMID: 7812796 [PubMed - indexed for MEDLINE]	ion of
□ 141:	Durham HD, Minotti S, Dooley NP, Nalbantoglu J.	elated Articles, Links
	Expression of the intermediate filament-associated prote beta-amyloid precursor protein is developmentally regu cells. J Neurosci Res. 1994 Aug 15;38(6):629-39.	
	PMID: 7807580 [PubMed - indexed for MEDLINE]	
□ 142:	Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA.	elated Articles, Links
	Development of an anti-A beta monoclonal antibody for of anyloid angionathy in Alzheimer's disease	r in vivo imaging

	M IN 12 1 1004 A B 200 20 20 20	
	Mol Neurobiol. 1994 Aug-Dec;9(1-3):107-13. PMID: 7888086 [PubMed - indexed for MEDLINE]	
□ 143:	Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y.	Related Articles, Links
	Visualization of A beta 42(43) and A beta 40 in senile specific A beta monoclonals: evidence that an initially is A beta 42(43). Neuron. 1994 Jul;13(1):45-53. PMID: 8043280 [PubMed - indexed for MEDLINE]	
□ 144:	Walker LC, Price DL, Voytko ML, Schenk DB.	Related Articles, Links
	Labeling of cerebral amyloid in vivo with a monoclor J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83. PMID: 8021711 [PubMed - indexed for MEDLINE]	nal antibody.
□ 145	Jucker M, Walker LC, Schwarb P, Hengemihle J, Kuo H, Snow AD, Bamert F, Ingram DK.	Related Articles, Links
	Age-related deposition of glia-associated fibrillar mat C57BL/6 mice. Neuroscience. 1994 Jun;60(4):875-89. PMID: 7936209 [PubMed - indexed for MEDLINE]	erial in brains of
□ 146	Kurochkin IV, Goto S.	Related Articles, Links
	Alzheimer's beta-amyloid peptide specifically interac degraded by insulin degrading enzyme. FEBS Lett. 1994 May 23;345(1):33-7. PMID: 8194595 [PubMed - indexed for MEDLINE]	ts with and is
□ 147:	Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P.	Related Articles, Links
	Soluble amyloid beta-protein is a marker of Alzheime but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994 May 16;200(3):1598-603 PMID: 8185615 [PubMed - indexed for MEDLINE]	•
□ 148:	Murphy GM Jr, Forno LS, Higgins L, Scardina JM, Eng LF, Cordell B.	Related Articles, Links
	Development of a monoclonal antibody specific for the of beta-amyloid 1-42 and its immunohistochemical realization Alzheimer's disease and related disorders. Am J Pathol. 1994 May;144(5):1082-8. PMID: 8178931 [PubMed - indexed for MEDLINE]	
□ 149:	Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS.	Related Articles, Links
	Glial cytokines as neuropathogenic factors in HIV infi similarities to Alzheimer's disease. J Neuropathol Exp Neurol. 1994 May;53(3):231-8. PMID: 8176406 [PubMed - indexed for MEDLINE]	ection: pathogenic
□ 150:	Akaaboune M, Ma J, Festoff BW, Greenberg BD, Hantai D.	Related Articles, Links
	Neurotrophic regulation of mouse muscle beta-amylo precursor and alpha 1-antichymotrypsin as revealed b J Neurobiol. 1994 May;25(5):503-14. PMID: 8071658 [PubMed - indexed for MEDLINE]	•

□ 151:	Higgins LS, Holtzman DM, Rabin J, Mobley WC, Cordell B.	Related Articles, Links
	Transgenic mouse brain histopathology resembles ear disease.	ly Alzheimer's
	Ann Neurol. 1994 May;35(5):598-607. PMID: 7513982 [PubMed - indexed for MEDLINE]	
□ 152:	<u>Hajimohammadreza I, Anderson VE, Cavanagh JB, Seville MP, Nolan CC, Anderton BH, Leigh PN.</u>	Related Articles, Links
	beta-Amyloid precursor protein fragments and lysoson are found in rat brain neurons after ventricular infusio Brain Res. 1994 Mar 21;640(1-2):25-32. PMID: 8004453 [PubMed - indexed for MEDLINE]	
□ 153:	Bickel U, Lee VM, Trojanowski JQ, Pardridge WM.	Related Articles, Links
	Development and in vitro characterization of a cationi antibody against beta A4 protein: a potential probe for disease.	
	Bioconjug Chem. 1994 Mar-Apr;5(2):119-25. PMID: 8031874 [PubMed - indexed for MEDLINE]	
□ 154:	Loffler J, Langui D, Probst A, Huber G.	Related Articles, Links
	Accumulation of a 50 kDa N-terminal fragment of bet Alzheimer's disease hippocampus and neocortex. Neurochem Int. 1994 Mar;24(3):281-8. PMID: 8025536 [PubMed - indexed for MEDLINE]	a-APP695 in
□ 155:	Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K.	Related Articles, Links
	Heparan sulfate proteoglycan in diffuse plaques of hip of cerebellum in Alzheimer's disease brain. Am J Pathol. 1994 Feb;144(2):337-47. PMID: 8311117 [PubMed - indexed for MEDLINE]	ppocampus but not
□ 156:	Hartig W, Hausen D, Brauer K, Arendt T, Bigl V, Bruckner G.	Related Articles, Links
	Digoxigenin-tagged anti-GFAP and multiple labelling vessels and beta-amyloid. Neuroreport. 1994 Jan 31;5(5):573-6. Erratum in: Neuroreport 19 (8):following 1014. PMID: 8025246 [PubMed - indexed for MEDLINE]	
□ 157:	Maat-Schieman ML, Radder CM, van Duinen SG, Haan J, Roos RA.	Related Articles, Links
	Hereditary cerebral hemorrhage with amyloidosis (Du congophilic plaque formation without neurofibrillary pacta Neuropathol (Berl). 1994;88(4):371-8. PMID: 7839831 [PubMed - indexed for MEDLINE]	
□ 158:	Zemlan FP, Vogelsang GD, McLaughlin L, Dean GE.	Related Articles, Links
	Alzheimer's paired helical filaments: amyloid precurso mapping. Brain Res Bull. 1994;33(4):387-92. PMID: 7510209 [PubMed - indexed for MEDLINE]	or protein epitope
□ 150·	Cummings BJ, Su JH, Cotman CW.	Related Articles Links
1		Related Articles, Links
	Neuritic involvement within bFGF immunopositive pl	aques of

	Alzheimer's disease. Exp Neurol. 1993 Dec;124(2):315-25. PMID: 8287930 [PubMed - indexed for MEDLINE]	
□ 160:	Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS.	Related Articles, Links
	Pathological changes in frontal cortex from biopsy to Alzheimer's disease. Neurobiol Aging. 1993 Nov-Dec;14(6):589-96. PMID: 8295661 [PubMed - indexed for MEDLINE]	autopsy in
□ 161:	Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB.	Related Articles, Links
	Characterization of beta-amyloid peptide from humar fluid.	n cerebrospinal
	J Neurochem. 1993 Nov;61(5):1965-8. PMID: 8229004 [PubMed - indexed for MEDLINE]	
□ 162:	Askanas V, Bilak M, Engel WK, Alvarez RB, Tome F, Leclerc A.	Related Articles, Links
	Prion protein is abnormally accumulated in inclusion Neuroreport. 1993 Oct 25;5(1):25-8. PMID: 8280854 [PubMed - indexed for MEDLINE]	-body myositis.
□ 163:	Askanas V, Bilak M, Engel WK, Leclerc A, Tome F.	Related Articles, Links
	Prion protein is strongly immunolocalized at the posts human normal neuromuscular junctions. Neurosci Lett. 1993 Sep 3;159(1-2):111-4. PMID: 8264949 [PubMed - indexed for MEDLINE]	synaptic domain of
□ 164:	Holmes C, Webster MT, Procter AW, Francis PT, Bowen DM.	Related Articles, Links
	Relationship between beta-amyloid precursor protein neurones and astrocytes in human neocortex. Biochem Soc Trans. 1993 Aug;21 (Pt 3)(3):238S. No abstract a PMID: 8224394 [PubMed - indexed for MEDLINE]	••
□ 165:	Miklossy J.	Related Articles, Links
	Alzheimer's diseasea spirochetosis? Neuroreport. 1993 Jul;4(7):841-8. PMID: 8369471 [PubMed - indexed for MEDLINE]	
□ 166:	Singhrao SK, Neal JW, Newman GR.	Related Articles, Links
	Corpora amylacea could be an indicator of neurodege Neuropathol Appl Neurobiol. 1993 Jun;19(3):269-76. PMID: 8355813 [PubMed - indexed for MEDLINE]	neration.
□ 167:	DeWitt DA, Silver J, Canning DR, Perry G.	Related Articles, Links
	Chondroitin sulfate proteoglycans are associated with Alzheimer's disease. Exp Neurol. 1993 Jun;121(2):149-52. PMID: 8339766 [PubMed - indexed for MEDLINE]	the lesions of
□ 168:	Stoll J, Balbo A, Ault B, Rapoport SI, Fine A.	Related Articles, Links
	Long-term transplants of mouse trisomy 16 hippocam model for Down's syndrome, do not develop Alzheim neuropathology.	

	Brain Res. 1993 May 7;610(2):295-304. PMID: 8319091 [PubMed - indexed for MEDLINE]	
□ 169:	Oyama F, Hirohashi S, Sakamoto M, Titani K, Sekiguchi K.	Related Articles, Links
	Coordinate oncodevelopmental modulation of alternative fibronectin pre-messenger RNA at ED-A, ED-B, and human liver tumors. Cancer Res. 1993 May 1;53(9):2005-11. PMID: 8481903 [PubMed - indexed for MEDLINE]	
□ 170:	<u>Lahiri DK.</u>	Related Articles, Links
	The stability of beta-amyloid precursor protein in nin types. Biochem Mol Biol Int. 1993 Apr;29(5):849-58. PMID: 8508138 [PubMed - indexed for MEDLINE]	e different cell
□ 171:	Gaskin F, Finley J, Fang Q, Xu S, Fu SM.	Related Articles, Links
	Human antibodies reactive with beta-amyloid protein disease. J Exp Med. 1993 Apr 1;177(4):1181-6. PMID: 8459212 [PubMed - indexed for MEDLINE]	in Alzheimer's
□ 172:	Buee L, Ding W, Delacourte A, Fillit H.	Related Articles, Links
	Binding of secreted human neuroblastoma proteoglyce Alzheimer's amyloid A4 peptide. Brain Res. 1993 Jan 22;601(1-2):154-63. PMID: 8431762 [PubMed - indexed for MEDLINE]	cans to the
□ 173:	Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, et al.	Related Articles, Links
	Secretion of beta-amyloid precursor protein cleaved a terminus of the beta-amyloid peptide. Nature. 1993 Jan 21;361(6409):260-3. PMID: 7678698 [PubMed - indexed for MEDLINE]	at the amino
□ 174:	Nelson PT, Marton L, Saper CB.	Related Articles, Links
	Alz-50 immunohistochemistry in the normal sheep st electron microscope study. Brain Res. 1993 Jan 15;600(2):285-97. PMID: 8094642 [PubMed - indexed for MEDLINE]	riatum: a light and
□ 175:	Wisniewski HM, Weigel J.	Related Articles, Links
	Migration of perivascular cells into the neuropil and to beta-amyloid plaque formation. Acta Neuropathol (Berl). 1993;85(6):586-95. PMID: 8337937 [PubMed - indexed for MEDLINE]	heir involvement in
□ 176:	Su JH, Cummings BJ, Cotman CW.	Related Articles, Links
	Localization of heparan sulfate glycosaminoglycan at core protein in aged brain and Alzheimer's disease. Neuroscience. 1992 Dec;51(4):801-13. PMID: 1488123 [PubMed - indexed for MEDLINE]	nd proteoglycan
□ 177:	Perlmutter LS, Scott SA, Barron E, Chui HC.	Related Articles, Links

	MHC class II-positive microglia in human brain: asso Alzheimer lesions. J Neurosci Res. 1992 Dec;33(4):549-58. Erratum in: J Neurosci (3):346.	
□ 178:	PMID: 1484388 [PubMed - indexed for MEDLINE] Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D,	Related Articles Links
	Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al.	
	Isolation and quantification of soluble Alzheimer's bebiological fluids. Nature. 1992 Sep 24;359(6393):325-7. PMID: 1406936 [PubMed - indexed for MEDLINE]	ta-peptide from
□ 179:	Arai H, Schmidt ML, Lee VM, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ.	Related Articles, Links
	Epitope analysis of senile plaque components in the hatients with Parkinson's disease. Neurology. 1992 Jul;42(7):1315-22. PMID: 1377804 [PubMed - indexed for MEDLINE]	ippocampus of
□ 180:	<u>Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DD, Cotman CW.</u>	Related Articles, Links
	Aggregation of the amyloid precursor protein within eneurons and dystrophic neurites in Alzheimer's diseas Neuroscience. 1992 Jun;48(4):763-77. PMID: 1378573 [PubMed - indexed for MEDLINE]	
□ 181:	Ohgami T, Kitamoto T, Tateishi J.	Related Articles, Links
	Alzheimer's amyloid precursor protein accumulates w swellings in human brain lesions. Neurosci Lett. 1992 Feb 17;136(1):75-8. PMID: 1635670 [PubMed - indexed for MEDLINE]	vithin axonal
□ 182:	Wunderlich D, Lee A, Fracasso RP, Mierz DV, Bayney RM, Ramabhadran TV.	Related Articles, Links
	Use of recombinant fusion proteins for generation and characterization of monoclonal antibodies. Application domain of human beta amyloid precursor protein. J Immunol Methods. 1992 Feb 14;147(1):1-11. PMID: 1371794 [PubMed - indexed for MEDLINE]	
□ 183:	Delvaux A, Van der Elst L, Octave JN.	Related Articles, Links
	Inhibition of trypsin by the beta-amyloid protein precomparative study between transfected cells, human becerebrospinal fluid. FEBS Lett. 1992 Feb 3;297(1-2):124-6. PMID: 1551418 [PubMed - indexed for MEDLINE]	
□ 184:	<u>Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M.</u>	Related Articles, Links
	SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol (Berl). 1992;83(3):260-4. PMID: 1373021 [PubMed - indexed for MEDLINE]	
	The state of the s	

	Expression patterns of beta-amyloid precursor protein neural and nonneural human tissues from Alzheimer's control subjects. Ann Neurol. 1991 Nov;30(5):686-93. PMID: 1763893 [PubMed - indexed for MEDLINE]	• ,
□ 186:	Frautschy SA, Baird A, Cole GM.	Related Articles, Links
	Effects of injected Alzheimer beta-amyloid cores in ra Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362-6. PMID: 1924295 [PubMed - indexed for MEDLINE]	nt brain.
□ 187:	Munoz DG.	Related Articles, Links
	Chromogranin A-like immunoreactive neurites are masenile plaques. Lab Invest. 1991 Jun;64(6):826-32. PMID: 1710735 [PubMed - indexed for MEDLINE]	ajor constituents of
□ 188:	Knops J, Johnson-Wood K, Schenk DB, Sinha S, Lieberburg I, McConlogue L.	Related Articles, Links
	Isolation of baculovirus-derived secreted and full-leng precursor protein. J Biol Chem. 1991 Apr 15;266(11):7285-90. PMID: 1901866 [PubMed - indexed for MEDLINE]	gth beta-amyloid
□ 189:	Henriksson T, Barbour RM, Braa S, Ward P, Fritz LC, Johnson-Wood K, Chung HD, Burke W, Reinikainen KJ, Riekkinen P, et al.	Related Articles, Links
	Analysis and quantitation of the beta-amyloid precurs cerebrospinal fluid of Alzheimer's disease patients wi antibody-based immunoassay. J Neurochem. 1991 Mar;56(3):1037-42. PMID: 1899691 [PubMed - indexed for MEDLINE]	-
□ 190:	Takahashi H, Hirokawa K, Ando S, Obata K.	Related Articles, Links
	Immunohistological study on brains of Alzheimer's diantibodies to fetal antigens, C-series gangliosides and associated protein 5. Acta Neuropathol (Berl). 1991;81(6):626-31. PMID: 1909079 [PubMed - indexed for MEDLINE]	_
□ 191:	Becker L, Mito T, Takashima S, Onodera K.	Related Articles, Links
	Growth and development of the brain in Down syndro Prog Clin Biol Res. 1991;373:133-52. Review. PMID: 1838182 [PubMed - indexed for MEDLINE]	ome.
□ 192:	Yankner BA, Caceres A, Duffy LK.	Related Articles, Links
	Nerve growth factor potentiates the neurotoxicity of b Proc Natl Acad Sci U S A. 1990 Nov;87(22):9020-3. PMID: 2174172 [PubMed - indexed for MEDLINE]	eta amyloid.
□ 193:	Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Wight TN.	Related Articles, Links
	Early accumulation of heparan sulfate in neurons and amyloid protein-containing lesions of Alzheimer's dis syndrome.	

	Am J Pathol. 1990 Nov;137(5):1253-70. PMID: 2146882 [PubMed - indexed for MEDLINE]	
□ 194:	Kanemaru K, Hasegawa M, Shimada H, Ihara Y.	Related Articles, Links
	The presence of a novel protein in calf serum that rec amyloid in the formalin-fixed section. Am J Pathol. 1990 Sep;137(3):677-87. PMID: 1698030 [PubMed - indexed for MEDLINE]	ognizes beta
□ 195:	<u>Tate-Ostroff B, Majocha RE, Walcott EC, Ventosa-Michelman M, Marotta CA.</u>	Related Articles, Links
	Colocalization of amino terminal and A4 (beta-amylo Alzheimer plaques: evidence for coordinated process precursor protein. J Geriatr Psychiatry Neurol. 1990 Jul-Sep;3(3):139-45. PMID: 2126439 [PubMed - indexed for MEDLINE]	, -
□ 196:	Stern RA, Trojanowski JQ, Lee VM.	Related Articles, Links
	Antibodies to the beta-amyloid peptide cross-react wi epitopes in human fibrinogen subunits from periphera FEBS Lett. 1990 May 7;264(1):43-7. PMID: 1692541 [PubMed - indexed for MEDLINE]	
□ 197:	Spillantini MG, Goedert M, Jakes R, Klug A.	Related Articles, Links
	Different configurational states of beta-amyloid and t relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci U S A. 1990 May;87(10):3947-51. PMID: 2111023 [PubMed - indexed for MEDLINE]	heir distributions
□ 198:	Singhrao S, Cole G, Henderson WJ, Newman GR.	Related Articles, Links
	LR White embedding allows a multi-method approach brain tissue from patients with Alzheimer's disease. Histochem J. 1990 May;22(5):257-68. PMID: 1966829 [PubMed - indexed for MEDLINE]	h to the analysis of
□ 199:	Arai H, Lee VM, Otvos L Jr, Greenberg BD, Lowery DE, Sharma SK, Schmidt ML, Trojanowski JQ.	Related Articles, Links
	Defined neurofilament, tau, and beta-amyloid precurs distinguish Alzheimer from non-Alzheimer senile pla Proc Natl Acad Sci U S A. 1990 Mar;87(6):2249-53. PMID: 1690426 [PubMed - indexed for MEDLINE]	
□ 200:	Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL.	Related Articles, Links
	Precursor of amyloid protein in Alzheimer disease un anterograde axonal transport. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1561-5. PMID: 1689489 [PubMed - indexed for MEDLINE]	dergoes fast
□ 201:	Chou WG, Zain SB, Rehman S, Tate-Ostroff B, Majocha RE, Benes FM, Marotta CA.	Related Articles, Links
	Alzheimer cortical neurons containing abundant amy Relationship to amyloid deposition and senile plaques J Psychiatr Res. 1990;24(1):37-50. PMID: 2195164 [PubMed - indexed for MEDLINE]	

□ 202:	Takahashi H, Kurashima C, Utsuyama M, Hirokawa K.	Related Articles, Links
	Immunohistological study of senile brains by using a antibody recognizing beta amyloid precursor protein: granular deposits in relation with senile plaques. Acta Neuropathol (Berl). 1990;80(3):260-5. PMID: 1698004 [PubMed - indexed for MEDLINE]	
□ 203:	Suenaga T, Hirano A, Llena JF, Ksiezak-Reding H, Yen SH, Dickson DW.	Related Articles, Links
	Modified Bielschowsky and immunocytochemical stuplaques in Alzheimer's disease. J Neuropathol Exp Neurol. 1990 Jan;49(1):31-40. PMID: 1688924 [PubMed - indexed for MEDLINE]	idies on cerebellar
□ 204:	Benes FM, Reifel JL, Majocha RE, Marotta CA.	Related Articles, Links
	Evidence for a diffusional model of Alzheimer amylo amyloid) deposition during neuritic plaque formation. Neuroscience. 1989;33(3):483-8. PMID: 2700016 [PubMed - indexed for MEDLINE]	
□ 205:	Marotta CA, Chou WG, Majocha RE, Watkins R, LaBonne C, Zain SB.	Related Articles, Links
	Overexpression of amyloid precursor protein A4 (beta immunoreactivity in genetically transformed cells: im cellular model of Alzheimer amyloidosis. Proc Natl Acad Sci U S A. 1989 Jan;86(1):337-41. PMID: 2563163 [PubMed - indexed for MEDLINE]	
□ 206:	Wisniewski HM, Wen GY, Kim KS.	Related Articles, Links
	Comparison of four staining methods on the detection plaques. Acta Neuropathol (Berl). 1989;78(1):22-7. PMID: 2472039 [PubMed - indexed for MEDLINE]	of neuritic
Display	Summary Show 500 Sort by Send	to 🖳

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

May 2 2005 17:45:08










All Databases	PubMed Nucleotide	Protein Genome	Structure OMI	M PMC Journals Bool
Search PubMed	for mono	oclonal antibody ANI	O Abeta	Go Clear Save Sea
	Limits Preview/In	ndex History	Clipboard Deta	ails
About Entrez	Display Summary	<u> </u>	00 Sort by	Send to
Text Version	All: 101 Review: 3 Items 1 - 101 of 101	*		0
Entrez PubMed	1: Klyubin I, Walsh	n DM Temere CA Ci	ıllen WK Shankar Gl	One page.
Overview	Betts V, Spooner	r ET, Jiang L, Anwyl	R, Selkoe DJ, Rowan	MJ. Related Articles, Links
Help FAQ Tutorial New/Noteworthy E-Utilities	disrupt synapt Nat Med. 2005 Ju	protein immunoth ic plasticity in viv un;11(6):556-61. Epu 7 [PubMed - in proces	o. b 2005 Apr 17.	Abeta oligomers that
PubMed Services Journals Database	2: Paganetti P, Cala	anca V, Galli C, Stefar	ni M, Molinari M.	Related Articles, Links
MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries LinkOut	Alzheimer's A J Cell Biol. 2005	ific intrabodies to beta peptide. Mar 14;168(6):863-8 0 [PubMed - indexed to	·	ent generation of
My NCBI (Cubby)	Geylis V, Kourile Steinitz M.	ov V, Meiner Z, Nenr	esmo I, Bogdanovic	N. Related Articles, Links
Related Resources Order Documents NLM Catalog NLM Gateway	Neurobiol Aging	clonal antibodies a g. 2005 May;26(5):597 4 [PubMed - indexed t	'- 606.	eta from healthy adults.
TOXNET Consumer Health	4: Zhang G, Wang I	LF, Wang HQ, Yao Z	<u>B.</u>	Related Articles, Links
Clinical Alerts ClinicalTrials.gov PubMed Central	of Abeta antib Di Yi Jun Yi Da		eb;25(2):160-4. Chin	nt protein and detection ese.
	5: Brendza RP, Bac Klunk WE, Math Holtzman DM.	eskai BJ, Cirrito JR, S nis CA, Bales KR, Pau		M. Related Articles, Links
	associated neu J Clin Invest. 200	tibody treatment paritic dystrophy in 05 Feb;115(2):428-33 [PubMed - indexed to 15]	PDAPP transgeni	recovery of amyloid- c mice.
	G: Qi-Takahara Y, M Hirotani N, Horik R, Ihara Y.	Morishima-Kawashim koshi Y, Kametani F,	a M, Tanimura Y, Do Maeda M, Saido TC,	lios G. Related Articles, Links Wang
	intramembrane J Neurosci. 2005	of amyloid beta pre e cleavage by gam Jan 12;25(2):436-45. 7 [PubMed - in proces	ma-secretase.	s for the mechanism of
	7: Chauhan NB, Sie	egel GJ.		Related Articles, Links

	Intracerebroventricular passive immunization in transger of Alzheimer's disease. Expert Rev Vaccines. 2004 Dec;3(6):717-25. PMID: 15606357 [PubMed - in process]	nic mouse models
□8:	Shivaprasad S, Wetzel R.	Related Articles, Links
	An intersheet packing interaction in A beta fibrils mapped cross-linking. Biochemistry. 2004 Dec 14;43(49):15310-7. PMID: 15581343 [PubMed - indexed for MEDLINE]	ed by disulfide
□9:	Albrecht H, Zbinden P, Rizzi A, Villetti G, Riccardi B, Puccini P, Catinella S, Imbimbo BP.	Related Articles, Links
	High throughput screening of beta-amyloid secretion inh homogenous time-resolved fluorescence. Comb Chem High Throughput Screen. 2004 Dec;7(8):745-56. PMID: 15578936 [PubMed - indexed for MEDLINE]	nibitors using
□ 10	Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K.	Related Articles, Links
	Simultaneous measurement of beta-amyloid(1-42), total phosphorylated tau (Thr181) in cerebrospinal fluid by technology. Clin Chem. 2005 Feb;51(2):336-45. Epub 2004 Nov 24. PMID: 15563479 [PubMed - indexed for MEDLINE]	
□ 11	Horikoshi Y, Mori T, Maeda M, Kinoshita N, Sato K, Yamaguchi H.	Related Articles, Links
	Abeta N-terminal-end specific antibody reduced beta-a Alzheimer-model mice. Biochem Biophys Res Commun. 2004 Dec 10;325(2):384-7. PMID: 15530403 [PubMed - indexed for MEDLINE]	myloid in
□ 12	van Horssen J, de Vos RA, Steur EN, David G, Wesseling P, de Waal RM, Verbeek MM.	Related Articles, Links
	Absence of heparan sulfate proteoglycans in Lewy bod neurites in Parkinson's disease brains. J Alzheimers Dis. 2004 Oct;6(5):469-74. PMID: 15505367 [PubMed - indexed for MEDLINE]	ies and Lewy
□ 13	Perez M, Cuadros R, Benitez MJ, Jimenez JS.	Related Articles, Links
	Interaction of Alzheimer's disease amyloid beta peptide with tau protein, and with a tau peptide containing the binding domain. J Alzheimers Dis. 2004 Oct;6(5):461-7. PMID: 15505366 [PubMed - indexed for MEDLINE]	, •
□14	: Manea M, Mezo G, Hudecz F, Przybylski M.	Related Articles, Links
	Polypeptide conjugates comprising a beta-amyloid place epitope as new vaccine structures against Alzheimer's objectives. 2004;76(6):503-11. PMID: 15499564 [PubMed - indexed for MEDLINE]	
□ 15	Prosperi C, Scali C, Barba M, Bellucci A, Giovannini MG, Pepeu G, Casamenti F.	Related Articles, Links
	Comparison between flurbiprofen and its nitric oxide-r	eleasing

	derivatives HCT-1026 and NCX-2216 on Abeta(1-42)-inflammation and neuronal damage in the rat. Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):317-30. PMID: 15461866 [PubMed - indexed for MEDLINE]	induced brain
□ 16:	Zirah S, Stefanescu R, Manea M, Tian X, Cecal R, Kozin SA, Debey P, Rebuffat S, Przybylski M.	Related Articles, Links
	Zinc binding agonist effect on the recognition of the be epitope by anti-beta-amyloid antibodies. Biochem Biophys Res Commun. 2004 Aug 20;321(2):324-8. PMID: 15358179 [PubMed - indexed for MEDLINE]	ta-amyloid (4-10)
□17:	Lopez EM, Bell KF, Ribeiro-da-Silva A, Cuello AC.	Related Articles, Links
	Early changes in neurons of the hippocampus and neocrats expressing intracellular human a-beta. J Alzheimers Dis. 2004 Aug;6(4):421-31; discussion 443-9. PMID: 15345813 [PubMed - indexed for MEDLINE]	ortex in transgenic
□ 18:	Schenk D, Hagen M, Seubert P.	Related Articles, Links
	Current progress in beta-amyloid immunotherapy. Curr Opin Immunol. 2004 Oct;16(5):599-606. Review. PMID: 15342006 [PubMed - indexed for MEDLINE]	
□19:	Nordberg A.	Related Articles, Links
	PET imaging of amyloid in Alzheimer's disease. Lancet Neurol. 2004 Sep;3(9):519-27. Review. PMID: 15324720 [PubMed - indexed for MEDLINE]	
□ 20:	Recuero M, Serrano E, Bullido MJ, Valdivieso F.	Related Articles, Links
	Abeta production as consequence of cellular death of a neuroblastoma overexpressing APP. FEBS Lett. 2004 Jul 16;570(1-3):114-8. PMID: 15251450 [PubMed - indexed for MEDLINE]	human
□21:	Schiltz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, Pavlovic J, Wollmer MA, Nitsch RM, Moelling K.	Related Articles, Links
	Antibodies from a DNA peptide vaccination decrease to burden in a mouse model of Alzheimer's disease. J Mol Med. 2004 Oct;82(10):706-14. PMID: 15241501 [PubMed - indexed for MEDLINE]	he brain amyloid
□ 22:	Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D.	Related Articles, Links
	Passive amyloid immunotherapy clears amyloid and tra microglia in a transgenic mouse model of amyloid depo J Neurosci. 2004 Jul 7;24(27):6144-51. PMID: 15240806 [PubMed - indexed for MEDLINE]	
□ 23:	Kowa H, Sakakura T, Matsuura Y, Wakabayashi T, Mann DM, Duff K, Tsuji S, Hashimoto T, Iwatsubo T.	Related Articles, Links
	Mostly separate distributions of CLAC- versus Abeta40 reactivities in senile plaques reveal two distinct subpop amyloid deposits. Am J Pathol. 2004 Jul;165(1):273-81. PMID: 15215182 [PubMed - indexed for MEDLINE]	

□ 24:	Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF.	Related Articles, Links
	Autoimmunity in Alzheimer's disease: increased levels IgGs binding Abeta and RAGE peptides. Neurobiol Aging. 2004 Sep;25(8):1023-32. PMID: 15212827 [PubMed - indexed for MEDLINE]	of circulating
□ 25:	Echeverria V, Ducatenzeiler A, Alhonen L, Janne J, Grant SM, Wandosell F, Muro A, Baralle F, Li H, Duff K, Szyf M, Cuello AC.	Related Articles, Links
	Rat transgenic models with a phenotype of intracellular accumulation in hippocampus and cortex. J Alzheimers Dis. 2004 Jun;6(3):209-19. PMID: 15201476 [PubMed - indexed for MEDLINE]	Abeta
□26:	Johnson JK, Vogt BA, Kim R, Cotman CW, Head E.	Related Articles, Links
	Isolated executive impairment and associated frontal not Dement Geriatr Cogn Disord. 2004;17(4):360-7. PMID: 15178954 [PubMed - indexed for MEDLINE]	europathology.
□ 27:	<u>Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Serrano J, Bentura ML, Martinez-Murillo R, Martinez A, Rodrigo J.</u>	Related Articles, Links
	Intra- and extracellular Abeta and PHF in clinically evaluated Alzheimer's disease. Histol Histopathol. 2004 Jul;19(3):823-44. PMID: 15168346 [PubMed - indexed for MEDLINE]	lluated cases of
□ 28:	Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Yamamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K.	Related Articles, Links
	A seed for Alzheimer amyloid in the brain. J Neurosci. 2004 May 19;24(20):4894-902. PMID: 15152051 [PubMed - indexed for MEDLINE]	
□ 29:	Karkos J.	Related Articles, Links
	[Immunotherapy of Alzheimer's disease. Results of expinvestigations and treatment of perspectives] Fortschr Neurol Psychiatr. 2004 Apr;72(4):204-19. Review. Germ PMID: 15095177 [PubMed - indexed for MEDLINE]	
□30:	Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, Do LH, Andreadis A, Van Hoesen G, Ksiezak-Reding H.	Related Articles, Links
W	Phosphorylation of tau by fyn: implications for Alzhein J Neurosci. 2004 Mar 3;24(9):2304-12. PMID: 14999081 [PubMed - indexed for MEDLINE]	ner's disease.
□31:	Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T.	Related Articles, Links
	Effect of different anti-Abeta antibodies on Abeta fibril assessed by atomic force microscopy. J Mol Biol. 2004 Jan 23;335(4):997-1006. PMID: 14698294 [PubMed - indexed for MEDLINE]	logenesis as
□32:	Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR.	Related Articles, Links
	Degradation of beta-amyloid by proteolytic antibody lig Biochemistry. 2003 Dec 9:42(48):14328-34.	ght chains.

	PMID: 14640701 [PubMed - indexed for MEDLINE]	
□ 33:	Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Wegiel J.	Related Articles, Links
	Humoral immune response to fibrillar beta-amyloid pe Biochemistry. 2003 Oct 14;42(40):11682-92. PMID: 14529278 [PubMed - indexed for MEDLINE]	ptide.
□ 34:	Wang DS, Iwata N, Hama E, Saido TC, Dickson DW.	Related Articles, Links
	Oxidized neprilysin in aging and Alzheimer's disease be Biochem Biophys Res Commun. 2003 Oct 10;310(1):236-41. PMID: 14511676 [PubMed - indexed for MEDLINE]	orains.
□ 35:	Solomon B.	Related Articles, Links
	Immunological approach for the treatment of Alzheime J Mol Neurosci. 2003;20(3):283-6. PMID: 14501009 [PubMed - indexed for MEDLINE]	er's disease.
□36:	Mruthinti S, Hill WD, Swamy-Mruthinti S, Buccafusco JJ.	Related Articles, Links
	Relationship between the induction of RAGE cell-surfi expression of amyloid binding sites. J Mol Neurosci. 2003;20(3):223-32. PMID: 14501001 [PubMed - indexed for MEDLINE]	ace antigen and the
□ 37:	Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE.	Related Articles, Links
	Evidence for peripheral clearance of cerebral Abeta prechronic, active Abeta immunization in PSAPP mice. Neurobiol Dis. 2003 Oct;14(1):10-8. PMID: 13678662 [PubMed - indexed for MEDLINE]	otein following
□ 38:	Chauhan NB, Siegel GJ.	Related Articles, Links
	Intracerebroventricular passive immunization with anti Tg2576. J Neurosci Res. 2003 Oct 1;74(1):142-7. PMID: 13130516 [PubMed - indexed for MEDLINE]	-Abeta antibody in
□ 39:	Uchihara T, Nakamura A, Nakayama H, Arima K, Ishizuka N, Mori H, Mizushima S.	Related Articles, Links
	Triple immunofluorolabeling with two rabbit polyclonal mouse monoclonal antibody allowing three-dimensional cotton wool plaques in Alzheimer disease. J Histochem Cytochem. 2003 Sep;51(9):1201-6. PMID: 12923245 [PubMed - indexed for MEDLINE]	
□ 40:	Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM.	Related Articles, Links
	Transient hypoxia causes Alzheimer-type molecular an abnormalities in cortical neurons: potential strategies for J Alzheimers Dis. 2003 Jun;5(3):209-28. PMID: 12897406 [PubMed - indexed for MEDLINE]	
□41:	Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL.	Related Articles, Links
	Caspase cleavage of tau: linking amyloid and neurofibra	rillary tangles in




□ 49:	<u>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M.</u>	Related Articles, Links
	Cerebral hemorrhage after passive anti-Abeta immunot Science. 2002 Nov 15;298(5597):1379. No abstract available. PMID: 12434053 [PubMed - indexed for MEDLINE]	herapy.
□ 50:	Wen GY, Yang SY, Kaczmarski W, He XY, Pappas KS.	Related Articles, Links
	Presence of hydroxysteroid dehydrogenase type 10 in a (APs) of Hsiao's APP-Sw transgenic mouse brains, but Alzheimer's disease brains. Brain Res. 2002 Nov 1;954(1):115-22. PMID: 12393239 [PubMed - indexed for MEDLINE]	
□ 51:	Grant SM, Ducatenzeiler A, Szyf M, Cuello AC.	Related Articles, Links
	Abeta immunoreactive material is present in several int compartments in transfected, neuronally differentiated, expressing the human amyloid beta-protein precursor. J Alzheimers Dis. 2000 Nov;2(3-4):207-22. PMID: 12214085 [PubMed]	
□ 52:	<u>Tammer AH, Coia G, Cappai R, Fuller S, Masters CL, Hudson P, Underwood JR.</u>	Related Articles, Links
	Generation of a recombinant Fab antibody reactive with disease-related Abeta peptide. Clin Exp Immunol. 2002 Sep;129(3):453-63. PMID: 12197886 [PubMed - indexed for MEDLINE]	h the Alzheimer's
□ 53:	Pan W, Solomon B, Maness LM, Kastin AJ.	Related Articles, Links
	Antibodies to beta-amyloid decrease the blood-to-brain amyloid peptide. Exp Biol Med (Maywood). 2002 Sep;227(8):609-15. PMID: 12192102 [PubMed - indexed for MEDLINE]	transfer of beta-
□ 54:	Bogdanovic N, Corder E, Lannfelt L, Winblad B.	Related Articles, Links
	APOE polymorphism and clinical duration determine reneuropathology in Swedish APP(670, 671) mutation cat for late-onset Alzheimer's disease. J Cell Mol Med. 2002 Apr-Jun;6(2):199-214. PMID: 12169205 [PubMed - indexed for MEDLINE]	
□ 55:	Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH.	Related Articles, Links
	Reversible memory loss in a mouse transgenic model o disease. J Neurosci. 2002 Aug 1;22(15):6331-5. PMID: 12151510 [PubMed - indexed for MEDLINE]	f Alzheimer's
□ 56:	Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM.	Related Articles, Links
	Immunization reverses memory deficits without reducing burden in Alzheimer's disease model. Nat Neurosci. 2002 May;5(5):452-7. PMID: 11941374 [PubMed - indexed for MEDLINE]	ng brain Abeta
□ 57:	Hashimoto T, Wakabayashi T, Watanabe A, Kowa H, Hosoda R,	Related Articles, Links

Nakamura A, Kanazawa I, Arai T, Takio K, Mann DM, Iwatsubo T. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J. 2002 Apr 2;21(7):1524-34. PMID: 11927537 [PubMed - indexed for MEDLINE] 58: DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Related Articles, Links Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002 Mar 22;295(5563):2264-7. PMID: 11910111 [PubMed - indexed for MEDLINE] 59: Frenkel D, Solomon B. Related Articles, Links Towards Alzheimer's beta-amyloid vaccination. Biologicals. 2001 Sep-Dec;29(3-4):243-7. PMID: 11851323 [PubMed - indexed for MEDLINE] ☐ 60: Milton NG. Related Articles, Links Inhibition of catalase activity with 3-amino-triazole enhances the cytotoxicity of the Alzheimer's amyloid-beta peptide. Neurotoxicology. 2001 Dec;22(6):767-74. PMID: 11829410 [PubMed - indexed for MEDLINE] ☐ 61: Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Related Articles, Links Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab. 2002 Feb;22(2):223-31. PMID: 11823720 [PubMed - indexed for MEDLINE] 62: Cummings BJ, Mason AJ, Kim RC, Sheu PC, Anderson AJ. Related Articles, Links Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol Aging, 2002 Mar-Apr;23(2):161-70. PMID: 11804699 [PubMed - indexed for MEDLINE] [63: Matsunaga Y, Saito N, Fujii A, Yokotani J, Takakura T, Related Articles, Links Nishimura T, Esaki H, Yamada T. A pH-dependent conformational transition of Abeta peptide and physicochemical properties of the conformers in the glial cell. Biochem J. 2002 Feb 1;361(Pt 3):547-56. PMID: 11802784 [PubMed - indexed for MEDLINE] 64: Solomon B. Related Articles, Links Immunotherapeutic strategies for prevention and treatment of Alzheimer's DNA Cell Biol. 2001 Nov;20(11):697-703. PMID: 11788047 [PubMed - indexed for MEDLINE] 55: Parvathy S. Davies P. Haroutunian V. Purohit DP, Davis KL, Related Articles, Links Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol. 2001 Dec;58(12):2025-32. Erratum in: Arch Neurol 2002 Feb;59(2):202. PMID: 11735776 [PubMed - indexed for MEDLINE]

□ 66:	Poduslo JF, Curran GL.	Related Articles, Links
	Amyloid beta peptide as a vaccine for Alzheimer's dise receptor-mediated transport at the blood-brain barrier. Neuroreport. 2001 Oct 29;12(15):3197-200. PMID: 11711855 [PubMed - indexed for MEDLINE]	ase involves
□ 67:	Chapoval SP, Marietta EV, Smart MK, David CS.	Related Articles, Links
	Requirements for allergen-induced airway inflammatio hyperreactivity in CD4-deficient and CD4-sufficient H mice. J Allergy Clin Immunol. 2001 Nov;108(5):764-71. PMID: 11692102 [PubMed - indexed for MEDLINE]	
□ 68:	Dobrogowska DH, Vorbrodt AW, Wegiel J, Wang KC, Shoji M, Mondadori C, Polatis G, Giovanni A, Wisniewski HM.	Related Articles, Links
	Cytochemical study of the involvement of cell organell and accumulation of fibrillar amyloid in the pancreas of transgenic mice. Histol Histopathol. 2001 Oct;16(4):1047-56. PMID: 11642724 [PubMed - indexed for MEDLINE]	
□ 69:	Nunan J, Shearman MS, Checler F, Cappai R, Evin G, Beyreuther K, Masters CL, Small DH.	Related Articles, Links
	The C-terminal fragment of the Alzheimer's disease amprecursor is degraded by a proteasome-dependent mech from gamma-secretase. Eur J Biochem. 2001 Oct;268(20):5329-36. PMID: 11606195 [PubMed - indexed for MEDLINE]	-
□ 70:	Chauhan NB, Siegel GJ, Lichtor T.	Related Articles, Links
	Distribution of intraventricularly administered antiamy (Abeta) antibody in the mouse brain. J Neurosci Res. 2001 Oct 15;66(2):231-5. PMID: 11592118 [PubMed - indexed for MEDLINE]	loid-beta peptide
□ 71:	Mann DM, Takeuchi A, Sato S, Cairns NJ, Lantos PL, Rossor MN, Haltia M, Kalimo H, Iwatsubo T.	Related Articles, Links
	Cases of Alzheimer's disease due to deletion of exon 9 gene show an unusual but characteristic beta-amyloid p as 'cotton wool' plaques. Neuropathol Appl Neurobiol. 2001 Jun;27(3):189-96. PMID: 11489138 [PubMed - indexed for MEDLINE]	
□ 72:	Ghoshal N, Garcia-Sierra F, Fu Y, Beckett LA, Mufson EJ, Kuret J, Berry RW, Binder LI.	Related Articles, Links
	Tau-66: evidence for a novel tau conformation in Alzhe J Neurochem. 2001 Jun;77(5):1372-85. PMID: 11389188 [PubMed - indexed for MEDLINE]	eimer's disease.
□ 73:	Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T.	Related Articles, Links
	beta-amyloid deposits in transgenic mice expressing hu precursor protein have the same characteristics as those disease. Neuroscience. 2001;104(2):299-310.	-

	PMID: 11377835 [PubMed - indexed for MEDLINE]	
□ 74:	Frenkel D, Kariv N, Solomon B.	Related Articles, Links
	Generation of auto-antibodies towards Alzheimer's dis Vaccine. 2001 Mar 21;19(17-19):2615-9. PMID: 11257400 [PubMed - indexed for MEDLINE]	ease vaccination.
□ 75:	Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E.	Related Articles, Links
	Standardization of measurement of beta-amyloid(1-42 fluid and plasma. Amyloid. 2000 Dec;7(4):245-58. PMID: 11132093 [PubMed - indexed for MEDLINE]) in cerebrospinal
□ 76:	Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Naslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L.	Related Articles, Links
	Quantification of Alzheimer amyloid beta peptides end and 42 by novel ELISA systems. Mol Med. 2000 Apr;6(4):291-302. PMID: 10949910 [PubMed - indexed for MEDLINE]	ding at residues 40
□ 77:	Haars R, Schneider A, Bode M, Schubert W.	Related Articles, Links
	Secretion and differential localization of the proteolyti Abeta40 and Abeta42 of the Alzheimer amyloid precu human fetal myogenic cells. Eur J Cell Biol. 2000 Jun;79(6):400-6. PMID: 10928455 [PubMed - indexed for MEDLINE]	U 1
□ 78:	Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA.	Related Articles, Links
	beta-amyloid (Abeta)42(43), abeta42, abeta40 and apo of plaques in fatal head injury. Neuropathol Appl Neurobiol. 2000 Apr;26(2):124-32. PMID: 10840275 [PubMed - indexed for MEDLINE]	E immunostaining .
□ 79:	Maat-Schieman ML, Yamaguchi H, van Duinen SG, Natte R, Roos RA.	Related Articles, Links
	Age-related plaque morphology and C-terminal hetero beta in Dutch-type hereditary cerebral hemorrhage wit Acta Neuropathol (Berl). 2000 Apr;99(4):409-19. PMID: 10787040 [PubMed - indexed for MEDLINE]	
□ 80:	Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C.	Related Articles, Links
	Presenilin-1 differentially facilitates endoproteolysis o precursor protein and Notch. Nat Cell Biol. 2000 Apr;2(4):205-11. PMID: 10783238 [PubMed - indexed for MEDLINE]	f the beta-amyloid
□81:	Nakayashiki N, Oshima M, Deitiker PR, Ashizawa T, Atassi MZ	Related Articles, Links
	Suppression of experimental myasthenia gravis by moragainst MHC peptide region involved in presentation of cell epitope. J Neuroimmunol. 2000 Jun 26;105(2):131-44.	

PMID: 10742555 [PubMed - indexed for MEDLINE] 82: Yasuda M, Maeda S, Kawamata T, Tamaoka A, Yamamoto Y, Related Articles, Links Kuroda S, Maeda K, Tanaka C. Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):220-3. PMID: 10644793 [PubMed - indexed for MEDLINE] 12 83: Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Related Articles, Links Mori H. Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol. 1999 Sep;56(9):1111-8. PMID: 10488812 [PubMed - indexed for MEDLINE] 84: Wang J, Dickson DW, Trojanowski JQ, Lee VM. Related Articles, Links The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 1999 Aug; 158(2):328-37. PMID: 10415140 [PubMed - indexed for MEDLINE] 85: Yuan H, Zhai P, Anderson LM, Pan J, Thimmapaya B, Koo EH, Related Articles, Links Marquez-Sterling NR. Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons. J Neurosci Methods. 1999 Apr 1;88(1):45-54. PMID: 10379578 [PubMed - indexed for MEDLINE] 86: Abraham CR, Marshall DC, Tibbles HE, Otto K, Long HJ, Related Articles, Links Billingslea AM, Hastey R, Johnson R, Fine RE, Smith SJ, Simons ER, Davies TA. Platelets and DAMI megakaryocytes possess beta-secretase-like activity. J Lab Clin Med. 1999 May;133(5):507-15. PMID: 10235134 [PubMed - indexed for MEDLINE] 87: Arai T, Akiyama H, Ikeda K, Kondo H, Mori H. Related Articles, Links Immunohistochemical localization of amyloid beta-protein with aminoterminal aspartate in the cerebral cortex of patients with Alzheimer's disease. Brain Res. 1999 Mar 27;823(1-2):202-6. PMID: 10095028 [PubMed - indexed for MEDLINE] 88: Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Related Articles, Links Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, Ihara Y. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol. 1999 Jan; 154(1):271-9. PMID: 9916941 [PubMed - indexed for MEDLINE] 89: Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini Related Articles, Links G, Chen S, Teller JK, Zaccheo D, Gambetti P, Tabaton M. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15598-602. PMID: 9861015 [PubMed - indexed for MEDLINE]



Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, Bird TD, Poorkaj P, Hardy J, Hutton M, Prihar G, Crook R, Rossor MN, Haltia M.

Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43).

Ann Neurol. 1996 Aug;40(2):149-56.

PMID: 8773595 [PubMed - indexed for MEDLINE]

99: Turner RS, Suzuki N, Chyung AS, Younkin SG, Lee VM.

Related Articles, Links



Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation.

J Biol Chem. 1996 Apr 12;271(15):8966-70.

PMID: 8621541 [PubMed - indexed for MEDLINE]

100: Singer SM, Umetsu DT, McDevitt HO.

Related Articles, Links



High copy number I-Ab transgenes induce production of IgE through an interluekin 4-dependent mechanism.

Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2947-52. PMID: 8610148 [PubMed - indexed for MEDLINE]

☐ 101: Bishop GA, Frelinger JA.

Related Articles, Links



Haplotype-specific differences in signaling by transfected class II molecules to a Ly-1+ B-cell clone.

Proc Natl Acad Sci U S A. 1989 Aug;86(15):5933-7. PMID: 2788281 [PubMed - indexed for MEDLINE]

Display Summary Show 500 Sort by Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

May 2 2005 17:45:08









All Databases	PubMed	Nuc	leotide	Protein	Genome	Structure	OMIM	PMC	Journals	Bool
Search PubMed		₹	for mo	noclonal a	antibody AN	D amyloid-be	ta	Go	Clear Sav	e Sea:
	Limit	s ¥	Preview	/Index	History	Clipboard	Details		-	
About Entrez	Displa	<u> </u>	nmary	\\	Show 5	00 Sort b	y 🔽 Se	end to		
Text Version	All: 4		Review: 7 of 44						One	page.
Entrez PubMed Overview Help FAQ	□1:	Betts '	V, Spoor	ner ET, Jia	ng L, Anwyl	ullen WK, Sha R, Selkoe DJ,	Rowan MJ		lated Articles,	
Tutorial New/Noteworthy E-Utilities		disru Nat M	pt syna led. 2005	ptic plast Jun;11(6)	ticity in viv	b 2005 Apr 17		eta oli	gomers that	
PubMed Services Journals Database	□ 2:	Pagan	etti P, C	alanca V, (Galli C, Stefa	ni M, Molinari	<u>M.</u>	Re	lated Articles,	Links
MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries LinkOut		Alzho J Cell	eimer's Biol. 20	Abeta po 05 Mar 14	eptide. ;168(6):863-8	decrease and B. for MEDLINE	•	genera	ation of	٠
My NCBI (Cubby)	□3:	Geylis Steini	s V, Kou tz M.	<u>rilov V, M</u>	einer Z, Neni	nesmo I, Bogda	anovic N,	Re	lated Articles,	Links
Related Resources Order Documents NLM Catalog NLM Gateway		Neuro	biol Agi	ng. 2005 N	May;26(5):59	ngainst amyl 7-606. for MEDLINE		from h	ealthy adult	ts.
TOXNET Consumer Health	□ 4:	Zhang	G, Wan	ig LF, War	ng HQ, Yao Z	<u>ZB.</u>		Re	lated Articles,	Links
Clinical Alerts ClinicalTrials.gov PubMed Central		of Al Di Yi	oeta ant Jun Yi I	tibody] Da Xue Xu		beta42 recon Feb;25(2):160- ss]	-		and detection	on
	5 :	Klunk		athis CA, I		immons KA, S al SM, Hyman		Re	lated Articles,	Links
		assoc J Clin	iated n Invest. 2	euritic dy 2005 Feb;1	ystrophy in 15(2):428-33	oromotes the PDAPP tran	nsgenic m	•	of amyloid	-
	□ 6:	Qi-Tal Hirota R, Iha	<u>ini N, Ho</u>	', Morishir orikoshi Y,	na-Kawashim Kametani F,	ia M, Tanimur Maeda M, Sai	a Y, Dolios do TC, Wa	<u>G</u> , Re	lated Articles,	Links
•		intrar J Neur	nembra rosci. 20	ane cleav 05 Jan 12;2				or the	mechanism	of
	□7:	Wang	YJ, Che	n GH, Hu	XY, Lu YP, Z	Zhou JN, Liu R	<u>RY.</u>	Re	lated Articles,	Links

	The expression of calcium/calmodulin-dependent protein the hippocampus of patients with Alzheimer's disease an AD-related pathology. Brain Res. 2005 Jan 7;1031(1):101-8. PMID: 15621017 [PubMed - indexed for MEDLINE]	
□8:	Shivaprasad S, Wetzel R.	Related Articles, Links
	An intersheet packing interaction in A beta fibrils mappeross-linking. Biochemistry. 2004 Dec 14;43(49):15310-7. PMID: 15581343 [PubMed - indexed for MEDLINE]	ed by disulfide
□9:	Albrecht H, Zbinden P, Rizzi A, Villetti G, Riccardi B, Puccini P, Catinella S, Imbimbo BP.	Related Articles, Links
	High throughput screening of beta-amyloid secretion in homogenous time-resolved fluorescence. Comb Chem High Throughput Screen. 2004 Dec;7(8):745-56. PMID: 15578936 [PubMed - indexed for MEDLINE]	nibitors using
□10	Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K.	Related Articles, Links
	Simultaneous measurement of beta-amyloid(1-42), total phosphorylated tau (Thr181) in cerebrospinal fluid by technology. Clin Chem. 2005 Feb;51(2):336-45. Epub 2004 Nov 24. PMID: 15563479 [PubMed - indexed for MEDLINE]	
□11	Horikoshi Y, Mori T, Maeda M, Kinoshita N, Sato K, Yamaguchi H.	Related Articles, Links
	Abeta N-terminal-end specific antibody reduced beta-a Alzheimer-model mice. Biochem Biophys Res Commun. 2004 Dec 10;325(2):384-7. PMID: 15530403 [PubMed - indexed for MEDLINE]	myloid in
□ 12	van Horssen J, de Vos RA, Steur EN, David G, Wesseling P, de Waal RM, Verbeek MM.	Related Articles, Links
	Absence of heparan sulfate proteoglycans in Lewy bod neurites in Parkinson's disease brains. J Alzheimers Dis. 2004 Oct;6(5):469-74. PMID: 15505367 [PubMed - indexed for MEDLINE]	ies and Lewy
□ 13	Perez M, Cuadros R, Benitez MJ, Jimenez JS.	Related Articles, Links
	Interaction of Alzheimer's disease amyloid beta peptide with tau protein, and with a tau peptide containing the binding domain. J Alzheimers Dis. 2004 Oct;6(5):461-7. PMID: 15505366 [PubMed - indexed for MEDLINE]	
□14	Manea M, Mezo G, Hudecz F, Przybylski M.	Related Articles, Links
	Polypeptide conjugates comprising a beta-amyloid place epitope as new vaccine structures against Alzheimer's of Biopolymers. 2004;76(6):503-11. PMID: 15499564 [PubMed - indexed for MEDLINE]	
□ 15	Prosperi C, Scali C, Barba M, Bellucci A, Giovannini MG, Pepeu G, Casamenti F.	Related Articles, Links

	Comparison between flurbiprofen and its nitric oxide-1 derivatives HCT-1026 and NCX-2216 on Abeta(1-42) inflammation and neuronal damage in the rat. Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):317-30. PMID: 15461866 [PubMed - indexed for MEDLINE]	
□ 16:	Zirah S, Stefanescu R, Manea M, Tian X, Cecal R, Kozin SA, Debey P, Rebuffat S, Przybylski M.	Related Articles, Links
	Zinc binding agonist effect on the recognition of the beepitope by anti-beta-amyloid antibodies. Biochem Biophys Res Commun. 2004 Aug 20;321(2):324-8. PMID: 15358179 [PubMed - indexed for MEDLINE]	eta-amyloid (4-10)
□ 17:	Motoi Y, Itaya M, Mori H, Mizuno Y, Iwasaki T, Hattori H, Haga S, Ikeda K.	Related Articles, Links
	Apolipoprotein E receptor 2 is involved in neuritic place APP sw mice. Neurosci Lett. 2004 Sep 23;368(2):144-7. PMID: 15351437 [PubMed - indexed for MEDLINE]	que formation in
□ 18:	Lopez EM, Bell KF, Ribeiro-da-Silva A, Cuello AC.	Related Articles, Links
	Early changes in neurons of the hippocampus and neodrats expressing intracellular human a-beta. J Alzheimers Dis. 2004 Aug;6(4):421-31; discussion 443-9. PMID: 15345813 [PubMed - indexed for MEDLINE]	cortex in transgenic
□ 19:	Schenk D, Hagen M, Seubert P.	Related Articles, Links
	Current progress in beta-amyloid immunotherapy. Curr Opin Immunol. 2004 Oct;16(5):599-606. Review. PMID: 15342006 [PubMed - indexed for MEDLINE]	
□ 20:	Venezia V, Russo C, Repetto E, Salis S, Dolcini V, Genova F, Nizzari M, Mueller U, Schettini G.	Related Articles, Links
	Apoptotic cell death influences the signaling activity o precursor protein through ShcA and Grb2 adaptor prot neuroblastoma SH-SY5Y cells. J Neurochem. 2004 Sep;90(6):1359-70. PMID: 15341520 [PubMed - indexed for MEDLINE]	
□ 21:	Zhang GR, Gao DL, Cao LG, Yin M.	Related Articles, Links
	[5-HT2C receptor subtype modulate production of secretary protein precursor in incubated rat hippocampal slices] Yao Xue Xue Bao. 2004 May;39(5):321-4. Chinese. PMID: 15338870 [PubMed - indexed for MEDLINE]	retory beta-amyloid
□ 22:	Nordberg A.	Related Articles, Links
	PET imaging of amyloid in Alzheimer's disease. Lancet Neurol. 2004 Sep;3(9):519-27. Review. PMID: 15324720 [PubMed - indexed for MEDLINE]	
□ 23:	Ricceri L, Minghetti L, Moles A, Popoli P, Confaloni A, De Simone R, Piscopo P, Scattoni ML, di Luca M, Calamandrei G.	Related Articles, Links
	Cognitive and neurological deficits induced by early ar forebrain cholinergic hypofunction in rats. Exp Neurol. 2004 Sep;189(1):162-72.	nd prolonged basal


PMID: 15296846 [PubMed - indexed for MEDLINE] 24: Yasuoka K, Hirata K, Kuraoka A, He JW, Kawabuchi M. Related Articles, Links Expression of amyloid precursor protein-like molecule in astroglial cells of the subventricular zone and rostral migratory stream of the adult rat forebrain. J Anat. 2004 Aug; 205(2):135-46. PMID: 15291796 [PubMed - indexed for MEDLINE] 25: Recuero M, Serrano E, Bullido MJ, Valdivieso F. Related Articles, Links Abeta production as consequence of cellular death of a human neuroblastoma overexpressing APP. FEBS Lett. 2004 Jul 16;570(1-3):114-8. PMID: 15251450 [PubMed - indexed for MEDLINE] 26: Schiltz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, Related Articles, Links Pavlovic J, Wollmer MA, Nitsch RM, Moelling K. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J Mol Med. 2004 Oct;82(10):706-14. PMID: 15241501 [PubMed - indexed for MEDLINE] 27: Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Related Articles, Links Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004 Jul 7;24(27):6144-51. PMID: 15240806 [PubMed - indexed for MEDLINE] 128: Kowa H, Sakakura T, Matsuura Y, Wakabayashi T, Mann DM, Related Articles, Links Duff K, Tsuji S, Hashimoto T, Iwatsubo T. Mostly separate distributions of CLAC- versus Abeta40- or thioflavin Sreactivities in senile plaques reveal two distinct subpopulations of betaamyloid deposits. Am J Pathol. 2004 Jul;165(1):273-81. PMID: 15215182 [PubMed - indexed for MEDLINE] 29: Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Related Articles, Links Zamrini EY, Schade RF. Autoimmunity in Alzheimer's disease: increased levels of circulating $\parallel \equiv \mid$ IgGs binding Abeta and RAGE peptides. Neurobiol Aging. 2004 Sep;25(8):1023-32. PMID: 15212827 [PubMed - indexed for MEDLINE] 30: Echeverria V, Ducatenzeiler A, Alhonen L, Janne J, Grant SM, Related Articles, Links Wandosell F, Muro A, Baralle F, Li H, Duff K, Szyf M, Cuello Rat transgenic models with a phenotype of intracellular Abeta accumulation in hippocampus and cortex. J Alzheimers Dis. 2004 Jun;6(3):209-19. PMID: 15201476 [PubMed - indexed for MEDLINE] 31: Johnson JK, Vogt BA, Kim R, Cotman CW, Head E. Related Articles, Links Isolated executive impairment and associated frontal neuropathology. Dement Geriatr Cogn Disord. 2004;17(4):360-7.

	PMID: 15178954 [PubMed - indexed for MEDLINE]	
□ 32:	<u>Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Serrano J, Bentura ML, Martinez-Murillo R, Martinez A, Rodrigo J.</u>	Related Articles, Links
	Intra- and extracellular Abeta and PHF in clinically evaluated Alzheimer's disease. Histol Histopathol. 2004 Jul;19(3):823-44. PMID: 15168346 [PubMed - indexed for MEDLINE]	aluated cases of
□ 33:	Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Yamamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K.	Related Articles, Links
	A seed for Alzheimer amyloid in the brain. J Neurosci. 2004 May 19;24(20):4894-902. PMID: 15152051 [PubMed - indexed for MEDLINE]	
□34:	Mathis CA, Wang Y, Klunk WE.	Related Articles, Links
	Imaging beta-amyloid plaques and neurofibrillary tang human brain. Curr Pharm Des. 2004;10(13):1469-92. Review. PMID: 15134570 [PubMed - indexed for MEDLINE]	les in the aging
□35:	Karkos J.	Related Articles, Links
	[Immunotherapy of Alzheimer's disease. Results of expinvestigations and treatment of perspectives] Fortschr Neurol Psychiatr. 2004 Apr;72(4):204-19. Review. Germ PMID: 15095177 [PubMed - indexed for MEDLINE]	
□ 36:	Aleksandrova IY, Kuvichkin VV, Kashparov IA, Medvinskaya NI, Nesterova IV, Lunin SM, Samokhin AN, Bobkova NV.	Related Articles, Links
	Increased level of beta-amyloid in the brain of bulbector Biochemistry (Mosc). 2004 Feb;69(2):176-80. PMID: 15000684 [PubMed - indexed for MEDLINE]	omized mice.
□37:	Woltjer RL, Maezawa I, Ou JJ, Montine KS, Montine TJ.	Related Articles, Links
	Advanced glycation endproduct precursor alters intrace beta/A beta PP carboxy-terminal fragment aggregation J Alzheimers Dis. 2003 Dec;5(6):467-76. PMID: 14757937 [PubMed - indexed for MEDLINE]	•
□ 38:	Burn DJ.	Related Articles, Links
	Cortical Lewy body disease. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):175-8. No abstract PMID: 14742580 [PubMed - indexed for MEDLINE]	t available.
□ 39:	Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T.	Related Articles, Links
	Effect of different anti-Abeta antibodies on Abeta fibril assessed by atomic force microscopy. J Mol Biol. 2004 Jan 23;335(4):997-1006. PMID: 14698294 [PubMed - indexed for MEDLINE]	llogenesis as
□ 40 :	Abe K, Hisatomi R, Misawa M.	Related Articles, Links
	Amyloid beta peptide specifically promotes phosphory translocation of the extracellular signal-regulated kinas	

cortical astrocytes. J Pharmacol Sci. 2003 Nov;93(3):272-8. PMID: 14646244 [PubMed - indexed for MEDLINE] 41: Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Related Articles, Links Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry. 2003 Dec 9;42(48):14328-34. PMID: 14640701 [PubMed - indexed for MEDLINE] 42: Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch Related Articles, Links T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, Beyreuther K. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J. 2004 Jan;18(1):203-5. Epub 2003 Nov 3. PMID: 14597556 [PubMed - indexed for MEDLINE] 143: Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Related Articles, Links Wegiel J. Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry. 2003 Oct 14;42(40):11682-92. PMID: 14529278 [PubMed - indexed for MEDLINE] 44: Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Related Articles, Links Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet. 2003 Nov 15;12(22):2949-56. Epub 2003 Sep 23. PMID: 14506131 [PubMed - indexed for MEDLINE] ☐ **45**: <u>Solomon B.</u> Related Articles, Links Immunological approach for the treatment of Alzheimer's disease. J Mol Neurosci. 2003;20(3):283-6. PMID: 14501009 [PubMed - indexed for MEDLINE] 46: Mruthinti S, Hill WD, Swamy-Mruthinti S, Buccafusco JJ. Related Articles, Links Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites. J Mol Neurosci. 2003;20(3):223-32. PMID: 14501001 [PubMed - indexed for MEDLINE] 1 47: Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Related Articles, Links Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis. 2003 Oct;14(1):10-8. PMID: 13678662 [PubMed - indexed for MEDLINE] ☐ 48: Chauhan NB, Siegel GJ. Related Articles, Links Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res. 2003 Oct 1;74(1):142-7. PMID: 13130516 [PubMed - indexed for MEDLINE]

□ 49:	Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C.	Related Articles, Links
	Biochemical diagnosis of Alzheimer disease by measu cerebrospinal fluid ratio of phosphorylated tau protein peptide42. Arch Neurol. 2003 Sep;60(9):1202-6. PMID: 12975284 [PubMed - indexed for MEDLINE]	_
□ 50:	Cottingham MG, Voskuil JL, Vaux DJ.	Related Articles, Links
	The intact human acetylcholinesterase C-terminal oligous alpha-helical in situ and in isolation, but a shorter fra sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry. 2003 Sep 16;42(36):10863-73. PMID: 12962511 [PubMed - indexed for MEDLINE]	
□ 51:	Uchihara T, Nakamura A, Nakayama H, Arima K, Ishizuka N, Mori H, Mizushima S.	Related Articles, Links
	Triple immunofluorolabeling with two rabbit polyclon mouse monoclonal antibody allowing three-dimension cotton wool plaques in Alzheimer disease. J Histochem Cytochem. 2003 Sep;51(9):1201-6. PMID: 12923245 [PubMed - indexed for MEDLINE]	
□ 52:	LeVine H 3rd.	Related Articles, Links
	Y10W beta(1-40) fluorescence reflects epitope exposu Alzheimer's beta-peptide. Arch Biochem Biophys. 2003 Sep 1;417(1):112-22. PMID: 12921787 [PubMed - indexed for MEDLINE]	re in conformers of
□ 53:	Morgan D.	Related Articles, Links
	Antibody therapy for Alzheimer's disease. Expert Rev Vaccines. 2003 Feb;2(1):53-9. Review. PMID: 12901597 [PubMed - indexed for MEDLINE]	
□ 54:	Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM.	Related Articles, Links
	Transient hypoxia causes Alzheimer-type molecular ar abnormalities in cortical neurons: potential strategies for J Alzheimers Dis. 2003 Jun;5(3):209-28. PMID: 12897406 [PubMed - indexed for MEDLINE]	
□ 55:	Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL.	Related Articles, Links
	Caspase cleavage of tau: linking amyloid and neurofibe Alzheimer's disease. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10032-7. Epub 2 PMID: 12888622 [PubMed - indexed for MEDLINE]	
□ 56:	Riedel A, Miettinen R, Stieler J, Mikkonen M, Alafuzoff I, Soininen H, Arendt T.	Related Articles, Links
	Reelin-immunoreactive Cajal-Retzius cells: the entorhinormal aging and Alzheimer's disease. Acta Neuropathol (Berl). 2003 Oct;106(4):291-302. Epub 2003 Jupp PMID: 12811583 [PubMed - indexed for MEDLINE]	

□ 57:	Radenahmad N, Neal JW, Wilcock G, Pearson RC.	Related Articles, Links
	A neurofilament antibody recognizes a subset of pyramhuman neocortex that are preserved in Alzheimer's disc Neuropathol Appl Neurobiol. 2003 Jun;29(3):316-20. No abstract PMID: 12787329 [PubMed - indexed for MEDLINE]	ease.
□ 58:	Farr SA, Banks WA, Uezu K, Sano A, Gaskin FS, Morley JE.	Related Articles, Links
	Antibody to beta-amyloid protein increases acetylcholi hippocampus of 12 month SAMP8 male mice. Life Sci. 2003 Jun 20;73(5):555-62. PMID: 12770611 [PubMed - indexed for MEDLINE]	ne in the
□ 59:	Taylor BM, Sarver RW, Fici G, Poorman RA, Lutzke BS, Molinari A, Kawabe T, Kappenman K, Buhl AE, Epps DE.	Related Articles, Links
	Spontaneous aggregation and cytotoxicity of the beta-a a kinetic model. J Protein Chem. 2003 Jan;22(1):31-40. PMID: 12739896 [PubMed - indexed for MEDLINE]	myloid Abeta1-40:
□ 60:	Tateyama M, Takeda A, Onodera Y, Matsuzaki M, Hasegawa T, Nunomura A, Hirai K, Perry G, Smith MA, Itoyama Y.	Related Articles, Links
	Oxidative stress and predominant Abeta42(43) depositive with rimmed vacuoles. Acta Neuropathol (Berl). 2003 Jun;105(6):581-5. Epub 2003 Mar PMID: 12734664 [PubMed - indexed for MEDLINE]	• •
□ 61:	Yoburn JC, Tian W, Brower JO, Nowick JS, Glabe CG, Van Vranken DL.	Related Articles, Links
	Dityrosine cross-linked Abeta peptides: fibrillar beta-st (1-40) is conducive to formation of dityrosine cross-link cross-link in Abeta(8-14) does not induce beta-structure Chem Res Toxicol. 2003 Apr;16(4):531-5. PMID: 12703970 [PubMed - indexed for MEDLINE]	ks but a dityrosine
□ 62:	Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R, Memo M.	Related Articles, Links
	Neutralization of TRAIL death pathway protects human from beta-amyloid toxicity. Cell Death Differ. 2003 Jan;10(1):134-41. PMID: 12655302 [PubMed - indexed for MEDLINE]	n neuronal cell line
□ 63:	Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T.	Related Articles, Links
	Epitope and isotype specificities of antibodies to beta - for protection against Alzheimer's disease-like neuropa Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Proc Natl Acad Sci U S A. 2004 Aug 3;101(3):11526. PMID: 12566568 [PubMed - indexed for MEDLINE]	thology.
□ 64: —	<u>Deininger MH, Fimmen BA, Thal DR, Schluesener HJ, Meyermann R.</u>	Related Articles, Links
	Aberrant neuronal and paracellular deposition of endos patients with Alzheimer's disease. J Neurosci. 2002 Dec 15;22(24):10621-6. Erratum in: J Neurosci.	



□ 73:	Underwood JR.	Related Articles, Links
	Generation of a recombinant Fab antibody reactive with disease-related Abeta peptide. Clin Exp Immunol. 2002 Sep;129(3):453-63. PMID: 12197886 [PubMed - indexed for MEDLINE]	h the Alzheimer's
□ 74:	Pan W, Solomon B, Maness LM, Kastin AJ.	Related Articles, Links
	Antibodies to beta-amyloid decrease the blood-to-brain amyloid peptide. Exp Biol Med (Maywood). 2002 Sep;227(8):609-15. PMID: 12192102 [PubMed - indexed for MEDLINE]	transfer of beta-
□ 75:	Kovacs GG, Zerbi P, Voigtlander T, Strohschneider M, Trabattoni G, Hainfellner JA, Budka H.	Related Articles, Links
	The prion protein in human neurodegenerative disorder Neurosci Lett. 2002 Sep 6;329(3):269-72. PMID: 12183028 [PubMed - indexed for MEDLINE]	rs.
□ 76:	Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA.	Related Articles, Links
	Proteomic identification of oxidatively modified protein disease brain. Part I: creatine kinase BB, glutamine synubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 2002 Aug 15;33(4):562-71. PMID: 12160938 [PubMed - indexed for MEDLINE]	
□ 77:	Beher D, Wrigley JD, Owens AP, Shearman MS.	Related Articles, Links
	Generation of C-terminally truncated amyloid-beta pep on gamma-secretase activity. J Neurochem. 2002 Aug;82(3):563-75. PMID: 12153480 [PubMed - indexed for MEDLINE]	tides is dependent
□ 78:	Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH.	Related Articles, Links
	Reversible memory loss in a mouse transgenic model o disease. J Neurosci. 2002 Aug 1;22(15):6331-5. PMID: 12151510 [PubMed - indexed for MEDLINE]	f Alzheimer's
□ 79:	Clamagirand C, Joulie C, Panchal M, Sekhri R, Hanquez C, Cohen P, Rholam M.	Related Articles, Links
	Specific cleavage of beta-amyloid peptides by a metallo Xenopus laevis skin secretions. Comp Biochem Physiol B Biochem Mol Biol. 2002 Aug;132(4):7. PMID: 12128061 [PubMed - indexed for MEDLINE]	• •
□ 80:	Takao M, Ghetti B, Hayakawa I, Ikeda E, Fukuuchi Y, Miravalle L, Piccardo P, Murrell JR, Glazier BS, Koto A.	Related Articles, Links
	A novel mutation (G217D) in the Presentilin 1 gene (PS Japanese family: present dementia and parkinsonism a cotton wool plaques in the cortex and striatum. Acta Neuropathol (Berl). 2002 Aug; 104(2):155-70. Epub 2002 Ap PMID: 12111359 [PubMed - indexed for MEDLINE]	are associated with
□ 81:	Nyabi O, Pype S, Mercken M, Herreman A, Saftig P, Craessaerts K, Serneels L, Annaert W, De Strooper B.	Related Articles, Links

	No endogenous A beta production in presenilin-deficient fibroblasts. Nat Cell Biol. 2002 Jul;4(7):E164; author reply E165-6. No abstract available. PMID: 12105423 [PubMed - indexed for MEDLINE]		
□ 82:	Grimm MO, Tomic I, Hartmann T.	Related Articles, Links	
	Potential external source of A beta in biological samples. Nat Cell Biol. 2002 Jul;4(7):E164-5; author reply E165-6. No abstract available. PMID: 12105422 [PubMed - indexed for MEDLINE]		
□ 83:	Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA.	Related Articles, Links	
	Calpain activity regulates the cell surface distribution of precursor protein. Inhibition of clapains enhances endo of beta-cleaved C-terminal APP fragments. J Biol Chem. 2002 Sep 27;277(39):36415-24. Epub 2002 Jun 26. PMID: 12087104 [PubMed - indexed for MEDLINE]		
□ 84:	Morley JE, Farr SA, Flood JF.	Related Articles, Links	
	Antibody to amyloid beta protein alleviates impaired a retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem. 2002 Jul;78(1):125-38. PMID: 12071671 [PubMed - indexed for MEDLINE]	cquisition,	
□ 85:	Green KN, Boyle JP, Peers C.	Related Articles, Links	
	Hypoxia potentiates exocytosis and Ca2+ channels in I increased amyloid beta peptide formation and reactive generation. J Physiol. 2002 Jun 15;541(Pt 3):1013-23. PMID: 12068059 [PubMed - indexed for MEDLINE]		
□ 86:	Green KN, Peers C.	Related Articles, Links	
	Divergent pathways account for two distinct effects of peptides on exocytosis and Ca(2+) currents: involveme kappaB. J Neurochem. 2002 Jun;81(5):1043-51. PMID: 12065617 [PubMed - indexed for MEDLINE]		
□ 87:	Chen S, Berthelier V, Hamilton JB, O'Nuallain B, Wetzel R.	Related Articles, Links	
	Amyloid-like features of polyglutamine aggregates and kinetics. Biochemistry. 2002 Jun 11;41(23):7391-9. PMID: 12044172 [PubMed - indexed for MEDLINE]	l their assembly	
□ 88:	Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM.	Related Articles, Links	
	Immunization reverses memory deficits without reduci burden in Alzheimer's disease model. Nat Neurosci. 2002 May;5(5):452-7. PMID: 11941374 [PubMed - indexed for MEDLINE]	ng brain Abeta	
□ 89:	Hashimoto T, Wakabayashi T, Watanabe A, Kowa H, Hosoda R, Nakamura A, Kanazawa I, Arai T, Takio K, Mann DM, Iwatsubo T.	Related Articles, Links	
	CLAC: a novel Alzheimer amyloid plaque component transmembrane precursor, CLAC-P/collagen type XXV		

	EMBO J. 2002 Apr 2;21(7):1524-34. PMID: 11927537 [PubMed - indexed for MEDLINE]	
□ 90:	DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM.	Related Articles, Links
	Brain to plasma amyloid-beta efflux: a measure of brain a mouse model of Alzheimer's disease. Science. 2002 Mar 22;295(5563):2264-7. PMID: 11910111 [PubMed - indexed for MEDLINE]	
□91:	Frenkel D, Solomon B.	Related Articles, Links
	Towards Alzheimer's beta-amyloid vaccination. Biologicals. 2001 Sep-Dec;29(3-4):243-7. PMID: 11851323 [PubMed - indexed for MEDLINE]	
□ 92:	Milton NG.	Related Articles, Links
	Inhibition of catalase activity with 3-amino-triazole enlicytotoxicity of the Alzheimer's amyloid-beta peptide. Neurotoxicology. 2001 Dec;22(6):767-74. PMID: 11829410 [PubMed - indexed for MEDLINE]	nances the
□ 93:	Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM.	Related Articles, Links
, =	Imaging brain amyloid of Alzheimer disease in vivo in with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab. 2002 Feb;22(2):223-31. PMID: 11823720 [PubMed - indexed for MEDLINE]	transgenic mice
□ 94:	O'Nuallain B, Wetzel R.	Related Articles, Links
	Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1485-90. Epub 2002 Jan 29. PMID: 11818542 [PubMed - indexed for MEDLINE]	
□ 95:	<u>Lichtenthaler SF, Beher D, Grimm HS, Wang R, Shearman MS, Masters CL, Beyreuther K.</u>	Related Articles, Links
	The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1365-70. Epub 2002 Jan 22. PMID: 11805291 [PubMed - indexed for MEDLINE]	
□ 96:	Cummings BJ, Mason AJ, Kim RC, Sheu PC, Anderson AJ.	Related Articles, Links
	Optimization of techniques for the maximal detection a of Alzheimer's-related neuropathology with digital images Neurobiol Aging. 2002 Mar-Apr;23(2):161-70. PMID: 11804699 [PubMed - indexed for MEDLINE]	
□ 97 :	Matsunaga Y, Saito N, Fujii A, Yokotani J, Takakura T, Nishimura T, Esaki H, Yamada T.	Related Articles, Links
	A pH-dependent conformational transition of Abeta per physicochemical properties of the conformers in the gli- Biochem J. 2002 Feb 1;361(Pt 3):547-56. PMID: 11802784 [PubMed - indexed for MEDLINE]	otide and al cell.
□ 98:	Solomon B.	Related Articles, Links
	Immunotherapeutic strategies for prevention and treatm disease. DNA Cell Biol. 2001 Nov;20(11):697-703.	ent of Alzheimer's

PMID: 11788047 [PubMed - indexed for MEDLINE] Goraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Related Articles, Links Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol. 2002 Jan; 160(1):101-12. PMID: 11786404 [PubMed - indexed for MEDLINE] 100: Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Related Articles, Links Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol. 2001 Dec;58(12):2025-32. Erratum in: Arch Neurol 2002 Feb;59(2):202. PMID: 11735776 [PubMed - indexed for MEDLINE] 101: Poduslo JF, Curran GL. Related Articles, Links Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport. 2001 Oct 29;12(15):3197-200. PMID: 11711855 [PubMed - indexed for MEDLINE] 102: Dobrogowska DH, Vorbrodt AW, Wegiel J, Wang KC, Shoji Related Articles, Links M, Mondadori C, Polatis G, Giovanni A, Wisniewski HM. Cytochemical study of the involvement of cell organelles in formation \equiv and accumulation of fibrillar amyloid in the pancreas of NORbeta transgenic mice. Histol Histopathol. 2001 Oct;16(4):1047-56. PMID: 11642724 [PubMed - indexed for MEDLINE] 103: Nunan J, Shearman MS, Checler F, Cappai R, Evin G. Related Articles, Links Beyreuther K, Masters CL, Small DH. The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur J Biochem. 2001 Oct;268(20):5329-36. PMID: 11606195 [PubMed - indexed for MEDLINE] 104. Carter DB, Dunn E, McKinley DD, Stratman NC, Boyle TP, Related Articles, Links Kuiper SL, Oostveen JA, Weaver RJ, Boller JA, Gurney ME. Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann Neurol. 2001 Oct;50(4):468-75. PMID: 11601499 [PubMed - indexed for MEDLINE] 105: Chauhan NB, Siegel GJ, Lichtor T. Related Articles, Links Distribution of intraventricularly administered antiamyloid-beta peptide (Abeta) antibody in the mouse brain. J Neurosci Res. 2001 Oct 15;66(2):231-5. PMID: 11592118 [PubMed - indexed for MEDLINE] 106: Rub U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H. Related Articles, Links The autonomic higher order processing nuclei of the lower brain stem are among the early targets of the Alzheimer's disease-related

cytoskeletal pathology. Acta Neuropathol (Berl). 2001 Jun;101(6):555-64. PMID: 11515783 [PubMed - indexed for MEDLINE] 107: Mikhailenko I, Battey FD, Migliorini M, Ruiz JF, Argraves K. Related Articles, Links Moayeri M. Strickland DK. Recognition of alpha 2-macroglobulin by the low density lipoprotein receptor-related protein requires the cooperation of two ligand binding cluster regions. J Biol Chem. 2001 Oct 19;276(42):39484-91. Epub 2001 Aug 15. PMID: 11507091 [PubMed - indexed for MEDLINE] 108: Mann DM, Takeuchi A, Sato S, Cairns NJ, Lantos PL, Rossor Related Articles, Links MN, Haltia M, Kalimo H, Iwatsubo T. Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as 'cotton wool' plaques. Neuropathol Appl Neurobiol. 2001 Jun;27(3):189-96. PMID: 11489138 [PubMed - indexed for MEDLINE] 109: Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski Related Articles, Links AW, Januszewski S. Possible reverse transport of beta-amyloid peptide across the blood-brain barrier. Acta Neurochir Suppl. 2000;76:73-7. PMID: 11450095 [PubMed - indexed for MEDLINE] 110: DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Related Articles, Links Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5. Epub 2001 Jul 3. PMID: 11438712 [PubMed - indexed for MEDLINE] 111: Jayasena UL, Gribble SK, McKenzie A, Beyreuther K, Masters Related Articles, Links CL, Underwood JR. Identification of structural variations in the carboxyl terminus of Alzheimer's disease-associated beta A4[1-42] amyloid using a monoclonal antibody. Clin Exp Immunol. 2001 May;124(2):297-305. PMID: 11422208 [PubMed - indexed for MEDLINE] 112: Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Related Articles, Links Yamaguchi T. beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience. 2001;104(2):299-310. PMID: 11377835 [PubMed - indexed for MEDLINE] 113: Takikawa M, Kamada M, Maegawa M, Yamano S, Irahara M, Related Articles, Links Aono T, Futaki S, Ohmoto Y, Koide SS. Evaluation of two sperm antigens, rSMP-B and YWK-II, as targets for immunocontraception. Zygote. 2001 May;9(2):145-51.

	PMID: 11358321 [PubMed - indexed for MEDLINE]	
□ 114	: Green KN, Peers C.	Related Articles, Links
	Amyloid beta peptides mediate hypoxic augmentatio channels. J Neurochem. 2001 May;77(3):953-6. PMID: 11331424 [PubMed - indexed for MEDLINE]	n of Ca(2+)
□ 115	: Jeong Lee H, Pardridge WM.	Related Articles, Links
	Drug targeting to the brain using avidin-biotin technologous (blood-brain barrier, monoclonal antibody, transferrigal Alzheimer's disease). J Drug Target. 2000;8(6):413-24. PMID: 11328667 [PubMed - indexed for MEDLINE]	
□ 116	Nebuloni M, Pellegrinelli A, Ferri A, Bonetto S, Boldorini R, Vago L, Grassi MP, Costanzi G.	Related Articles, Links
	Beta amyloid precursor protein and patterns of HIV primmunohistochemistry in different brain areas of AII AIDS. 2001 Mar 30;15(5):571-5. PMID: 11316993 [PubMed - indexed for MEDLINE]	
□ 117	Englund P, Jacobsson SO, Fowler CJ.	Related Articles, Links
	Investigation into the effects of amyloid (1-42) beta- and antigen-stimulated hexosaminidase and serotonin RBL-2H3 basophilic leukemia cells. Methods Find Exp Clin Pharmacol. 2000 Nov;22(9):657-61. PMID: 11294005 [PubMed - indexed for MEDLINE]	
□ 118	Frenkel D, Kariv N, Solomon B.	Related Articles, Links
	Generation of auto-antibodies towards Alzheimer's d Vaccine. 2001 Mar 21;19(17-19):2615-9. PMID: 11257400 [PubMed - indexed for MEDLINE]	isease vaccination.
□ 119	Borroni B, Colciaghi F, Pastorino L, Pettenati C, Cottini E, Rozzini L, Monastero R, Lenzi GL, Cattabeni F, Di Luca M, Padovani A.	Related Articles, Links
	Amyloid precursor protein in platelets of patients wit disease: effect of acetylcholinesterase inhibitor treatm Arch Neurol. 2001 Mar;58(3):442-6. PMID: 11255448 [PubMed - indexed for MEDLINE]	h Alzheimer nent.
□ 120:	Rebeck GW, Moir RD, Mui S, Strickland DK, Tanzi RE, Hyman BT.	Related Articles, Links
	Association of membrane-bound amyloid precursor p the apolipoprotein E receptor LRP. Brain Res Mol Brain Res. 2001 Mar 5;87(2):238-45. PMID: 11245926 [PubMed - indexed for MEDLINE]	orotein APP with
□ 121:	Finnie JW, Van den Heuvel C, Gebski V, Manavis J, Summersides GE, Blumbergs PC.	Related Articles, Links
	Effect of impact on different regions of the head of la J Comp Pathol. 2001 Feb-Apr;124(2-3):159-64. PMID: 11222013 [PubMed - indexed for MEDLINE]	mbs.
□ 122:	Lin B, Ginsberg MD, Busto R.	Related Articles, Links

	Hyperglycemic but not normoglycemic global ischemearly intraneuronal expression of beta-amyloid precur Brain Res. 2001 Jan 5;888(1):107-116. PMID: 11146057 [PubMed - indexed for MEDLINE]	
□ 123:	Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E.	Related Articles, Links
	Standardization of measurement of beta-amyloid(1-42 fluid and plasma. Amyloid. 2000 Dec;7(4):245-58. PMID: 11132093 [PubMed - indexed for MEDLINE]	2) in cerebrospinal
□ 124:	Mileusnic R, Lancashire CL, Johnston AN, Rose SP.	Related Articles, Links
	APP is required during an early phase of memory for Eur J Neurosci. 2000 Dec;12(12):4487-95. PMID: 11122359 [PubMed - indexed for MEDLINE]	nation.
□ 125:	Seiffert D, Mitchell T, Stern AM, Roach A, Zhan Y, Grzanna R.	Related Articles, Links
	Positive-negative epitope-tagging of beta amyloid preidentify inhibitors of A beta processing. Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):115-26. PMID: 11113538 [PubMed - indexed for MEDLINE]	cursor protein to
□ 126:	Masumura M, Hata R, Nishimura I, Uetsuki T, Sawada T, Yoshikawa K.	Related Articles, Links
	Caspase-3 activation and inflammatory responses in r inoculated with a recombinant adenovirus expressing amyloid precursor protein. Brain Res Mol Brain Res. 2000 Sep 15;80(2):219-27. PMID: 11038254 [PubMed - indexed for MEDLINE]	at hippocampus the Alzheimer
□ 127:	Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Naslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L.	Related Articles, Links
	Quantification of Alzheimer amyloid beta peptides en and 42 by novel ELISA systems. Mol Med. 2000 Apr;6(4):291-302. PMID: 10949910 [PubMed - indexed for MEDLINE]	ding at residues 40
□ 128:	Haars R, Schneider A, Bode M, Schubert W.	Related Articles, Links
	Secretion and differential localization of the proteolyt products Abeta40 and Abeta42 of the Alzheimer amyl protein in human fetal myogenic cells. Eur J Cell Biol. 2000 Jun;79(6):400-6. PMID: 10928455 [PubMed - indexed for MEDLINE]	
□ 129:	Lah JJ, Levey AI.	Related Articles, Links
	Endogenous presenilin-1 targets to endocytic rather th compartments. Mol Cell Neurosci. 2000 Aug;16(2):111-26. PMID: 10924255 [PubMed - indexed for MEDLINE]	an biosynthetic
□ 130:	Ando Y.	Related Articles, Links

	[Analyses of amyloid formation mechanism in familia polyneuropathy and therapeutic trial] Rinsho Byori. 2000 May;48(5):425-9. Review. Japanese. PMID: 10892290 [PubMed - indexed for MEDLINE]	al amyloidotic
□131:	Sasaki A, Nakazato Y, Ogawa A, Sugihara S.	Related Articles, Links
	The immunophenotype of perivascular cells in the hur Pathol Int. 1996 Jan;46(1):15-23. PMID: 10846545 [PubMed - indexed for MEDLINE]	man brain.
□ 132:	Piccini A, Ciotti MT, Vitolo OV, Calissano P, Tabaton M, Galli C.	Related Articles, Links
	Endogenous APP derivatives oppositely modulate apo autocrine loop. Neuroreport. 2000 May 15;11(7):1375-9. PMID: 10841341 [PubMed - indexed for MEDLINE]	optosis through an
□ 133:	Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA.	Related Articles, Links
	beta-amyloid (Abeta)42(43), abeta42, abeta40 and apof plaques in fatal head injury. Neuropathol Appl Neurobiol. 2000 Apr;26(2):124-32. PMID: 10840275 [PubMed - indexed for MEDLINE]	oE immunostaining
□ 134:	Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, Lehrach H, Wanker EE.	Related Articles, Links
	Inhibition of huntingtin fibrillogenesis by specific ant molecules: implications for Huntington's disease there Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6739-44. PMID: 10829068 [PubMed - indexed for MEDLINE]	
□ 135:	Valeriani V, Dewar D, McCulloch J.	Related Articles, Links
	Quantitative assessment of ischemic pathology in axo oligodendrocytes, and neurons: attenuation of damage ischemia. J Cereb Blood Flow Metab. 2000 May;20(5):765-71. PMID: 10826526 [PubMed - indexed for MEDLINE]	•
□ 136:	Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM.	Related Articles, Links
	Platelet APP isoform ratios correlate with declining conversely 2000 May 23;54(10):1907-9. PMID: 10822427 [PubMed - indexed for MEDLINE]	
□ 137:	Rohn TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH.	Related Articles, Links
	A monoclonal antibody to amyloid precursor protein i apoptosis. J Neurochem. 2000 Jun;74(6):2331-42. PMID: 10820193 [PubMed - indexed for MEDLINE]	induces neuronal
□ 138:	Roher AE, Kuo YM, Potter PE, Emmerling MR, Durham RA, Walker DG, Sue LI, Honer WG, Beach TG.	Related Articles, Links
	Cortical cholinergic denervation elicits vascular A bet Ann N Y Acad Sci. 2000 Apr;903:366-73. PMID: 10818527 [PubMed - indexed for MEDLINE]	a deposition.
□ 139:	Friedland RP, Shi J, Lamanna JC, Smith MA, Perry G.	Related Articles, Links

	Prospects for noninvasive imaging of brain amyloid bedisease. Ann N Y Acad Sci. 2000 Apr;903:123-8. PMID: 10818497 [PubMed - indexed for MEDLINE]	oeta in Alzheimer's
□ 140:	Cornish R, Blumbergs PC, Manavis J, Scott G, Jones NR, Reilly PL.	Related Articles, Links
	Topography and severity of axonal injury in human susing amyloid precursor protein as a marker of axona Spine. 2000 May 15;25(10):1227-33. PMID: 10806498 [PubMed - indexed for MEDLINE]	
□141:	Gargiulo L, Bermejo M, Liras A.	Related Articles, Links
	[Reduced neuronal nitric oxide synthetase and c-prote Alzheimer's disease] Rev Neurol. 2000 Feb 16-29;30(4):301-3. Spanish. PMID: 10789135 [PubMed - indexed for MEDLINE]	ein kinase levels in
□ 142:	Maat-Schieman ML, Yamaguchi H, van Duinen SG, Natte R, Roos RA.	Related Articles, Links
	Age-related plaque morphology and C-terminal heter amyloid beta in Dutch-type hereditary cerebral hemoramyloidosis. Acta Neuropathol (Berl). 2000 Apr;99(4):409-19. PMID: 10787040 [PubMed - indexed for MEDLINE]	
□ 143:	Van Everbroeck B, Pals P, Dziedzic T, Dom R, Godfraind C, Sciot R, Brucher JM, Martin JJ, Cras P.	Related Articles, Links
	Retrospective study of Creutzfeldt-Jakob disease in B neuropathological findings. Acta Neuropathol (Berl). 2000 Apr;99(4):358-64. PMID: 10787033 [PubMed - indexed for MEDLINE]	elgium:
□ 144:	Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C.	Related Articles, Links
	Presenilin-1 differentially facilitates endoproteolysis of precursor protein and Notch. Nat Cell Biol. 2000 Apr;2(4):205-11. PMID: 10783238 [PubMed - indexed for MEDLINE]	of the beta-amyloid
□ 145:	Lee J, Hong H, Im J, Byun H, Kim D.	Related Articles, Links
	The formation of PHF-1 and SMI-31 positive dystrop hippocampus following acute injection of okadaic aci Neurosci Lett. 2000 Mar 17;282(1-2):49-52. PMID: 10713393 [PubMed - indexed for MEDLINE]	hic neurites in rat d.
□ 146:	Nakagawa T, Kabuto M, Kubota T, Kodera T, Sato K.	Related Articles, Links
	Production of amyloid beta protein precursor as a pro- human astrocytic tumors. Anticancer Res. 1999 Jul-Aug;19(4B):2963-8. PMID: 10652580 [PubMed - indexed for MEDLINE]	teinase inhibitor by
□ 147: —	Yasuda M, Maeda S, Kawamata T, Tamaoka A, Yamamoto Y, Kuroda S, Maeda K, Tanaka C.	Related Articles, Links
	Novel presenilin-1 mutation with widespread cortical deposition but limited cerebral amyloid angiopathy.	amyloid

J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):220-3. PMID: 10644793 [PubMed - indexed for MEDLINE] ☐ 148: Jung SS, Gauthier S, Cashman NR. Related Articles, Links Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease. Neurobiol Aging. 1999 May-Jun;20(3):249-57. PMID: 10588572 [PubMed - indexed for MEDLINE] 149: Taylor SC, Batten TF, Peers C. Related Articles, Links Hypoxic enhancement of quantal catecholamine secretion. Evidence for the involvement of amyloid beta-peptides. J Biol Chem. 1999 Oct 29;274(44):31217-22. PMID: 10531316 [PubMed - indexed for MEDLINE] 150: Lin L, Georgievska B, Mattsson A, Isacson O. Related Articles, Links Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12108-13. PMID: 10518584 [PubMed - indexed for MEDLINE] 151: Young MJ, Lee RK, Jhaveri S, Wurtman RJ. Related Articles, Links Intracellular and cell-surface distribution of amyloid precursor protein in cortical astrocytes. Brain Res Bull. 1999 Sep 1;50(1):27-32. PMID: 10507468 [PubMed - indexed for MEDLINE] 152: Lundgren E, Persson H, Andersson K, Olofsson A, Dacklin I, Related Articles, Links Goldsteins G. Mapping protein conformations in fibril structures using monoclonal antibodies. Methods Enzymol. 1999;309:591-605. No abstract available. PMID: 10507050 [PubMed - indexed for MEDLINE] 153: Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka Related Articles, Links S, Mori H. Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol. 1999 Sep;56(9):1111-8. PMID: 10488812 [PubMed - indexed for MEDLINE] ☐ 154: Lin H, Zhu YJ, Lal R. Related Articles, Links Amyloid beta protein (1-40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. Biochemistry. 1999 Aug 24;38(34):11189-96. PMID: 10460176 [PubMed - indexed for MEDLINE] ☐ 155: Kaur B, Rutty GN, Timperley WR. Related Articles, Links The possible role of hypoxia in the formation of axonal bulbs. J Clin Pathol. 1999 Mar;52(3):203-9. PMID: 10450180 [PubMed - indexed for MEDLINE] 156: Kurt MA, Davies DC, Kidd M. Related Articles, Links beta-Amyloid immunoreactivity in astrocytes in Alzheimer's disease

	brain biopsies: an electron microscope study. Exp Neurol. 1999 Jul;158(1):221-8. PMID: 10448435 [PubMed - indexed for MEDLINE]	
□ 157:	Ginsberg SD, Galvin JE, Lee VM, Rorke LB, Dickson DW, Wolfe JH, Jones MZ, Trojanowski JQ.	Related Articles, Links
	Accumulation of intracellular amyloid-beta peptide (Amucopolysaccharidosis brains. J Neuropathol Exp Neurol. 1999 Aug;58(8):815-24. PMID: 10446806 [PubMed - indexed for MEDLINE]	A beta 1-40) in
□ 158:	Wang J, Dickson DW, Trojanowski JO, Lee VM.	Related Articles, Links
	The levels of soluble versus insoluble brain Abeta dis Alzheimer's disease from normal and pathologic aging Exp Neurol. 1999 Aug;158(2):328-37. PMID: 10415140 [PubMed - indexed for MEDLINE]	
□ 159:	Yuan H, Zhai P, Anderson LM, Pan J, Thimmapaya B, Koo EH, Marquez-Sterling NR.	Related Articles, Links
	Recombinant adenovirus is an appropriate vector for extrafficking studies in cultured neurons. J Neurosci Methods. 1999 Apr 1;88(1):45-54. PMID: 10379578 [PubMed - indexed for MEDLINE]	endocytotic protein
□ 160:	Diehlmann A, Ida N, Weggen S, Grunberg J, Haass C, Masters CL, Bayer TA, Beyreuther K.	Related Articles, Links
	Analysis of presenilin 1 and presenilin 2 expression at newly developed monoclonal antibodies. J Neurosci Res. 1999 May 15;56(4):405-19. PMID: 10340748 [PubMed - indexed for MEDLINE]	nd processing by
□ 161:	Ohsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S.	Related Articles, Links
	Amino-terminal region of secreted form of amyloid prestimulates proliferation of neural stem cells. Eur J Neurosci. 1999 Jun;11(6):1907-13. PMID: 10336659 [PubMed - indexed for MEDLINE]	recursor protein
□ 162:	Abraham CR, Marshall DC, Tibbles HE, Otto K, Long HJ, Billingslea AM, Hastey R, Johnson R, Fine RE, Smith SJ, Simons ER, Davies TA.	Related Articles, Links
	Platelets and DAMI megakaryocytes possess beta-sec J Lab Clin Med. 1999 May;133(5):507-15. PMID: 10235134 [PubMed - indexed for MEDLINE]	retase-like activity.
□ 163:	Frenkel D, Balass M, Katchalski-Katzir E, Solomon B.	Related Articles, Links
	High affinity binding of monoclonal antibodies to the EFRH of beta-amyloid peptide is essential for modula aggregation. J Neuroimmunol. 1999 Mar 1;95(1-2):136-42.	
	PMID: 10229123 [PubMed - indexed for MEDLINE]	
	Lin B, Schmidt-Kastner R, Busto R, Ginsberg MD. Progressive perceptive denosition of hete anytheid a	Related Articles, Links
	Progressive parenchymal deposition of beta-amyloid print in rat brain following global cerebral ischemia. Acta Neuropathol (Berl). 1999 Apr;97(4):359-68. PMID: 10208275 [PubMed a indexed for MEDI INF]	precursor protein


□ 165:	Okonkwo DO, Povlishock JT.	Related Articles, Links
	An intrathecal bolus of cyclosporin A before injury primitochondrial integrity and attenuates axonal disruption brain injury. J Cereb Blood Flow Metab. 1999 Apr;19(4):443-51. PMID: 10197514 [PubMed - indexed for MEDLINE]	
□ 166:	Arai T, Akiyama H, Ikeda K, Kondo H, Mori H.	Related Articles, Links
	Immunohistochemical localization of amyloid beta-pr terminal aspartate in the cerebral cortex of patients wi disease. Brain Res. 1999 Mar 27;823(1-2):202-6.	
	PMID: 10095028 [PubMed - indexed for MEDLINE]	
□ 167:	Goldsteins G, Persson H, Andersson K, Olofsson A, Dacklin I, Edvinsson A, Saraiva MJ, Lundgren E.	Related Articles, Links
	Exposure of cryptic epitopes on transthyretin only in a amyloidogenic mutants. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3108-13. PMID: 10077645 [PubMed - indexed for MEDLINE]	amyloid and in
□ 168:	Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA.	Related Articles, Links
	Reverse relationship between beta-amyloid precursor amyloid peptide plaques in Down's syndrome versus s' Alzheimer's disease. Acta Neuropathol (Berl). 1999 Feb;97(2):113-8. PMID: 9928821 [PubMed - indexed for MEDLINE]	
□ 169:	Nakamura S, Nakayama H, Goto N, Ono F, Sakakibara I, Yoshikawa Y.	Related Articles, Links
	Histopathological studies of senile plaques and cerebr cynomolgus monkeys. J Med Primatol. 1998 Oct;27(5):244-52. PMID: 9926980 [PubMed - indexed for MEDLINE]	al amyloidosis in
□ 170:	Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, Ihara Y.	Related Articles, Links
	Appearance of sodium dodecyl sulfate-stable amyloid (Abeta) dimer in the cortex during aging. Am J Pathol. 1999 Jan;154(1):271-9. PMID: 9916941 [PubMed - indexed for MEDLINE]	beta-protein
□ 171:	Baum L, Ng HK.	Related Articles, Links
	A new kind of Alzheimer's disease plaque. Adv Anat Pathol. 1998 May;5(3):170-4. Review. No abstract ava PMID: 9868523 [PubMed - indexed for MEDLINE]	uilable.
□ 172:	Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, Chen S, Teller JK, Zaccheo D, Gambetti P, Tabaton M.	Related Articles, Links
	Opposite roles of apolipoprotein E in normal brains and disease. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15598-602. PMID: 9861015 [PubMed - indexed for MEDLINE]	nd in Alzheimer's

□ 173:	Leanza G.	Related Articles, Links
	Chronic elevation of amyloid precursor protein expreneocortex and hippocampus of rats with selective cho Neurosci Lett. 1998 Nov 20;257(1):53-6. PMID: 9857964 [PubMed - indexed for MEDLINE]	
□174:	Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V.	Related Articles, Links
	Neurotrophin binding to the p75 neurotrophin receptor not sufficient to mediate NGF-effects on APP secretic J Neural Transm Suppl. 1998;54:279-85. PMID: 9850936 [PubMed - indexed for MEDLINE]	
□ 175:	Van Den Heuvel C, Lewis S, Wong M, Manavis J, Finnie J, Blumbergs P, Jones N, Reilly P.	Related Articles, Links
	Diffuse neuronal perikaryon amyloid precursor protei immunoreactivity in a focal head impact model. Acta Neurochir Suppl. 1998;71:209-11. PMID: 9779186 [PubMed - indexed for MEDLINE]	n
□ 176:	Le Brocque D, Henry A, Cappai R, Li QX, Tanner JE, Galatis D, Gray C, Holmes S, Underwood JR, Beyreuther K, Masters CL, Evin G.	Related Articles, Links
	Processing of the Alzheimer's disease amyloid precur Pichia pastoris: immunodetection of alpha-, beta-, and products. Biochemistry. 1998 Oct 20;37(42):14958-65. PMID: 9778373 [PubMed - indexed for MEDLINE]	
□177:	McRae A, Ling EA, Schubert P, Rudolphi K.	Related Articles, Links
□ 177: □	McRae A, Ling EA, Schubert P, Rudolphi K. Properties of activated microglia and pharmacologic i propentofylline. Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S15-20. PMID: 9769025 [PubMed - indexed for MEDLINE]	
	Properties of activated microglia and pharmacologic i propentofylline. Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S15-20.	
	Properties of activated microglia and pharmacologic i propentofylline. Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S15-20. PMID: 9769025 [PubMed - indexed for MEDLINE] Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza	nterference by Related Articles, Links
☐ 178: ☐	Properties of activated microglia and pharmacologic i propentofylline. Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S15-20. PMID: 9769025 [PubMed - indexed for MEDLINE] Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM. Protease inhibitor coinfusion with amyloid beta-prote enhanced deposition and toxicity in rat brain. J Neurosci. 1998 Oct 15;18(20):8311-21.	nterference by Related Articles, Links
☐ 178: ☐	Properties of activated microglia and pharmacologic i propentofylline. Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S15-20. PMID: 9769025 [PubMed - indexed for MEDLINE] Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM. Protease inhibitor coinfusion with amyloid beta-prote enhanced deposition and toxicity in rat brain. J Neurosci. 1998 Oct 15;18(20):8311-21. PMID: 9763475 [PubMed - indexed for MEDLINE]	nterference by Related Articles, Links in results in Related Articles, Links
☐ 178: ☐ 179:	Properties of activated microglia and pharmacologic i propentofylline. Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S15-20. PMID: 9769025 [PubMed - indexed for MEDLINE] Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM. Protease inhibitor coinfusion with amyloid beta-prote enhanced deposition and toxicity in rat brain. J Neurosci. 1998 Oct 15;18(20):8311-21. PMID: 9763475 [PubMed - indexed for MEDLINE] Ono S, Matsuno S, Shimizu N, Shoji S, Tamaoka A. Amyloid beta protein in skin of patients with amyotro sclerosis. Lancet. 1998 Mar 28;351(9107):956-7. No abstract available.	nterference by Related Articles, Links in results in Related Articles, Links
☐ 178: ☐ 179:	Properties of activated microglia and pharmacologic is propentofylline. Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S15-20. PMID: 9769025 [PubMed - indexed for MEDLINE] Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM. Protease inhibitor coinfusion with amyloid beta-prote enhanced deposition and toxicity in rat brain. J Neurosci. 1998 Oct 15;18(20):8311-21. PMID: 9763475 [PubMed - indexed for MEDLINE] Ono S, Matsuno S, Shimizu N, Shoji S, Tamaoka A. Amyloid beta protein in skin of patients with amyotro sclerosis. Lancet. 1998 Mar 28;351(9107):956-7. No abstract available. PMID: 9734946 [PubMed - indexed for MEDLINE]	Related Articles, Links in results in Related Articles, Links phic lateral Related Articles, Links phic lateral


	Histological markers in nasal mucosa of patients with disease. Eur Neurol. 1998 Jul;40(1):31-6. PMID: 9693230 [PubMed - indexed for MEDLINE]	Alzheimer's
□ 182:	Frenkel D, Balass M, Solomon B.	Related Articles, Links
	N-terminal EFRH sequence of Alzheimer's beta-amyl represents the epitope of its anti-aggregating antibodic J Neuroimmunol. 1998 Aug 1;88(1-2):85-90. PMID: 9688328 [PubMed - indexed for MEDLINE]	
□ 183:	Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V.	Related Articles, Links
	p75 and TrkA receptor signaling independently regular precursor protein mRNA expression, isoform compossecretion in PC12 cells. J Neurochem. 1998 Aug;71(2):757-66. PMID: 9681467 [PubMed - indexed for MEDLINE]	
□ 184:	Su Y, Ni B.	Related Articles, Links
	Selective deposition of amyloid-beta protein in the en projection of a transgenic mouse model of Alzheimer' J Neurosci Res. 1998 Jul 15;53(2):177-86. PMID: 9671974 [PubMed - indexed for MEDLINE]	
□ 185:	Tamaoka A.	Related Articles, Links
	[Characterization of amyloid beta protein species in the cerebrospinal fluid and brains of patients with Alzhein Nippon Ronen Igakkai Zasshi. 1998 Apr;35(4):273-7. Japanese. PMID: 9643008 [PubMed - indexed for MEDLINE]	
□ 186:	Meckelein B, Marshall DC, Conn KJ, Pietropaolo M, Van Nostrand W, Abraham CR.	Related Articles, Links
	Identification of a novel serine protease-like molecule Brain Res Mol Brain Res. 1998 Apr;55(2):181-97. PMID: 9582421 [PubMed - indexed for MEDLINE]	e in human brain.
□ 187:	Rhee SK, Quist AP, Lal R.	Related Articles, Links
	Amyloid beta protein-(1-42) forms calcium-permeable channel. J Biol Chem. 1998 May 29;273(22):13379-82. PMID: 9593665 [PubMed - indexed for MEDLINE]	e, Zn2+-sensitive
□ 188:	Nakabayashi J, Yoshimura M, Morishima-Kawashima M, Funato H, Miyakawa T, Yamazaki T, Ihara Y.	Related Articles, Links
	Amyloid beta-protein (A beta) accumulation in the pu mammillary body during aging and in Alzheimer dise J Neuropathol Exp Neurol. 1998 Apr;57(4):343-52. PMID: 9600228 [PubMed - indexed for MEDLINE]	
□ 189:	Honda S, Itoh F, Yoshimoto M, Hinoda Y, Imai K.	Related Articles, Links
	Changes in morphology of neuroblastoma cells treated retinoic acid combined with transfer of the C-terminal amyloid precursor protein. J Clin Lab Anal. 1998;12(3):172-8. PMID: 9591705 [PubMed - indexed for MEDLINE]	

□ 190:	Rossner S.	Related Articles, Links
	Cholinergic immunolesions by 192IgG-saporinuseft pathogenic aspects of Alzheimer's disease. Int J Dev Neurosci. 1997 Nov;15(7):835-50. Review. PMID: 9568532 [PubMed - indexed for MEDLINE]	ul tool to simulate
□ 191:	Yanagisawa K, Ihara Y.	Related Articles, Links
	GM1 ganglioside-bound amyloid beta-protein in Alzhbrain. Neurobiol Aging. 1998 Jan-Feb;19(1 Suppl):S65-7. PMID: 9562471 [PubMed - indexed for MEDLINE]	neimer's disease
□ 192:	Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E.	Related Articles, Links
	Sequential phosphorylation of Tau by glycogen synth and protein kinase A at Thr212 and Ser214 generates specific epitope of antibody AT100 and requires a parfilament-like conformation. Eur J Biochem. 1998 Mar 15;252(3):542-52. PMID: 9546672 [PubMed - indexed for MEDLINE]	the Alzheimer-
□ 193:	Friedman LM, Matsuda Y, Lazarovici P.	Related Articles, Links
	The microbial alkaloid toxin staurosporine blocks the induced increase in beta-amyloid precursor protein in Nat Toxins. 1997;5(5):173-9. PMID: 9496375 [PubMed - indexed for MEDLINE]	*
□ 194:	Nagai A, Kobayashi S, Shimode K, Imaoka K, Umegae N, Fujihara S, Nakamura M.	Related Articles, Links
	No mutations in cystatin C gene in cerebral amyloid a cystatin C deposition. Mol Chem Neuropathol. 1998 Jan;33(1):63-78. PMID: 9493177 [PubMed - indexed for MEDLINE]	ngiopathy with
□ 195:	Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM.	Related Articles, Links
	Age-related congophilic inclusions in the brains of ap deficient mice. Neuroscience. 1998 Jan;82(1):171-80. PMID: 9483513 [PubMed - indexed for MEDLINE]	olipoprotein E-
□ 196:	Morimoto T, Ohsawa I, Takamura C, Ishiguro M, Kohsaka S.	Related Articles, Links
	Involvement of amyloid precursor protein in functions formation in cultured hippocampal neurons. J Neurosci Res. 1998 Jan 15;51(2):185-95. PMID: 9469572 [PubMed - indexed for MEDLINE]	al synapse
□ 197:	Yanagisawa K, McLaurin J, Michikawa M, Chakrabartty A, Ihara Y.	Related Articles, Links
	Amyloid beta-protein (A beta) associated with lipid mimmunoreactivity distinct from that of soluble A beta. FEBS Lett. 1997 Dec 22;420(1):43-6. PMID: 9450547 [PubMed - indexed for MEDLINE]	
□ 198:	Shalit F, Sredni B, Rosenblatt-Bin H, Kazimirsky G, Brodie C,	Related Articles, Links

	Huberman M.	
	Beta-amyloid peptide induces tumor necrosis factor-a oxide production in murine macrophage cultures. Neuroreport. 1997 Nov 10;8(16):3577-80. PMID: 9427329 [PubMed - indexed for MEDLINE]	alpha and nitric
□ 199 :	Rossner S, Ueberham U, Yu J, Kirazov L, Schliebs R, Perez- Polo JR, Bigl V.	Related Articles, Links
	In vivo regulation of amyloid precursor protein secre neocortex by cholinergic activity. Eur J Neurosci. 1997 Oct;9(10):2125-34. PMID: 9421172 [PubMed - indexed for MEDLINE]	tion in rat
□ 200:	Sloane JA, Pietropaolo MF, Rosene DL, Moss MB, Peters A, Kemper T, Abraham CR.	Related Articles, Links
	Lack of correlation between plaque burden and cognimonkey. Acta Neuropathol (Berl). 1997 Nov;94(5):471-8. PMID: 9386780 [PubMed - indexed for MEDLINE]	tion in the aged
□ 201:	Walker LC.	Related Articles, Links
	Animal models of cerebral beta-amyloid angiopathy. Brain Res Brain Res Rev. 1997 Sep 30;25(1):70-84. Review. PMID: 9370051 [PubMed - indexed for MEDLINE]	
□ 202:	Goodwin JL, Kehrli ME Jr, Uemura E.	Related Articles, Links
	Integrin Mac-1 and beta-amyloid in microglial release Brain Res. 1997 Sep 12;768(1-2):279-86. PMID: 9369326 [PubMed - indexed for MEDLINE]	e of nitric oxide.
□ 203:	Aizawa Y, Fukatsu R, Takamaru Y, Tsuzuki K, Chiba H, Kobayashi K, Fujii N, Takahata N.	Related Articles, Links
	Amino-terminus truncated apolipoprotein E is the ma amyloid deposits in Alzheimer's disease-affected brai for apolipoprotein E in Alzheimer's disease. Brain Res. 1997 Sep 12;768(1-2):208-14. PMID: 9369317 [PubMed - indexed for MEDLINE]	· -
□ 204:	Lahiri DK, Farlow MR, Sambamurti K, Nall C.	Related Articles, Links
	The effect of tacrine and leupeptin on the secretion of precursor protein in HeLa cells. Life Sci. 1997;61(20):1985-92. PMID: 9366505 [PubMed - indexed for MEDLINE]	the beta-amyloid
□ 205:	Maury CP, Sletten K, Totty N, Kangas H, Liljestrom M.	Related Articles, Links
	Identification of the circulating amyloid precursor and metabolites in patients with G654A mutation in the g (Finnish familial amyloidosis): pathogenetic and diag implications. Lab Invest. 1997 Oct;77(4):299-304. PMID: 9354764 [PubMed - indexed for MEDLINE]	elsolin gene
□ 206:	Lahiri DK, Farlow MR, Nurnberger JI Jr, Greig NH.	Related Articles, Links
	Effects of cholinesterase inhibitors on the secretion of precursor protein in cell cultures.	f beta-amyloid



	immunoassay of beta-amyloid. FEBS Lett. 1997 Jul 28;412(2):341-5. PMID: 9256248 [PubMed - indexed for MEDLINE]	
□ 215	Schmidt ML, Lee VM, Forman M, Chiu TS, Trojanowski JQ.	Related Articles, Links
	Monoclonal antibodies to a 100-kd protein reveal abunegative plaques throughout gray matter of Alzheime Am J Pathol. 1997 Jul;151(1):69-80. PMID: 9212733 [PubMed - indexed for MEDLINE]	
□ 216:	Yamada T, Wakabayashi K, Kakihara T, Gejyo F, Takahashi H. Itoh Y.	Related Articles, Links
	Further characterization of a monoclonal antibody recapolipoprotein E peptides in amyloid deposits. Ann Clin Lab Sci. 1997 Jul-Aug;27(4):276-81. PMID: 9210972 [PubMed - indexed for MEDLINE]	cognizing
□ 217:	Gomez-Isla T, Wasco W, Pettingell WP, Gurubhagavatula S, Schmidt SD, Jondro PD, McNamara M, Rodes LA, DiBlasi T, Growdon WB, Seubert P, Schenk D, Growdon JH, Hyman BT, Tanzi RE.	Related Articles, Links
	A novel presentiin-1 mutation: increased beta-amyloi neurofibrillary changes. Ann Neurol. 1997 Jun;41(6):809-13. PMID: 9189043 [PubMed - indexed for MEDLINE]	d and
□ 218:	Kim KS, Wegiel J, Sapienza V, Chen J, Hong H, Wisniewski HM.	Related Articles, Links
	Immunoreactivity of presenilin-1 in human, rat and m Brain Res. 1997 May 16;757(1):159-63. PMID: 9200512 [PubMed - indexed for MEDLINE]	nouse brain.
□ 219:	Ghiso J, Calero M, Matsubara E, Governale S, Chuba J, Beavis R, Wisniewski T, Frangione B.	Related Articles, Links
	Alzheimer's soluble amyloid beta is a normal comporurine. FEBS Lett. 1997 May 12;408(1):105-8. PMID: 9180278 [PubMed - indexed for MEDLINE]	nent of human
□ 220:	Sasaki A, Iijima M, Yokoo H, Shoji M, Nakazato Y.	Related Articles, Links
	Human choroid plexus is an uniquely involved area of amyloidosis: a histochemical, immunohistochemical study. Brain Res. 1997 May 2;755(2):193-201. PMID: 9175887 [PubMed - indexed for MEDLINE]	
□ 221:	Takamatsu J, Kimura T, Kondo A, Iwatsubo T.	Related Articles, Links
	Subpial amyloid plaques in the cerebellum in a case of	of Alzheimer's
	disease. Dement Geriatr Cogn Disord. 1997 May-Jun;8(3):157-62. PMID: 9137893 [PubMed - indexed for MEDLINE]	
□ 222:	Solomon B, Koppel R, Frankel D, Hanan-Aharon E.	Related Articles, Links
	Disaggregation of Alzheimer beta-amyloid by site-dir Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4109-12. PMID: 9108113 [PubMed - indexed for MEDLINE]	rected mAb.



□ 231:	Wang R, Sweeney D, Gandy SE, Sisodia SS.	Related Articles, Links
	The profile of soluble amyloid beta protein in cultured Detection and quantification of amyloid beta protein a immunoprecipitation-mass spectrometry. J Biol Chem. 1996 Dec 13;271(50):31894-902. PMID: 8943233 [PubMed - indexed for MEDLINE]	
□ 232:	Nielson KA, Cummings BJ, Cotman CW.	Related Articles, Links
	Constructional apraxia in Alzheimer's disease correlat neuropathology in occipital cortex. Brain Res. 1996 Nov 25;741(1-2):284-93. PMID: 9001734 [PubMed - indexed for MEDLINE]	tes with neuritic
□ 233:	Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ.	Related Articles, Links
	Evidence that the 42- and 40-amino acid forms of amy are generated from the beta-amyloid precursor protein protease activities. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5. PMID: 8917563 [PubMed - indexed for MEDLINE]	
□ 234:	Jung SS, Nalbantoglu J, Cashman NR.	Related Articles, Links
	Alzheimer's beta-amyloid precursor protein is express of immediately ex vivo brain cells: a flow cytometric J Neurosci Res. 1996 Nov 1;46(3):336-48. PMID: 8933373 [PubMed - indexed for MEDLINE]	
□ 235:	Stephens DJ, Austen BM.	Related Articles, Links
□ 235: <u>□</u>	Stephens DJ, Austen BM. Metabolites of the beta-amyloid precursor protein gensecretase localise to the trans-Golgi network and late cells. J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE]	nerated by beta-
	Metabolites of the beta-amyloid precursor protein gensecretase localise to the trans-Golgi network and late cells. J Neurosci Res. 1996 Oct 15;46(2):211-25.	nerated by beta- endosome in 293
	Metabolites of the beta-amyloid precursor protein ger secretase localise to the trans-Golgi network and late cells. J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE] Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi	nerated by beta- endosome in 293 Related Articles, Links
☐ 236: ☐	Metabolites of the beta-amyloid precursor protein gensecretase localise to the trans-Golgi network and late cells. J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE] Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T. Amyloid beta 2-microglobulin is modified with N eps (carboxymethyl)lysine in dialysis-related amyloidosis Kidney Int. 1996 Oct;50(4):1303-9.	nerated by beta- endosome in 293 Related Articles, Links
☐ 236: ☐	Metabolites of the beta-amyloid precursor protein gensecretase localise to the trans-Golgi network and late cells. J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE] Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T. Amyloid beta 2-microglobulin is modified with N eps (carboxymethyl)lysine in dialysis-related amyloidosis Kidney Int. 1996 Oct;50(4):1303-9. PMID: 8887292 [PubMed - indexed for MEDLINE]	Related Articles, Links Related Articles, Links
☐ 236: ☐ 237: ☐ ☐	Metabolites of the beta-amyloid precursor protein gensecretase localise to the trans-Golgi network and late cells. J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE] Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T. Amyloid beta 2-microglobulin is modified with N eps (carboxymethyl)lysine in dialysis-related amyloidosis Kidney Int. 1996 Oct;50(4):1303-9. PMID: 8887292 [PubMed - indexed for MEDLINE] De La Monte SM, Carlson RI, Brown NV, Wands JR. Profiles of neuronal thread protein expression in Alzh J Neuropathol Exp Neurol. 1996 Oct;55(10):1038-50.	Related Articles, Links Related Articles, Links
☐ 236: ☐ 237: ☐ 238: ☐ □	Metabolites of the beta-amyloid precursor protein gensecretase localise to the trans-Golgi network and late cells. J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE] Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T. Amyloid beta 2-microglobulin is modified with N eps (carboxymethyl)lysine in dialysis-related amyloidosis Kidney Int. 1996 Oct;50(4):1303-9. PMID: 8887292 [PubMed - indexed for MEDLINE] De La Monte SM, Carlson RI, Brown NV, Wands JR. Profiles of neuronal thread protein expression in Alzh J Neuropathol Exp Neurol. 1996 Oct;55(10):1038-50. PMID: 8858001 [PubMed - indexed for MEDLINE] Storey E, Spurck T, Pickett-Heaps J, Beyreuther K, Masters	Related Articles, Links eimer's disease. Related Articles, Links eimer's disease.



Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay.

J Biol Chem. 1996 Sep 13;271(37):22908-14.

PMID: 8798471 [PubMed - indexed for MEDLINE]

☐ 240: Kanemaru K, Iwatsubo T, Ihara Y.

Related Articles, Links

Comparable amyloid beta-protein (A beta) 42(43) and A beta 40 deposition in the aged monkey brain.

Neurosci Lett. 1996 Aug 23;214(2-3):196-8.

PMID: 8878117 [PubMed - indexed for MEDLINE]

241: Bullido MJ, Munoz-Fernandez MA, Recuero M, Fresno M, Valdivieso F.

Related Articles, Links

Alzheimer's amyloid precursor protein is expressed on the surface of hematopoietic cells upon activation.

Biochim Biophys Acta. 1996 Aug 21;1313(1):54-62. PMID: 8781550 [PubMed - indexed for MEDLINE]

242: Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi Related Articles, Links SM, Bird TD, Poorkaj P, Hardy J, Hutton M, Prihar G, Crook R, Rossor MN, Haltia M.

Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43).

Ann Neurol. 1996 Aug; 40(2):149-56.

PMID: 8773595 [PubMed - indexed for MEDLINE]

243: Wegiel J, Wisniewski HM, Dziewiatkowski J, Tarnawski M, Dziewiatkowska A, Morys J, Soltysiak Z, Kim KS.

Related Articles, Links

Subpopulation of dogs with severe brain parenchymal beta amyloidosis distinguished with cluster analysis.

Brain Res. 1996 Jul 22;728(1):20-6.

PMID: 8864293 [PubMed - indexed for MEDLINE]

☐ 244: Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J. Related Articles, Links

Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins.

Biochem Biophys Res Commun. 1996 Jun 25;223(3):592-7. PMID: 8687441 [PubMed - indexed for MEDLINE]

245: Yanagisawa K, Asami-Odaka A, Suzuki N, Ihara Y.

Related Articles, Links

Fractionation of amyloid beta-protein (A beta) in Alzheimer's disease and Down's syndrome brains. Presence of membrane-bound A beta. Ann N Y Acad Sci. 1996 Jun 15;786:184-94.

PMID: 8687018 [PubMed - indexed for MEDLINE]

☐ 246: Mann DM, Iwatsubo T.

Related Articles, Links

Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43).

Neurodegeneration. 1996 Jun;5(2):115-20.

PMID: 8819131 [PubMed - indexed for MEDLINE]

☐ 247: Fraser SP, Suh YH, Chong YH, Djamgoz MB.

Related Articles, Links


Membrane currents induced in Xenopus oocytes by the C-terminal

	fragment of the beta-amyloid precursor protein. J Neurochem. 1996 May;66(5):2034-40. PMID: 8780033 [PubMed - indexed for MEDLINE]	
□ 248:	Conn KJ, Pietropaolo M, Ju ST, Abraham CR.	Related Articles, Links
	Monoclonal antibodies against the human metallopro label neurofibrillary tangles in Alzheimer's disease br J Neurochem. 1996 May;66(5):2011-8. PMID: 8780030 [PubMed - indexed for MEDLINE]	
□ 249:	Yamazaki T, Koo EH, Selkoe DJ.	Related Articles, Links
	Trafficking of cell-surface amyloid beta-protein precu Endocytosis, recycling and lysosomal targeting detect immunolocalization. J Cell Sci. 1996 May;109 (Pt 5):999-1008. PMID: 8743947 [PubMed - indexed for MEDLINE]	
□ 250:	Koo EH, Squazzo SL, Selkoe DJ, Koo CH.	Related Articles, Links
	Trafficking of cell-surface amyloid beta-protein precuendocytosis and recycling as detected by labeled mon J Cell Sci. 1996 May;109 (Pt 5):991-8. PMID: 8743946 [PubMed - indexed for MEDLINE]	
□ 251:	Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, Teplow DB, Selkoe DJ, Mori H.	Related Articles, Links
	Antibodies to amyloid beta protein (A beta) crossread glyceraldehyde-3-phosphate dehydrogenase (GAPDH Neurobiol Aging. 1996 May-Jun;17(3):405-14. PMID: 8725902 [PubMed - indexed for MEDLINE]	
□ 252:	Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J.	Related Articles, Links
	Glycoprotein 330/megalin: probable role in receptor- of apolipoprotein J alone and in a complex with Alzha amyloid beta at the blood-brain and blood-cerebrospin Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4229-34. PMID: 8633046 [PubMed - indexed for MEDLINE]	eimer disease
□ 253:	Nelson PT, Saper CB.	Related Articles, Links
	Injections of okadaic acid, but not beta-amyloid pepti immunoreactive dystrophic neurites in the cerebral con Neurosci Lett. 1996 Apr 19;208(2):77-80. PMID: 8859894 [PubMed - indexed for MEDLINE]	
□ 254:	Nagy JI, Hossain MZ, Hertzberg EL, Marotta CA.	Related Articles, Links
	Induction of connexin43 and gap junctional communicells overexpressing the carboxy terminal region of arprotein. J Neurosci Res. 1996 Apr 15;44(2):124-32. PMID: 8723220 [PubMed - indexed for MEDLINE]	
□ 255:	Turner RS, Suzuki N, Chyung AS, Younkin SG, Lee VM.	Related Articles, Links
	Amyloids beta40 and beta42 are generated intracellul human neurons and their secretion increases with mat	

	J Biol Chem. 1996 Apr 12;271(15):8966-70. PMID: 8621541 [PubMed - indexed for MEDLINE]	
□ 256	Schoonover S, Davies P, Bowser R.	Related Articles, Links
	Immunolocalization and redistribution of the FAC1 p Alzheimer's disease. J Neuropathol Exp Neurol. 1996 Apr;55(4):444-55. PMID: 8786404 [PubMed - indexed for MEDLINE]	rotein in
□ 257	Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N, Lannfelt L, Winblad B, Maat-Schieman ML, Rossor MN.	Related Articles, Links
	Predominant deposition of amyloid-beta 42(43) in pla Alzheimer's disease and hereditary cerebral hemorrha mutations in the amyloid precursor protein gene. Am J Pathol. 1996 Apr;148(4):1257-66. PMID: 8644866 [PubMed - indexed for MEDLINE]	
□ 258	Zhang M, Olsson Y.	Related Articles, Links
	Beta-amyloid precursor protein accumulates in axons hematogenous metastases of the human brain: immun observations. Clin Neuropathol. 1996 Mar-Apr;15(2):74-8. PMID: 8925600 [PubMed - indexed for MEDLINE]	
□ 259	Liberski PP, Yanagihara R, Brown P, Kordek R, Kloszewska I, Bratosiewicz J, Gajdusek DC.	Related Articles, Links
	Microwave treatment enhances the immunostaining of in both the transmissible and non-transmissible brain Neurodegeneration. 1996 Mar;5(1):95-9. PMID: 8731388 [PubMed - indexed for MEDLINE]	
□ 260 :	Konig G, Graham P, Bushnell A, Webster S, Wunderlich D, Perlmutter LS.	Related Articles, Links
	Development and characterization of a monoclonal are specific for the carboxyl-terminus of the beta A4 pept Ann N Y Acad Sci. 1996 Jan 17;777:344-55. PMID: 8624111 [PubMed - indexed for MEDLINE]	•
□ 261:	Solomon B, Koppel R, Hanan E, Katzav T.	Related Articles, Links
	Monoclonal antibodies inhibit in vitro fibrillar aggreg Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5. PMID: 8552659 [PubMed - indexed for MEDLINE]	ration of the
□ 262:	Nakano N, Fukatsu R, Fujii M, Miyazawa J, Utsumi K, Hayashi S, Midorikawa Y, Tsuzuki K, Takahata N.	Related Articles, Links
	[Relationship between SPECT and pathological alteral Alzheimer's diseasea study of a case with left-hemis lesions] Seishin Shinkeigaku Zasshi. 1996;98(7):441-59. Japanese. PMID: 8911088 [PubMed - indexed for MEDLINE]	
□ 263:	Lahiri DK, Farlow MR.	Related Articles, Links
	Differential effect of tacrine and physostigmine on the	

beta-amyloid precursor protein in cell lines. J Mol Neurosci. 1996 Spring;7(1):41-9. PMID: 8835781 [PubMed - indexed for MEDLINE] ☐ 264: Mann DM, Iwatsubo T, Snowden JS. Related Articles, Links Atypical amyloid (A beta) deposition in the cerebellum in Alzheimer's disease: an immunohistochemical study using end-specific A beta monoclonal antibodies. Acta Neuropathol (Berl). 1996;91(6):647-53. PMID: 8781665 [PubMed - indexed for MEDLINE] 265: Southwick PC, Yamagata SK, Echols CL Jr, Higson GJ, Related Articles, Links Neynaber SA, Parson RE, Munroe WA. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem. 1996 Jan;66(1):259-65. PMID: 8522962 [PubMed - indexed for MEDLINE] 266: Tsuzuki K, Fukatsu R, Takamaru Y, Yoshida T, Hayashi Y, Related Articles, Links Yamaguchi H, Fujii N, Takahata N. Amyloid beta protein in rat soleus muscle in chloroquine-induced myopathy using end-specific antibodies for A beta 40 and A beta 42: immunohistochemical evidence for amyloid beta protein. Neurosci Lett. 1995 Dec 29;202(1-2):77-80. PMID: 8787835 [PubMed - indexed for MEDLINE] 1267: Nakamura S, Tamaoka A, Sawamura N, Shoji S, Nakayama H, Related Articles, Links Ono F, Sakakibara I, Yoshikawa Y, Mori H, Goto N, et al. Carboxyl end-specific monoclonal antibodies to amyloid beta protein (A beta) subtypes (A beta 40 and A beta 42(43)) differentiate A beta in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys. Neurosci Lett. 1995 Dec 8;201(2):151-4. PMID: 8848240 [PubMed - indexed for MEDLINE] ☐ 268: Sunaga K, Takahashi H, Chuang DM, Ishitani R. Related Articles, Links Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Neurosci Lett. 1995 Nov 17;200(2):133-6. PMID: 8614562 [PubMed - indexed for MEDLINE] 269: Saito Y, Buciak J, Yang J, Pardridge WM. Related Articles, Links Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10227-31. PMID: 7479757 [PubMed - indexed for MEDLINE] 270: Gehrmann J, Banati RB, Cuzner ML, Kreutzberg GW, Related Articles, Links Newcombe J. Amyloid precursor protein (APP) expression in multiple sclerosis lesions. Glia. 1995 Oct;15(2):141-51. PMID: 8567065 [PubMed - indexed for MEDLINE]

□ 271:	Link CD.	Related Articles, Links
	Expression of human beta-amyloid peptide in transge elegans. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9368-72. PMID: 7568134 [PubMed - indexed for MEDLINE]	nic Caenorhabditis
□ 272:	Carretero MT, Harrington CR, Wischik CM.	Related Articles, Links
	Changes in a CSF antigen associated with dementia. Dementia. 1995 Sep-Oct;6(5):281-5. PMID: 8528375 [PubMed - indexed for MEDLINE]	
□ 273:	Clarris HJ, Key B, Beyreuther K, Masters CL, Small DH.	Related Articles, Links
	Expression of the amyloid protein precursor of Alzhe the developing rat olfactory system. Brain Res Dev Brain Res. 1995 Aug 28;88(1):87-95. PMID: 7493410 [PubMed - indexed for MEDLINE]	imer's disease in
□ 274:	Mann DM, Pickering-Brown SM, Siddons MA, Iwatsubo T, Ihara Y, Asami-Odaka A, Suzuki N.	Related Articles, Links
	The extent of amyloid deposition in brain in patients syndrome does not depend upon the apolipoprotein E Neurosci Lett. 1995 Aug 18;196(1-2):105-8. PMID: 7501233 [PubMed - indexed for MEDLINE]	with Down's genotype.
□ 275:	Webster MT, Groome N, Francis PT, Pearce BR, Sherriff FE, Thinakaran G, Felsenstein KM, Wasco W, Tanzi RE, Bowen DM.	Related Articles, Links
	A novel protein, amyloid precursor-like protein 2, is pbrain, cerebrospinal fluid and conditioned media. Biochem J. 1995 Aug 15;310 (Pt 1):95-9. PMID: 7646477 [PubMed - indexed for MEDLINE]	present in human
□ 276:	Davis DR, Brion JP, Couck AM, Gallo JM, Hanger DP, Ladhani K, Lewis C, Miller CC, Rupniak T, Smith C, et al.	Related Articles, Links
	The phosphorylation state of the microtubule-associate affected by glutamate, colchicine and beta-amyloid in cortical neuronal cultures. Biochem J. 1995 Aug 1;309 (Pt 3):941-9. PMID: 7639714 [PubMed - indexed for MEDLINE]	
□ 277:	Crino PB, Martin JA, Hill WD, Greenberg B, Lee VM, Trojanowski JQ.	Related Articles, Links
	Beta-Amyloid peptide and amyloid precursor proteins mucosa of patients with Alzheimer's disease, Parkinso Down syndrome. Ann Otol Rhinol Laryngol. 1995 Aug;104(8):655-61. PMID: 7639477 [PubMed - indexed for MEDLINE]	•
□ 278:	Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK.	Related Articles, Links
	LDL receptor-related protein, a multifunctional ApoE secreted beta-amyloid precursor protein and mediates Cell. 1995 Jul 28;82(2):331-40. PMID: 7543026 [PubMed - indexed for MEDLINE]	
□ 279:	Zaidi SH, Malter JS.	Related Articles, Links



•	Hanger DP, Ladhani K, Latimer DA, Lewis C, Lovestone S, et al.	
	Modulation of PHF-like tau phosphorylation in cultu transfected cells.	
	Neurobiol Aging. 1995 May-Jun;16(3):389-97; discussion 398-PMID: 7566348 [PubMed - indexed for MEDLINE]	402.
□ 288:	Cazorla P, Aldudo J, Haas C, Vazquez J, Valdivieso F, Bullido MJ.	Related Articles, Links
	Location of an epitope shared by Alzheimer's amyloi creatine kinase using a newly developed monoclonal Biochim Biophys Acta. 1995 Apr 24;1270(2-3):149-56. PMID: 7537106 [PubMed - indexed for MEDLINE]	d peptide and brain antibody.
□ 289:	Oohira A, Kushima Y, Matsui F, Watanabe E.	Related Articles, Links
	Detection of Alzheimer's beta-amyloid precursor relabearing chondroitin sulfate both in the juvenile rat broconditioned medium of primary cultured astrocytes. Neurosci Lett. 1995 Apr 7;189(1):25-8. PMID: 7603617 [PubMed - indexed for MEDLINE]	ted proteins ain and in the
□ 290:	Yamazaki T, Selkoe DJ, Koo EH.	Related Articles, Links
	Trafficking of cell surface beta-amyloid precursor pro and transcytotic transport in cultured neurons. J Cell Biol. 1995 Apr;129(2):431-42. PMID: 7721945 [PubMed - indexed for MEDLINE]	otein: retrograde
□ 291:	Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, Suzuki N, Younkin SG.	Related Articles, Links
	Amyloid beta protein (A beta) in Alzheimer's disease and immunocytochemical analysis with antibodies spending at A beta 40 or A beta 42(43). J Biol Chem. 1995 Mar 31;270(13):7013-6. PMID: 7706234 [PubMed - indexed for MEDLINE]	
□ 292:	Kim CS, Han YF, Etcheberrigaray R, Nelson TJ, Olds JL, Yoshioka T, Alkon DL.	Related Articles, Links
	Alzheimer and beta-amyloid-treated fibroblasts demoin a memory-associated GTP-binding protein, Cp20. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3060-4. PMID: 7708775 [PubMed - indexed for MEDLINE]	nstrate a decrease
□ 293:	Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I.	Related Articles, Links
	Ligand-dependent G protein coupling function of amy transmembrane precursor. J Biol Chem. 1995 Mar 3;270(9):4205-8. PMID: 7876177 [PubMed - indexed for MEDLINE]	yloid
□ 294:	Golden JA, Nielsen GP, Pober BR, Hyman BT.	Related Articles, Links
	The neuropathology of Williams syndrome. Report of with presentle beta/A4 amyloid plaques and neurofibit Arch Neurol. 1995 Feb;52(2):209-12. PMID: 7848137 [PubMed - indexed for MEDLINE]	f a 35-year-old man fillary tangles.
□ 295:	Kataoka H, Seguchi K, Iwamura T, Moriyama T, Nabeshima K,	Related Articles, Links

	Koono M. Reverse-zymographic analysis of protease nexin-II/ar precursor of human carcinoma cell lines, with special grade of differentiation and metastatic phenotype. Int J Cancer. 1995 Jan 3;60(1):123-8. PMID: 7814144 [PubMed - indexed for MEDLINE]	myloid beta protein reference to the
□ 296:	Maslinska D, Kaluza J.	Related Articles, Links
	Overexpression of amyloid precursor protein of Alzhbrains of intoxicated children. Folia Neuropathol. 1995;33(3):129-33. PMID: 8705279 [PubMed - indexed for MEDLINE]	eimer's type in
□ 297:	<u>Cabal A, Alonso-Cortina V, Gonzalez-Vazquez LO, Naves FJ, Del Valle ME, Vega JA.</u>	Related Articles, Links
	beta-Amyloid precursor protein (beta APP) in human reference to the enteric nervous system. Brain Res Bull. 1995;38(5):417-23. PMID: 8665264 [PubMed - indexed for MEDLINE]	gut with special
□ 298:	Mann DM, Iwatsubo T, Fukumoto H, Ihara Y, Odaka A, Suzuki N.	Related Articles, Links
	Microglial cells and amyloid beta protein (A beta) depassociation with A beta 40-containing plaques. Acta Neuropathol (Berl). 1995;90(5):472-7. PMID: 8560980 [PubMed - indexed for MEDLINE]	position;
□ 299:	Reig S, Buee-Scherrer V, Mourton-Gilles C, Defossez A, Delacourte A, Beauvillain JC, Mazzuca M.	Related Articles, Links
	Immunogold labelling of paired helical filaments and specific monoclonal and polyclonal antibodies. Acta Neuropathol (Berl). 1995;90(5):441-7. PMID: 8560975 [PubMed - indexed for MEDLINE]	amyloid fibrils by
□300:	Liberski PP, Kloszewska I, Kordek R, Bratosiewicz J, Omulecka A, Papierz W, Alwasiak J.	Related Articles, Links
	Diagnosis of Alzheimer's disease with commercially a peptide (beta A4) antibodies following microwave ov Pol J Pathol. 1995;46(1):43-6. PMID: 7780697 [PubMed - indexed for MEDLINE]	available anti-beta en pretreatment.
□ 301:	Mangone CA, Castano EM, Levy E, Abiusi G, Wisniewski T, Marques MR, Faccio E, Gorelick PB, Frangione B, Sica RE.	Related Articles, Links
	Early onset Alzheimer's disease in a South American Argentina. Acta Neurol Scand. 1995 Jan;91(1):6-13. PMID: 7732777 [PubMed - indexed for MEDLINE]	pedigree from
□ 302:	Mena R, Edwards P, Perez-Olvera O, Wischik CM.	Related Articles, Links
	Monitoring pathological assembly of tau and beta-amy Alzheimer's disease. Acta Neuropathol (Berl). 1995;89(1):50-6. PMID: 7709731 [PubMed - indexed for MEDLINE]	yloid proteins in
□ 303:	Yasuhara O, Matsuo A, Tooyama I, Kimura H, McGeer EG, McGeer PL.	Related Articles, Links

	Pick's disease immunohistochemistry: new alterations disease comparisons. Acta Neuropathol (Berl). 1995;89(4):322-30. PMID: 7610763 [PubMed - indexed for MEDLINE]	s and Alzheimer's
□ 304:	Pirttila T, Kim KS, Mehta PD, Frey H, Wisniewski HM.	Related Articles, Links
	Soluble amyloid beta-protein in the cerebrospinal flui with Alzheimer's disease, vascular dementia and cont J Neurol Sci. 1994 Dec 1;127(1):90-5. PMID: 7699397 [PubMed - indexed for MEDLINE]	d from patients rols.
□ 305:	Neill D, Hughes D, Edwardson JA, Rima BK, Allsop D.	Related Articles, Links
	Human IMR-32 neuroblastoma cells as a model cell l disease research. J Neurosci Res. 1994 Nov 1;39(4):482-93. PMID: 7884825 [PubMed - indexed for MEDLINE]	ine in Alzheimer's
□ 306:	Katsetos CD, Krishna L, Friedberg E, Reidy J, Karkavelas G, Savory J.	Related Articles, Links
	Lobar pilocytic astrocytomas of the cerebral hemisphe Pathobiologymorphogenesis of the eosinophilic gran Clin Neuropathol. 1994 Nov-Dec;13(6):306-14. PMID: 7851045 [PubMed - indexed for MEDLINE]	
□ 307:	McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG.	Related Articles, Links
	Pathological proteins in senile plaques. Tohoku J Exp Med. 1994 Nov;174(3):269-77. PMID: 7761992 [PubMed - indexed for MEDLINE]	
□308:	Yang F, Mak K, Vinters HV, Frautschy SA, Cole GM.	Related Articles, Links
	Monoclonal antibody to the C-terminus of beta-amylo Neuroreport. 1994 Oct 27;5(16):2117-20. PMID: 7865758 [PubMed - indexed for MEDLINE]	oid.
□ 309:	Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Cataldo AM, Nixon RA.	Related Articles, Links
	Degenerative changes in epinephrine tonic vasomotor Alzheimer's disease. Brain Res. 1994 Oct 24;661(1-2):35-42. PMID: 7834382 [PubMed - indexed for MEDLINE]	neurons in
□ 310:	Kimura T, Hisano T, Yoshida H, Ueda K, Miyakawa T.	Related Articles, Links
	Re-evaluation of classic senile plaques by three-dimer J Neurol. 1994 Oct;241(10):624-7. PMID: 7836967 [PubMed - indexed for MEDLINE]	nsional analysis.
□311:	<u>Dreyer RN, Bausch KM, Fracasso P, Hammond LJ, Wunderlich D, Wirak DO, Davis G, Brini CM, Buckholz TM, Konig G, et al.</u>	Related Articles, Links
	Processing of the pre-beta-amyloid protein by catheps by a familial Alzheimer's disease mutation. Eur J Biochem. 1994 Sep 1;224(2):265-71. PMID: 7523115 [PubMed - indexed for MEDLINE]	in D is enhanced
□312:	Durham HD, Minotti S, Dooley NP, Nalbantoglu J.	Related Articles, Links

	Expression of the intermediate filament-associated probeta-amyloid precursor protein is developmentally recells. J Neurosci Res. 1994 Aug 15;38(6):629-39. PMID: 7807580 [PubMed - indexed for MEDLINE]	
□313:	<u>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y.</u>	Related Articles, Links
	Visualization of A beta 42(43) and A beta 40 in senil-specific A beta monoclonals: evidence that an initiall is A beta 42(43). Neuron. 1994 Jul;13(1):45-53. PMID: 8043280 [PubMed - indexed for MEDLINE]	
□ 314:	Walker LC, Price DL, Voytko ML, Schenk DB.	Related Articles, Links
	Labeling of cerebral amyloid in vivo with a monoclos J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83. PMID: 8021711 [PubMed - indexed for MEDLINE]	nal antibody.
□315:	Koo EH, Squazzo SL.	Related Articles, Links
	Evidence that production and release of amyloid beta the endocytic pathway. J Biol Chem. 1994 Jul 1;269(26):17386-9. PMID: 8021238 [PubMed - indexed for MEDLINE]	-protein involves
□316:	Perlmutter LS, Myers MA, Barron E.	Related Articles, Links
	Vascular basement membrane components and the le Alzheimer's disease: light and electron microscopic a Microsc Res Tech. 1994 Jun 15;28(3):204-15. PMID: 8068983 [PubMed - indexed for MEDLINE]	sions of nalyses.
□317:	Clarris HJ, Nurcombe V, Small DH, Beyreuther K, Masters CL.	Related Articles, Links
	Secretion of nerve growth factor from septum stimular outgrowth and release of the amyloid protein precurse disease from hippocampal explants. J Neurosci Res. 1994 Jun 15;38(3):248-58. PMID: 7932862 [PubMed - indexed for MEDLINE]	
□318:	Kurochkin IV, Goto S.	Related Articles, Links
	Alzheimer's beta-amyloid peptide specifically interac degraded by insulin degrading enzyme. FEBS Lett. 1994 May 23;345(1):33-7. PMID: 8194595 [PubMed - indexed for MEDLINE]	ts with and is
□319:	Jakes R, Spillantini MG, Goedert M.	Related Articles, Links
	Identification of two distinct synucleins from human FEBS Lett. 1994 May 23;345(1):27-32. PMID: 8194594 [PubMed - indexed for MEDLINE]	brain.
□ 320:	Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P.	Related Articles, Links
	Soluble amyloid beta-protein is a marker of Alzheime but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994 May 16;200(3):1598-603 PMID: 8185615 [PubMed - indexed for MEDLINE]	•

□ 321:	Murphy GM Jr, Forno LS, Higgins L, Scardina JM, Eng LF, Cordell B.	Related Articles, Links
	Development of a monoclonal antibody specific for the of beta-amyloid 1-42 and its immunohistochemical realization Alzheimer's disease and related disorders. Am J Pathol. 1994 May;144(5):1082-8. PMID: 8178931 [PubMed - indexed for MEDLINE]	
□ 322:	Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS.	Related Articles, Links
	Glial cytokines as neuropathogenic factors in HIV infi similarities to Alzheimer's disease. J Neuropathol Exp Neurol. 1994 May;53(3):231-8. PMID: 8176406 [PubMed - indexed for MEDLINE]	fection: pathogenic
□ 323:	Akaaboune M, Ma J, Festoff BW, Greenberg BD, Hantai D.	Related Articles, Links
	Neurotrophic regulation of mouse muscle beta-amylo precursor and alpha 1-antichymotrypsin as revealed b J Neurobiol. 1994 May;25(5):503-14. PMID: 8071658 [PubMed - indexed for MEDLINE]	id protein y axotomy.
□ 324:	Higgins LS, Holtzman DM, Rabin J, Mobley WC, Cordell B.	Related Articles, Links
	Transgenic mouse brain histopathology resembles ear disease. Ann Neurol. 1994 May;35(5):598-607. PMID: 7513982 [PubMed - indexed for MEDLINE]	'ly Alzheimer's
□ 325:	Hajimohammadreza I, Anderson VE, Cavanagh JB, Seville MP, Nolan CC, Anderton BH, Leigh PN.	Related Articles, Links
	beta-Amyloid precursor protein fragments and lysoso are found in rat brain neurons after ventricular infusio Brain Res. 1994 Mar 21;640(1-2):25-32. PMID: 8004453 [PubMed - indexed for MEDLINE]	mal dense bodies on of leupeptin.
□ 326:	Takamaru Y.	Related Articles, Links
	[Analysis of the 80 kDa antigen in senile plaque amyl Hokkaido Igaku Zasshi. 1994 Mar;69(2):191-201. Japanese. PMID: 8157246 [PubMed - indexed for MEDLINE]	oid]
□ 327:	Bickel U, Lee VM, Trojanowski JQ, Pardridge WM.	Related Articles, Links
	Development and in vitro characterization of a cationiantibody against beta A4 protein: a potential probe for disease. Bioconjug Chem. 1994 Mar-Apr;5(2):119-25. PMID: 8031874 [PubMed - indexed for MEDLINE]	
□ 328:	Loffler J, Langui D, Probst A, Huber G.	Related Articles, Links
	Accumulation of a 50 kDa N-terminal fragment of bet Alzheimer's disease hippocampus and neocortex. Neurochem Int. 1994 Mar;24(3):281-8. PMID: 8025536 [PubMed - indexed for MEDLINE]	ta-APP695 in
□ 329:	<u>Takeda M, Tanaka S, Kido H, Daikoku S, Oka M, Sakai K, Katunuma N.</u>	Related Articles, Links
	Chromaffin cells express Alzheimer amyloid precurso	r protein in the

	same manner as brain cells. Neurosci Lett. 1994 Feb 28;168(1-2):57-60. PMID: 8028794 [PubMed - indexed for MEDLINE]	
□ 330:	Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K.	Related Articles, Links
	Heparan sulfate proteoglycan in diffuse plaques of his of cerebellum in Alzheimer's disease brain. Am J Pathol. 1994 Feb;144(2):337-47. PMID: 8311117 [PubMed - indexed for MEDLINE]	ppocampus but not
□ 331:	Hartig W, Hausen D, Brauer K, Arendt T, Bigl V, Bruckner G.	Related Articles, Links
	Digoxigenin-tagged anti-GFAP and multiple labelling vessels and beta-amyloid. Neuroreport. 1994 Jan 31;5(5):573-6. Erratum in: Neuroreport 1 (8):following 1014. PMID: 8025246 [PubMed - indexed for MEDLINE]	
□ 332:	Okuda R, Uchida K, Tateyama S, Yamaguchi R, Nakayama H, Goto N.	Related Articles, Links
	The distribution of amyloid beta precursor protein in Acta Neuropathol (Berl). 1994;87(2):161-7. PMID: 8171967 [PubMed - indexed for MEDLINE]	canine brain.
□333:	Masliah E, Honer WG, Mallory M, Voigt M, Kushner P, Hansen L, Terry R.	Related Articles, Links
	Topographical distribution of synaptic-associated proplaques of Alzheimer's disease hippocampus. Acta Neuropathol (Berl). 1994;87(2):135-42. PMID: 8171963 [PubMed - indexed for MEDLINE]	teins in the neuritic
□ 334:	Bignami A, LeBlanc A, Perides G.	Related Articles, Links
	A role for extracellular matrix degradation and matrix metalloproteinases in senile dementia? Acta Neuropathol (Berl). 1994;87(3):308-12. PMID: 8009963 [PubMed - indexed for MEDLINE]	
□ 335:	Wen GY, Wisniewski HM, Blondal H, Benedikz E, Frey H, Pirttila T, Rudelli R, Kim KS.	Related Articles, Links
	Presence of non-fibrillar amyloid beta protein in skin Alzheimer's disease (AD), Down's syndrome and non persons. Acta Neuropathol (Berl). 1994;88(3):201-6. PMID: 7810290 [PubMed - indexed for MEDLINE]	
□ 336:	Zemlan FP, Vogelsang GD, McLaughlin L, Dean GE.	Related Articles, Links
	Alzheimer's paired helical filaments: amyloid precurs mapping. Brain Res Bull. 1994;33(4):387-92. PMID: 7510209 [PubMed - indexed for MEDLINE]	or protein epitope
□ 337:	Hilbich C, Monning U, Grund C, Masters CL, Beyreuther K.	Related Articles, Links
	Amyloid-like properties of peptides flanking the epito precursor protein-specific monoclonal antibody 22C1 J Biol Chem. 1993 Dec 15;268(35):26571-7. PMID: 7504673 [PubMed - indexed for MEDLINE]	

□ 338:	Philippe B, Brion JP, Macq AF, Octave JN.	Related Articles, Links
	A new monoclonal antibody against the anionic doma precursor protein of Alzheimer's disease. Neuroreport. 1993 Dec 13;5(3):289-92. PMID: 7507727 [PubMed - indexed for MEDLINE]	in of the amyloid
□ 339:	Cummings BJ, Su JH, Cotman CW.	Related Articles, Links
	Neuritic involvement within bFGF immunopositive p. Alzheimer's disease. Exp Neurol. 1993 Dec;124(2):315-25. PMID: 8287930 [PubMed - indexed for MEDLINE]	laques of
□ 340:	Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS.	Related Articles, Links
	Pathological changes in frontal cortex from biopsy to Alzheimer's disease. Neurobiol Aging. 1993 Nov-Dec;14(6):589-96. PMID: 8295661 [PubMed - indexed for MEDLINE]	autopsy in
□341:	Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB.	Related Articles, Links
	Characterization of beta-amyloid peptide from human fluid. J Neurochem. 1993 Nov;61(5):1965-8. PMID: 8229004 [PubMed - indexed for MEDLINE]	cerebrospinal
□ 342:	Edwards RJ, McKenzie JE, Roberts GW, Royston MC.	Related Articles, Links
	Alzheimer's disease and Lewy body dementia. Br J Psychiatry. 1993 Nov;163:692; author reply 694-5. No abstr PMID: 8155132 [PubMed - indexed for MEDLINE]	ract available.
□ 343:	Wagner SL, Van Nostrand WE, Lau AL, Farrow JS, Suzuki M, Bartus RT, Schuppek R, Nguyen A, Cotman CW, Cunningham DD.	Related Articles, Links
	Co-distribution of protease nexin-1 and protease neximon-human primates. Brain Res. 1993 Oct 29;626(1-2):90-8. PMID: 8281456 [PubMed - indexed for MEDLINE]	n-2 in brains of
□ 344:	Ohta M, Kitamoto T, Iwaki T, Ohgami T, Fukui M, Tateishi J.	Related Articles, Links
	Immunohistochemical distribution of amyloid precurs normal rat development. Brain Res Dev Brain Res. 1993 Oct 15;75(2):151-61. PMID: 7505208 [PubMed - indexed for MEDLINE]	or protein during
□ 345:	Harrington CR, Quinn GB, Hurt J, Day IN, Wischik CM.	Related Articles, Links
	Characterisation of an epitope specific to the neuron-shuman enolase recognised by a monoclonal antibody synthetic peptide corresponding to the C-terminus of believed Biochim Biophys Acta. 1993 Oct 3;1158(2):120-8. PMID: 7691181 [PubMed - indexed for MEDLINE]	aised against a
□ 346:	Masliah E, Mallory M, Ge N, Godson C, Saitoh T.	Related Articles, Links
	Phorbol ester-induced neuritic alterations in the rat neuronal immunocytochemical studies	ocortex. Structural

Mol Chem Neuropathol. 1993 Oct;20(2):125-45. PMID: 8297418 [PubMed - indexed for MEDLINE] ☐ 347: Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Related Articles, Links Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7789-93. PMID: 8356085 [PubMed - indexed for MEDLINE] ☐ 348: Holmes C, Webster MT, Procter AW, Francis PT, Bowen DM. Related Articles, Links Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex. Biochem Soc Trans. 1993 Aug;21 (Pt 3)(3):238S. No abstract available. PMID: 8224394 [PubMed - indexed for MEDLINE] ☐ **349**: Miklossy J. Related Articles, Links Alzheimer's disease--a spirochetosis? Neuroreport. 1993 Jul;4(7):841-8. PMID: 8369471 [PubMed - indexed for MEDLINE] ☐ 350: Behl C, Schubert D. Related Articles, Links Heat shock partially protects rat pheochromocytoma PC12 cells from amyloid beta peptide toxicity. Neurosci Lett. 1993 May 14;154(1-2):1-4. PMID: 8361618 [PubMed - indexed for MEDLINE] □ 351: Stoll J, Balbo A, Ault B, Rapoport SI, Fine A. Related Articles, Links Long-term transplants of mouse trisomy 16 hippocampal neurons, a model for Down's syndrome, do not develop Alzheimer's disease neuropathology. Brain Res. 1993 May 7;610(2):295-304. PMID: 8319091 [PubMed - indexed for MEDLINE] 352: Oyama F, Hirohashi S, Sakamoto M, Titani K, Sekiguchi K. Related Articles, Links Coordinate oncodevelopmental modulation of alternative splicing of \equiv fibronectin pre-messenger RNA at ED-A, ED-B, and CS1 regions in human liver tumors. Cancer Res. 1993 May 1;53(9):2005-11. PMID: 8481903 [PubMed - indexed for MEDLINE] 1353: Imaizumi K, Iwata H, Yoshida S, Sun G, Okumura N, Shiosaka Related Articles, Links <u>S.</u> Coexistence of amyloid beta-protein precursor and basic fibroblast growth factor in single cells of the rat parietal cortex, hippocampus and basal magnocellular nucleus. J Chem Neuroanat. 1993 May-Jun;6(3):159-65. PMID: 8343215 [PubMed - indexed for MEDLINE] ☐ 354: Piccardo P, Dagenais A, Cuello AC, St-Pierre S, Nalbantoglu J. Related Articles, Links An antibody against the Alzheimer's disease amyloid precursor protein recognizes distinct conformational isoforms. Histochemistry. 1993 May;99(5):347-53. PMID: 8335481 [PubMed - indexed for MEDLINE] Van Gool D, De Strooper B, Van Leuven F, Triau E, Dom R.

□ 355	· •	Related Articles, Links
	alpha 2-Macroglobulin expression in neuritic-type plawith Alzheimer's disease. Neurobiol Aging. 1993 May-Jun;14(3):233-7. PMID: 7686641 [PubMed - indexed for MEDLINE]	aques in patients
□ 356	Rozemuller AJ, Roos RA, Bots GT, Kamphorst W, Eikelenboom P, Van Nostrand WE.	Related Articles, Links
	Distribution of beta/A4 protein and amyloid precurso hereditary cerebral hemorrhage with amyloidosis-Du Alzheimer's disease. Am J Pathol. 1993 May;142(5):1449-57. Review. PMID: 7684195 [PubMed - indexed for MEDLINE]	
□ 357	Lahiri DK.	Related Articles, Links
	The stability of beta-amyloid precursor protein in nin	•
	types. Biochem Mol Biol Int. 1993 Apr;29(5):849-58. PMID: 8508138 [PubMed - indexed for MEDLINE]	·
□ 358	Gaskin F, Finley J, Fang Q, Xu S, Fu SM.	Related Articles, Links
	Human antibodies reactive with beta-amyloid protein disease. J Exp Med. 1993 Apr 1;177(4):1181-6. PMID: 8459212 [PubMed - indexed for MEDLINE]	in Alzheimer's
□ 359:	Buee L, Ding W, Delacourte A, Fillit H.	Related Articles, Links
	Binding of secreted human neuroblastoma proteoglyce Alzheimer's amyloid A4 peptide. Brain Res. 1993 Jan 22;601(1-2):154-63. PMID: 8431762 [PubMed - indexed for MEDLINE]	cans to the
□ 360:	Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, et al.	Related Articles, Links
	Secretion of beta-amyloid precursor protein cleaved a terminus of the beta-amyloid peptide. Nature. 1993 Jan 21;361(6409):260-3. PMID: 7678698 [PubMed - indexed for MEDLINE]	at the amino
□ 361:	Cole G, Neal JW, Singhrao SK, Jasani B, Newman GR.	Related Articles, Links
	The distribution of amyloid plaques in the cerebellum Down's syndrome and Alzheimer's disease: a light mi analysis. Acta Neuropathol (Berl). 1993;85(5):542-52. PMID: 8493862 [PubMed - indexed for MEDLINE]	and brain stem in croscopical
□ 362:	Ota M, Imai K, Saito N, Ito F, Tsujisaki M, Sugiyama T, Hinoda Y, Yachi A, Kasai M, Kawaharada M, et al.	Related Articles, Links
	[Immunological study on Alzheimer's disease using a monoclonal antibodies] Nippon Ronen Igakkai Zasshi. 1993 Jan;30(1):23-9. Japanese. PMID: 8474224 [PubMed - indexed for MEDLINE]	nti-beta-protein
□ 363:	Majocha RE, Tate B, Marotta CA.	Related Articles, Links


	PC12 cells release stimulatory factors after transfection terminal DNA of the Alzheimer amyloid precursor promoted Chem Neuropathol. 1993 Jan-Feb;18(1-2):99-113. PMID: 8466596 [PubMed - indexed for MEDLINE]	
□ 364:	Takahashi H, Utsuyama M, Kurashima C, Mori H, Hirokawa K.	Related Articles, Links
	Monoclonal antibody to beta peptide, recognizing ammeuronal cells and lipofuscin pigments in systemic orgacta Neuropathol (Berl). 1993;85(2):159-66. PMID: 8442408 [PubMed - indexed for MEDLINE]	
□ 365:	Wisniewski HM, Weigel J.	Related Articles, Links
	Migration of perivascular cells into the neuropil and the beta-amyloid plaque formation. Acta Neuropathol (Berl). 1993;85(6):586-95. PMID: 8337937 [PubMed - indexed for MEDLINE]	heir involvement in
□ 366:	Majocha RE, Reno JM, Friedland RP, VanHaight C, Lyle LR, Marotta CA.	Related Articles, Links
	Development of a monoclonal antibody specific for be Alzheimer's disease brain for application to in vivo imangiopathy. J Nucl Med. 1992 Dec;33(12):2184-9. PMID: 1460513 [PubMed - indexed for MEDLINE]	
□ 367:	Anderson JP, Chen Y, Kim KS, Robakis NK.	Related Articles, Links
	An alternative secretase cleavage produces soluble Al precursor protein containing a potentially amyloidoge J Neurochem. 1992 Dec;59(6):2328-31. PMID: 1431910 [PubMed - indexed for MEDLINE]	
□ 368:	Pappolla MA, Omar RA, Sambamurti K, Anderson JP, Robakis NK.	Related Articles, Links
	The genesis of the senile plaque. Further evidence in sneuronal origin. Am J Pathol. 1992 Nov;141(5):1151-9. PMID: 1443049 [PubMed - indexed for MEDLINE]	support of its
□ 369:	Masliah E, Mallory M, Ge N, Saitoh T.	Related Articles, Links
	Amyloid precursor protein is localized in growing neurat brain. Brain Res. 1992 Oct 16;593(2):323-8. PMID: 1450940 [PubMed - indexed for MEDLINE]	rites of neonatal
□ 370:	Hanger DP, Mann DM, Neary D, Anderton BH.	Related Articles, Links
	Tau pathology in a case of familial Alzheimer's diseas glycine mutation at position 717 in the amyloid precur Neurosci Lett. 1992 Oct 12;145(2):178-80. PMID: 1465214 [PubMed - indexed for MEDLINE]	e with a valine to rsor protein.
□ 371:	Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al.	Related Articles, Links
	Isolation and quantification of soluble Alzheimer's berbiological fluids. Nature, 1992 Sep 24:359(6393):325-7	a-peptide from

PMID: 1406936 [PubMed - indexed for MEDLINE] ☐ 372: Knops J, Lieberburg I, Sinha S. Related Articles, Links Evidence for a nonsecretory, acidic degradation pathway for amyloid precursor protein in 293 cells. Identification of a novel, 22-kDa, betapeptide-containing intermediate. J Biol Chem. 1992 Aug 15;267(23):16022-4. PMID: 1644790 [PubMed - indexed for MEDLINE] 373: Tate B, Aboody-Guterman KS, Morris AM, Walcott EC, Related Articles, Links Majocha RE, Marotta CA. Disruption of circadian regulation by brain grafts that overexpress Alzheimer beta/A4 amyloid. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7090-4. PMID: 1496005 [PubMed - indexed for MEDLINE] 374: Bush AI, Whyte S, Thomas LD, Williamson TG, Van Tiggelen Related Articles, Links CJ, Currie J, Small DH, Moir RD, Li QX, Rumble B, et al. An abnormality of plasma amyloid protein precursor in Alzheimer's disease. Ann Neurol. 1992 Jul;32(1):57-65. PMID: 1642473 [PubMed - indexed for MEDLINE] 375: Arai H, Schmidt ML, Lee VM, Hurtig HI, Greenberg BD, Adler Related Articles, Links CH, Trojanowski JQ. Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease. Neurology. 1992 Jul;42(7):1315-22. PMID: 1377804 [PubMed - indexed for MEDLINE] 1376: Kim T, Choi BH, Choe W, Kim RC, Van Nostrand W, Wagner Related Articles, Links S, Cunningham D. Expression of protease nexin-II in human dorsal root ganglia. A correlative immunocytochemical and in situ hybridization study. Mol Chem Neuropathol. 1992 Jun;16(3):225-39. PMID: 1418219 [PubMed - indexed for MEDLINE] 1377: Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner Related Articles, Links SL, Cunningham DD, Cotman CW. Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease. Neuroscience. 1992 Jun;48(4):763-77. PMID: 1378573 [PubMed - indexed for MEDLINE] 378: Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick Related Articles, Links M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmerman J, Cotman CW, et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2551-5. PMID: 1557359 [PubMed - indexed for MEDLINE] 379: Miao SY, Liu QY, Wang LF, Zhao M, Yan YC, Koide SS. Related Articles, Links Expression of a gene encoding a specific human sperm protein in

Chinese hamster ovarian cells. Arch Androl. 1992 Mar-Apr;28(2):91-7.


	PMID: 1520040 [PubMed - indexed for MEDLINE]		
□ 380	: Ohgami T, Kitamoto T, Tateishi J.	Related Articles, Links	
	Alzheimer's amyloid precursor protein accumulates v swellings in human brain lesions. Neurosci Lett. 1992 Feb 17;136(1):75-8. PMID: 1635670 [PubMed - indexed for MEDLINE]	vithin axonal	
□ 381	Nakamura Y, Takeda M, Niigawa H, Hariguchi S, Nishimura T. Related Articles, Links		
	Amyloid beta-protein precursor deposition in rat hipp by ibotenic acid injection. Neurosci Lett. 1992 Feb 17;136(1):95-8. PMID: 1321970 [PubMed - indexed for MEDLINE]	oocampus lesioned	
□ 382	Wisniewski KE, Gordon-Majszak W, Maslinski S, Heaney- Kieras J.	Related Articles, Links	
	Altered protein patterns in brains of children with neulipofuscinosis. Am J Med Genet. 1992 Feb 15;42(4):568-74. PMID: 1376969 [PubMed - indexed for MEDLINE]	uronal ceroid	
□ 383	Wunderlich D, Lee A, Fracasso RP, Mierz DV, Bayney RM, Ramabhadran TV.	Related Articles, Links	
	Use of recombinant fusion proteins for generation an characterization of monoclonal antibodies. Application domain of human beta amyloid precursor protein. J Immunol Methods. 1992 Feb 14;147(1):1-11. PMID: 1371794 [PubMed - indexed for MEDLINE]		
□ 384	Delvaux A, Van der Elst L, Octave JN.	Related Articles, Links	
	Inhibition of trypsin by the beta-amyloid protein pred comparative study between transfected cells, human in cerebrospinal fluid. FEBS Lett. 1992 Feb 3;297(1-2):124-6. PMID: 1551418 [PubMed - indexed for MEDLINE]		
□ 385	Perry G, Cras P, Siedlak SL, Tabaton M, Kawai M.	Related Articles, Links	
	Beta protein immunoreactivity is found in the majorit tangles of Alzheimer's disease. Am J Pathol. 1992 Feb;140(2):283-90. PMID: 1739122 [PubMed - indexed for MEDLINE]	ty of neurofibrillary	
□ 386:	Candy JM, McArthur FK, Oakley AE, Taylor GA, Chen CP, Mountfort SA, Thompson JE, Chalker PR, Bishop HE, Beyreuther K, et al.	Related Articles, Links	
	Aluminium accumulation in relation to senile plaque tangle formation in the brains of patients with renal far J Neurol Sci. 1992 Feb;107(2):210-8. PMID: 1564520 [PubMed - indexed for MEDLINE]		
□ 387:	Murphy GM Jr, Ellis WG, Lee YL, Stultz KE, Shrivastava R, Tinklenberg JR, Eng LF.	Related Articles, Links	
	Astrocytic gliosis in the amygdala in Down's syndron disease. Prog Brain Res. 1992;94:475-83. No abstract available.	ne and Alzheimer's	

	PMID: 1287731 [PubMed - indexed for MEDLINE]		
□388	: Hyman BT, Tanzi RE, Marzloff K, Barbour R, Schenk D.	Related Articles, Links	
	Kunitz protease inhibitor-containing amyloid beta pro immunoreactivity in Alzheimer's disease. J Neuropathol Exp Neurol. 1992 Jan;51(1):76-83. PMID: 1740675 [PubMed - indexed for MEDLINE]		
□ 389	Yan YC, Miao SY, Zong C, Li YH, Wang LF, Koide SS.	Related Articles, Links	
	Gene expression of human sperm component related precursor protein. Arch Androl. 1992 Jan-Feb;28(1):1-6. PMID: 1550421 [PubMed - indexed for MEDLINE]	to A4 amyloid	
□ 390	: Nukina N, Kanazawa I, Mannen T, Uchida Y.	Related Articles, Links	
	Accumulation of amyloid precursor protein and beta- immunoreactivities in axons injured by cerebral infar Gerontology. 1992;38 Suppl 1:10-4. PMID: 1459467 [PubMed - indexed for MEDLINE]		
□ 391	Schubert W, Prior R, Weidemann A, Dircksen H, Multhaup G, Masters CL, Beyreuther K.	Related Articles, Links	
	Localization of Alzheimer beta A4 amyloid precursor and peripheral synaptic sites. Brain Res. 1991 Nov 1;563(1-2):184-94. PMID: 1786532 [PubMed - indexed for MEDLINE]	r protein at central	
□ 392	Arai H, Lee VM, Messinger ML, Greenberg BD, Lowery DE, Trojanowski JQ.	Related Articles, Links	
	Expression patterns of beta-amyloid precursor protein neural and nonneural human tissues from Alzheimer's control subjects. Ann Neurol. 1991 Nov;30(5):686-93. PMID: 1763893 [PubMed - indexed for MEDLINE]		
□ 393	: Frautschy SA, Baird A, Cole GM.	Related Articles, Links	
	Effects of injected Alzheimer beta-amyloid cores in r Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362-6. PMID: 1924295 [PubMed - indexed for MEDLINE]	at brain.	
□ 394	McKee AC, Kosik KS, Kowall NW.	Related Articles, Links	
	Neuritic pathology and dementia in Alzheimer's disea Ann Neurol. 1991 Aug;30(2):156-65. PMID: 1910274 [PubMed - indexed for MEDLINE]	ise.	
□ 395	Bauer J, Konig G, Strauss S, Jonas U, Ganter U, Weidemann A, Monning U, Masters CL, Volk B, Berger M, et al.	Related Articles, Links	
	In-vitro matured human macrophages express Alzheimer's beta A4- amyloid precursor protein indicating synthesis in microglial cells. FEBS Lett. 1991 May 6;282(2):335-40. PMID: 1903718 [PubMed - indexed for MEDLINE]		
□ 396	Knops J, Johnson-Wood K, Schenk DB, Sinha S, Lieberburg I, McConlogue L.	Related Articles, Links	
	Isolation of baculovirus-derived secreted and full-leng	gth beta-amyloid	



PMID: 2146882 [PubMed - indexed for MEDLINE] 1 405: Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Related Articles, Links Currie J, Ames D, Weidemann A, Fischer P, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem. 1990 Sep 15;265(26):15977-83. PMID: 2118534 [PubMed - indexed for MEDLINE] 406: Kametani F, Tanaka K, Sato M, Haga S, Saitoh T, Shinoda T, Related Articles, Links Ishii T. A monoclonal antibody Hy20-54-16-3L to lambda (lambda) light chain of human immunoglobulin reacts with amyloid in Alzheimer's disease brain. Neurosci Lett. 1990 Sep 4;117(1-2):62-7. PMID: 2127088 [PubMed - indexed for MEDLINE] 1 407: Tate-Ostroff B, Majocha RE, Walcott EC, Ventosa-Michelman Related Articles, Links M, Marotta CA. Colocalization of amino terminal and A4 (beta-amyloid) antigens in Alzheimer plaques: evidence for coordinated processing of the amyloid precursor protein. J Geriatr Psychiatry Neurol. 1990 Jul-Sep;3(3):139-45. PMID: 2126439 [PubMed - indexed for MEDLINE] 408: Van Nostrand WE, Wagner SL, Farrow JS, Cunningham DD. Related Articles, Links Immunopurification and protease inhibitory properties of protease nexin-2/amyloid beta-protein precursor. J Biol Chem. 1990 Jun 15;265(17):9591-4. PMID: 2112543 [PubMed - indexed for MEDLINE] 409: Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD, Related Articles, Links Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Science. 1990 May 11;248(4956):745-8. PMID: 2110384 [PubMed - indexed for MEDLINE] ☐ 410: Stern RA, Trojanowski JO, Lee VM. Related Articles, Links Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood. FEBS Lett. 1990 May 7;264(1):43-7. PMID: 1692541 [PubMed - indexed for MEDLINE] 411: Kitaguchi T, Wisniewski KE, Maslinski S, Maslinska D, Related Articles, Links Wisniewski TM, Kim KS. Beta-protein immunoreactivity in brains of patients with neuronal ceroid lipofuscinosis: ultrastructural and biochemical demonstration. Neurosci Lett. 1990 May 4;112(2-3):155-60. PMID: 2193254 [PubMed - indexed for MEDLINE] ☐ 412: Spillantini MG, Goedert M, Jakes R, Klug A. Related Articles, Links Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci U S A. 1990 May;87(10):3947-51. PMID: 2111023 [PubMed - indexed for MEDLINE]

□ 413:	Yan YC, Bai Y, Wang LF, Miao SY, Koide SS.	Related Articles, Links
	Characterization of cDNA encoding a human sperm nelated to A4 amyloid protein. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2405-8. PMID: 1690887 [PubMed - indexed for MEDLINE]	nembrane protein
□ 414:	Arai H, Lee VM, Otvos L Jr, Greenberg BD, Lowery DE, Sharma SK, Schmidt ML, Trojanowski JQ.	Related Articles, Links
	Defined neurofilament, tau, and beta-amyloid precurs distinguish Alzheimer from non-Alzheimer senile place Proc Natl Acad Sci U S A. 1990 Mar;87(6):2249-53. PMID: 1690426 [PubMed - indexed for MEDLINE]	
□ 415:	Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL.	Related Articles, Links
	Precursor of amyloid protein in Alzheimer disease und anterograde axonal transport. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1561-5. PMID: 1689489 [PubMed - indexed for MEDLINE]	dergoes fast
□ 416:	Chou WG, Zain SB, Rehman S, Tate-Ostroff B, Majocha RE, Benes FM, Marotta CA.	Related Articles, Links
	Alzheimer cortical neurons containing abundant amyl Relationship to amyloid deposition and senile plaques J Psychiatr Res. 1990;24(1):37-50. PMID: 2195164 [PubMed - indexed for MEDLINE]	
□ 417:	Yamamoto K, Yamamoto M, Ishi-i K, Eitoku H, Ikuta S, Ishi-i T, Tomonaga M, Ooyama T.	Related Articles, Links
	Immunocytochemical identification of beta-protein pr vascular cells. Artery. 1990;17(4):213-32. PMID: 2113803 [PubMed - indexed for MEDLINE]	ecursor in cultured
□ 418:	Takahashi H, Kurashima C, Utsuyama M, Hirokawa K.	Related Articles, Links
	Immunohistological study of senile brains by using a rantibody recognizing beta amyloid precursor protein: granular deposits in relation with senile plaques. Acta Neuropathol (Berl). 1990;80(3):260-5. PMID: 1698004 [PubMed - indexed for MEDLINE]	
□ 419:	Wisniewski KE, Maslinska D, Kitaguchi T, Kim KS, Goebel HH, Haltia M.	Related Articles, Links
	Topographic heterogeneity of amyloid B-protein epitovarious forms of neuronal ceroid lipofuscinoses sugge processing of amyloid precursor protein. Acta Neuropathol (Berl). 1990;80(1):26-34. PMID: 1694383 [PubMed - indexed for MEDLINE]	
□ 420:	Suenaga T, Hirano A, Llena JF, Ksiezak-Reding H, Yen SH, Dickson DW.	Related Articles, Links
	Modified Bielschowsky and immunocytochemical stuplaques in Alzheimer's disease. J Neuropathol Exp Neurol. 1990 Jan;49(1):31-40. PMID: 1688924 [PubMed - indexed for MEDLINE]	dies on cerebellar



Immunoreactivity of neuronal lipofuscin with monoclonal antibodies to

	the amyloid beta-protein. Neurobiol Aging. 1989 Mar-Apr;10(2):125-32. PMID: 2657463 [PubMed - indexed for MEDLINE]	
□ 430:	Wisniewski KE, Maslinska D.	Related Articles, Links
	Immunoreactivity of ceroid lipofuscin storage pigmer with monoclonal antibodies to the amyloid beta-prote N Engl J Med. 1989 Jan 26;320(4):256-7. No abstract available. PMID: 2911317 [PubMed - indexed for MEDLINE]	in.
□ 431:	Haga S, Akai K, Ishii T.	Related Articles, Links
	Demonstration of microglial cells in and around senil in the Alzheimer brain. An immunohistochemical stumonoclonal antibody. Acta Neuropathol (Berl). 1989;77(6):569-75. PMID: 2750476 [PubMed - indexed for MEDLINE]	
□ 432:	Benes FM, Reifel JL, Majocha RE, Marotta CA.	Related Articles, Links
	Evidence for a diffusional model of Alzheimer amylo amyloid) deposition during neuritic plaque formation Neuroscience. 1989;33(3):483-8. PMID: 2700016 [PubMed - indexed for MEDLINE]	
□ 433:	Bancher C, Grundke-Iqbal I, Iqbal K, Kim KS, Wisniewski HM.	Related Articles, Links
	A 31 kilodalton beta-protein immunoreactive polyper lipofuscin. Prog Clin Biol Res. 1989;317:913-24. Review. PMID: 2690128 [PubMed - indexed for MEDLINE]	otide in neuronal
□ 434:	Glenner GG.	Related Articles, Links
	Amyloid beta protein and the basis for Alzheimer's di Prog Clin Biol Res. 1989;317:857-68. Review. PMID: 2690126 [PubMed - indexed for MEDLINE]	sease.
□ 435:	Barcikowska M, Wisniewski HM, Bancher C, Grundke-Iqbal I.	Related Articles, Links
	About the presence of paired helical filaments in dyst participating in the plaque formation. Acta Neuropathol (Berl). 1989;78(3):225-31. PMID: 2669434 [PubMed - indexed for MEDLINE]	rophic neurites
□ 436:	Ikeda S, Allsop D, Glenner GG.	Related Articles, Links
	Morphology and distribution of plaque and related de of Alzheimer's disease and control cases. An immuno study using amyloid beta-protein antibody. Lab Invest. 1989 Jan;60(1):113-22. PMID: 2642985 [PubMed - indexed for MEDLINE]	posits in the brains histochemical
□ 437:	Landon M, Smith MA, Clarke K, Kidd M.	Related Articles, Links
	Immunoaffinity chromatographic purification of amyl proteins from Alzheimer's disease brain tissue. Prog Clin Biol Res. 1989;317:903-12. PMID: 2574878 [PubMed - indexed for MEDLINE]	oid-related
	Tate-Ostroff B. Majocha P.F. Marotta CA	

□ 438: Related Articles, Links Identification of cellular and extracellular sites of amyloid precursor protein extracytoplasmic domain in normal and Alzheimer disease brains. Proc Natl Acad Sci U S A. 1989 Jan;86(2):745-9. PMID: 2563169 [PubMed - indexed for MEDLINE] 1 439: Marotta CA, Chou WG, Majocha RE, Watkins R, LaBonne C, Related Articles, Links Zain SB. Overexpression of amyloid precursor protein A4 (beta-amyloid) immunoreactivity in genetically transformed cells: implications for a cellular model of Alzheimer amyloidosis. Proc Natl Acad Sci U S A. 1989 Jan;86(1):337-41. PMID: 2563163 [PubMed - indexed for MEDLINE] Wisniewski HM, Bancher C, Barcikowska M, Wen GY, Currie Related Articles, Links **□ 440:** Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease. Acta Neuropathol (Berl). 1989;78(4):337-47. PMID: 2551122 [PubMed - indexed for MEDLINE] 441: Ihara Y, Kondo J. Related Articles, Links Polypeptide composition of paired helical filaments. Ann Med. 1989;21(2):121-5. Review. PMID: 2548540 [PubMed - indexed for MEDLINE] 442: Ikeda S, Allsop D, Glenner GG. Related Articles, Links A study of the morphology and distribution of amyloid beta protein immunoreactive plaque and related lesions in the brains of Alzheimer's disease and adult Down's syndrome. Prog Clin Biol Res. 1989;317:313-23. PMID: 2532370 [PubMed - indexed for MEDLINE] 443: Allsop D, Ikeda S, Glenner GG. Related Articles, Links Evidence for the derivation of a peptide ligand from the amyloid betaprotein precursor of Alzheimer's disease. Prog Clin Biol Res. 1989;317:893-902. Review. PMID: 2513585 [PubMed - indexed for MEDLINE] 444: Tagliavini F, Giaccone G, Frangione B, Bugiani O. Related Articles, Links Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett. 1988 Nov 11;93(2-3):191-6. PMID: 3241644 [PubMed - indexed for MEDLINE] 1 445: Roberts GW, Lofthouse R, Allsop D, Landon M, Kidd M, Related Articles, Links Prusiner SB, Crow TJ. CNS amyloid proteins in neurodegenerative diseases. Neurology. 1988 Oct;38(10):1534-40. PMID: 2901696 [PubMed - indexed for MEDLINE] 446: Allsop D, Wong CW, Ikeda S, Landon M, Kidd M, Glenner Related Articles, Links Immunohistochemical evidence for the derivation of a peptide ligand



from the amyloid beta-protein precursor of Alzheimer disease.

Proc Natl Acad Sci U S A. 1988 Apr;85(8):2790-4. PMID: 3282239 [PubMed - indexed for MEDLINE]

447: Ikeda S, Wong CW, Allsop D, Landon M, Kidd M, Glenner

Related Articles, Links

Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-beta protein monoclonal antibody.

Lab Invest. 1987 Oct;57(4):446-9.

PMID: 3312810 [PubMed - indexed for MEDLINE]

Display Summary Show 500 Sort by Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

May 2 2005 17:45:08